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Abbreviations and Acronyms 
2D, 3D = two-, three-dimensional, respectively 
Ala = alanine 
AMBER = assisted model building with energy refinement 
Amo = 5-aminomethyl-oxazolidine-2,4-dione 
AMPUMP = 1-(4-(aminomethyl)phenyl)-3-(o-methylphenyl)urea 
APTES = amnopropyltriethoxysilane 
Asn = asparagine 
Asp = aspartic acid 
2-Pro = (S)-pyrrolidine-3-carboxylic acid 
Boc = tert-butyloxycarbonyl 
Boc2O = Boc anhydride 
Bn = benzyl 
Bz = benzoyl 
BSA = bovine serum albumin 
Cbz or Z = carboxybenzyl 
CDCl3 = deuterated chloroform 
CDI = 1,1′-carbonyldiimidazole 
CMFDA = chloromethylfluorescein diacetate 
c[RGDfK] = cyclo-(L)-Arg-(L)-Gly-(L)-Asp-(D)-Phe-(L)-Lys 
Abu = 2,3-dehydro-2-aminobutyric acid 
Ala = dehydroalanine 
Phe = dehydroPhe  
DBU = 1,5-diazabiciclo (5.4.0) undec-5-ene 
DCM = dichlorometane 
DGR = Asp-Gly-Arg 
DIPEA = N,N-Diisopropylethylamine 
DMA = dimethylamine 
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DMF = dimethylformamide 
DMSO = dimethyl sulfoxide 
DSC = disuccinimidyldicarbonate 
DXP = N,N’-bis(2,6-dimethylphenyl)perylene-3,4,9,10-tetracarboxylic acid diimide 
ECM = extracellular matrix 
EDCI = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDX = energy dispersive X-ray spectroscopy 
EM-1 = endomorphin-1 
ES-MS = electrospray ionization mass spectrometry 
Et2O = ether 
EtOAc = ethyl acetate 
Fmoc = 9H-fluoren-9-ylmethoxycarbonyl 
FN = fibronectin 
FT-IR = fourier transform infrared spectroscopy 
gCOSY = gradient correlation spectroscopy 
Gly = glycine 
HATU = 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
HBTU = 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HMBC = heteronuclear multiple bond correlation 
HOBt = hydroxybenzotriazole 
HSQC = heteronuclear single quantum coherence 
IDS = Ile-Asp-Ser 
Imd = 2-imidazolidinone 
iSer = isoserine 
LDV = Leu-Asp-Val 
MAOS = microwave-assisted organic synthesis 
MD = molecular dynamics 
MPUPA = o-methylphenylureaphenylacetyl 
Mtr = 4-Methoxy-2,3,6-trimethylbenzenesulphonyl  
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MW = microwave 
NCA = N-carboxyanhydride 
NPs = nanoparticles 
Oxd = 2-oxazolidinone 
p-NBC = 4-Nitrobenzyl chloroformate 
p-NPC = 4-Nitrophenyl chloroformate 
PDMS = polydimethylsiloxane 
PEG = polyethylene glycol 
PFA = paraformaldehyde 
PG = protecting group 
Phe = phenyalanine 
Phg = D-phenylGly 
PhSer = Phenylserine 
PPI = protein-protein interaction 
Pro = proline 
RGD = Arg-Gly-Asp 
Rmsd = root-mean-square deviation 
Roesy = rotating-frame nuclear overhauser effect correlation spectroscopy 
RP = reversed phase; 
rt = room temperature 
SAM = self-assembled monolayer 
Sar = sarcosine 
SEM = scanning electron microscopy 
Ser = serine 
SP = solid phase 
SPA = scintillation proximity-binding assay; 
SPPS = solid phase peptide synthesis 
TEA = triethilamine 
TFA = trifluoroacetic acid 
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TGA = thermogravimetric analysis 
THF = tetrahydrofuran 
Thr = threonine 
Trp = tryptophan 
Ts = N-tosyl 
Tyr = tyrosine 
Val = valine 
VCAM = vascular cell adhesion molecule 
VCAM-1 = vascular cell adhesion molecule-1 
VT = vitronectin or variable temperature 
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Chapter 1 
From peptides to drugs: peptidomimetics 
 
The major striking features of the abundantly existing peptides and proteins are the enormous diversity in biological 
function, and the tremendous variations in structure. The biological functions range from hormones, toxins, and enzymes to 
antibodies, receptors, structural proteins, and beyond. Some of the most toxic compounds known are peptides,
1
 and among 
the molecules capable of binding ligands noncovalently we also find proteins, such as avidin and antibodies. Similarly, 
their structural complexity varies from simple, small, randomly structured peptides, to turns and helices, and on to 
complicated assemblies of turns, helices, sheets, and structured assemblies of proteins. Responsible for this incredible 
diversity are “only” 20 different proteinogenic amino acids, which are linked by an identical, repeating, connecting amide 
linkage, often denoted as the “peptide bond”. These 20 amino acids can lead to 8000 different tripeptides and as many as 64 
million possible hexapeptides and one can easily imagine the structural diversity as larger peptides assume more defined 
structures. It is therefore self-evident that, together with the large diversity of amino acid residues, which contain a wide 
range of side chain functional groups, this structural diversity will lead to a gigantic plurality in biological function. 
Furthermore, nature increases the diversity of both structure and function of peptides and proteins even further by post-
translational modifications; this allows, for example, the introduction of an on–off switch for the activity of a protein by 
phosphorylation. 
In addition, the set of the 20 amino acids that are present in proteins is greatly expanded and also includes the damino acids 
found in many small natural products and peptides, which are synthesized by non-ribosomal biosynthetic pathways. The 
situation is even more complicated, since different peptides can affect the same physiological function.
2
  
Finally, nowadays, with the exciting methods of expanding the genetic code, the set of 20 proteinogenic amino acid 
residues has been increased to well over 20.
3
  
Nevertheless there is the need to expand this impressive diversity of peptides and proteins even more by entering the realm 
of peptidomimetics and protein mimics. The reason can be found in their biological properties and structures, which are 
reminiscent of the structural features of peptides, proteins and their constituent amino acid residues. In many cases the 
structural and biological properties have to be improved or altered. In fact, despite of their clinical potential, seldom native 
peptides may be used directly as drugs, especially for oral administration. This is due to some very important limitations, 
such as: limitate stability toward proteolysis by peptidase; poor absorbition from intestine to the blood and across the 
blood-brain barrier, due for example to the high molecular weight; rapid excretion through the liver and/or kidneys; rapid 
photolytic degradation; high conformational flexibility, which often allows interactions with multiple receptors, resulting in 
several undesired side-effects.
4
  
Therefore, solubility, stability, bioavailability, and affinity of peptides and proteins were and still are important properties 
that limit, to a considerable extent, the development of peptides and proteins as drugs, and in many pharmaceutical 
companies this was considered to be a “no-go” area and the Lipinski “Rule of Five” was used to underpin it. Much effort 
has been expended to find ways to replace portions of biologically active peptides with non-peptide structures, with the aim 
of obtaining orally bioavailable entities. Such compounds, containing non-peptidic structural elements, that are capable of 
mimicking or antagonizing the biological action of a natural parent peptide are defined as peptidomimetics.
4a
 
Peptidomimetics might be able to remedy, at least partly, the objections pointed out by the Rule of Five.  
The Rule of Five states that poor absorption or permeation is more likely when more than five H-bond donors (sum of OHs 
and NHs) and more than ten H-bond acceptors (sum of Os and Ns) are present, in addition to a molecular weight greater 
than 500, and a log P greater than 5.  
Thus, there is still a lot to gain when peptidomimetics of a particular bioactive peptide can be developed, because peptides 
usually contain plenty of hydrogen bond donors and acceptors, have a molecular weight greater than 500 (even with only 
four residues), and can be very hydrophilic or hydrophobic. Nevertheless, the last two decades have also shown tremendous 
developments with respect to “biologics” such as hormones, monoclonal antibodies, nanobodies (variable domains of 
camelid heavychain-only antibodies), etc. None of them obeys the Rule of Five, and there is usually more than a problem 
with respect to solubility, stability, bioavailability and affinity; however, all are often used in extremely valuable treatments 
of severe diseases. 
Anyway the rational design of mimetics would be great if one could “transform” any conceivable amino acid sequence (a 
peptide chain) into a corresponding peptidomimetic chain, while retaining the required peptide properties, such as the 
presence of the amino acid side chains, its repetitive nature, the possibility for interaction with and by the backbone, as well 
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as eradicating or diminishing at least some unfavorable characteristics such as biodegradability. 
 
In this optic, modified 
peptides have been commonly obtained by different modifications of amino acids and peptide structures.  
The first approaches were based on simple modifications of N- or C- terminus, N- and Cα- methylation, or single amino 
acid replacement with its D-amino acid equivalent.
5
 The introduction of these variants in an aminoacidic sequence provides 
an increased stability to peptides, since enzymes have difficult to hydrolyze unnatural amino acids. Moreover, the above 
mentioned modifications, such as the insertion of D-residues, often enforce a different conformation of the peptide,
6
 and 
strongly influence receptor affinity and selectivity.
7
 
 
The  introduction of isosteric groups represents another peptide bond modifications approach.
21,8
 The replacement of a 
labile peptide bond with an isoster was of great help for designing therapeutic agents targeting proteases; very often, the 
isoster imitates the transition state of peptide bond cleavage, including the hydroxyl group resulting from enzyme 
nucleophilic addition.This strategy
 
resulted in the development of a variety of peptidomimetic classes, the most common 
and studied are peptoids,
9
 introduced by Zuckermann, in which the side chain of an amino acid is “shifted” to the-amino 
group. This leads to alkylated peptide amide bonds, thereby explaining the resistance towards degradation by proteases. In 
fact, alkylation, in particular methylation, of amino acids in biologically active peptides is a useful principle to reduce 
biodegradation and increase bioavailability, for example in cyclosporine and somatostatin analogues.
10
 
Also  peptide-bond reversal represents an important structural alteration for peptides,
11 
and proved to be useful to reduce 
the degradation rate of the peptides by peptidases. Retro-inverso peptides have found applications as immunogens, 
immunomodulators, immunostimulators, antimicrobial, and diagnostic reagents, as well as modified isomers of membrane- 
penetrating peptides as delivery systems.
12
  
Finally azapeptides,
13
 urea-peptidomimetics,
14
 and sulphonamide peptides/peptoids,
15
 are part of this class of mimetics 
(Figure 1).  
 
Figure 1. Some common peptide bond isoster. 
Peptide analogs have also been obtained by introducing unusual residues, which can be achieved by a number of ways,
16
  
such as β-,17 γ- and δ-amino acids,18 or α- or β-substituted amino acids.19 These particular amino acids have been utilized to 
construct the mimetics of naturally occurring peptide hormones, MHC-binding beta-peptides, opioid peptides, somatostatin, 
or amphipathic -peptide inhibitors of membrane-bound proteins.20 
Unfortunately, the major problem and collateral effect of the great part of peptidomimetic strategies illustrated until now is 
that, in principle, a mimetic, just like its corresponding peptide, is very flexible. In particular, the high flexibility of 
peptides is due to the multiple conformations that are energetically possible for each residue of the incorporated amino 
acids. To get an idea of how important the issue of conformational freedom,  just think that inasmuch as every amino acid 
has two degrees of conformational freedom, N–Cα (Φ) and Cα–CO (Ψ), are possible approximately 9 (32) stable local 
conformations. For a polypeptide with only 40 amino acids in length the number of possible conformations which need to 
be considered escalates to nearly 10
40
.
5a 
 
Pioneering work by Ramachandran et al. resulted in the so-called Ramachandran plots which restrict the allowed values for 
the torsion angles Φ and Ψ and with that the conformational space accessible to the amino acids to about one third of the 
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total structural space. Nevertheless the remaining degrees of freedom still make a prediction of the structure extremely 
difficult.  
This extraordinary high flexibility leads to the fact that short polypeptides rarely form any stable 3D structures in solution.
5b
 
There are only few examples reported in the literature where short to medium-sized peptides (<30-50 amino acids) were 
able to form stable structures. In most cases they exist in aqueous solution in numerous dynamically interconverting 
conformations.  Additionally, the number of stable short peptide structures, which are accessible, is very limited because of 
the need to use amino acids having a strong structure inducing effect, like for example helix-inducing amino acids as 
leucine, glutamic acid or lysine. Finally, it is questionable whether the solid state conformations determined by X-ray 
analysis are identical to those occurring in solution or during the interactions of proteins with each other.
21
 
This tricky trouble is extended also to the great part of peptidomimetics illustrated until now, for example in peptoids the 
side chain on the-carbon atom is missing, thereby leading to a large range of allowable  and  angles, despite the 
presence of the side chain on the amide-nitrogen atom that affects the range of allowable  angles.22 Understandably, 
increased conformational flexibility will lead to decreased binding affinity, as described above.  
The problem was resolved with two interesting approaches, which purpose was reduce flexibility: by cyclization to afford 
cyclic peptoids or by noncovalent intramolecular interactions.  
Rigid molecules are considered promising also for the evidence that a lot of biological processes are controlled by 
interactions between proteins (protein-protein interaction PPI), that, in most cases, are due to the contribution of just few 
amino acid residues, often arranged in a well defined folding structure (turn).   
According to the most common definition, a turn is a structural motif where the Cα atoms of two residues separated by few, 
usually 1 to 5, peptide bonds are in close approach, less than 7 Å, while the corresponding residues do not form a regular 
secondary structure element such as in an α-helix or β-sheet (Figure 2). 
The most renowned PPI processes are, for instance, the formation of hormone-receptor, protease-inhibitor, or antibody-
antigen complexes.
23
 Others, less specific, occur when proteins aggregate, like in amyloid fibrils which form in the tissues 
in several diseases such as Alzheimer’s, familial amyloidotic polyneuropathy, the spongiform encephalopathies, familial 
Mediterranean fever, and some forms of rheumatoid arthritis.
24
  
It’s therefore self-evident how important it could be to interact and interfere with this kind of mechanisms in order to play a 
key role in their control and modulation.   
 
Figure 2. A fast way to distinguish between α-, β-, and γ-turns. 
The first class of rigid mimics consists in the peptide cyclic analogues that are much more stable respect to the native 
peptides, conformationally more defined, and more selective towards the specific target. In addition, these covalent 
constraints also play a decisive role in controlling the three-dimensional structure of a molecule, for example by forming 
cavity or shell-like structures that are capable of binding other (small) molecules. 
Peptide cyclization has been performed by simple condensation of the N- and C- terminus or by connecting functionalized 
side chains.
25
 Another efficient method for preparing both small and macrocyclic rings, is the ring-closing metathesis 
approach,
26
 though in certain cases the occurrence of inappropriate secondary structural elements precluding peptide 
cyclization required introducing a reversible backbone protection.
27 
 
Examples of cyclopeptidomimetics prepared by simple condensation are the RGD integrin inhibitors developed by Kessler 
for treatment of human tumor metastasis and tumor induced angiogenesis, bone remodelling and osteoporosis.
28
 N-
methylation scan on some cyclic peptides provided c[Arg-Gly-Asp-D-Phe-NMeVal], Cilengitide, with enhanced biological 
activity and affinity. The conformationally defined RGD mimetics have been utilized also for investigating the relationship 
between the 3D display of the pharmacophores and the different selectivity towards different kinds of RGD-binding 
integrins.
29
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Figure 3. Chemical structure of Cilengitide, developed by Kessler. 
Noteworthy advancements have been recently reported also in the development of non-cyclic conformationally defined 
peptidomimetics, designed to interfere with cell adhesion mechanisms, therefore constituting interesting tools in the 
synthesis of imaging biomarkers and assessment of therapy response as well as in the engineering of cell-targeted agents.
30
  
To induce the peptide folding were proposed constraining elements like dehydro amino acids, cyclic amino acids,
31
 and 
other mimics of specific residues, which have been used to design acyclic peptides because of their turn-inducing or helix-
forming propensity (Figure 4).
32
 
 
Figure 4. Some of the conformationally constrained residues aforementioned. 
An important role among the backbone elements, which induce constrained conformations, is played by Pro and its 
derivatives. The peculiar features of this cyclic amino acid (among others the ability to induce cis peptide bond 
conformation)
33
 makes it a priceless ally while looking for rigidity. A number of pseudo-Pro building blocks have also been 
assessed in several occasions and with various results, giving libraries of compounds with different properties, and with the 
capability to induce either the trans or the cis conformation
34
 depending on the type of heterocycle used. 
Another powerful element, widely used to constrain angles in peptidomimetics, is the so called Freidinger lactam. This 
lactam’s peculiarity is the fact of being a bridge between the α carbon and the following amide nitrogen, resulting in five- 
six- or seven-membered heterocycles. Contrary to the pseudo-Pro, Freidinger lactam directly constrains the Ψ and the ω 
angles.
35
 Since its introduction in the early 80’s it has been widely used to constrain peptide conformations, stabilizing β- 
and γ-turn structures and acting as a β-strand mimetic in linear peptides,36 with lots of applications in the medicinal 
chemistry field, especially in the interaction with G-protein coupled receptors, as reported in a study aiming to reproduce 
the active conformation of the Growth hormone-releasing peptides (GHRPs) by incorporating a Freidinger lactam in it.
37
 
Some more recent work also focused on the development of new analogues of the Freidinger lactam, by introducing several 
kinds of modifications on its initial structure, such as heteroatoms substituting the simple sp
3
 carbons, in order to give 
rigidity to the ring, or the use of fused bicyclic or spirocyclic extensions.
4a
 
As seen, in recent years, research in the field of peptidomimetics is expanding always more and accordingly also its 
chemistry is growing. This led to the development of different synthetic methods for obtaining oligomeric peptidomimetics, 
such as the solid-phase peptide synthesis (SPPS), developed by B. Merrifield between 1950 and 1960, that made possible to 
synthesize polypeptides, with fifty or more amino acids in length, in large quantities making them available for 
pharmacological and clinical testing.
4b
  
In addition, in the early 1990’s, the Kent group reported a chemoselective ligation of unprotected peptides.38 They later 
developed the ‘‘native chemical ligation’’ method for the conjugation of unprotected polypeptide/peptoid molecules. This 
new strategy initiated an era of chemical protein synthesis,
39
 during which a variety of proteins and mimics have been 
prepared.
40
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Moreover, the ever-increasing demand of techniques to obtain a large number of compounds in relatively short time, 
allowed microwaves to gain importance among the synthetic technologies. In fact, MAOS (Microwave-Assisted Organic 
Synthesis) is been successfully coupled with the SPPS or with in solution peptide synthesis, enabling to reduce significantly 
the reaction time, because this kind of technique, raising the temperature very quickly, allows to fasten the reaction and 
may give access to different reaction routes, leading to unexpected yields, conversions and selectivities.  
Analyzing these aspects, it is evident that the development of synthetic procedures for the synthesis of unnatural amino 
acids and peptides/mimetics, for istance with a milder environmental impact, is a field of actual interest. 
The context shown and analized, highlights the developments on this area that might now also have a strong impetus on the 
growth and significance of modified peptides, peptidomimetics, and protein mimics as drugs. Moreover, this will also be 
favorably influenced by the recent enormous developments in drug delivery methods for these compounds, that guarantees 
the preservation of their biological activity during an acceptable shelf-life and ideally the effective and safe transport and 
delivery to its site of action.  
However, during the last three decades, there has been an exponential growth in an average number of peptide therapeutics 
entering clinical studies. Peptide and mimics drugs are being investigated in a wide variety of therapeutic areas, with the 
highest number of them entering clinical trials for metabolic disorders and cancer treatments (Figure 4).
41
 
 
Figure 4. The distribution of peptide pipeline drugs by therapeutic areas. Other indications that are not speciﬁed on the 
chart include: Endocrinology, Respiratory, Bones, Hematology, Ophthalmology, OB-GYN (obstetrics and gynecology). 
The highest number of peptides has entered clinical study for cancer treatments and metabolic disorders. Data was taken 
from a 2012 report provided by the Peptide Therapeutic Foundation.
42
 
These results prove that peptidomimetic approach represents a well-established strategy for developing novel, effective 
non-toxic therapeutic agents.  
Apart from their uses as drugs, it is important to mention that peptidomimetic derivatives may have other applications such 
as in the study of binding mode, in the diagnostic and in the foldamers field. For example, determining the receptor-bound 
structure of biologically active peptides is fundamental in drug design. In fact, recent evidences have stated that the 
peptidomimetic strategy is the front runner in biotechnology and nanotechnology, for creating new biomaterials and 
biodevices, biosensors, bioelectronics, to perform specific operations within a physiological environment.  
The field is so vast that it would be reductive to even try to make an overall view of it in this introductive chapter, but there 
is good literature that covers it all (see references herein).  
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Chapter 2 
Solid phase peptide synthesis using N-carboxyanhydrides and PEG resins in water 
The increasing need for large quantities of biologically active peptides for the market strongly raised the problem of the 
environmental sustainability of their synthesis. In this respect, in this chapter is described a solid phase procedure in water, 
using PEG peptide amide resins and NCAs under controlled conditions. This procedure afforded with reasonable yield and 
purity a short peptide amide, without the need of coupling reagents nor protecting groups. 
2.1. Introduction 
The market for biologically active peptides is expected to grow rapidly in the next years. Besides to the current interest in 
peptide as drugs and active pharmaceutical ingredients, and as cosmeceuticals, recent findings suggest a wide range of 
novel applications in medicine, biotechnology, and surgery.
1
 Peptides do not persist in the environment, giving innocuous 
degradation products; their components are the amino acids, which are renewable feedstocks available from biomasses
2
 or 
agricultural byproduct streams.
3
  
However, peptides are typical examples of products that impose an environmental burden during their manufacture. Both 
the solution and the solid phase (SP) syntheses
4
 require large amounts of organic solvent, the use of reagents to activate the 
coupling between the residues, and the massive use of protecting groups (PGs), resulting in very poor atom economy and 
the release of harmful organic wastes.
5
 As a consequence, the development of environmentally benign conditions has 
emerged as an important issue in green chemistry.
6
 
One of the major problems concerns the huge amount of solvents needed, particularly for synthesis on solid supports. A 
convenient approach would be to carry out solvent-free reactions; this can be done with techniques such as mixing, 
grinding, or ball-milling.
7
 So far, most of the efforts focused on the development of synthetic procedures in water. Since the 
common carbamate PGs are hydrophobic, reactivity can be improved suspending in water nanoparticle reactants generated 
by using a planetary ball mill,
8
 or by MW activation.
9
 Alternatively, new hydrophilic PGs have been proposed to improve 
water solubility.
10
 
Also the reagents for coupling and protection/deprotection steps should be reduced wherever possible. Significant 
reductions of organic wastes have been obtained using enzymatic catalysis for coupling reactions,
11
 or for PG removal.
12
 
The use of PGs was partially reduced on performing peptide coupling in aqueous solution utilizing the N-acylbenzotriazole 
derivatives and unprotected amino acids,
13
 or by using the native chemical ligation reaction of unprotected peptides in 
solution
14
 on a water-compatible solid support.
15
 
In this chapter is reported the SP preparation of peptides-amides in water on a PEG resin, by using N-carboxyanhydride 
(NCA) derivatives, conveniently prepared in turn under solvent-free conditions and MW irradiation. NCA, or Leuch’s 
anhydrides, constitute a special class of α-amino acid mixed anhydrides in which the amino group is protected and the 
carboxylate is activated at the same time.
16
 The attractiveness of peptide synthesis by NCA lies in its simplicity and atom 
economy; the molecular bulk of the reactants remains with the newly formed peptide, the only byproduct being carbon 
dioxide, and the condensation sequence may be rapidly repeated to build polypeptides requiring only control to avoid NCA 
polymerization. 
To test the efficacy of different kinds of PEG-based resins for peptide amides, we synthesized the endogenous opioid 
peptide endomorphin-1 (EM1), H-Tyr-Pro-Trp-Phe-NH2. This tetrapeptide was isolated from mammalian brain and it was 
found to activate -opioid receptors with high affinity and selectivity.17 
2.2. Results and discussion 
In the last years, our research group have been involved in the synthesis and investigation of EM-1 and mimetics as 
potential remedies for pain relief devoid of unwanted side-effects.
18
 Since we became aware of the environmental impact of 
the classical syntheses, we faced the opportunity to develop a more sustainable procedure. We designed a very simple SP 
methodology in water, using PEG resins for the preparation of peptide amides, and the NCAs of the amino acids Tyr, Pro, 
Trp, and Phe. 
These NCAs were prepared in almost quantitative yields from the unprotected amino acids and one third of triphosgene 
(Scheme 1). Though still hazardous (GHS05, GHS06), triphosgene can be used as a safe-to-handle phosgene substitute, and 
in recent years emerged as an important green chemical.
19
 The classic procedure reported in the literature
20
 was modified in 
that the condensation was performed under solvent-free conditions and MW irradiation. In the case of Pro, the N-carbamoyl 
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intermediate did not cyclize spontaneously, and the use of a non nucleophilic base was required; eventually, the use of 
polymer-supported bases has been also proposed.
21
 The resulting NCAs were checked by 
1
H-NMR, and ESI-MS, and the 
spectra are reported in Experimental section; purities (70-85%) were determined by RP-HPLC. The analyses of the 
byproducts were compatible with the presence of amino acid salts, isocyanatoacyl chlorides, N-chloroformyl amino acids,
22
 
and for Pro triethylammonium chloride. Polymerization at this stage was excluded on the basis of the HPLC-ESI analyses. 
Interestingly, the crude NCAs were utilized without purification, a significant advantage consented by the SP approach. 
 
 
Scheme 1. MW-assisted synthesis of NCAs. 
The NCAs are prone to polymerization; indeed, poly-amino acids can be conveniently synthesized from NCAs.
23
 As a 
consequence, we operated under carefully controlled conditions; the key factor is the relative stability of the intermediate 
carbamic acid in an aqueous environment at a basic pH, that prevents the formation of the free aminopeptide while the 
NCA is still present in the reaction mixture (Scheme 2). 
The PEG-based resins are highly chemically stable and allow the use of almost any kind of solvent, including water.
9,24
 
PEG has a very low toxicity and is used in a variety of biocompatible products.
25
 Three different peptide ChemMatrix
®
 
amide resins were tested, H-Rink Amide, H-PAL, and H-Ramage (Table 1). A suspension of the amino-free resin in borate 
buffer pH = 10.2 was treated with a 3 equiv. of PheNCA, and the suspension was mechanically shaken at 5°C. After 3 h the 
resin was filtered and washed three times with citrate buffer pH = 3.0, rapidly to avoid peptide cleavage.  
 
Scheme 2. SPPS of EM-1 in aqueous medium by coupling NCAs on a PEG peptide-amide resin. 
Table 1. SPPS of EM-1 on different PEG based ChemMatrix
® 
peptide-amide resins. 
entry resin loading 
(mmol/g) 
bead size 
(mesh)a 
cleavage mixture 
TFA/H2O/Et3SiH (%) 
purity, 
crude (%)b 
yield, isolated 
(%)c,d 
purity, 
isolated (%)d 
1 H-Rink 
Amide 
0.4-0.60 100-200 95.0/2.5/2.5 70 68 95 
2 H-PAL 0.4-0.5 100-200 95.0/2.5/2.5 65 66 95 
3 H-Ramage 0.25-0.50 100-200 5.0/2.5/2.5e 73 52 97 
a 
Dry. 
b 
After crystallization, determined by analytical RP-HPLC. 
c
 Based on the average loading. 
d
 After semi-preparative 
RP-HPLC. 
e 
The rest being DCM. 
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The remaining NCAs were added in turn under the same conditions. The cleavage of the peptide amide from the resin was 
performed with TFA in the presence of scavengers. The crude peptides were analyzed by reversed phase HPLC and ESI. 
The analyses were compatible with the presence of traces of peptide byproducts, in particular failure sequences, and 
sequences with duplicate amino acids, possibly arising from NCA polymerization during the coupling step, and excluded 
racemization.  
Final purification was performed by semi-preparative reversed phase HPLC, which afforded EM-1, ≥ 95% pure; EM-1 was 
identified by ESI-MS, 
1
H-NMR, and gCOSY spectroscopy (Experimental section). The 
1
H-NMR spectra of the isolated 
peptides excluded the presence of epimers. 
Figure 1 shows the chromatogram of the preparation performed with the H-Ramage resin (Entry 3). This afforded the 
highest purity but a slightly reduced yield, possibly due to the comparatively lower stability in the decarboxylation step 
(Scheme 2). 
 
 
Figure 1. RP-HPLC analysis of crude EM-1 as obtained from entry 3 of Table 1. 
From the general point of view of sustainability, the proposed synthetic protocol gives some advantages respect to the 
standard SP approach. The entire protocol was conducted in the almost complete absence of organic solvents. The solvent-
free preparation of the NCAs required only the amino acids and one third of triphosgene, apart for Pro which required 1 
equiv. of TEA. Swelling and coupling were conducted in borate buffer, and the washes were performed with citrate buffer. 
The high reactivity of the NCAs allowed using a reasonable excess of 3 equiv. for the couplings, comparable or inferior to 
classic SP synthesis.
2b,9,24
 The cleavage step was done as usual with TFA and scavengers; EtOH, Et2O, and CH3CN were 
utilized in the conclusive stages to recover and isolate the peptides. 
2.3. Conclusions 
A short peptide-amide was synthesized in SP and in aqueous conditions, by employing a PEG resin and NCAs as 
activated/protected derivatives of the amino acids. These NCAs have been prepared with triphosgene under MW 
irradiation, a very convenient method also for its efficient energy use. EM-1 was obtained with moderate yield and purity, 
so that for the moment the method seems less competitive than the classic procedures for longer sequences. Nevertheless, 
the entire protocol is attractive for its environmental sustainability; apart from the amino acids and some reagents used 
occasionally, the only bulk chemical was triphosgene, a relatively safe reagent which danger and toxicity is justified by 
excellent atom economy and the absence of wastes of the overall protocol, including organic solvents.  
2.4. Experimental section 
2.4.1. General Methods 
Unless stated otherwise, chemicals were obtained from commercial sources and used without further purification. The 
solid phase syntheses were conducted on ChemMatrix
®
, 100% PEG based resin from PCAS BioMatrix. The MW-assisted 
synthesis was performed using a Milestone Mycrosynth multimode labstation. Purities were determined by analytical RP-
HPLC performed on a C18 column, 4.6 μm particle size, 100 Å pore diameter, 250 μm, DAD 210 nm, from a 9:1 
H2O/CH3CN to a 2:8 H2O/CH3CN in 20 min, (for the analysis of EM-1: from a 9:1 H2O/CH3CN/0.1% TFA to 2:8 
H2O/CH3CN/0.1% TFA ) at a flow rate of 1.0 mL/min, followed by 10 min at the same composition. Semipreparative 
RP-HPLC was performed on a C18 column (7 μm particle size, 21.2 mm × 150 mm, from 8:2 H2O/CH3CN/0.1% TFA to 
100% CH3CN/0.1% TFA in 10 min) at a flow rate of 12 mL/min. Mass analysis was done by ESI. 
1
H NMR were 
recorded at 400 MHz, in 5 mm tubes, at rt. Chemical shifts are reported as δ values relative to the solvent peak. 
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2.4.2. Synthetic procedures 
Synthesis of the NCAs. A limp mixture of triphosgene (0.35 mmol) and the amino acid (1.0 mmol) was mixed under MW 
irradiation in an open vessel equipped with a refrigerator under a fume hood, while gently blowing with nitrogen. The 
microwave-assisted reaction was performed keeping irradiation power fixed at 150W and monitoring internal reaction 
temperature 80°C with a built-in ATC-FO advanced fiber optic automatic temperature control. After 20 min. the mixture 
was cooled at rt and the resulting NCA (90-95 %, 80-85 % pure by analytical RP-HPLC) was used as a waxy solid 
without further purification. 
Procedure for the synthesis of ProNCA. Proline (1.0 mmol) was treated with triphosgene as described above. After 20 
min the mixture was cooled at 0°C, TEA (1.0 mmol) was added and the limp mixture was mixed for additional 30 
minutes. Crude ProNCA (90 %, 70 % pure by analytical RP-HPLC) was used without further purification. 
SP synthesis of EM-1. NCA coupling: The PEG resin or PEG resin-peptide (0.3 mmol in free amino group) was swollen 
with borate buffer pH=10.2 (4.0 ml). The NCA (0.9  mmol) was added at 5°C and the suspension was mechanically 
shaken for 3 hours. Then the mixture was filtered, and the resin was washed three times with citrate buffer pH=3.0, and 
finally with borate buffer pH=10.2. 
Cleavage procedure. The resin-peptide was suspended in mixture of TFA and scavengers (5 mL, Table 1), and 
mechanically shaken at rt. After 2 h, the mixture was filtered, the resin was washed twice with 10% TFA in Et2O (5 mL), 
and the collected filtrates were poured into 50 mL of ice-cold Et2O. The precipitate was filtered, and the crude peptide 
TFA salt was re-crystallized from EtOH/Et2O and collected by centrifugation (65-73 % pure by analytical RP-HPLC, 
Table 1). The peptide was isolated after semi-preparative RP-HPLC (52-68 % yield, 95-97% pure by analytical RP-
HPLC, Table 1). 
TyrNCA.
26
 
1
H-NMR (400 MHz, CDCl3) δ: 2.99 (dd, 1H, J = 6.9, 13.9 Hz, TyrH), 3.20 (d, 1H, J = 4.6, 13.9 Hz, 
TyrH), 4.54 (m, 1H, TyrH), 6.02 ( br s, 1H, TyrNH), 6.91 (d, 2H, J = 8.2 Hz, TyrArH3,5), 7.14 (d, 2H, J = 8.2 Hz, 
TyrArH2,6). 
ES-MS m/z [M+1]; 208.1; calcd. for C10H10NO4: 208.1. 
ProNCA.
27,28 1
H-NMR (400 MHz, CDCl3) δ: 2.04 (m, 1H, ProH), 2.11-2.32 (m, 2H, ProH + ProH), 2.44 (m, 1H, 
ProH), 3.31 (m, 1H, ProH), 3.69 (dd, J = 7.5, 10.4 Hz, 1H, ProH), 4.35 (dd, J = 7.2, 9.2 Hz, 1H, ProH). 
ES-MS m/z [M+1]: 142.1; calcd. C6H8NO3: 142.0. 
TrpNCA.
28 1
H-NMR (400 MHz, CDCl3) δ: 3.13 (dd, 1H, J = 9.1, 14.9 Hz, TrpH), 3.49 (dd, 1H, J = 3.6, 14.9 Hz, 
TrpH), 4.55 (dd, J = 3.6, 9.1 Hz, 1H, TrpH), 5.99 (br.s, 1H, TrpNH), 7.11 (s, 1H, TrpH2), 7.15-7.31 (m, 2H, 
TrpH5+TrpH6), 7.41 (d, J = 8.0 Hz, 1H, TrpH7), 7.57 (d, J = 7.6 Hz, 1H, TrpH4), 8.27 (br. s, 1H, TrpH). 
ES-MS m/z [M+1]; 232.2; calcd. for C12H11N2O3: 232.1. 
PheNCA.
29,30 1
H-NMR (400 MHz, CDCl3) δ: 3.00 (dd, 1H, J = 8.4, 13.8 Hz, PheH), 3.32 (dd, 1H, J = 4.1 13.8 Hz, 
PheH), 4.54 (dd, J = 4.1, 8.4 Hz, 1H, PheH), 5.95 (br s, 1H, PheNH), 7.18-7.26 (m, 2H, ArH), 7.27-7.41 (m, 3H, ArH). 
ES-MS m/z [M+1]: 192.1; calcd. for C11H9NO3: 192.1. 
EM-1, H-Tyr-Pro-Trp-PheNH2.
31
 
1
H-NMR (400MHz, DMSO-d6); 3:1 trans:cis a 1.38-1.56 (m, 4H<, Pro< + Pro<), 
1.57-1.78 (m, 3H>, Pro> + Pro>), 1.92 (m, 1H>, Pro>), 2.66-2.79 (m, 2H<, TyrH< + 1H>, TyrH> + 1H><, PheH><), 
2.80-2.90 (m, 1H<, TrpH<, + 2H>, TyrH> + TrpH>), 2.90-2.95 (m, 1H><, PheH><), 3.01 (m, 1H>, ProH> + 1H><, 
TrpH><), 3.20-3.32 (m, 2H<, ProH<), 3.45-3-62 (m, 1H>, ProH> + 2H<, ProH< + TyrH<), 4.18 (br.t, 1H>, TyrH>), 
4.32-4.53 (m, 2H><, TrpH>< + PheH>< + 1H>, ProH>), 6.61 (d, J = 8.4 Hz, 2H><, TyrArH3,5><), 6.84 (d, J = 8.4 Hz, 
2H<, TyrArH2,6<), 6.92-7.00 (m, 2H><, TrpH6>< + TrpH5><, + 2H>, TyrArH2,6>), 7.15-7.00 (m, 7H><, PheArH>< + 
CONH2>< + TrpH2><),7.20-7.30 (m, 2H><, TrpH7>< + CONH2><), 7.51 (d, J = 7.6 Hz, 1H><, TrpH4><), 7.85 (d, J = 7.1 Hz, 
1H>, PheNH>), 8.05-7.94 (m, 1H>, TrpNH> + 1H<, PheNH< + 2H><, TyrNH><), 8.20 (d, J = 6.9 Hz, 1H<, TrpNH<), 9.36 (s, 
1H>, TyrOH>), 9.43 (s, 1H<, TyrOH<), 10.72 (s, 1H<, TrpH1<), 10.80 (s, 1H>, TrpH1>). 
a
 > = major isomer, < = minor isomer, >< = the resonances of major and minor conformers for the same proton appear 
under the same peak. ES-MS m/z [M+1]: 611.1; calcd. for C34H39N6O5: 611.3. 
 
 
Chapter 2  
 
11 
 
References
                                                 
1  a) Hruby, V. J. Nat. Rev. Drug Discov., 2002, 1, 847; b) Gentilucci, L.; Tolomelli, A.; Squassabia, F. Curr. Med. Chem., 2006, 13, 2449; c) Zhang, L.; 
Falla, T. J. Clin. Dermatol., 2009, 27, 485; d) Stevenson, C. L. Curr. Pharm. Biotechnol., 2009, 10, 122. 
2  a) Scott, E.; Peter, F.; Sanders, J. Appl. Microbiol. Biotechnol., 2007, 75, 751; b) Williams, P. J. le B.; Laurens, L. M. L. Energy Environ. Sci., 2010, 
3, 554. 
3  Lammens, T.M.; Franssen, M.C.R.; Scott, E.L.; Sanders, J.P.M. Biomass Bioenergy, 2012, 44, 168. 
4  Synthesis of peptides and peptidomimetics, Vol. E22 (Eds.: M. Goodman, A. Felix, L. Moroder, C. Toniolo), Thieme, Stuttgart, 2002. 
5  Green chemistry: Frontiers in benign chemical syntheses and processes (Eds.: P. T. Anastas, T. C. Williamson), Oxford University Press, New York, 
1999. 
6  a) Dunn, P. J.; Wells, A. S.; Williams, M. T.; Eds. Green chemistry in the pharmaceutical industry; WILEY-VCH Verlag GmbH & Co.: Weinheim, 
2010; b) Silpi, D.; Abha, S.; Torok, M. Curr. Org. Synth., 2011, 8, 262. 
7  a) Declerck, V.; Nun, P.; Martinez, J.; Lamaty, L. Angew. Chem. Int. Ed., 2009, 48, 9318; b) Štrukil, V.;  Bartolec, B.; Portada, T.; Ðilović, I.;  
Halaszc, I.;  Margetić, D. Chem. Commun. 2012, 48, 12100; c) Bonnamour, J.; Métro, T.-X.; Martinez, J.; Lamaty, F. Green Chem., 2013, 15, 1116. 
8  Hojo, K.; Ichikawa, H.; Onishi, M.; Fukumori, Y.; Kawasaki, K. J. Pept. Sci., 2011, 17, 487, and references herein. 
9  Athanassios, S.; Albericio, F.; Grøtli, M. SolidOrg. Lett., 2009, 11, 4488. 
10  Hojo, K.; Maeda, M.; Tanakamaru, N.; Mochida, K.; Kawasaki, K. Prot. Pept. Lett., 2006, 13, 189, and references herein. 
11  a) Schellenberger, V.; Jakubke, H. D. Angew. Chem. Int. Ed. Engl., 1991, 30, 1437; b) Wong, C. H. Science, 1989, 244, 1145. 
12  Góngora-Benítez, M.; Basso, A.; Bruckdorfer, T.; Royo, M.; Tulla-Puche, J.; Albericio, F. Chem. Eur. J., 2012, 18, 16166. 
13  Katritzky, A. R.; Zhang, Y.; Singh, S. K. Synthesis, 2003, 48, 2795. 
14  Dawson, P. E.; Muir, T. W.; Clark-Lewis, I.; Kent, S. B. Science, 1994, 266, 776. 
15  Johnson, E. C. B.; Durek, T.; Kent, S. B. H. Angew. Chem. Int. Ed., 2006, 45, 3283. 
16  a) Denkewalter, R. G.; Schwam, H.; Strachan, R. G., Beesley, T. E.; veber, D. F.; Schoenwaldt, E. F.; Barkemeyer, H.; Paleveda, Jr. W. J.; Jacob, T. 
A.; Hirschmann, R. J. Am. Chem. Soc., 1966, 83, 3163; b) Montalbetti, C. A. G. N.; Falque, V. Tetrahedron, 2005, 61, 10827; c) Spina, R.; Colacino, 
E.; Gabriele, B.; Salerno, G.; Martinez, J.; Lamaty, F. J. Org. Chem., 2013, 78, 2698. 
17  a) Zadina, J. E.; Hackler, L.; Lin-Jun, G.; Kastin, A. J. Nature, 1997, 386, 499; b) Keresztes, A.; Borics, A.; Tóth, G. Chem. Med. Chem., 2010, 5, 
1176. 
18  a) Gentilucci, L. In Neuropeptides in neuroprotection and neuroregeneration. Nyberg, F. Ed.; CRC Press, Boca Raton USA, pp 229-252; b) De 
Marco, R.; Tolomelli, A.; Spampinato, S.; Bedini, A.; Gentilucci, L. J. Med. Chem., 2012, 55, 10292. 
19  a) Trotzki, R.; Nüchter, M.; Ondruschka, B. Green Chem., 2003, 5, 285; b) Fuse, S.; Tanabe, N.; Takahashi, T. Chem. Commun., 2011, 47, 12661. 
20  Wilder, R.; Mobashery, S. J. Org. Chem., 1992, 57, 2755. 
21  Gulin, P. O.; Rabanal, F.; Giralt, E. Org. Lett., 2006, 8, 5385. 
22  Kramer, J. R.; Deming, T. J. Biomacromolecules, 2010, 11, 3668. 
23  Palacios, P.; Bussat, P.; Bichon, D. Synthesis Angew. Chem. Int. Ed., 1991, 193, 77. 
24  García-Ramos, Y.; Paradís-Bas, M.; Tulla-Puche. J.; Albericio, F. J. Pept. Sci., 2010, 16, 675. 
25  Webster, R.; Elliott, V.; Park, B. K.; Walker, D.; Hankin, M.; Taupin, Milestones in Drug Therapy, Veronese, F. M., Ed.; Birkhäuser: Basel, Swiss, 
2009. 
26    Lu, Y.-S.; Lin, Y.-C.; Kuo, S.-W. Macromolecules, 2012, 45, 6547. 
27  Gulin, P. O.; Rabanal, F.; Giralt, E. Org. Lett., 2006, 8, 5385. 
28  Our spectra for ProNCA and TrpNCA appear different from that reported in the following paper: Akssira, M.; Boumzebra, M.; Kasmi, H.; Dahdouh, 
A. Tetrahedron, 1994, 50, 9051.We argue that the spectral data reported in this Ref. 3 are rather rough. On the other hand, our data for ProNCA 
nicely agree with Ref. 2; for instance (δ in CDCl3), the two ProH are described as 3.50 (m, 2H) in Ref. 3, while they are at 3.33 (1H), and 3.79 (1H) 
in Ref. 2; ProH is at 4.15 in Ref. 3, while it is at 4.36 in Ref. 2.  
29  Wilder, R.; Mobashery, S. J. Org. Chem., 1992, 57, 2755.  
30 Daly, W. H.; Poché, D. Tetrahedron Lett., 1998, 29, 5859. 
31 Podlogar, B. L.; Paterlini, M. G.; Ferguson; D. M.; Leo, G. C.; Demeter, D. A.; Brown, F. K.; Reitz, A. B. FEBS Lett., 1998, 439, 13. 
 
Chapter 3 
 
12 
 
Chapter 3 
Preparation of Ala equipped with Oxd chiral auxiliaries for the stereoselective synthesis of 
substituted tryptophans 
Chiral dehydroamino acid building blocks are versatile starting materials for the preparation of optically active unusual 
amino acids and other compounds of pharmacological interest. In this chapter is disclosed the expedient preparation of 
dehydroalanines (Ala) equipped with oxazolidin-2-one (Oxd) chiral auxilixaries, Ts-Oxd-Ala-OMe. These compounds 
have been obtained in high yields from dipeptides Ts-Ser/Thr/phenylSer-Ser-OMe by the one-pot cyclization-elimination 
reaction with N,N-disuccinimidyl carbonate and catalytic DIPEA. To test the efficacy of the chiral auxiliaries in controlling 
asymmetric transformations, the Friedel-Crafts alkylations of indoles carrying diverse substituents were performed in the 
presence of Lewis and Brønsted acids. The reactions proceeded with good to excellent diastereomeric ratios giving (S)- or 
(R)-tryptophan derivatives, isolated very conveniently by simple flash chromatography. To verify the utility of this 
approach, optically pure (S)-2-methyltryptophan and (S)-5-fluorotryptophan were obtained and utilized to prepare 
analogues of endogenous opioid peptide endomorphin-1, H-Tyr-Pro-Trp-PheNH2. 
3.1. Introduction 
Among the unusual amino acids, the ,-dehydroamino acids (or aas) represent a noteworthy class for their presence in 
naturally occurring toxins and antibiotics, and for their important role in the biosynthesis of other non-proteinogenic amino 
acids.
1
 
aas display unusual conformational features; when inserted into peptides, they induce conformational constrains which 
lead to changes in the secondary structure. The double bond rigidifies the conformation of the side chain; χ is fixed to 0° 
(Z) or 180° (E), and favors the formation of - or -turns when the aas are placed at the i+2 position of the putative turn 
sequence (Figure 1a). Besides, the presence of these unnatural and constrained residues confer resistance to enzymatic 
degradation. The folding properties of aas have been utilized for the design of foldamers, oligomers which have a 
tendency to form well-defined secondary structures stabilized by non-covalent, nonadjacent interactions. For instance, it 
was reported that the sequential introduction in oligomers of ΔPhe gave repeated β-turns, forming a 310 helix.
2
 
Besides, aas have demonstrated their utility in organic synthesis as versatile intermediates, giving access to a variety of 
derivatives.
1
 The double bond permits to perform several reactions (Figure 1b), which can be utilized for the preparation of 
interesting biologically active compounds, such as the oligosaccharide-peptide ligation by the addition of complex 
oligosaccharide thiolates to dehydroalanine (Ala)-containing peptides,3 or the synthesis of a lanthionine-bridged 
enkephalin mimetics.
4
 
 
Figure 1 a) aas are -turn inducers when placed at the position i+2 of the putative turn; b) aas as substrates for different 
synthetic reactions; c) selected examples of chiral cyclic aas recently utilized for C-C bond formation (Michael-additions). 
Non-functionalized aas are enamines prone to hydrolysis; on the other hand, N-acyl derivatives or aas already 
incorporated into peptide sequences, are more stable, therefore several protocols for their preparations have been reported, 
including elimination reactions, Horner-Wadsworth-Emmons and Wittig reactions, Erlenmeyer synthesis and ring-opening 
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of oxazolones, Schöllkopf formylamino-methylenation, etc.
1
 One of the most direct methods is the dehydration of -
hydroxy--amino acids (e.g. Ser or Thr). For instance, Ferreira et al. reported the anti selective elimination with 
Boc2O/DMAP, that afforded only one of the two possible E/Z isomers,
5
 the Z isomer being practically more accessible 
from threo reagents than the E.  
Chiral Ala derivatives constitute suitable starting materials for many asymmetric transformations.1 Selected examples 
from the literature of compounds containing Ala recently utilized for diastereoselective Michael additions are shown in 
Figure 1c. The addition of the benzophenone glycine-tert-butylester imine to 2-phenyloxazolidin-5-one gave the Michael 
adduct with control of the two new stereocenters and a diastereoselectivity of 97:3;
6
 the 2-tert-butyloxazolidin-5-one 
underwent addition of enamine in a preferentially cis manner with a ratio of 83:17;
7
 the organocuprate addition to 
dehydrodiketopiperazine gave the cis product in high yields and >95% diastereomeric excess.
8
 
In this chapter is reported the expedient preparation of Ala equipped with Oxd chiral auxilixaries (3), by one-pot 
cyclization-elimination of dipeptides of sequence Ts-Ser (or Thr, phenylSer)-Ser-OMe (1). To test the efficacy of these 
chiral building blocks for the preparation of non-racemic and non-natural amino acids, it is been performed the tandem 
Friedel-Crafts (F.-C.) alkylation/asymmetric protonation of substituted indoles,
9
 to afford tryptophans functionalized at the 
indole with alkyl, aryl groups, halogens, or their combinations. Modified tryptophans are present in peptides of microbial or 
marine origins (e.g. halotryptophans),
10
 and unnatural Trp analogs have been utilized as important building blocks for the 
total synthesis of biologically active products,
11
 as biological probes,
12
 and finally as chiral small molecule catalysts.
13
 
Several authors developed asymmetric syntheses of optically pure indole-substituted tryptophans.
14
 Halotryptophans can be 
obtained by palladium-mediated heteroannulation of a chiral auxiliary,
15
 by electrochemical oxidation of proline followed 
by Fischer indole synthesis,
16
 from serine and commercially available microorganism containing tryptophan synthase,
17
 by 
enzymatic resolutions.
18
 The F.-C. alkylation of substituted indoles with methyl acetamidoacrylate
19
 gave Trp derivatives in 
non-stereoselective fashion. On the other hand, non-racemic tryptophan derivatives were prepared with moderate 
stereoselectivities by F.-C. alkylation when Ala was incorporated into peptides.20 Some asymmetric catalytic syntheses 
have been reported to afford with high levels of enantioselectivity (S)- or (R)-tryptophans carrying a limited number of 
distinct modifications.
21
 Heck reaction between N-Ts-indoles and methyl 2-acetamidoacrylate furnished the 
dehydrotryptophans, whose asymmetric catalytic hydrogenation with [(COD)Rh(R,R)-Et-DuPHOS]
+
TfO
- 
as catalyst 
furnished enantiomerically pure (R)-5-and 6-substituted tryptophans.
22
 More recently, the F.-C. alkylation of methyl 
acetamidoacrylate catalyzed by 3,3-dibromo-BINOL·SnCl4 complex furnished 2-substituted tryptophans in good yields and 
high enantioselectivity.
23
 
Finally, herein is described the synthesis of two analogues of the endogenous agonist of the -opioid receptor 
endomorphin-1 (EM1), H-Tyr-Pro-Trp-PheNH2.
24
 Among the opioid peptides, EM1 shows a unique sequence and 
extraordinary receptor affinity and selectivity. In fact, as mentioned above, our research group have been interested in the 
preparation, conformational analysis and pharmacological characterization of EM1 analogues
25
 as potential drugs for pain 
management.
26
 Since none of the other endogenous opioid peptides contain a Trp in the sequence, SAR studies on EM1 
analogues containing modified Trp could shed light into the role of this pharmacophore in ligand-receptor recognition.
27
 
Besides, the introduction of substituents at the indole of Trp could improve metabolic stability, bioavailability, and CNS 
exposure.
25d,28
 
3.2. Results and discussion 
Recently, in our research group, was observed that the reaction of the N-tosyl (Ts) dipeptide ester Ts-Ser-Ser-OMe (1a) 
with N,N-disuccinimidyl carbonate (DSC) and a catalytic amount of DIPEA in DCM/DMF, gave a 1:1 mixture of the 
compound containing two oxazolidin-2-one-4-carboxylate rings (Oxd), Ts-Oxd-Oxd-OMe (2a), and of the compound 
containing one Oxd and a Ala, Ts-Oxd-Ala-OMe (3a) (Figure 2, and Table 1, entry 1). This compound 3a can be 
regarded as a Ala equipped with a oxazolidin-2-one chiral auxiliary, 29,30 potentially useful for the asymmetric synthesis of 
optically active unusual -amino acids.1,20 This opportunity prompted us to preparare dipeptides Ts-Oxd-Ala-OMe 
carrying different substituents at the position 5 of the Oxd (Figure 2). 
The dipeptides 1a-c, precursors of 3a-c (Figure 2), were easily prepared by coupling in solution Ts-Ser (R = H), Ts-Thr (R 
= Me), and (S/R)-Ts-phenylSer (R = Ph), respectively, with H-Ser-OMe. Amino acid tosylation was performed according 
to the literature.
31
 The two -hydroxy--amino acid building blocks were incorporated without a protection for the OH 
function, according to a protocol largerly emploied by us (chapter 4, 5 and 6),
32
 using HOBt, HBTU, and DIPEA, as 
activating agents, at 80°C under MW irradiation.
33
 Under these expedient conditions, acylation of the OH-function and thus 
the formation of a depsipeptide side product was not observed, as confirmed by the 
1
H NMR and RP-HPLC MS analyses of 
the crude reaction mixture.  
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The reaction of 1a with DSC/DIPEA was performed in different solvents (Figure 2), giving different outcomes: in pure 
DCM the reaction gave a 92:8 mixture of 2a and 3a (Table 1, entry 2), while in DMF the situation was completely 
reversed, giving a 5:95 ratio in favor of 3a (entry 3). Finally, the slow addition of DSC to a solution of 1a-c and catalytic 
DIPEA in DMF at 0°C further reduced the amount of 2 (traces), as determined by HPLC-MS analysis of the reaction 
mixture, while the corresponding Ts-Oxd-Ala esters 3a were obtained in almost quantitative yields after isolation by flash 
chromatography (entry 4). In a similar way, the reaction of 1b and 1c performed under the same conditions gave the 
corresponding 3b (entry 5) and 3c (entry 6) in very good yields. 
 
 
Figure 2. One-pot synthesis of Ala equipped with Oxd chiral auxiliaries 3a-c. 
 
Table 1. Reactions of 1a-c with DSC/DIPEA under different conditions. 
entry 1 solvent Temp (°C) 2+3 (%)
a 2:3 (%)b 
1 a DCM/DMF 20 93 51.49 
2 a DCM 20 88 92:8 
3 a DMF 20 86 5:95 
4c a DMF 0 94 2:98 
5c b DMF 0 92 3:97 
6c c DMF 0 90 2:98 
a
 determined after isolation by flash chromatography over silica gel. 
b
 Determined by RP- HPLC of the reaction mixtures. 
c
 
Slow addition of DSC to 1. 
 
The analysis of the reaction mixtures at successive reaction times indicated that the reaction proceeds via the cyclization of 
Ts-Ser mojety promoted by DIPEA, followed by the dehydration of Ser-OMe to Ala (Figure 3). It was proposed that the 
cyclization of the Ts-Ser moiety can be promoted by the presence of the arylsulfonyl group,
25b,31
 while the comparatively 
higher acidity of the Hα of Ser-ester respect to that of the Hα of Ser-amide accounts for the elimination of the intermediate 
Ser-O-succinimidyl carbonate to Ala.5 
 
 
Figure 3.  Synthesis of peptides Ts-Oxd-AlaOMe (3) from dipeptides Ts-Ser/Thr/PhSer-SerOMe (1): proposed two-step 
mechanism. 
As anticipated in the introduction, we decided to assess the utility of the Oxd-equipped Ala as chiral building blocks for 
the preparation of non-racemic non-natural amino acids. In particular, we tested the efficacy of 3a (R = H), 3b (R = Me), or 
3c (R = Ph), to furnish optically active tryptophan derivatives by the Lewis acids-promoted F.-C. alkylation of substituted 
indoles
9,19,20
 in the presence of a Lewis acids-assisted Brønsted acid.
23
 In essence, the process consists in a tandem Michael 
addition-enolate protonation, a process which is very difficult to control under the point of view of the 
stereochemistry.
11a,23,34
 Initially, we screened different conditions for the reaction of 3a with un-substituted indole. The 
reactions were carried out in DCM, in the presence of different Lewis acids,
19,20,23
 of molecular sieves,
34
 of phenol as 
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protonating agent (Lewis acid-assisted Brønsted acid
23
), and afforded the dipeptide Ts-Oxd-Trp-OMe as a mixture of 
diastereoisomers (S,S)-4a and (S,R)-5a (Figure 4).  
 
Figure 4. Lewis-Brønsted acid-promoted asymmetric F.-C. alkylation of substituted indoles with dipeptides 3a-c. 
 
Yields and d.r. strongly varied depending on the Lewis acid selected. Yb(OTf)3, Sc(OTf)3, ZnCl4, MgBr2, SnBu2Cl2, 
ZnOTf2, FeCl3, InCl3, CeCl3, RuCl3 gave no products; other Lewis acids, MgBr2, BBu2OTf, TiCl4, Cu(OTf)2, gave 4a and 
5a in traces. Finally, the reaction gave reasonable-to-good yields with AlEtCl2, AlEt2Cl,
19,20
 or SnCl4,
23
 as reported in Table 
2. The reaction with 1.5 equiv. of AlEt2Cl gave a 18:82 mixture of the diastreoisomers in favor of (S,R)-5a (entry 1), as 
determined by the HPLC analyses of the reaction mixtures; 4a and 5a were isolated by flash chromatography over silica gel 
in 10% and 45% yield, respectively. The use of AlEtCl2 gave a higher yield (4a 17%, 5a 52%) but a reduced selectivity of 
25:75 (entry 2). On the other hand, SnCl4 (1.05 equiv.) gave 4a and 5a in good yield (7% and 67%) after flash 
chromatography, with a d.r. of 90:10 in favor of (S,R)-5a (entry 3). 
The configuration of the newly created stereocentre on Trp was determined by comparison with authentic samples of Ts-
(S)-Oxd-(S)-Trp-OMe and Ts-(S)-Oxd-(R)-Trp-OMe, prepared by standard peptide synthesis in solution from the 
commercially available amino acids. The analyses of the crude reaction mixtures revealed no evidence of concurrent -
amidoalkylation reaction.
19,35
 Increasing time and temperature did not lead to significantly higher yields; on the other hand, 
lower temperatures gave negligible improvements in terms of streoselectivity. The reduction of the amounts of Lewis acids 
to less than 1.0 equiv. gave reduced yields, consistent with the observation that stoichiometric Lewis-Brønsted acid was 
required due to its binding to the product, resulting in product inhibition.
23
 As for aluminum Lewis acids, a moderate excess 
was recommended for good reactivity and high selectivity in the conjugate addition reactions.
36
 In the absence of molecular 
sieves, the reactions gave scarce d.r., and variable quantities of by-products arising from peptide bond and/or ester 
hydrolysis, as revealed by reversed phase (RP)-HPLC and electro-spray (ESI)-MS analyses. Finally, the absence of the 
proton donor phenol gave similar yields but accompanied by a significant drop of stereoselectivity, while the substitution of 
phenol with 2-naphthol or 2,2′-biphenol did not alter the reaction outcome.  
Consequently, the reactions of 3a with substituted indoles (Table 2, entries 4-25 were performed with AlEt2Cl, or AlEtCl2, 
or with SnCl4 in the presence of phenol and activated molecular sieves in DCM. In all cases (including 4a, 5a), the analyses 
of the diastereoisomers 4 and 5 by reversed-phase HPLC under different conditions was unfeasible. However, the 
separation was possible by normal phase-HPLC using an analytical Kromasil Diol column, so allowing the determination 
of d.r. (Table 2). Gratifying, in most cases the diastereoisomers were easily isolated in preparative scale by low-pressure 
flash chromatography over silica-gel using standard solvents. 
The reaction of 3a with 2-methylindole (entries 4-6) gave the dipeptides Ts-Oxd-(S)-2-Me-Trp-OMe (4b) and Ts-Oxd-(R)-
2-Me-Trp-OMe (5b) in good to excellent yields and d.r. up to 8:92 with SnCl4 in favor of the (S,R)-stereoisomer 5b (entry 
6), while AlEt2Cl and AlEtCl2 gave inferior results (entries  4 and 5). A similar trend was observed for the reaction of 3a, 5-
fluoroindole, and the same Lewis acids, which gave 4c and 5c (entries 7-9). The reactions of 3a with 7-bromoindole 
(entries 10-12) and 1-methylindole (entries 13-15) gave good yields and outstanding d.r. In particular, in the presence of 
SnCl4 7-bromoindole gave 4d/5d in 6:94 ratio (entry 12). In a similar way, the reaction of 1-methylindole and 3a with 
SnCl4 (entry 15) afforded 5e as the largely predominant product, being the diastereoisomer 4e present only in traces.  
On the contrary, 2-phenylindole or 6-chloroindole reacted with 3a in the presence of AlEtCl2 and SnCl4, but not AlEt2Cl, 
giving the corresponding products 4f/5f,
23
 or 4g/5g in modest yields, albeit the diastereoselectivities were comparable to 
that of the previous experiments (not shown). As for 5-nitroindole, the reaction with 3a gave only traces of 4h/5h with all 
of the Lewis acids utilized. For these low-yielding reactions the analyses of the reaction mixtures by HPLC, ESI-MS, and 
1
H NMR, excluded the formation of large quantities of by-products and confirmed the presence of un-reacted 3a. 
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Finally, we tested the F.-C. alkylation of indoles carrying two substituents, 7-bromo-2-methylindole (entries 16-18) and 5-
chloro-2-methylindole (entries 19-21). Interestingly, the reaction of 7-bromo-2-methylindole with 3a afforded the best 
yield and d.r. with AlEtCl2 (4i 9% and 5i 75%, 4i/5i 11:89, entry 17), while the reaction of 5-chloro-2-methylindole gave 
the best d.r. with AlEt2Cl (4l/5l 9:91, entry 19), but the best yield with AlEtCl2 (4l 13% and 5l 68%, entry 20). 
 
Table 2 Yields and d.r. for the F.-C. reaction of R-indoles with 3a-c with different Lewis Acids. 
Entry 3 L.A. (eq.) R1-Indole (eq.) 4/5 (%)
a 4, 5 4 (%)b 5 (%)b 4+5 (%)b 
1 a AlEt2Cl (1.5) H 18:82 a 10 45 54 
2 a AlEtCl2 (1.5) H 25:75 a 17 52 69 
3 a SnCl4 (1.05) H 10:90 a 7 67 74 
4 a AlEt2Cl (1.5) 2-Me 15:85 b 10 59 69 
5 a AlEtCl2 (1.5) 2-Me 23:77 b 20 68 88 
6 a SnCl4 (1.05) 2-Me 8:92 b 7 82 89 
7 a AlEt2Cl (1.5) 5-F 16:85 c 8 47 55 
8 a AlEtCl2  
(1.5) 
5-F 22:78 c 17 62 79 
9 a SnCl4 (1.05) 5-F 10:90 c 8 74 82 
10 a AlEt2Cl (1.5) 7-Br 11:89 d 6 51 60 
11 a AlEtCl2 (1.5) 7-Br 8:92 d 6 69 75 
12 a SnCl4 (1.05) 7-Br 6:94 d 4.5 71 75 
13 a AlEt2Cl (1.5) 1-Me 5
c:95 e -
c 76 80 
14 a AlEtCl2  
(1.5) 
1-Me 9c:91 e -
c 85 93 
15 a SnCl4 (1.05) 1-Me 3
c:97 e -
c 92 95 
16 a AlEt2Cl  
(1.5) 
7-Br-2-Me 17:83 i 12 61 73 
17 a AlEtCl2 (1.5) 7-Br-2-Me 11:89 i 9 75 84 
18 a SnCl4 (1.05) 7-Br-2-Me 14:86 i 12 71 82 
19 a AlEt2Cl (1.5) 5-Cl-2-Me 9:91 l 6 63 69 
20 a AlEtCl2 (1.5) 5-Cl-2-Me 16:84 l 13 68 81 
21 a SnCl4 (1.05) 5-Cl-2-Me 12:88 l 9 68 78 
22 b AlEt2Cl (1.5) 2-Me 19:81 m 11 46 57 
23 b AlEtCl2 (1.5) 2-Me 27:73 m 16 43 59 
24 b SnCl4 (1.05) 2-Me 15:85 m 9 51 60 
25 b AlEt2Cl (1.5) 7-Br-2-Me 18:82
d 
n 49
d 49 
26 b AlEtCl2  
(1.5) 
7-Br-2-Me 18:82d n 54
d 54 
27 b SnCl4 (1.05) 7-Br-2-Me 22:78
d n 60
d 60 
28 c AlEt2Cl (1.5) 1-Me 23:77
d o 55
d 55 
29 c AlEtCl2 (1.5) 1-Me 30:70
d o 62
d 62 
30 c SnCl4 (1.05) 1-Me 20:80
d o 64
d 64 
31 c AlEt2Cl (1.5) 2-Ph 20:80
d p 50
d 50 
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32 c AlEtCl2  
(1.5) 
2-Ph 25:75d p 64
d 64 
33 c SnCl4 (1.05) 2-Ph 20:80
d p 65
d 65 
34 c AlEt2Cl (1.5) 5-Cl-2-Me 16:84
d q 54
d 54 
35 c AlEtCl2 (1.5) 5-Cl-2-Me 28:72
d q 60
d 60 
36 c SnCl4 (1.05) 5-Cl-2-Me 21:79
d q 66
d 66 
a
 Diastereomeric ratios determined by normal phase HPLC of the reaction mixtures, using a Kromasil Diol column. 
b
 Yields 
calculated after isolation by flash chromatography over silica gel. 
c 
Not isolated. 
d
 The diastereoisomers were not separated. 
n.d.: not determined. 
Subsequently, to check any effects of diverse groups at the position 5 of the Oxd chiral auxiliary, we repeated the F.-C. 
alkylation of some selected substituted indoles with the dipeptides Ts-5-Me-Oxd-Ala-OMe (3b) and (S/R)-Ts-5-Ph-Oxd-
Ala-OMe (3c) with AlEt2Cl, AlEtCl2, and SnCl4, under the same conditions utilized for 3a. The reaction of 3b with 2-
methylindole gave in all cases lower yields and reduced diastereoselectivities (entries 22-24) compared to the 
corresponding results observed for 3a (entries 4-6). The isolation of the diastereomeric dipeptides 4m and 5m by flash 
chromatography over silica-gel was still feasible. Similarly, moderate yields and d.r. were obtained also for the reaction of 
3b with 7-Br-2-Me indole (entries 25-27). Nevertheless, the separation of the diastereoisomers by flash chromatography 
was not possible, and 4n, 5n were obtained as a mixture. Finally, the F.-C. reactions of 3c and 1-methylindole (entries 28-
30), 2-phenylindole (entries 31-33), and 5-Cl-2-Me-indole (entries 34-36) afforded the products 4o/5o, 4p/5p, and 4q/5q, 
respectively. In all cases, the isolation of the diastereoisomers (S,S)-4 and (S,R)-5 by flash chromatography over silica-gel 
was not possible. As observed for 3b, yields and d.r. for the reactions of 3c with 1-methylindole and 5-Cl-2-Me-indole 
were modest compared to the corresponding results for 3a. In contrast, the  moderate reactivity of 2-phenylindole with 3c 
to give 4p/5p (entries 31-33) can be regarded as a improvement compared to the reaction with 3a, since the latter gave 
inferior yields. Possibly, the moderate yields and d.r. of the reactions of 3b and 3c and all the indoles can be correlated to a 
significant instability of the respective 5-Me-Oxd and 5-Ph-Oxd auxiliaries; indeed, the analyses of the crude reaction 
mixtures (entries 26-40) by NMR and HPLC-ESI-MS revealed the presence of variable amounts of dipeptides containing 
Thr or phenylserine, possibly resulting from the degradation of the 5-substituted Oxd rings.  
In summary, from the comparison of the results of the tandem F.-C. alkylation/asymmetric enolate protonation reported in 
Table 2, it appears that in most cases the substrate 3a is the most performing both in terms of yields and d.r. Besides, the 
un-substituted Ts-Oxd chiral auxilixary of 3a allowed a very easy separation of the stereoisomers. Reaction yields strongly 
varied depending on the nature of the substituents at the indole ring. As expected, activating groups such as 1-methyl or 2-
methyl gave very good yields, while weakly deactivating group such as 5-fluoro or 7-bromo still gave reasonable to good 
yields, in some cases superior to indole, albeit 6-chloroindole reacted poorly under the same conditions. Not surprisingly, 
the strongly deactivating 5-nitro group prevented the reaction. On the other hand, the modest reactivity of 2-phenylindole 
and 3a with all of the Lewis acids tested was unexpected.
23
 Also unexpected was the comparatively higher reactivity of 2-
phenylindole and 3c. Possibly, these reactions can be improved by increasing the amounts of Lewis acid and/or indoles;
19
 
for the moment, the reactions have been not optimized further. As for the disubstituted indoles (5-Cl-2-Me-indole and 7-Br-
2-Me-indole), the F.-C. reactions with 3a proceeded with good yields possibly for the activating effect of the 2-methyl 
group. 
In general, the stereochemical trend was very similar for all of the tested indoles, giving predominantly the (S,R)-5 
stereoisomers. For the monosubstituted indoles, the best d.r. were obtained with SnCl4, including 7-bromoindole and 1-
methylindole which reacted with 3a very nicely giving a outstanding d.r., so that the minor (S,S)-stereoisomer could not be 
recovered after purification of the reaction mixture by flash chromatography. The disubstituted indoles behaved differently; 
for 7-bromo-2-methylindole and 5-chloro-2-methylindole the best d.r. were obtained with AlEtCl2, and AlEt2Cl, 
respectively. 
The absolute configurations of all diastereoisomers 4 and 5 were determined by comparison of the HPLC analyses on 
Kromasil Diol column, and of the chiral HPLC analyses on CHIRALPAK IC column, with that of compounds 4a and 5a; 
the latter analysis also excluded racemization. Some representative examples of chiral HPLC analyses are reported in 
Figure 5: the analyses of 2’-methyl substituted 4b and 5b, of 5’-chloro-2’-methyl-4l and -5l, and of compounds 4m and 5m 
equipped with 5-methyl oxazolidin-2-one, clearly match the analyses of 4a and 5a. The latter were confirmed in turn by 
comparison with authentic samples of Ts-(S)-Oxd-(S)-Trp-OMe (4a) and Ts-(S)-Oxd-(R)-Trp-OMe (5a), prepared from the 
commercially available (S)- or (R)-tryptophan. The absolute stereochemistry of 4b and 5b, and of 4c and 5c, was also 
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confirmed after removal of the chiral auxiliary, by comparing the specific optical rotations of enantiopure (S)-2-
methyltryptophan and (S)-5-fluorotryptophan with the values reported in the literature.
15,17a,b,18a,37
 
 
Figure 5 HPLC analyses of the representative compounds 4a, 5a 4b, 5b, 4l, 5l, 4m, 5m, performed on a chiral stationary 
phase, using CHIRALPAK IC column (cellulose tris 3,5-dichlorophenylcarbamate, particle size 5 µm, lenght 250 mm, 
internal diameter 4.6 mm, DAD 210); mobile phase: 1:1 n-hexane/2-propanol, at 0.8 mL min
-1
. 
To rationalize the stereochemical outcome of the reactions, we analyzed the in solution conformation of Ts-Oxd-Ala-
OMe (3a). Previous analyses including Electronic Circular Dichroism, 2D NMR, and molecular dynamics computations
30
 
showed Ts group of 3a facing the double bond of Ala at a distance of about 3.7 Å (Figure 6), perfectly compatible with 
the values reported in the literature for π-stacking interactions.38  
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Figure 6. Representative low-energy structure of 3a consistent with ROESY analysis (see also Figure 7), calculated by 
restrained molecular dynamics. The calculated geometry of the Ala residue matches the structures reported in the 
literature.
39
 
Reasonably, the Lewis acid effectively promotes the conjugate addition of the indoles by forming a complex with the 
carbonyl oxygen of Ala.19,34b,40 The Michael addition gives rise to a intermediate enolate (Figure 7). The ability of 
arylsulfonamido groups to form sandwich structures with enolates by π-stacking interactions is well known.41 Electron-
poor aromatic rings have been reported to promote the reactivity of delocalized anions such as enolates by means of a 
donor-acceptor π-stacking stabilization of the transition states.42 As proposed in Figure 7, the Ts group could shield the Si 
face of the enolate, leaving the Re face more accessible to the PhOH-Lewis acid complex that serves as a Brønsted acid to 
protonate the intermediate enolate.
11a,13,23
 
 
Figure 7. Proposed model for the tandem Michael addition-enolate protonation of indoles and Ala, and role of the 
oxazolidin-2-one chiral auxilixary. 
The F.-C. reaction between the indoles and Ts-Oxd-Ala-OMe appears as a practical method to give access to peptides 
containing modified Trp. To exploit this opportunity, we synthesized in a few steps the analogues of the opioid peptide H-
Tyr-Pro-Trp-PheNH2 (EM1) containing 2-methyltryptophan or 5-fluorotryptophan
15,17a,b,18a,c,37a,b
 [2-Me-Trp
3
]-EM1 (8), and 
[5-F-Trp
3
]-EM1 (9), respectively (Figure 8 and 9). Since we were interested in (S)-configures amino acids, we performed 
the F.-C. reactions of the indoles with the (R)-enantiomer of 3a, in the presence of SnCl4 and PhOH. (R)-3a was obtained in 
turn by treatment of (R,R)-1a with DSC and DIPEA as described for 3a. The reactions of 2-methylindole and 5-
fluoroindole afforded (R,S)-5b or (R,S)-5c, respectively, as the major products, with the same yields and d.r. as reported in 
Table 2, entries 6 and 9. After isolation by flash chromatography, (R,S)-5b or (R,S)-5c were treated with 10% HBr at reflux 
under conventional heating, giving 2-methyltryptophan (6b) or 5-fluorotryptophan (6c) in moderate yields. Gratifyingly, 
heating at 95°C under MW irradiation afforded 6b or 6c in more satisfactory yields (Figure 8). The reaction mixture was 
adjusted to pH 3, and crude Ts-Ser-OH was easily separated from 6b or 6c and recovered in almost quantitative yield by 
extraction with EtOAc (Figure 8). The tryptophans 6b or 6c were isolated using a Dowex H
+
 form resin.
18c
 Spectroscopic 
characterization and specific optical rotation were found to match with the literature above reported, confirming the 
absolute stereochemistry attributed in the previous paragraph.  
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Figure 8. Synthesis of Fmoc-2-Me-Trp-OH, and Fmoc-5-F-Trp-OH, by F.-C. reaction of the indoles with (R)-3a. 
Finally, 6b or 6c were protected at the N-terminus with the Fmoc group under standard conditions,
18c
 and the resulting 7b 
or 7c were utilized for the solid-phase peptide synthesis (SPPS) of modified EM1. 
The tetrapeptide-amides [2-Me-Trp
3
]-EM1 (8b), and [5-F-Trp
3
]-EM1 (8c) were rapidly obtained by standard SPPS on a 
Rink amide resin in DCM/DMF, using Fmoc-protected amino acids, and HBTU/HOBt/DIPEA as coupling agents (Figure 
9). The reaction was performed under MW-assisted conditions, keeping temperature at 45°C while mechanically shaking, 
which allowed to complete the reactions in 10 min. Coupling efficiency was monitored by the Kaiser or Chloranyl tests. 
After each coupling, Fmoc was removed very rapidly (1 min) with DMF/piperidine at 45°C under MW irradiation. Peptide 
cleavage was performed by treatment with trifluoroacetic acid (TFA) in the presence of scavengers. After filtration, the 
crude peptides were precipitated from ice-cold Et2O, and collected by centrifuge. The peptide 8b or 8c were isolated >95% 
pure by semi-preparative RP-HPLC on a C18 column. 
 
Figure 9. Solid phase synthesis of the EM1 analogues 8b and 8c containing substituted Trp
3
. 
3.3. Conclusions 
In summary, we proposed a practical route for the preparation of dehydroalanine equipped with a oxazolidinone chiral 
auxiliary, by one-pot cyclization-elimination of the dipeptide Ts-Ser-Ser-OMe, and we demonstrated the efficacy of the 
resulting Ts-Oxd-Ala-OMe chiral building block for the preparation of non-racemic non-natural amino acids. The F.-C. 
alkylation of substituted indoles with Ala carrying (S)-configured chiral auxiliary in the presence of Lewis/Brønsted acids 
allowed obtaining (R)-tryptophans with diverse substituents at different positions of the indole, in good to excellent d.r over 
the (S)-isomers. The tryptophans were easily isolated in optical pure form after simple flash chromatography and cleavage 
of the chiral auxiliary. As a preliminary demonstration of the utility of this protocol, we introduced 2-methyl or 5-fluoro 
tryptophan into a peptide sequence of pharmacological interest, the opioid peptide EM1. The procedure can be utilized to 
synthesize a library of EM1 analogues, aiming at obtaining new opioid peptides with improved in vivo performances, as 
well as to deduce information about the role of Trp in peptide-receptor recognition and activation by SAR studies.  
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3.4. Experimental section 
3.4.1.  General methods 
Standard chemicals were purchased from commercial sources and used without further purification. The reactions were 
monitored by thin layer chromatography. Flash chromatography was performed on silica gel (230-400 mesh), using 
mixtures of distilled solvents. Analytical RP-HPLC was performed on an Agilent 1100 series apparatus, using a RP 
column Phenomenex mod. Gemini 3 C18 110A 100x3.0 mm (P/No 00D-4439-Y0); column description: stationary 
phase octadecyl carbon chain-bonded silica (C18) with TMS endcapping, fully porous organo-silica solid support, 
particle size 3 m, pore size 110 Å, length 100 mm, internal diameter 3 mm;  DAD 210 nm; mobile phase: from a 9:1 
H2O-MECN to a 2:8 H2O-MECN in 20 min at a flow rate of 1.0 mL min
-1
, followed by 10 min at the same composition. 
Semi-preparative RP-HPLC was performed on an Agilent 1100 series apparatus, using a RP column ZORBAX mod. 
Eclipse XDB-C18 PrepHT cartridge 21.2x150 mm 7 (P/No 977150-102); column description: stationary phase 
octadecyl carbon chain-bonded silica (C18), double endcapped, particle size 7 µm, pore size 80 Å, lenght 150 mm, 
internal diameter 21.2 mm; DAD 210 nm; mobile phase from 8:2 H2O-MeCN with 0.1% TFA to 100% MECN/0.1% 
TFA in 10 min at a flow rate of 12 mL min
-1
. Chiral HPLC analysis was performed on an Agilent 1200 series apparatus, 
using a CHIRALPAK IC column (P/No 83325); column description: chiral stationary phase cellulose tris (3,5-
dichlorophenylcarbamate) immobilized on silica, particle size 5 µm, lenght 250 mm, internal diameter 4.6 mm, DAD 
210/254 nm; mobile phase: 1:1 n-hexane/2-propanol, at 0.8 mL min
-1
. Direct phase-HPLC analyses were performed on an 
Agilent 1100 series apparatus, using a Kromasil 60-5Diol column (P/No E42500); column description: stationary phase 
silica, particle size 5 μm, pore size 60 Å, lenght 250 mm, internal diameter 4.6 mm, DAD 210 nm; mobile phase 
hexane/2-propanol 60:40, at a flow rate of 0.6 mL min
-1
. ESI analysis was performed using a MS single quadrupole HP 
1100MSD detector, with a drying gas flow of 12.5 l/min, nebulizer pressure 30 psgi, drying gas temp. 350°C, capillary 
voltage 4500 (+) and 4000 (-),  scan 50-2600 amu. Elemental analyses were performer using a Thermo Flash 2000 
CHNS/O analyzer. The synthetic procedures by MW irradiation were performed using a microwave oven (MicroSYNTH 
Microwave Labstation for Synthesis) equipped with a built-in ATC-FO advanced fiber optic automatic temperature 
control. 
1
H NMR spectra were recorded using a Varian Gemini apparatus at 400 MHz in 5 mm tubes, using 0.01 M 
peptide at room temperature. Solvent suppression was performed by the solvent presaturation procedure implemented in 
Varian (PRESAT). 
13
C NMR spectra were recorded at 100 MHz. Chemical shifts are reported as values relative to 
residual CHCl3 H (7.26 p.p.m.), DMSO H (2.50 p.p.m.) and CDCl3 C (77.16 p.p.m.) as internal standards. The 
unambiguous assignment of 
1
H NMR resonances was performed by 2D gCOSY.  
3.4.2. Synthetic procedures 
General procedure for the synthesis of Ts-Ser/Thr/phenylSer-Ser-OMe (1). A stirred solution of the N-tosylamino acid 
(1.0 mmol) in 4:1 DCM/DMF (5 mL) was treated with HOBt (1.2 mmol) and HBTU (1.2 mmol), at r.t. and under inert 
atmosphere. After 5 min, the amino acid esters (1.1 mmol), and DIPEA (2.4 mmol) were added and the reaction was 
stirred under MW irradiation.
33
 The microwave-assisted reaction was performed by setting maximum irradiation power at 
150W and monitoring the internal reaction temperature at 80°C. After 10 min, the mixture was concentrated at reduced 
pressure, and the residue was diluted with EtOAc (25 mL). The solution was washed with 0.1 M HCl (5 mL), and a 
saturated solution of NaHCO3 (5 mL). The organic layer was dried over Na2SO4 and the solvent was evaporated at 
reduced pressure. The crude peptides (80-90 % yield, 70-80 % pure by analytical RP-HPLC) were identified by ESI-MS 
and 
1
H NMR analysis, and were used without further purifications.   
Ts-L-Ser-L-Ser-OMe (1a). 
1
H NMR (CDCl3) : 2.31 (s, 3H, TsMe), 3.49 (m, 1H, SerH), 3.62 (s, 3H, OMe), 3.70-3.90 
(m, 4H, SerH), 4.41 (m, 1H, SerH), 6.66 (d, J=7.2 Hz, 1H, SerNH), 7.18-7.22 (m, 2H, TsArH), 7.63-7.69 (m, 3H, 
TsArH+SerNH); ES-MS m/z: 361.1 [M+H]
+
, calcd 361.0. 
Ts-L-Thr-L-Ser-OMe (1b). 
1
H NMR (CDCl3) : 1.00 (d, J=6.4 Hz, 3H, ThrMe), 2.38 (s, 3H, TsMe), 3.72 (s, 3H, OMe), 
3.74 (t, J=3.0 Hz, 1H, ThrH), 3.85-3.89 (m, 2H, SerH), 4.18-4.24 (m, 2H, ThrH), 4.46 (q, J=3.8 Hz, 1H, SerH), 6.31 
(d, J= 8.0 Hz, 1H, ThrNH), 7.21-7.25 (m, 2H, TsArH), 7.60 (d, J=7.6 Hz, SerNH), 7.69-7.63 (m, 2H, TsArH); ES-MS 
m/z: 375.2 [M+H]
+
, calcd 375.1.  
Ts-L/D-phenylSer-L-Ser-OMe (1c). 
1
H NMR (CDCl3)two diastereoisomers): 2.39+2.40 (s, 3H, TsMe), 3.80 (s, 3H, 
OMe), 3.90-4.06 (m, 3H, PhSerH+SerH-4.65 (m, 1H, SerH), 5.27+5.31 (m, 1H, PhSerH), 7.02-7.40 (m, 10H, 
TsArH+PhSerArH+PhSerNH), 7.90+7.93 (d, J=7.6 Hz, 1H, SerNH); ES-MS m/z: 437.3 [M+H]
+
, calcd 437.1.  
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General procedure for the synthesis of Ts-Oxd-Ala-OMe (3). N,N-disuccinimidyl carbonate (0.73 mmol) was added in 
60 min by using a temporized syringe to a stirred solution of 1 (0.33 mmol) in DMF (4 mL) and a catalytic amount of 
DIPEA (0.07 mmol) at 0°C and under inert atmosphere. After 60 min, the solvent was removed under reduced pressure. 
The residue was diluted with 0.1 M HCl (5 mL), and the mixture was extracted three times with DCM (5 mL). The 
combined organic layers were dried over Na2SO4, filtered, and concentrated at reduced pressure. The residue was purified 
by flash chromatography over silica-gel (eluant cyclohexane/EtOAc 70:30), giving 3 (yields: see Table 1; 94-96 % pure 
by analytical RP-HPLC) as waxy solids. 
Ts-L-Oxd-Ala-OMe (3a). []D
20
 -26.8 (c 1.0, MeOH); 
1
H NMR (CDCl3) : 2.42 (s, 3H, Me), 3.88 (s, 3H, COOMe), 
4.45 (dd, J=4.6, 9.0 Hz, 1H, OxdH5), 4.52 (t, J=9.1 Hz, 1H, OxdH5), 4.99 (dd, J=4.4, 9.2 Hz, 1H, OxdH4), 6.05 (s, 1H, 
CH), 6.65 (s, 1H, CH), 7.33-7.37 (m, 2H, TsArH), 7.92-7.96 (m, 2H, TsArH), 8.54 (s, 1H, AlaNH); 13C NMR 
(CDCl3) : 21.4, 52.6, 57.9, 66.0, 111.0, 128.7, 128.9, 129.1, 129.1, 131.0, 133.8, 145.4, 151.5, 163.6, 166.8; ES-MS m/z: 
369.1 [M+H]
+
, calcd 369.1. Elem. Anal. for C15H16N2O7S, calcd: C 48.91, H 4.38, N 7.60, S 8.70; found: C 49.15, H 
4.51, N 7.51, S 8.57. 
Ts-L-5-Me-Oxd-Ala-OMe (3b). []D
20
 -18.3 (c 0.5, MeOH); 
1
H NMR (CDCl3) δ: 1.44 (d, J=12.4 Hz, 3H, 5-Me), 2.44 
(s, 3H, TsMe), 3.86 (s, 3H, COOMe), 4.54 (d, J=10.0 Hz, 1H, OxdH4), 4.71 (m, 1H, OxdH5), 6.03 (s, 1H, =CH), 6.65 (s, 
1H, =CH), 7.33-7.37 (m, 2H, TsArH), 7.92-7.96 (m, 2H, TsArH), 8.55 (s, 1H, AlaNH); 13C NMR (CDCl3) δ: 20.7, 20.8, 
53.5, 65.4, 75.1, 111.4, 129.2, 130.0, 130.1, 130.9, 133.8, 146.5, 151.4, 164.2, 166.2; ES-MS m/z: 400.2 [M+18], calcd 
400.4. Elem. Anal. for C16H24N2O7S, calcd: C, 50.26; H, 4.74; N, 7.33; S, 8.39. found: C, 49.97; H, 4.89; N, 7.45; S, 8.22.    
Ts-L/D-5-Ph-Oxd-Ala-OMe (3c). 1H NMR (CDCl3) δ: 2.47 (s, 3H, TsMe), 3.88 (s, 3H, OMe), 4.71 (d, J=4.6 Hz, 1H, 
OxdH4), 5.64 (d, J=4.6 Hz, 1H, OxdH5), 6.08 (s, 1H, CH), 6.72 (s, 1H, =CH), 7.14-7.21 (m, 2H, TsArH), 7.32-7.39 (m, 
5H, 5-Ph), 7.86-7.90 (m, 2H, TsArH), 8.55 (s, 1H, AlaNH); 13C NMR (CDCl3) 21.8, 53.2, 66.3, 78.1, 111.1, 125.0, 
128.8, 129.3, 129.6, 129.8, 130.6, 133.4, 136.5, 151.2, 163.7, 165.6; ES-MS m/z 445.2 [M+H]+, calcd 445.1. Elem. Anal. 
for C21H20N2O7S, calcd: C, 56.75; H, 4.54; N, 6.30; S, 7.21; found: C, 56.45; H, 4.58; N, 6.33; S, 7.12. 
General procedure for the Michael addition with substituted indoles. A flame-dried flask containing freshly activated 
powdered 4 Å molecular sieves (200 wt %) under inert atmosphere was charged with anhydrous DCM (5 mL), then the 
indole (Table 2, 1.0 mmol), 3 (1.0 mmol) and, PhOH (0.20 mmol) were added under inert atmosphere at r.t. The Lewis 
acid (1 M in DCM, 1.0 mmol) was slowly added under inert atmosphere at 0°C. The reaction was stirred at 0°C for 24 h, 
then it was quenched with 0.5 M HCl (5 mL). The mixture was filtered over celite
®
, and concentrated at reduced pressure 
to a final volume of 5 mL. The residual aqueous layer was extracted with EtOAc (3×15 mL), the combined organic layers 
were washed with saturated NaHCO3 (5 mL), and dried over Na2SO4. The solvent was evaporated at reduced pressure, 
and the crude residue was purified by flash chromatography over silica-gel (eluant cyclohexane/EtOAc 70:20) giving 4 
and 5 (Table 2, 94-97% pure by analytical HPLC) as waxy solids. 
Ts-L-Oxd-L-Trp-OMe (4a). []D
20
 +44.0 (c 1.0, CHCl3); 
1
H NMR (CDCl3) : 2.40 (s, 3H, TsMe), 3.38 (d, J=5.0 Hz, 2H, 
TrpH), 3.67 (s, 3H, OMe), 4.10-4.15 (m, 2H, OxdH5), 4.73 (dd, J=6.4, 7.6 Hz, 1H, OxdH4), 4.94 (dt, J=5.0, 7.6 Hz, 1H, 
TrpH), 6.94 (d, J=7.6 Hz, 1H, TrpNH), 7.12 (t, J=7.6 Hz, 1H, TrpH5), 7.16 (m, 2H, TrpH2,6), 7.21-7.23 (m, 2H, TsArH), 
7.36 (d, J=8.0 Hz, 1H, TrpH7), 7.54 (d, J=8.0 Hz, 1H, TrpH4), 7.83-7.85 (m, 2H, TsArH), 8.47 (s, 1H, TrpH1); 
13
C NMR 
(CDCl3) : 21.7, 27.5, 52.6, 53.0, 57.8, 65.9, 108.8, 111.5, 118.2, 119.6, 122.2, 124.0, 127.2, 128.9, 129.6, 136.1, 151.8, 
167.4, 171.9; ESI-MS m/z 486.2 [M+H]
+
, calcd 486.1. Elem. Anal. for C23H23N3O7S, calcd: C, 56.90; H, 4.77; N, 8.65; S, 
6.60; found: C, 57.47; H, 4.80; N, 8.59; S, 6.55.  
Ts-L-Oxd-D-Trp-OMe (5a). []D
20 
-22.0 (c 0.5, CHCl3); 
1
H NMR (CDCl3) : 2.41 (s, 3H, TsMe), 3.37 (dd, J=6.4, 15.5 
Hz, 1H, TrpH), 3.39 (dd, J=6.2, 15.5 Hz, 1H, TrpH), 3.73 (s, 3H, OMe), 4.05 (dd, J=5.0, 9.0 Hz, 1H, OxdH5), 4.20 (m, 
1H, OxdH5), 4.77 (dd, J=5.0, 9.0 Hz, 1H, OxdH4), 4.93 (ddd, J=6.2, 6.4, 7.6 Hz, 1H, TrpH), 7.03 (d, J= 7.6 Hz, 1H, 
TrpNH), 7.10 (t, J=7.2 Hz, 1H, TrpH6), 7.12 (br.s, 1H, TrpH2),  7.18 (t, J=7.4 Hz, 1H, TrpH5), 7.24-7.26 (m, 2H, TsArH), 
7.35 (d, J=8.0 Hz, 1H, TrpH7), 7.49 (d, J=8.0 Hz, 1H, TrpH4), 7.84-7.86 (m, 2H, TsArH), 8.54 (br.s, 1H, TrpH1); 
13
C 
NMR (CDCl3) : 22.1, 27.6, 38.1, 53.5, 58.3, 66.1, 109.6, 111.9, 118.7, 120.0, 122.7, 123.9, 128.0, 129.3, 130.1, 133.9,  
136.6, 146.5, 167.7, 170.2, 171.3; ESI-MS m/z 486.2 [M+H]
+
, calcd 486.1. Elem. Anal. for C23H23N3O7S, calcd: C, 56.90; 
H, 4.77; N, 8.65; S, 6.60; found: C, 56.34; H, 4.84; N, 8.73; S, 6.45.  
Ts-L-Oxd-L-2-Me-Trp-OMe (4b): []D
20 
-65.0 (c 0.7, CHCl3); 
1
H NMR (CDCl3) : 2.39 (s, 3H, TrpMe), 2.40 (s, 3H, 
TsMe), 3.26 (dd, J=6.2, 14.8 Hz, 1H, TrpH), 3.35 (dd, J=6.0, 14.8 Hz, 1H, TrpH), 3.73 (s, 3H, OMe), 4.12 (m, 1H, 
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OxdH5), 4.29 (t, J=9.0 Hz, 1H, OxdH5), 4.75 (dd, J=4.4, 9.0 Hz, 1H, OxdH4), 4.91 (ddd, J=6.0, 6.2, 8.0 Hz, 1H, TrpH), 
6.69 (d, J=8.0 Hz, 1H, TrpNH), 7.10-7.17 (m, 6H, TrpH4-7+TsArH), 7.76-7.78 (m, 2H, TsArH), 8.00 (s, 1H, TrpH1); 
13
C 
NMR (CDCl3) : 11.6, 21.7, 29.7, 52.6, 57.7, 65.8, 105.2, 110.5, 117.6, 119.8, 121.5, 128.5, 128.9, 129.6, 133.2, 133.6, 
135.3, 145.9, 151.6, 167.2, 171.9; ESI-MS m/z 500.2 [M+H]
+
, calcd 500.1. Elem. Anal. for C24H25N3O7S, calcd: C, 57.70; 
H, 5.04; N, 8.41; S, 6.42. found : C, 58.68; H, 4.98; N, 8.52; S, 6.39.  
Ts-L-Oxd-D-2-Me-Trp-OMe (5b): []D
20
 +13.8 (c 0.13, CHCl3); 
1
H NMR (CDCl3) : 2.40 (s, 3H, TrpMe), 2.41 (s, 3H, 
TsMe), 3.24 (dd, J=6.6, 14.6 Hz, 1H, TrpH), 3.36 (dd, J=5.8, 14.6 Hz, 1H, TrpH3.73(s, 3H, OMe), 3.94 (dd, J=4.8 
8.8 Hz, 1H, OxdH5), 4.11 (dd, J=8.8, 9.4 Hz, 1H, OxdH5), 4.64 (dd, J=4.8, 9.4 Hz, 1H, OxdH4), 4.88 (ddd, J=5.8, 6.6, 7.2 
Hz, 1H, TrpHα), 6.73 (d, J=7.2 Hz, 1H, TrpNH), 7.08-7.18 (m, 4H, TrpH4-7), 7.20-7.22 (m, 2H, TsArH), 7.80-7.82 (m, 
2H, TsArH), 7.98 (s, 1H, TrpH1); 
13
C NMR (CDCl3) : 12.0, 22.1, 27.3, 53.0, 53.7, 58.1, 65.7, 105.7, 111.0, 118.0, 120.0, 
121.8, 128.8, 129.2, 129.3, 130.0, 133.7, 135.7, 146.3, 152.0, 172.1, 172.3; ESI-MS m/z 500.2 [M+H]
+
, calcd: 500.1. 
Elem. Anal. for C24H25N3O7S, calcd: C, 57.70; H, 5.04; N, 8.41; S, 6.42. found: C, 57.61; H, 5.10; N, 8.46; S, 6.30. 
Ts-L-Oxd-L-5-F-Trp-OMe (4c). []D
20
 +16.2 (c 0.5, CHCl3); 
1
H NMR (CDCl3) : 2.44 (s, 3H, TsMe), 3.37 (d, J=4.8 Hz, 
2H, TrpH), 3.76 (s, 3H, OMe), 4.28 (dd, J=4.4, 9.8 Hz, 1H, OxdH5), 4.39 (t, J=9.6 Hz, 1H, OxdH5), 4.76 (dd, J=4.4, 9.0 
Hz, 1H, OxdH4), 4.92 (m, 1H, TrpH), 6.88 (br.d, 1H, TrpNH), 6.93 (d, J=6.8 Hz, 1H, TrpH6),  7.05 (s, 1H, TrpH2), 7.12 
(s, 1H, TrpH4), 7.28-7.29 (m, 2H, TsArH), 7.53 (d, J=6.8 Hz, 1H, TrpH7), 7.84-7.86 (m, 2H, TsArH), 8.16 (s, 1H, TrpH1); 
13
C NMR (CDCl3) : 22.1, 30.1, 53.3, 53.8, 58.3, 66.1, 103.3, 110.4, 113.2, 115.0, 123.0, 127.6, 128.1, 129.3, 130.2, 
133.7, 137.6, 151.9, 157.6, 170.2, 171.7; ES-MS m/z 504.0 [M+H]
+
, calcd 504.1. Elem. Anal. for C23H22FN3O7S, calcd: 
C, 54.87; H, 4.40; N, 8.35; S, 6.37; found: C, 54.58; H, 4.68; N, 8.38; S, 6.33. 
Ts-L-Oxd-D-5-F-Trp-OMe (5c) []D
20 
+38.5 (c 0.2, CHCl3);  
1
H NMR (CDCl3) : 2.44 (s, 3H, TsMe), 3.36 (d, J=5.2 Hz, 
2H, TrpH), 3.76 (s, 3H, OMe), 4.27 (dd, J=5.6, 8.2 Hz, 1H, OxdH5), 4.37 (dd, J=8.2, 9.4 Hz, 1H, OxdH5), 4.75 (dd, 
J=5.6, 9.4 Hz, 1H, OxdH4), 4.91 (m, 1H, TrpH), 7.04 (br.d, 1H, TrpNH), 6.96-7.10 (m, 2H, TrpH2,6), 7.12 (s, 1H, 
TrpH4), 7.28-7.30 (m, 2H, TsArH), 7.54 (d, J=8.0 Hz, 1H, TrpH7), 7.84-7.87 (m, 2H, TsArH), 8.48 (s, 1H, TrpH1); 
13
C 
NMR (CDCl3) : 21.0, 28.0, 51.1, 52.9, 56.9, 60.8, 101.6, 107.9, 110.6, 113.2, 121.0, 125.5, 126.1, 127.1, 130.0, 131.5, 
135.3, 149.3, 155.0, 168.6, 168.8; ES-MS m/z 504.0 [M+H]
+
, calcd 504.1. Elem. Anal. for C23H22FN3O7S, calcd: C, 
54.87; H, 4.40; N, 8.35; S, 6.37; found: C, 55.16; H, 4.43; N, 8.29; S, 6.30. 
Ts-L-Oxd-L-7-Br-Trp-OMe (4d). []D
20
 +51.0 (c 0.1, CHCl3); 
1
H NMR (CDCl3, 400 MHz) : 2.40 (s, 3H, TsMe), 3.38 
(d, J=4.8 Hz, 2H, TrpH), 3.73 (s, 3H, OMe), 4.34 (dd, J=4.4, 7.8 Hz, 1H, OxdH5), 4.44 (dd, J=7.8, 10.0 Hz, 1H, OxdH5), 
4.83 (dd, J=4.4, 10.0 Hz, 1H, OxdH4), 4.98 (m, 1H, TrpH), 6.71 (br.d, 1H, TrpNH), 6.90 (t, J=8.0 Hz, 1H, TrpH5), 7.16 
(br.s, 1H, TrpH2), 7.22-7.31 (m, 3H, TsArH+TrpH6), 7.51 (d, J=8.0 Hz, 1H, TrpH4), 7.81 (d, J=8.0 Hz, 2H, TsAr), 8.30 
(s, 1H, TrpH1); 
13
C NMR (CDCl3, 400 MHz) : 20.8, 28.0, 50.9, 51.3, 56.6, 60.7, 98.1, 107.5, 115.4, 118.7, 120.5, 122.0, 
125.7, 126.7, 127.0, 131.0, 132.8, 134.8, 149.0, 168.1, 168.3; ES-MS m/z 563.8/565.8 [M+H]
+
, calcd 564.0/566.0. Elem. 
Anal. for C23H22BrN3O7S, calcd: C, 48.94; H, 3.93; N, 7.45; S, 5.68; found: C, 49.34; H, 3.96; N, 7.37; S, 5.61. 
Ts-L-Oxd-D-7-Br-Trp-OMe (5d). []D
20 
-11.0 (c 0.5, CHCl3
1
H NMR (CDCl3) : 2.45 (s, 3H, TsMe), 3.40 (d, J=4.8 Hz, 
2H, TrpH), 3.73 (s, 3H, OMe), 4.30 (dd, J=5.0, 8.4 Hz, 1H, OxdH5), 4.38 (dd, J=8.4, 9.0 Hz, 1H, OxdH5), 4.75 (dd, 
J=5.0, 9.0 Hz, 1H, OxdH4), 4.93 (dt, J=4.8, 7.6 Hz, 1H, TrpH), 6.83 (d, J=7.6 Hz, 1H, TrpNH), 6.91 (t, J=7.8 Hz, 1H, 
TrpH5), 7.16 (br.s, 1H, TrpH2), 7.22-7.31 (m, 3H, TsArH+TrpH6), 7.47 (d, J=8.0 Hz, 1H, TrpH4), 7.85-7.88 (m, 2H, 
TsArH), 8.30 (br.s, 1H, TrpH1); 
13
C NMR (CDCl3) : 21.0, 28.1, 51.1, 51.6, 57.0, 61.0, 98.5, 108.1, 116.1, 119.3, 121.2, 
122.6, 126.4, 127.4, 127.7, 131.7, 133.5, 135.5, 149.6, 169.0, 169.2; ES-MS m/z 563.9/565.9 [M+H]
+
, calcd 564.0/566.0. 
Elem. Anal. for C23H22BrN3O7S, calcd: C, 48.94; H, 3.93; N, 7.45; S, 5.68; found: C, 49.55; H, 3.90; N, 7.49; S, 5.63. 
Ts-L-Oxd-D-1-Me-Trp-OMe (5e). []D
20 
+20.7 (c 0.3, CHCl3); 
1
H NMR (CDCl3) :  2.43 (s, 6H, TrpMe+ TsMe), 3.41 
(d, J= 4.4 Hz, 2H, TrpH), 3.73(s, 3H, OMe), 4.24 (dd, J=4.4, 9.6 Hz, 1H, OxdH5), 4.35 (t, J=9.2 Hz, 1H, OxdH5), 4.74 
(dd, J=4.8, 9.0 1H, OxdH4), 4.90 (dt, J=4.4, 8.0 Hz, 1H, TrpHα), 6.51 (br.s, 1H, TrpH2), 6.78 (d, J=8.0 Hz, 1H, TrpNH), 
7.02-7.12 (m, 2H, TrpH5,7), 7.32-7.36 (m, 2H, TsArH), 7.48 (d, J=8.0 Hz, 1H, TrpH6), 7.59 (d, J=7.6 Hz, 1H, TrpH4), 
7.61-7.66 (m, 2H, TsArH); 
13
C NMR (CDCl3)  20.9, 28.2, 33.3, 50.9, 52.7, 56.6, 60.7, 107.4, 107.5, 116.4, 117.4, 
119.3, 122.7, 125.1, 125.7, 126.7, 131.0, 134.8, 135.0, 149.0, 168.1, 168.3; ESI-MS m/z 500.1 [M+H]
+
, calcd: 500.1,  
Elem. Anal. for C24H25N3O7S, calcd: C, 57.70; H, 5.04; N, 8.41; S, 6.42. found: C, 58.54; H, 5.08; N, 8.35; S, 6.39. 
Ts-L-Oxd-L-7-Br-2-Me-Trp-OMe (4i). []D
20 
+7.0 (c 0.4, CHCl3); 
1
H NMR (CDCl3) : 2.42 (s, 3H, TrpMe), 2.44 (s, 3H, 
TsMe), 3.25 (dd, J=4.8, 13.2 Hz, 1H, TrpH), 3.31 (dd, J=3.6, 13.2 Hz, 1H, TrpH), 3.74 (s, 3H, OMe), 4.20 (dd, J=4.5, 
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8.8 Hz, 1H, OxdH5), 4.40 (dd, J=8.8, 9.1 Hz, OxdH5), 4.75 (dd, J=4.5, 9.1 Hz, 1H, OxdH4), 4.94 (ddd, J=3.6, 4.8, 7.6, 1H, 
TrpH), 6.63 (d, J=7.6 Hz, 1H, TrpNH), 6.98-7.15 (m, 2H, TrpH4,5), 7.22-7.24 (m, 2H, TsArH), 7.46 (d, J=7.6 Hz, 1H, 
TrpH6), 7.78-7.82 (m, 2H, TsArH), 8.03 (br.s, 1H, TrpH1); 
13
C NMR (CDCl3) : 12.2, 22.4, 28.0, 51.7, 53.8, 59.2, 62.5, 
100.9, 108.0, 118.6, 121.8, 123.1, 128.0, 130.0, 131.5, 136.9, 138.7, 153.2, 170.7. ES-MS m/z 591.1 [M+Na] calcd 591.0, 
Elem. Anal. for C24H24BrN3O7S, calcd: C, 49.83; H, 4.18; N, 7.26; S, 5.54. found: C, 49.51; H, 4.21; N, 7.35; S, 5.49. 
Ts-L-Oxd-D-7-Br-2-Me-Trp-OMe (5i). []D
20
 -38.0 (c 0.5, CHCl3); 
1
H NMR (CDCl3) : 2.47 (s, 3H, TrpMe), 2.49 (s, 
3H, TsMe), 3.24 (dd, J=5.8, 14.9 Hz, 1H, TrpH), 3.34 (dd, J=6.4, 14.9 Hz, 1H, TrpH), 3.73 (s, 3H, OMe), 4.19 (dd, 
J=4.8, 8.8 Hz, 1H, OxdH5), 4.26 (t, J=8.9 Hz, OxdH5), 4.68 (dd, J=4.8, 8.9 Hz, 1H, OxdH4), 4.93 (ddd, J=5.8, 6.4, 7.2 Hz, 
1H, TrpH), 6.73 (d, J=7.2 Hz, 1H, TrpNH), 7.00-7.20 (m, 2H, TrpH4,5), 7.44 (m, 2H, TsArH), 7.46 (d, J=7.6 Hz, 1H, 
TrpH6), 7.84 (d, J=8.0 Hz, 2H, TsArH), 8.47 (s, 1H, TrpH1); 
13
C NMR (CDCl3) : 12.2, 22.4, 28.0, 51.7, 53.8, 59.2, 62.5, 
100.9, 108.0, 118.6, 121.8, 123.1, 127.9, 128.2, 130.0, 131.5, 136.9, 138.7, 153.2, 167.7, 170.7. ES-MS m/z  591.1 
[M+Na] calcd 591.0, Elem. Anal. for C24H24BrN3O7S, calcd: C, 49.83; H, 4.18; N, 7.26; S, 5.54 found: C, 49.42; H, 4.22; 
N, 7.19; S, 5.54. 
Ts-L-Oxd-L-5-Cl-2-Me-Trp-OMe (4l). []D
20 
-13.6 (c 0.6, CHCl3); 
1
H NMR (CDCl3) : 2.39 (s, 3H, TrpMe), 2.43 (s, 3H, 
TsMe), 3.23 (dd, J=7.0, 14.6 Hz, 1H, TrpHβ), 3.28 (dd, J=6.0, 14.6 Hz, 1H, TrpHβ), 3.76 (s, 3H, OMe), 4.26 (dd, J=4.5, 
9.2 Hz, 1H, OxdH5), 4.37 (t, J=9.1 Hz, OxdH5), 4.75 (dd, J=4.5, 9.0 Hz, 1H, OxdH4), 4.89 (ddd, J=6.0, 7.0, 7.6 Hz, 1H, 
TrpHα), 6.64 (d, J=7.6 Hz, 1H, TrpNH), 7.10 (d, J=8.4 Hz, TrpH6), 7.18 (d, J=8.4 Hz, 1H, TrpH7), 7.19-7.23 (m, 2H, 
TsArH), 7.46 (s, 1H, TrpH4), 7.75-7.79 (m, 2H, TsArH), 7.97 (s, 1H, TrpH1); 
13
C NMR (CDCl3) : 11.7, 21.7, 26.9, 52.7, 
53.2, 57.8, 65.7, 105.2, 111.5, 117.2, 121.7, 125.5, 128.8, 129.6, 129.7, 133.6, 134.9, 151.5, 167.2, 171.7; ESI-MS m/z 
534.0 [M+H]
+
, calcd 534.1. Elem. Anal. for C24H24ClN3O7S, calcd: C, 53.98; H, 4.53; N, 7.87; S, 6.00. found: C, 54.58; 
H, 4.50; N, 7.79; S, 6.06. 
Ts-L-Oxd-D-5-Cl-2-Me-Trp-OMe (5l). []D
20 
-12.0 (c 0.2, CHCl3); 
1
H NMR (CDCl3) : 2.39 (s, 3H, TrpMe), 2.42 (s, 3H, 
TsMe), 3.22 (dd, J= 5.8, 14.6 Hz, 1H, TrpHβ), 3.33 (dd, J=6.2, 14.6 Hz, 1H, TrpHβ), 3.78 (s, 3H, OMe), 4.15 (dd, J=4.6, 
8.8 Hz, 1H, OxdH5), 4.29 (t, J=9.0 Hz, 1H, OxdH5), 4.70 (dd, J=4.6, 9.0 Hz, 1H, OxdH4), 4.87 (ddd, J=5.8, 6.2, 7.6 Hz, 
1H, TrpHα), 6.76 (d, J=7.6 Hz, 1H, TrpNH), 7.08 (d, J=8.4 Hz, 1H, TrpH6), 7.19 (d, J=8.4 Hz, 1H, TrpH7), 7.20-7.24 (m, 
2H, TsArH), 7.32 (s, 1H, TrpH4), 7.80-7.83 (m, 2H, TsArH), 8.00 (s, 1H, TrpH1); 
13
C NMR (CDCl3) : 11.5, 21.5, 29.5, 
52.2, 53.0, 57.3, 65.5, 105.2, 111.4, 117.0, 120.5, 124.3, 128.8, 129.2, 129.9, 133.4, 133.9, 135.0, 145.3, 151.6, 167.3, 
171.7; ESI-MS m/z 534.0 [M+H]
+
, calcd 534.1. Elem. Anal. for C24H24ClN3O7S, calcd: C, 53.98; H, 4.53; N, 7.87; S, 
6.00; found: C, 53.67; H, 4.50; N, 7.91; S, 6.05. 
Ts-L-5-Me-Oxd-L-2-Me-Trp-OMe (4m). []D
20 
+37.9 (c 0.2, CHCl3); 
1
H NMR (CDCl3) : 1.11 (d, J=6.4 Hz, 3H, 
OxdMe), 2.36 (s, 3H, TrpMe), 2.41 (s, 3H, TsMe), 3.29 (dd, J=6.4, 14.8 Hz, 1H, TrpH), 3.32 (dd, J=6.0, 14.8 Hz, 1H, 
TrpH), 3.70 (s, 3H, OMe), 4.26 (d, J=4.8 Hz, 1H, OxdH4), 4.36 (m, 1H, OxdH5), 4.92 (ddd, J=6.0, 6.4, 7.6 Hz, 1H, 
TrpH), 6.71 (d, J=7.6 Hz, 1H, TrpNH), 7.10-7.16 (m, 4H, TrpH4-7), 7.18-7.22 (m, 2H, TsArH), 7.79-7.83 (m, 2H, 
TsArH), 7.95 (s, 1H, TrpH1); 
13
C NMR (CDCl3) : 11.6, 14.1, 21.6, 27.3, 52.3, 58.8, 64.0, 75.0, 105.2, 110.7, 118.5, 
119.0, 120.7, 127.1, 128.5, 128.9, 129.4, 129.6, 133.9, 135.6, 137.5, 151.4, 167.3, 172.3; ESI-MS m/z 534.1 [M+H]
+
, 
calcd 534.1. Elem. Anal. for C25H27N3O7S, calcd: C, 58.47; H, 5.30; N, 8.18; S, 6.24; found: C, 58.05; H, 5.33; N, 8.25; 
S, 6.18. 
Ts-L-5-Me-Oxd-D-2-Me-Trp-OMe (5m). []D
20
 -6.5 (c 0.1, CHCl3); 
1
H NMR (CDCl3) : 1.18 (d, J=6.4 Hz, 3H, 
OxdMe), 2.41 (s, 3H, TrpMe), 2.41 (s, 3H, TsMe), 3.27 (dd, J=6.0, 14.8 Hz, 1H, TrpH), 3.37 (dd, J=6.4, 14.8 Hz, 1H, 
TrpH), 3.74 (s, 3H, OMe), 4.18 (d, J=4.4 Hz, 1H, OxdH4), 4.34 (m, 1H, OxdH5), 4.87 (ddd, J=6.0, 6.4, 7.2 Hz, 1H, 
TrpH), 6.67 (d, J=7.2 Hz, 1H, TrpNH), 7.10-7.15 (m, 4H, TrpH4-7), 7.19-7.22 (m, 2H, TsArH), 7.80 (m, 2H, TsArH), 
7.96 (s, 1H, TrpH1); 
13
C NMR (CDCl3) : 11.7, 14.2, 21.7, 28.8, 53.3, 60.4, 64.4, 110.6, 117.5, 119.7, 121.4, 128.8, 
129.7, 135.2, 164.5, 167.1, 171.8; ES-MS m/z 514.4 [M+H]
+
, calcd 514.2. Elem. Anal. for C25H27N3O7S, calcd: C, 58.47; 
H, 5.30; N, 8.18; S, 6.24; found: C, 59.00; H, 5.26; N, 8.22; S, 6.19.  
Ts-L-5-Me-Oxd-L/D-7-Br-2-Me-Trp-OMe (4n, 5n). 
1
H NMR (CDCl3) two diastereoisomers): 1.11 (d, J=6.4 Hz, 3H, 
OxdMe), 2.40 (s, 3H, TsMe), 2.47 (s, 3H, TrpMe), 3.13+3.23 (d, J=6.0 Hz, 2H, TrpH), 3.67 (s, 3H, OMe), 4.27+4.33 (d, 
J=4.6 Hz, 1H, OxdH4), 4.34 (m, 1H, OxdH5), 4.71+4.79 (m, 1H, TrpH), 6.94+7.00 (t, J=7.8 Hz, 1H, TrpH5), 7.08 (d, 
J=8.0 Hz, 1H, TrpH4), 7.06-7.09 (m, 1H, TrpNH), 7.22-7.31 (m, 3H, TsArH+TrpH6), 7.65-7.69 (m, 2H, TsArH), 
8.11+8.20 (s, 1H, TrpH1). ES-MS m/z 609.2 [M+18], calcd 609.1.  
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Ts-L/D-5-Ph-Oxd-L/D-1-Me-Trp-OMe (4o, 5o). 
1
H NMR (CDCl3) racemic, two diastereoisomers): 2.42 (s, 6H, 
TsMe+TrpMe), 3.35-3.46 (m, 2H, TrpH), 3.69+3.71 (s, 3H, OMe), 4.53+4.54 (d, J=4.0 Hz, 1H, OxdH4), 4.91-4.98 (m, 
1H, TrpH), 5.42+5.44 (d, J=4.0 Hz, 2H, OxdH5), 6.63+6.79 (d, J=7.0 Hz, 1H, TrpNH), 6.81+6.82 (br.s, 1H, TrpH2), 
6.97 (t, J=7.2 Hz, 1H, TrpH5), 7.00-7.05 (m, 2H, TsArH), 7.30-7.61 (m, 8H, Ph+TrpH4,6,7), 7.68-7.72 (m, 2H, TsArH); 
ES-MS m/z 576.3 [M+H]
+
, 
 
calcd 576.2, found 576.3.  
Ts-L/D-5-Ph-Oxd-L/D-2-Ph-Trp-OMe (4p, 5p). 
1
H NMR (CDCl3) racemic, two diastereoisomers): 2.43+2.47 (s, 3H, 
TsMe), 3.88 (s, 3H, OMe), 3.42-3.61 (m, 2H, TrpH), 4.83+4.87 (m, 1H, TrpH), 4.90 (br.d, 1H, OxdH4), 5.34+5.43 
(br.d, 1H, OxdH5), 6.91 (d, J=7.6 Hz, 1H, TrpNH), 7.10 (t, J  = 7.2 Hz, 1H, TrpH6), 7.13-7.20 (m, 3H, TrpH5+TsArH), 
7.22-7.40 (m, 10H, Ph), 7.52+7.54 (br.d, 1H, TrpH7), 7.75+7.80 (d, J=7.8 Hz, 1H, TrpH4), 7.86-7.88 (m, 2H, TsArH), 
8.57 (s, 1H, TrpH1); ES-MS m/z 638.3 [M+H]
+
, calcd 638.2.  
Ts-L/D-5-Ph-Oxd-L/D-5-Cl-2-Me-Trp-OMe (4q, 5q). 
1
H NMR (CDCl3) racemic, two diastereoisomers): 2.37+2.39 (s, 
3H, TsMe), 2.43 (s, 3H, TrpMe), 3.22-3.37 (m, 2H, TrpH), 3.77+3.78 (s, 3H, OMe), 4.51+4.52 (d, J=4.0 Hz, 1H, 
OxdH4), 4.88+4.95 (m, 1H, TrpH), 5.44+5.50 (d, J=4.0 Hz, 1H, OxdH5), 6.62+6.86 (d, J=7.4 Hz, 1H, TrpNH), 6.97 (d, 
J=7.2 Hz, 2H, TrpH6), 7.07-7.50 (m, 8H, Ph+TsArH+TrpH7), 7.69-7.72 (m, 2H, TsArH), 7.95+7.99 (s, 1H, TrpH1); ES-
MS m/z 627.1 [M+Na], found 627.3.  
Synthesis of modified EM1. (S)-2-methyltryptophan (6b), (S)-5-fluorotryptophan (6c). 10% HBr (4.0 ml) was added to 
(R,S)-5b or (R,S)-5c (1.0 mmol), and the mixture was heated while stirring for 45 min by MW irradiation at 150 W, while 
monitoring the internal reaction temperature at 95°C. The pH of the mixture was adjusted to about 3 with 1 M NaOH, and 
the aqueous mixture was washed three times with EtOAc (5 mL) to recover (R)-Ts-Ser-OH (not isolated). The aqueous 
layer was concentrated at reduced pressure and passed through Dowex 50X2-200 resin H
+
 form. The resin washed with 
water (100 ml). The amino acids were eluted using 10% ammonia in methanol (200 ml), and the solvent removed in 
vacuo to afford 6b (0.73 mmol, 73%) or 6c (0.74 mmol, 74%). 
6b (commercially available). Optical rotation []D20 = -9.8 (c 0.26 in H2O) was found to match with the literature;
37a
 
NMR characterization was found to match with the literature;
37b
 ES-MS m/z 219.2 [M+H]
+
, calcd 219.1. 
6c. Optical rotation []D20 = +5.6 (c 1.0 in 0.1 M HCl) was found to match with the literature;
15
 NMR characterization 
was found to match with the literature;
15,18c
 ES-MS m/z 223.2 [M+H]
+
, found 223.2. 
N-Fmoc-(S)-2-methyltryptophan (7b), N-Fmoc-(S)-5-fluorotryptophan (7c). NaHCO3 (118 mg, 1.4 mmol) and 9-
fluorenylmethyloxycarbonyl succinimide (270 mg, 0.8 mmol) were added to the a suspension of amino acid 6b or 6c (0.7 
mmol) in 1:1 water/dioxane (6 mL) at 0°C, and the mixture was stirred overnight at r.t. Dioxane was removed at reduced 
pressure, and the pH of the aqueous mixture was adjusted to 3 with 1 M HCl. The mixture was extracted three times with 
EtOAc (10 mL), and the collected organic layers were dried over Mg2SO4. The solvent was evaporated at reduced 
pressure, affording the crude Fmoc-protected amino acid. The residues were purified by flash-chromatography over 
silica-gel (eluant: EtOAc/MeOH 97:3), giving 7b or 7c (for both 95% yield, 92% pure by RP-HPLC). 
N-Fmoc-(S)-2-methytryptophan (7b). 
1
H NMR (DMSO-d6) δ: 1.90 (s, 3H, TrpMe), 2.73 (dd, J=7.0, 14.5 Hz, 1H, TrpH), 
2.99 (dd, J=2.5, 14.5 Hz, 1H, TrpH), 4.12-4.33 (m, 3H, FmocH), 4.65 (m, 1H, TrpH), 6.05 (br.d, 1H, TrpNH), 7.00 
(br.t, 1H, TrpH6), 7.19-7.30 (m, 4H, FmocArH+TrpH4,5), 7.36 (t, J=7.5 Hz, 2H, FmocArH), 7.56 (d, J=7.5 Hz, 2H, 
FmocArH), 7.76 (d, J=7.5 Hz, 2H, FmocArH), 8.01 (d, J=7.0 Hz, 1H, TrpH7), 8.55 (s, 1H, TrpH1); ES-MS m/z 441.3 
[M+H]
+
, calcd 441.2. 
N-Fmoc-(S)-5-fluorotryptophan (7c). 
1
H NMR characterization was found to match with the literature;
18c
 ES-MS m/z 
444.2 [M + H]
+
, calcd 444.2. 
[2-Me-Trp
3
]-EM1 (8), [5-F-Trp
3
]-EM1 (9). A measure of Fmoc-Rink amide resin (0.3 g, 1.1 mmol/g, resin particle size: 
100-200 mesh) was introduced into a reactor for SPPS. Fmoc was removed with 4:1 DMF/piperidine (4 mL) under MW 
irradiation (40W) for 1 min under mechanical shaking, monitoring the internal temperature at 45°C. The suspension was 
filtered, the resin was washed with DCM (5 mL) and treated with a second portion of DMF/piperidine as above described. 
Then the suspension was filtered, and the resin was washed three times in sequence with DCM (5 mL) and MeOH (5 
mL). 
All coupling steps were performed according to the following general procedure. The resin was swollen in DCM (5 mL), 
and a solution of 7b or 7c (0.6 mmol) and HOBt (0.1 g, 0.7 mmol) in DMF (4 mL) was added at r.t. and under nitrogen 
atmosphere, followed by HBTU (0.26 g, 0.7 mmol) and DIPEA (0.2 mL, 1.2 mmol). The mixture was mechanically 
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shaken under MW irradiation with a initial irradiation power of 40W and monitoring the internal reaction temperature at 
45°C, and after 10 min the resin was filtered and washed three times with the sequence DCM (5 mL) and MeOH (5 mL). 
Coupling efficacy was determined by Kaiser or Chloranyl test. All subsequent Fmoc deprotection steps were performed 
as above reported. The resin-bound peptide was suspended in a solution of TFA (9.0 mL), TIPS (0.40 mL), H2O (0.40 
mL), and PhOH (0.20 g), and mechanically shaken at r.t. After 2 h, the mixture was filtered, the resin was washed twice 
with 10% TFA in Et2O (10 mL) and twice Et2O (10 mL). Filtrate and washes were collected, and solvent and volatiles 
were removed under N2 flow at r.t. The resulting residue was suspended in ice-cold Et2O, and the crude solid which 
precipitated was triturated and collected by centrifuge. The peptide 8 or 9 was isolated by semi-preparative RP-HPLC 
(80% yield based on the average resin loading; >95% pure by analytical RP-HPLC, see General Methods).  
[2-Me-Trp
3
]-EM1 (8). 
1
H NMR (DMSO-d6) ( about 3:1 mixture of two conformers, t = major-trans isomer, c = minor-
cis isomer 1.38-1.62 (m, 4Hc+1Ht), 1.72-1.84 (m, 2Ht), 1.95 (m, 1Ht), 2.09 (s, 3Hc), 2.10 (s, 3Ht), 2.62 (dd, J=6.5, 14.5 
Hz, 1Ht), 2.65-2.76 (m, 3Hc), 2.78 (dd, J=7.5, 15.0 Hz, 1Ht), 2.82 (dd, J=8.0, 14.0 Hz, 1Ht), 2.86 (m, 1Hc), 2.90 (m, 1Ht), 
2.93 (m, 1Hc), 2.95-3.09 (m, 2Ht+1Hc), 3.09 (dd, J=7.0, 15.5 Hz, 1Ht), 3.21-3.32 (m, 2Hc), 3.45-3.61 (m, 1Ht+2Hc), 4.35-
4.47 (m, 3Ht+2Hc), 4.55 (m, 1Ht), 6.68 (m, 2Ht+2Hc), 6.90 (dd, J= 4.8, 7.2 Hz, 1Ht), 6.98-7.05 (m, 2Ht+1Hc), 7.10 (m, 
2Ht+2Hc), 7.10-7.25 (m, 7Ht+7Hc), 7.50 (d, J=7.2 Hz, 1Ht+1Hc), 7.81 (d, J=7.8 Hz, 1Ht), 7.87 (br.d, 2Ht), 7.94-8.05 (m, 
3Hc), 8.20 (br.d, 1Hc), 8.21 (d, J=9.0 Hz, 1Ht), 9.31 (s, 1Hc ), 9.33 (s, 1Ht), 10.60 (s, 1Hc). 10.66 (s, 1Ht); ES-MS m/z: 
625.3 [M+H]
+
; calcd: 625.3. 
[5-F-Trp
3
]-EM1 (9). 
1
H NMR (DMSO-d6)  (about 3:1 mixture of two conformers, t = major-trans isomer, c = minor-cis 
isomer 1.42-1.55 (m, 4Hc), 1.62-1.73 (m, 3Ht), 1.91 (m, 1Ht), 2.68-2.83 (m, 3Ht+2Hc), 2.83-2.95 (m, 2Ht+2Hc), 2.95-
3.05 (m, 2Ht+2Hc), 3.20 (m, 1Hc), 3.30 (m, 1Hc), 3.40-3.67 (m, 1Ht+2Hc), 4.15 (m, 1Ht), 4.35 (dd, J=4.6, 8.2 Hz, 1Ht), 
4.37-4.40 ( m, 1Ht + 1Hc ), 4.40-4.48 (m, 1Ht + 1Hc ), 6.60 (m, 2Ht+2Hc), 6.87 (m, 2Hc), 7.07 (m, 2Ht), 7.10-7.35 (m, 
9Ht+9Hc), 7.90 (d, J=8.4 Hz, 1Ht), 7.95 (d, J=8.0 Hz, 1Ht), 8.01 (br.s, 2Ht), 8.11 (d, J=8.4 Hz, 1Hc), 8.25- 8.32 (m, 3Hc), 
9.30 (br.s, 1Ht + 1Hc), 10.80 (s, 1Hc), 10.88 (s, 1Ht); ES-MS m/z: 629.2 [M+H]
+
; calcd: 629.7.
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Chapter 4 
In-peptide synthesis of constraining motives containing di-Oxd and Abu-Oxd as -turn 
inducers 
Small and easy-to-do mimetics of the β-turns are of great interest to interfere with protein-protein recognition events 
mediated by β-turn recognition motifs. Herein is proposed a straightforward procedure for constraining the conformation of 
tetrapeptides lacking a pre-formed scaffold. According to the stereochemistry array, N-Ts tetrapeptides including Thr or 
PhSer (phenylserine) at the positions 2 or 3 gave rise in a single step to the sequences Oxd
2
-Oxd
3
 or Abu2-Oxd3 (Oxd, 
oxazolidin-2-one; Abu, 2,3-dehydro-2-aminobutyric). These pseudo-Pro residues displayed highly constrained , , and  
dihedral angles, and induced clear -turns or inverse turns of type I or II, as determined by extensive spectroscopic and 
computational analyses.  
4.1. Introduction 
Interactions between proteins (PPI) are important for the majority of biological functions and cellular signaling.
1
 
Systematic studies have revealed that there is typically a small cluster of residues at the interface of the proteins that 
contributes the majority of the recognition or binding affinity. Very often, these key regions adopt well defined turn 
structures.
2
 As a consequence, small molecules mimicking the 3D features of the turn regions can find applications as 
therapeutic agents.  
The β-turn occurs where the polypeptide backbone reverses direction, and consists of four amino acid residues i to i+3 in 
which the distance between Ci and Ci+3 is about 7Å; according to the dihedral angles  and  of the residues i+1 and 
i+2, the turns are classified in different types. Small mimetics of β-turns, such as the privileged structures benzodiazepines, 
Freidinger lactams, internal or external bicyclic dipeptide mimetics, spirocyclic dipeptides, etc., have been extensively 
investigated and utilized to discover compounds that can mimic or disrupt β-turn-mediated recognition events.3 
However, the preparation of the scaffolds and their incorporation in the sequence may require multi-step procedures, 
resulting in low overall yields. Besides, most synthetic methods lack flexibility and are therefore not suited to introduce 
diversity.
3
 As a consequence, the development of a high yielding, single step procedure for the introduction of a 
conformational constraint that forces the peptide to adopt a -turn is currently of considerable interest. 
In this thesis chapter is reported a straightforward procedure for constraining the conformation of tetrapeptides lacking a 
pre-formed scaffold. The resulting -turn mimetics include 2-oxo-1,3-oxazolidine-4-carboxylate rings (or oxazolidin-2-
one, in short: Oxd), that can be proposed as constrained pseudo-Pro residues.
4
 Pro strongly impacts the structural and 
conformational properties of peptide and protein backbones and their molecular recognition.
5
 It does not have a hydrogen 
on the amide group and therefore cannot act as a H-bond donor. The cyclic structure forces the angle to about -65°, 
therefore Pro is known as a classical breaker of both the -helical and -sheet structures in proteins and peptides, while it 
promotes the formation of -turns.2,6 Besides, due to the small free enthalpy difference between the cis and trans Xaa-Pro 
bond isomers of 2.0 kJ·mol
-1
 (compared to 10.0 kJ·mol
-1
 for other peptide bonds), there is a relatively high intrinsic 
probability of 30% cis conformation at r.t.
7
 Interestingly, the cis-trans interconversion of X-Pro is one of the rate-
determining steps in protein folding.
8
 
In order to understand the relationship between peptide bond geometry and bioactivity, many synthetic Pro analogues have 
been developed that provide restrictions of the Xaa-Pro conformation. In general, the modifications consist in ring 
substitutions with alkyl and aromatic groups, incorporation of heteroatoms, or the expansion or contraction of the five-
membered ring.
9
 
To take advantage of the conformational bias exerted by the Oxd pseudo-Pro, we planned to synthesize diastereomeric N-
sulfonyl tetrapeptides containing two consecutive Oxd rings, as -turn inducers. According to the stereochemistry array of 
the amino acids, the reaction of two -hydroxy -amino acids (Thr or threo-phenylserine, PhSer) already present within the 
sequences at the positions 2 and 3, with bis(succinimidyl)carbonate (DSC), afforded two consecutive Oxd or a 2,3-
dehydro-2-aminobutyric acid (Abu) in 2 and a Oxd in 3. These combinations resulted in highly constrained extended or 
folded structures, in particular turns or inverse turns of type I and II, and are especially interesting because they can control 
not only the  and  dihedral angles of the backbone but also the  angles of the side chains.  
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Peptides containing Oxd rings constitute a infrequent but remarkable class of peptidomimetics. They have found some 
applications in medicinal chemistry,
10
 in the construction of foldamers
11
 or as self-assembling scaffolds forming 
nanostructures.
12
 Also the compounds with the Abu-Oxd sequence are of some interest, since they contain two distinct 
secondary structure-forming elements. The dehydroamino acids are well known -turn inducers; for instance, sequential 
placement of dehydroPhe (Phe) in oligomers gave repeated -turns forming 310 helices.
13
 
4.2. Results and Discussion 
4.2.1. Synthesis of tetrapeptides containing di-Oxd and Abu-Oxd. 
Few years ago our research group has published the synthesis of Oxd rings directly within peptide sequences, by 
treatment of N-arylsulfonyl peptides containing L- or D-configured Ser with DSC and a catalytic amount of a base, in 
solution or in the solid phase (Scheme 1, path a).
4
  
 
Scheme 1. Different reactivity of the N-carbamate and N-sulfonyl oligopeptides. a) DSC, cat. base (B:). 
Apparently, the reaction was due to the presence of the N-sulfonyl group; indeed, the reaction of the corresponding Fmoc- 
or Boc-peptides under the same conditions with carbonates or dicarbonates gave elimination to dehydroalanine (Ala), as 
reported in the literature (Scheme 1, path b).
13
 Interestingly, peptides having the sulfonyl group directly connected to the 
Ser or separated by one or two amino acids, gave similar results (Scheme 1, Xaa = 0, 1, or 2 residues).
4 
This observation 
prompted us to perform in a single step the contemporary cyclization of sulfonyl-oligopeptides containing two 
consecutive ring-forming residues, to afford highly rigid structures. 
Accordingly, we prepared a series of distereomeric tetrapeptides containing two Thr residues, or Thr and threo-PhSer, at 
the positions 2 and 3, and we reacted the tetrapeptides (Scheme 2) with a moderate excess of DSC and a catalytic amount 
of diisopropylethylamine (DIPEA). The preparation of the N-tosyl tetrapeptides 1a-g was conducted by coupling the 
amino acids under MW irradiation, using a microwave oven specifically designed for organic synthesis,
14
 with 
HBTU/HOBt as activating agents (Experimental Section, Table 4). N-tosyl (Ts)-Ala was prepared as described in the 
literature;
15
 L- or D-threo-PhSer were obtained via optical resolution of the racemate,
16
 since the resolution by enzymatic 
hydrolysis
17
 gave poor results. 
The reaction of Ts-Ala-Thr-Thr-PheOMe (1a) with 2.2 equiv. of DSC in 3:1 DCM/DMF and in the presence of 0.1 equiv 
of DIPEA (Scheme 2, entry 1) provided the corresponding di-Oxd-containing Ts-Ala-Oxd-Oxd-PheOMe (2a) in excellent 
yield after isolation by flash chromatography (Table 1). 
 
Chapter 4  
 
30 
 
 
Scheme 2. Reactions of the sulfonyl-peptides 1a-e, containing L- or D-Thr at the positions 2 and 3, and of 1f,g containing 
L-Thr in 2 and threo L- or D-PhSer in 3, respectively. a) DSC, cat. DIPEA. 
On the other hand, the reaction of Ts-Ala-D-Thr-Thr-PheOMe (1b), under the same reaction conditions, gave exclusively 
a tetrapeptide containing Abu at position 2, Ts-Ala-Abu-Oxd-PheOMe (3b), while the tetrapeptide containing two Oxd 
(2b) was observed only in traces. (Scheme 2, and Table 1, entry 2). 
The reaction of Ts-Ala-Thr-D-Thr-PheOMe (1c) under the same conditions gave a 74:26 mixture of Ts-Ala-Oxd-D-Oxd-
PheOMe (2c) and Ts-Ala-Abu-D-Oxd-PheOMe (3c) (entry 3). The reaction outcome changed upon varying the solvent 
utilized; in pure DCM the yield of 2c increased up to 85% (entry 4), while in DMF the reaction afforded mainly 3c, with a 
78% yield (entry 5). 
The tetrapeptide Ts-Ala-Thr-D-Thr-D-PheOMe (1d) exclusively gave Ts-Ala-Oxd-D-Oxd-D-PheOMe (2d) (entry 6), 
while Ts-Ala-D-Thr-Thr-D-PheOMe (1e) failed in giving either 2 or 3 in significant amounts (entry 7) under diverse 
reaction conditions (not shown). 
Table 1. Synthesis of the constrained peptidomimetics 2 or 3 from the stereoisomers 1. 
entry 1 Ala
1 Thr2 Xaa3,  R Phe4 Solvent[a] 2 (%)[b] 3 (%)[b] 
1 a L L L Me L DCM/DMF 87 tr. 
2 b L D L Me L DCM/DMF - 90 
3 c L L D Me L DCM/DMF 67 23 
4 c “ “ “ Me “ DCM 85 9 
5 c “ “ “ Me “ DMF 5 78 
6 d L L D Me D DCM/DMF 90 - 
7 e L D L Me D DCM and/or 
DMF 
tr.[c] tr.[c] 
8 f L L L Ph L DCM/DMF 92 - 
9 g L L D Ph L DCM/DMF 93 tr. 
[a] All compounds 1a-g were tested in different solvent mixtures (3:1 DCM/DMF, DCM, DMF); with the exception of 
entries 3-5, the reaction outcomes were practically unaffected, therefore these results are not shown. [b] Determined after 
purification by flash chromatography over silica-gel; tr. = traces. [c] The rest being the reagent. 
 
Finally, the reaction was repeated with the sequences Ts-Ala-Thr-PhSer-PheOMe (1f) or Ts-Ala-Thr-D-PhSer-PheOMe 
(1g), which gave the di-Oxd compounds 2f and 2g in very satisfactory yields (entries 8 and 9). These peptides include a 
2-oxo-5-phenyloxazolidine-4-carboxylate residue at position 3, which might effectively represent a constrained Phe 
mimetic, with fixed , and  dihedral angles (Table 2). 
Table 2. Angles  and  of the residues i+1, i+2 observed for the compounds analyzed and ideal values. 
compd i+1  i+1  i+1  i+2  i+2  i+2
2a (A) -73 158 -114 -81 76 -115 
2a (B) -104 -179 -90 -40 -50 -140 
2c (C) -45 129 -122 69 -86 118 
2c (D) -51 144 -117 77 -27 110 
2d -55 139 -117 77 -29 113 
3b  -38 -59 -2 -96 29 -114 
3c (E) 61 55 2 93 -2 117 
3c (F) 37 63 0 81 -36 113 
I -60 -30 - -90 0 - 
II -60 120 - 80 0 - 
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This result suggests the opportunity to develop analogues of proteinogenic or unusual amino acids, carrying the side chain 
at the position 5 of the Oxd ring. Indeed, the literature reports many procedures for the stereocontrolled preparation of a 
variety of -hydroxy -amino acids.18 Nevertheless, the synthesis of Oxds functionalized with different side chains is 
beyond the scope of this work, which is primarily addressed to the synthesis of model tetrapeptides and investigation of 
the secondary structures. 
Epimerization during the reactions was excluded on the basis of the comparison of the NMR and HPLC analyses of the 
compounds, including the HPLC analysis on a chiral stationary phase (see General methods).  
From the comparison of the results (entries 1-9) it appeared that the stereochemistry array exerted a major bias in 
determining the cyclization versus the elimination in 2. Homochiral sequences at the positions 1 and 2 tended to give 
exclusively or predominantly the di-Oxd compounds, as observed for 1a, 1c, and 1d. On the contrary, the peptide 1e 
containing the sequence L-Ala-D-Thr failed in giving 2 or 3 in significant amounts, and 1b solely afforded the Abu-Oxd 
sequence. The diastereomeric peptides 1f, 1g containing PhSer behaved in a similar way as the corresponding peptides 1a 
and 1c (the formation of 3g was observed only in traces in different solvents).  
The proposed reaction mechanism of Scheme 1 path a, postulates that for n = 1 or 2, as occurring for the compounds 1a-
g, the electron-poor aromatic ring of the arylsulfonylamido group might effectively stabilize the anionic intermediate A 
by π-stacking interaction, thus driving to the Oxd ring. Possibly, the diastereoisomer 1b adopted in solution a 
conformation which allowed promoting the cyclization at position 3, but not in 2, therefore giving elimination, as 
expected on the basis of the literature. For 1c, the different results observed for the entries 3 to 5 could be attributed to a 
preference for different conformations in the different solvents. As for 1e, showing alternated absolute stereochemistry, it 
appeared that the compound was unable to attain the cyclization either in 2 or 3; the compound did not eliminate in a 
significant extent as well, as observed by treatment with different bases in different solvents at r.t. or under heating. 
The tosyl group was removed in good yield with iodotrimethylsilane,
19
 while the treatment with SmI2-pyrrolidine-water
20
 
was less efficient. 
4.2.2. Conformational analyses of the di-Oxd and Abu-Oxd peptides. 
To investigate the conformational bias exerted by the two consecutive L- or D-configured Oxd, or Abu and L- or D-Oxd 
residues at positions 2 and 3, on the overall structure of the peptides, we analyzed the model compounds 2a, 2c, 2d, and 
3b, 3c, by FT-IR and NMR spectroscopy.  
FT-IR spectroscopy was utilized to analyze the amide N-H stretching regions; generally, non H-bonded amide protons 
show a peak above 3400 cm
-1
, while H-bonded amide NH bonds exhibit a peak below 3400 cm
-1
.
21 
 
Figure 1. Amide NH stretching regions of the IR absorption spectra for samples of tetrapeptide 3c (3 mM in DCM, r.t.). 
The FT-IR absorption spectra of  2d only showed a strong band above 3400 cm
-1 
(Experimental section Figure 6). The 
spectra of 2a, 2c, 3b, and 3c (Experimental section Figure 6) showed a mayor peak at about 3400 cm
-1
,
 
 and a second 
peak at about 3340 cm
-1
. The latter became predominant in 3c, suggestive of a significant population of H-bonded 
conformations in equilibrium with non bonded structures. The spectra of 3c dissolved in DCM is reported in Figure 1.  
The 
1
H-NMR experiments were done at 400 MHz in CDCl3 or in 8:2 DMSO-d6/H2O. 2D gCOSY experiments were 
utilized for the unambiguous assignment of the resonances. In each solvent, all spectra showed a single set of sharp 
resonances, consistent with conformational homogeneity or a fast equilibrium between slightly different conformers. For 
most compounds, the 
1
H-NMR resonances showed modest variations of the chemical shifts in the two solvents (Table 5) 
suggesting that the peptidomimetic sequences were conformationally stable; exceptions are highlighted in Table 5. 
It has been shown that the Oxd confers the preceding amide bond a exclusive trans conformation.
11
 The 
1
H-NMR 
analyses of all of the compounds showed a significantly downfield position of the H proton of the residues preceding 
the Oxd rings (Experimental section Table 5). For instance, the resonances of AlaH in Ts-Ala-Thr-Thr-PheOMe (1a) 
and Ts-Ala-ΔAbu-L-(5'-Me-Oxd)-PheOMe (3b) appeared at about 3.9 and 3.8 p.p.m. (CDCl3), respectively, while in Ts-
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Ala-(5’-Me-Oxd2)-(5’-Me-Oxd3)-PheOMe (2a) AlaH was at about 5.2 p.p.m. On the other hand, in the same compound 
2a, Oxd
3
H4 was at 4.2 p.p.m, while Oxd
2
H4 was at about 5.3 p.p.m., for the deshielding effect of Oxd
3
C=O. These 
observations were compatible with a non-conventional, CH···O=C intramolecular H-bond,
22
 confirming the trans 
conformation of the amide bond between the Oxd and the preceding, deshielded residue. 
The occurrence of intramolecular H-bonds in 2a, 2c, 2d, 3b, and 3c, was evaluated by analyzing the variation of the NH 
proton chemical shifts upon addition of increasing percentages of DMSO-d6 to 2 mM solutions of the compounds in 
CDCl3. As representative example, the titration curves of 3c are shown in Figure 2. The titration of 2a gave no evidence 
of H-bonds involving PheNH nor AlaNH, since these signals exhibited a considerable downfield shift;
23
 2c, 2d gave 
similar results (Figure 8). On the contrary, the titration of 3c (Figure 2) and 3b (Figure 8) revealed that PheNH, but not 
AlaNH nor AbuNH, was much less sensitive, therefore less accessible, accounting for a H-bonded structure. 
Variable temperature (VT)-
1
H-NMR experiments in CDCl3 and 8:2 DMSO-d6/H2O were also utilized to deduce the 
presence of intramolecular H-bonds (Table 3). For almost all compounds, the comparatively lower VT-
1
H-NMR t 
parameters of PheNH with respect to AlaNH (and AbuNH) were suggestive of a moderate preference for conformations 
having PheNH involved in a H-bond t| < or close to 2.5 p.p.b..⁄K).21,24 The only exception was  observed for 2d in 
CDCl3, since the t (p.p.b..⁄K) of AlaNH was lower than that of PheNH (-1.7 and -2.7, respectively). 
From the comparison of the results above discussed for the Oxd-Oxd compounds (2), it appeared that the possible 
existence or not of H-bonds was differently supported by the methods employed. Reasonably, the inconsistencies 
reflected the existence of equilibria between H-bonded and non H-bonded structures. As for the Abu-Oxd compounds 
(3), all of the evidences were highly coherent in support of a H-bonded PheNH. 
 
Figure 2. Variation of NH proton chemical shift (p.p.m.) of 3c as a function of increasing percentages of DMSO-d6 to the 
CDCl3 solution (v/v). 
Table 3.t values (p.p.b..⁄K) for the amide protons of 2a, 2c, 2d, and 3b, 3c, in CDCl3 and 8:2 DMSO-d6/H2O; 
solvents: S1 = CDCl3; S2 = 8:2 DMSO-d6/H2O; amino acid stereochemistry has been omitted.  
 
 
To determine the preferred conformations in solution and their dynamic behaviours, the compounds were analyzed by 
2D-ROESY in 8:2 DMSO-d6/H2O and molecular dynamics (MD) simulations. DMSO-d6
 
or DMSO-d6/H2O
 
mixtures have 
been recommended by several authors as biomimetic media.
25
 Structures consistent with the spectroscopic analyses were 
obtained by MD using the distances derived from ROESY as constraints. The intensities of the ROESY cross-peaks were 
ranked to infer the distances (Tables 6-10). The  bonds were set at 180°, since the absence of Hi-H(i+1) cross-peaks 
excluded cis peptide bonds. Simulations were conducted in a box of explicit water molecules. Random structures were 
generated by unrestrained high-temperature MD; the structures were subjected to high-temperature restrained MD with a 
scaled force field, followed by a simulation with full restraints. Finally, the system was gradually cooled, and the 
structures were minimized with the AMBER force field.
26
 The results were clustered by the RMSD analysis of the 
backbone atoms.  
compd solvent Ala1NH Abu2NH Phe
4NH 
2a S1 -2.7 - -2.4 
 S2 -6.1 - -3.9 
3b S1 -13.5 -8.0 -3.8 
 S2 -5.0 -7.2 -4.1 
2c S1 -2.3 - -1.2 
 S2 -6.3 - -3.8 
3c S1 -9.0 -4.4 -4.0 
 S2 -6.5 -7.0 -4.1 
2d S1 -1.7 - -2.7 
 S2 -6.0 - -4.2 
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For Ts-Ala-(5’-Me-Oxd)-(5’-Me-Oxd)-PheOMe (2a), the analysis gave two clusters comprising all-together more than 
90% of the structures. For each cluster, the representative geometries A and B with the lowest internal energy were 
selected and analyzed (Figure 3). The occurrence of these two different structures, which differ almost exclusively by the 
opposite orientation of the Phe residue, reflected the observation of contradictory cross-peaks: the cross-peaks PheNH-
Oxd
3
H4 and PheNH-Oxd
3
H5 accounted for the conformation A, while the cross peak PheNH-Oxd
2
H5 was coherent with 
B. Possibly, the two structures represented conformers in fast equilibrium. 
To investigate the dynamic behaviour of 2a (A) and (B), unrestrained MD were performed for 10 ns in a box of standard 
TIP3P water molecules. The simulations showed the conversion of one conformation into the other. The analyses of the 
trajectories of the conformer (A) revealed very few structures compatible with a -turn centered on Oxd3 with a explicit 
H-bond between PheNH and Oxd
2
C=O, while (B) gave no evidence of secondary structures. 
 
 
Figure 3. Left. Representative low-energy structures of 2a (A and B), 2c (C), and 2d consistent with ROESY analysis, 
calculated by restrained MD; low energy structure of 2c (D) calculated by unrestrained MD. All structures determined in 
a 30×30×30 box of standard TIP3P water molecules. Backbones and Oxd are rendered in balls-and cylinders, the rest in 
sticks. The peptide bond connecting Oxd
2
-Oxd
3
 are shown horizontally and perpendicularly with respect to the viewer. 
Right. Schetches of the extended structure of 2a (A), and of the folded 2c (D) and 2d. 
For Ts-Ala-(5’-Me-Oxd)-D-(5’-Me-Oxd)-PheOMe (2c) and Ts-Ala-(5’-Me-Oxd)-(5’-Me-Oxd)-D-PheOMe (2d), the 
analyses gave one mayor clusters each comprising about 80% of the structures. For each compound’s cluster, the 
representative geometries with the lowest internal energy are shown in Figure 3. These structures 2c (C) and 2d are 
compatible with a well-defined type II-turn secondary structure (Table 10). The structures 2c (C) and 2d were analyzed 
by unrestrained MD; besides to the different random conformations, the analysis of the trajectories of 2c (C), but not of 
2d, revealed a explicit H-bond between PheNH and the AlaC=O, as shown in 2c (D), Figure 3. 
The conformational analyses of the peptides 3b, 3c containing in their sequences Abu2 and L- or D-Oxd3, respectively, 
gave one cluster each, comprising the large majority of the structures; the representative geometries are shown in Figure 
4. The calculated geometry of Abu closely matched that of dehydroamino acids reported in the literature.13,27 
The structure 3b, stabilized by a explicit H-bond between AlaC=O and PheNH, was compatible with a type I -turn. The 
structure of 3c (E) nicely reproduced a inverse type I -turn (Table 10), and showed a H-bond between AlaC=O and 
PheNH. The unrestrained MD simulations revealed also a tendency for structures characterized by a H-bond between 
PheC=O and AlaNH, such as the representative 3c (F), Figure 4.  
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Figure 4. Left. Representative low-energy structures of 3b and 3c (E) consistent with ROESY analysis, calculated by 
restrained MD; low energy structure of 3c (F) calculated by unrestrained MD. All structures determined in a 30×30×30 
box of standard TIP3P water molecules. Backbones and Oxd are rendered in balls-and cylinders, the rest in sticks. The 
peptide bond connecting Abu2-Oxd3 are shown horizontally and perpendicularly with respect to the viewer. Right. 
Schetches of the folded structures 3b and 3c (E). 
To further confirm the presence of folded structures, we used Electronic Circular Dichroism (ECD) spectroscopy. Spectra 
of model peptides 2a, 2d, and 3b, were recorded both in dichloromethane and in methanol.   
The spectra in dichloromethane (Figure 5) showed a negative band centered at about 230 nm, less intense for 2a. These 
spectral features could be indicative of a significant population of bent conformers, in particular in the case of 2d and 3b. 
In fact, a negative nπ* ECD band near 225 nm is generally observed in the presence of β-turn structures (I or II type).21,28 
The observed different intensities of ECD signals were in agreement with ROESY and MD data which evidenced 
homogeneous conformations for 2d and 3b. 
By moving from dichloromethane to methanol, intensities of the negative ECD bands slightly reduced for all compounds 
(Experimental section, Figure 7). This spectral behavior could be ascribed to a dependence of the conformer population 
on the polarity and/or the competitive nature of the solvent. 
 
Figure 5. ECD spectra recorded in dichloromethane at room temperature (2a dotted line, 3b dashed line, 2d full line). 
Taken together, all of the experimental evidences support that the peptides 3 containing the Abu at the position 2 formed 
highly stable type I -turns reinforced by H-bonds, normal or inverse depending on the stereochemistry of the Oxd3. This 
result is particularly gratifying, since the formation of the Abu-Oxd motif was somewhat unpredictable. 
On the other hand, the data of the peptides 2 collected by ROESY/MD analyses confirmed a certain flexibility of the Phe
4
 
residue. This observation could explain the discrepancies in the determination of H-bonds by IR, VT-NMR, and NMR 
titration experiments. Nevertheless, the results highlighted the rigidity of the Ala-Oxd-Oxd portions; the rotation of the 
Ala and the two Oxd rings one respect to the other was not observed during the unrestrained MD simulations. The 
conformational homogeneity was correlated to the strong preference for all-trans conformations stabilized by the weak 
interactions between the Oxd carbonyls and the H protons of the preceding residues. 
In particular, the heterochiral Oxd
2
-D-Oxd
3 
scaffold induced a stable and well defined type II -turn, albeit the H-bond 
between the residues i-i+3 was relatively loose. This ability to promote folded structures makes sense, and is consistent 
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with the observations on previously described Oxd-peptides.
11,12
 The Oxd ring can be regarded to as a pseudo-Pro; it is 
well known that heterochiral linear oligopeptides including a Pro show higher propensity to fold compared to the 
homochiral sequences.
21,24
  
4.3. Conclusions 
In this chapter is reported a straightforward, one-step procedure for constraining a peptide backbone without the need for a 
pre-formed scaffold. The cyclization of two consecutive -hydroxy amino acid residues (L/D-Thr or threo-L/D-PhSer) 
embedded in N-arylsulfonyl tetrapeptide sequences, afforded in excellent yields the peptides containing Oxd
2
-L/D-Oxd
3
 (2) 
or Abu2-L/D-Oxd3 (3), according to the stereochemistry array of the precursors. 
Conformational analyses of the model peptides revealed that the homochiral Oxd
2
-Oxd
3
 dipeptidomimetic induced a 
extended disposition of the backbone. The heterochiral sequences exerted a strong conformational control, giving rise to 
type II -turns. The unrestrained MD simulations confirmed the rigidity of the conformations, since the rotation of the two 
Oxd rings one with respect to the other was not observed during the simulations. On the other hand, the sequence Abu2-
Oxd
3
 induced highly stable -turns of type I, stabilized by clear H-bonds. 
For their ability to control the  and  dihedral angles of the backbone as well as the dihedral angles of side chains, 
peptide mimetics based on the structures of the model peptides 2 and 3 might find applications in medicinal chemistry as 
3D rigid scaffolds, in the field of the foldamers, or as self-assembling scaffolds to form nanostructures. 
4.4. Experimental section 
4.4.1. General Methods 
Unless stated otherwise, standard chemicals were obtained from commercial sources and used without further 
purification. Flash chromatography was performed on silica gel (230-400 mesh), using mixtures of distilled solvents. 
Analytical RP-HPLC was performed on an ODS column (4.6 μm particle size, 100 Å pore diameter, 250 μm, DAD 210 
nm, from a 9:1 H2O-CH3CN to a 2:8 H2O-CH3CN in 20 min) at a flow rate of 1.0 mL min-1, followed by 10 min at the 
same composition. Semi-preparative RP-HPLC was performed on a C18 column (7 μm particle size, 21.2 mm × 150 mm, 
from 8:2 H2O-CH3CN to 100% CH3CN in 10 min) at a flow rate of 12 mL min−
1
. Purities were assessed by analytical 
RP-HPLC under the above reported conditions and elemental analysis. Chiral HPLC analysis was performed on a 
CHIRALPAK IC column (0.46 cm × 25 cm), 1:1 n-hexane/2-propanol, at 0.8 mL min-1. Semi-preparative and analytical 
RP-HPLC of the peptide 14 was performed as reported above, with the addition of 0.1% TFA in the mobile phase. 
Elemental analyses were performer using a Thermo Flash 2000 CHNS/O analyzer. High-quality IR were obtained at 2 
cm−1 resolution using a FT-IR spectrometer  and 1 mm NaCl solution cell. 1H-NMR spectra were recorded on a Varian 
instrument at 400MHz, 
13
C-NMR spectra at 100 MHz. Circular Dichroism (CD) spectra were recorded on a Jasco J-710 
spectropolarimeter. The synthetic procedure by MW irradiation was performed using a microwave oven (MicroSYNTH 
Microwave Labstation for Synthesis).  
4.4.2. Synthetic procedures 
Synthesis of the peptides 1a-g.A stirred solution of the N-protected amino acid in 4:1 DCM-DMF (5 mL) was treated with 
HOBt (1.2 equiv.) and HBTU (1.2 equiv.), at r.t. and under inert atmosphere. After 5 min, the C-protected amino acid 
(1.1 equiv.) and DIPEA (2.4 equiv.) were added, and the mixture was stirred under inert atmosphere and under MW 
irradiation (150W). After  10 min, the mixture was concentrated at reduced pressure, and the residue was diluted with 
EtOAc (25 mL). The solution was washed with 0.1 M HCl (5 mL), and a saturated solution of NaHCO3 (5 mL). The 
organic layer was dried over Na2SO4 and the solvent was evaporated at reduced pressure. The crude peptides were 
analyzed by HPLC-MS analysis, and were used without further purifications. 
Table 4. RP-HPLC and ES-MS analyses of the linear peptides 1a-f. 
1 ES-MS m/z 
[M+1] vs 
calcd 
Puritya 
(%) 
1 
 
ES-MS 
[M+1] vs 
calcd 
Puritya 
(%) 
a  607.3/607.2 85 e 607.2/607.2 84 
b 607.2/607.2 83 f 669.3/669.3 84 
c 607.3/607.2 81 g 669.4/669.3 83 
d  607.1/607.2 80    
a
 Determined by analytical RP-HPLC, see General methods. 
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The intermediate N-Boc peptides were deprotected by treatment with 1:2 TFA-DCM (5 mL), while stirring at r.t. After 15 
min, the solution was evaporated under reduced pressure, and the treatment was repeated. The residue was suspended in 
Et2O (20 mL). The peptide-TFA salts were collected by centrifuge, and used for the next couplings without further 
purifications (80-85% pure, Table 4). 
Synthesis of Ts-Ala-Oxd-(5’-R-Oxd)-PheOMe (2a,c,d,f,g), Ts-Ala-Abu-(5’-Me-Oxd)-PheOMe (3b,c). DSC (0.73 mmol) 
was added to a stirred solution of 1 (0.33 mmol) in the solvent mixture of Table 1 (4 mL) followed by DIPEA (0.07 
mmol) at r.t. and under inert atmosphere. After 3 h, the solvent was removed under reduced pressure, the residue was 
diluted with 0.1 M HCl (5 mL), and the mixture was extracted three times with DCM (5 mL). The combined organic 
layers were dried over sodium sulfate, filtered, and concentrated at reduced pressure. The residue was purified by semi-
preparative RP-HPLC (see General methods), giving 2 (85-93%, see Table 1, 94-97% pure by analytical RP-HPLC) or 3 
(78-90%, see Table 1, 95-98% pure by analytical RP-HPLC), as waxy solids. 
Ts-Ala-(5’-Me-Oxd2)-(5’-Me-Oxd3)-PheOMe (2a). IR (CH2Cl2) ν: 3406, 3335, 1789, 1736, 1703, 1670 cm
−1
; 
1
H-NMR 
(CDCl3) δ: 1.43 (d, J=6.8 Hz, 3H, AlaMe), 1.52 (d, J=6.3 Hz, 6H, Oxd
2
Me+Oxd
3
Me), 2.43 (s, 3H, TsMe), 3.11 (dd, 
J=5.5, 14.1 Hz, 1H, PheHβ), 3.15 (dd, J=5.4, 14.1 Hz, 1H, PheHβ), 3.77 (s, 3H, OMe), 4.26 (d, J=3.7 Hz, 1H, Oxd3H4), 
4.58 (dq, J=2.1, 6.3 Hz, 1H, Oxd
2
H5), 4.75 (dq, J=3.7, 6.3 Hz, 1H, Oxd
3
H5), 4.85 (q, J=7.6 Hz, 1H, PheHα), 5.22 (dq, 
J=6.8, 10.4 Hz, 1H, AlaHα), 5.26 (d, J=2.1 Hz, 1H, Oxd2H4), 5.39 (d, J=10.4 Hz, 1H, AlaNH), 6.28 (d, J=7.6 Hz, 1H, 
PheNH), 7.04-7.11 (m, 2H, PheArH), 7.21-7.26 (m, 3H, PheArH), 7.31 (d, J=8.0 Hz, 2H, TsArH), 7.75 (d, J=8.0 Hz, 2H, 
TsArH); 
1
H-NMR (8:2 DMSO-d6/H2O) δ: 1.18 (d, J=6.7 Hz, 3H, AlaMe), 1.44-1-47 (m, 6H, Oxd
3
Me+Oxd
2
Me), 2.37 (s, 
3H, TsMe), 2.94 (dd, J=8.4, 13.9 Hz, 1H, PheHβ), 3.01 (dd, J=5.7, 13.9 Hz, 1H, PheHβ), 3.56 (s, 3H, OMe), 4.48-4.52 
(m, 2H, PheHα+Oxd3H5), 4.57 (d, J=1.9 Hz, 1H, Oxd
3
H4), 4.66 (dq, J=2.0, 7.0 Hz, 1H, Oxd
2
H5), 5.02 (dq, J=6.7, 8.5 Hz, 
1H, AlaHα), 5.17 (d, J=2.0 Hz, 1H, Oxd2H4), 7.11 (d, J=7.6 Hz, 2H, PheArH), 7.14-7.26 (m, 3H, PheArH) 7.37 (d, J=8.0 
Hz, 2H, TsArH), 7.63 (d, J=8.0 Hz, 2H, TsArH), 8.36 (d, J=8.5 Hz, 1H, AlaNH), 8.98 (d, J=7.0 Hz, 1H, PheNH). 
13
C-
NMR (DMSO-d6) δ: 18.5, 20.5, 21.3, 21.4, 36.9, 50.1, 52.5, 54.3, 61.0, 61.6, 74.7, 76.6, 126.0, 127.2, 128.6, 128.8, 
129.6, 130.1, 137.0, 138.2, 143.5, 152.0, 153.2, 167.4, 167.7, 171.7, 172.4; ES-MS (m/z) 659.3 [M+1], calcd 659.2; 
Elem. Anal. for C30H34N4O11S , calcd: C 54.70, H 5.20, N 8.51, S 4.87; found: C 54.67, H 5.17, N 8.45, S 4.81. 
Ts-Ala-ΔAbu-(5'-Me-Oxd)-PheOMe (3b). IR (CH2Cl2) ν: 3407, 3318, 1789, 1748, 1708 cm
−1
; 
1
H-NMR (CDCl3) δ: 1.23 
(d, J=6.8 Hz, 3H, AlaMe), 1.43 (d, J=6.0 Hz, 3H, OxdMe), 1.79 (d, J=7.2 Hz, 3H, ΔAbuMe), 2.43 (s, 3H, TsMe), 3.03 
(dd, J=8.2, 13.8 Hz, 1H, PheHβ), 3.23 (dd, J=5.4, 13.8 Hz, 1H, PheHβ), 3.71 (s, 3H, OMe), 3.85 (quint, J=7.2 Hz, 1H, 
AlaHα), 4.36-4.41 (m, 2H, OxdH4,5), 4.84 (q, J=8.2 Hz, 1H, PheHα), 5.92 (d, J=6.8 Hz, 1H, AlaNH), 6.04 (q, J=7.2 Hz, 
1H, ΔAbuHβ), 7.14-7.22 (m, 2H, PheArH), 7.24-7.34 (m, 5H, PheArH+TsArH), 7.64 (d, J=8.0 Hz, 1H, PheNH), 7.77 (d, 
J=7.6 Hz, 2H, TsArH), 8.66 (s, 1H, ΔAbuNH); 1H-NMR (8:2 DMSO-d6/H2O) δ: 1.03 (d, J=7.2 Hz, 3H, AlaMe), 1.36 (d, 
J=6.2 Hz, 3H, OxdMe), 1.66 (d, J=7.2 Hz, 3H, ΔAbuMe), 2.40 (s, 3H, TsMe), 2.98 (dd, J=7.2, 14.0 Hz, 1H, PheHβ), 3.04 
(dd, J=6.0, 14.0 Hz, 1H, PheHβ), 3.59 (s, 3H, OMe), 3.90 (quint, J=6.4 Hz, 1H, AlaHα), 4.33 (dq, J=2.8, 6.2 Hz, 1H, 
OxdH5), 4.42 (d, J=2.8 Hz, 1H, OxdH4), 4.54 (q, J=7.4 Hz, 1H, PheHα), 5.71 (q, J=7.2 Hz, 1H, ΔAbuHβ), 7.18-7.25 (m, 
3H, PheArH), 7.31 (t, J=7.4 Hz, 2H, PheArH), 7.38 (d, J=8.1 Hz, 2H, TsArH), 7.68 (d, J=8.1 Hz, 2H, TsArH), 7.94 (d, 
J=7.6 Hz, 1H, AlaNH), 8.78 (d, J=7.2 Hz, 1H, PheNH), 9.53 (s, 1H, ΔAbuNH).  13C-NMR (DMSO-d6) δ: 12.8, 19.4, 
20.3, 37.0, 51.9, 52.4, 54.1, 62.1, 75.0, 120.5, 126.9, 127.2, 128.8, 129.6, 130.1, 130.5, 134.1, 137.1, 138.7, 143.2, 151.8,  
168.6, 170.8, 170.9, 171.9; ES-MS (m/z) 615.4 [M+1], calcd 615.2; Elem. Anal. for C29H34N4O9S, calcd: C 56.67, H 
5.58, N 9.11, S 5.22; found: C 56.78, H 5.56, N 9.08, S 5.18.  
Ts-Ala-(5’-Me-Oxd2)-D-(5’-Me-Oxd3)-PheOMe (2c) IR (CH2Cl2) ν 3406, 3347, 1793, 1736, 1707 cm
−1
; 
1
H-NMR 
(CDCl3) δ: 1.33 (d, J=6.6 Hz, 3H, AlaMe), 1.47 (d, J=6.2 Hz, 3H, Oxd
2
Me), 1.53 (d, J=6.4 Hz, 3H, Oxd
3
Me), 2.42 (s, 3H, 
TsMe), 3.01 (dd, J=6.4, 14.1 Hz, 1H, PheHβ), 3.20 (dd, J=6.4, 14.1 Hz, 1H, PheHβ), 3.77 (s, 3H, OMe), 4.29 (d, J=4.8 
Hz, 1H, Oxd
3
H4), 4.53 (dq, J=2.4, 6.4 Hz, 1H, Oxd
2
H5), 4.64 (quint, 1H, J=6.2 Hz, Oxd
3
H5), 4.82 (q, J=6.4 Hz, 1H, 
PheHα), 5.11 (dq, J=6.8, 13.6 Hz, 1H, AlaHα), 5.24 (d, J=2.4 Hz, 1H, Oxd2H4), 5.44 (d, J=10.0 Hz, 1H, AlaNH), 6.55 (d, 
J=7.6 Hz, 1H, PheNH), 7.09 (d, J=7.2 Hz, 2H, PheArH), 7.24-7.31 (m, 5H, PheArH+TsArH), 7.73 (d, J=7.6 Hz, 2H, 
TsArH); 
1
H-NMR(8:2 DMSO-d6/H2O) δ: 1.17 (d, J=6.8 Hz, 3H, AlaMe), 1.35 (d, J=6.2 Hz, 3H, Oxd
2
Me), 1.39 (d, J=6.4 
Hz, 3H, Oxd
3
Me), 2.36 (s, 3H, TsMe), 2.83 (dd, J=8.1, 13.8 Hz, 1H, PheHβ), 3.11 (dd, J=8.1, 13.8 Hz, 1H, PheHβ), 3.63 
(s, 3H, OMe), 3.84 (quint, J=5.6 Hz, 1H, Oxd
3
H5), 4.36 (d, J=4.8 Hz, 1H, Oxd
3
H4), 4.51 (dq, J=8.1, 9.6 Hz, 1H, PheHα), 
4.95-5.03 (m, 2H, Oxd
2
H4+AlaHα), 5.06 (q, 1H, J=6.2 Hz, Oxd
2
H5), 7.17 (d, J=6.8 Hz, 2H, PheArH), 7.19-7.30 (m, 3H, 
PheArH), 7.37 (d, J=8.2 Hz, 2H, TsArH), 7.62 (d, J=8.2 Hz, 2H, TsArH), 8.42 (d, J=9.2 Hz, 1H, AlaNH), 8.94 (d, J=8.1 
Hz, 1H, PheNH).
13
C-NMR (DMSO-d6) δ: 18.5, 20.4, 20.5, 21.4, 37.4, 50.3, 52.6, 53.8, 61.3, 62.0, 69.4, 70.1, 127.2, 
128.4, 128.7, 129.8, 130.1, 137.4, 138.3, 143.5, 152.3, 153.3, 166.5, 167.1, 171.7, 172.0; ES-MS (m/z) 659.4 [M+1], 
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calcd 659.2; Elem. Anal. for C30H34N4O11S , calcd: C 54.70, H 5.20, N 8.51, S 4.87; found: C 54.60, H 5.14, N 8.44, S 
4.81. 
Ts-Ala-ΔAbu-D-(5'-Me-Oxd)-PheOMe (3c). IR (CH2Cl2) ν: 3400, 3334, 1781, 1744, 1707 cm
−1
; 
1
H-NMR (CDCl3) δ: 
1.28 (d, J=7.2 Hz, 3H, AlaMe), 1.54 (d, J=6.0 Hz, 3H, OxdMe), 1.89 (d, J=7.2 Hz, 3H, ΔAbuMe), 2.46 (s, 3H, TsMe), 
3.09 (dd, J=9.0, 13.8 Hz, 1H, PheHβ), 3.18 (dd, J=6.2, 13.8 Hz, 1H, PheHβ), 3.72 (s, 3H, OMe), 3.87 (m, 1H, AlaHα), 
4.45 (d, J=7.2 Hz, 1H, OxdH4), 4.59 (quint, J=6.5 Hz, 1H, OxdH5), 4.79 (q, J=8.4 Hz, 1H, PheHα), 5.66 (br.d, 1H, 
AlaNH), 6.27 (q, J=6.6 Hz, 1H, ΔAbuHβ), 7.21 (d, J=8.4, 2H, PheArH), 7.23-7.33 (m, 3H, PheArH), 7.35 (d, J=7.8 Hz, 
2H, TsArH), 7.80 (d, J=7.8 Hz, 2H, TsArH), 7.98 (d, J=8.0 Hz, 1H, PheNH), 8.28 (s, 1H, ΔAbuNH); 1H-NMR(8:2 
DMSO-d6/H2O) δ: 1.03 (d, J=7.2 Hz, 3H, AlaMe), 1.20 (d, J=6.0 Hz, 3H, OxdMe), 1.67 (d, J=7.2 Hz, 3H, ΔAbuMe), 
2.36 (s, 3H, TsMe), 2.85 (dd, J=10.4, 13.5 Hz, 1H, PheHβ), 3.12 (dd, J=4.8, 13.5 Hz, 1H, PheHβ), 3.58-3.69 (m, 4H, 
OxdH5+OMe), 3.99 (quint, J=7.1 Hz, 1H, AlaHα), 4.25 (d, J=2.0 Hz, 1H, OxdH4), 4.58 (m, 1H, PheHα), 5.65 (q, J=6.8 
Hz, 1H, ΔAbuHβ), 7.13-7.24 (m, 2H, PheArH), 7.28 (t, J=7.0 Hz, 2H, PheArH), 7.35 (d, J=6.6 Hz, 2H, TsArH), 7.65 (d, 
J=6.6 Hz, 2H, TsArH), 7.93 (d, J=8.4 Hz, 1H, AlaNH), 8.85 (d, J=8.4 Hz, 1H, PheNH), 9.73 (s, 1H, ΔAbuNH).13C-NMR 
(DMSO-d6) δ: 12.8, 16.9, 21.5, 25.7, 37.8, 52.8, 54.7 56.9, 62.0, 75.2, 121.9, 126.0, 127.0, 128.7, 129.9, 132.0, 134.4, 
136.3, 143.0, 154.8, 168.4, 170.8, 171.6; ES-MS (m/z) 615.4 [M+1], calcd 615.2; Elem. Anal. for C29H34N4O9S , calcd: C 
56.67, H 5.58, N 9.11, S 5.22; found: C 56.60, H 5.52, N 9.02, S 5.15. 
Ts-Ala-(5’-Me-Oxd2)-D-(5’-Me-Oxd3)-D-PheOMe (2d). IR (CH2Cl2) ν: 3409, 1776, 1747, 1707, 1608, 1420 cm
−1
; 
1
H-
NMR (CDCl3) δ: 1.40 (d, J=7.0 Hz, 3H, AlaMe), 1.46 (d, J=6.0 Hz, 3H, Oxd
3
Me), 1.58 (d, J=6.3 Hz, 3H, Oxd
2
Me), 2.44 
(s, 3H, TsMe), 3.05 (dd, J=8.3, 13.9 Hz, 1H, PheHβ), 3.17 (dd, J=5.3, 13.9 Hz, 1H, PheHβ), 3.74 (s, 3H, OMe), 4.29-4.37 
(m, 2H, Oxd
3
H4,5), 4.58 (dq, J=3.5, 6.3 Hz, 1H, Oxd
2
H5), 4.88 (ddd, J=5.3, 8.3, 8.5 Hz, 1H, PheHα), 5.16 (dq, J=7.0, 10.8 
Hz, 1H, AlaHα), 5.42 (d, J=3.5 Hz, 1H, Oxd2H4), 5.61 (d, J=10.8 Hz, 1H, AlaNH), 6.63 (d, J=8.5 Hz, 1H, PheNH), 7.14 
(d, J=6.6 Hz, 2H, PheArH), 7.22-7.37 (m, 5H, PheArH+TsArH), 7.76 (d, J=8.0 Hz, 2H, TsArH);
 1
H-NMR (8:2 DMSO-
d6/H2O) δ: 1.15 (d, J=6.6 Hz, 3H, AlaMe), 1.40 (d, J=6.2 Hz, 3H, Oxd
2
Me), 1.46 (d, J=6.0 Hz, 3H, Oxd
3
Me), 2.37 (s, 3H, 
TsMe), 2.97 (d, J=6.8 Hz, 2H, PheHβ), 3.58 (s, 3H, OMe), 4.46-4.52 (m, 3H, PheHα+Oxd3H4,5), 5.02 (m, 1H, AlaHα), 
5.03 (d, J=1.6 Hz, 1H, Oxd
2
H4), 5.10 (dq, J=1.6, 6.2 Hz, 1H, Oxd
2
H5), 7.18 (d, J=6.7 Hz, 2H, PheArH), 7.19-7.23 (m, 3H, 
PheArH), 7.37 (d, J=8.2 Hz, 2H, TsArH), 7.62 (d, J=8.2 Hz, 2H, TsArH), 8.41 (d, J=9.6 Hz, 1H, AlaNH), 8.89 (d, J=7.6 
Hz, 1H, PheNH). 
13
C-NMR (CDCl3) δ: 18.9, 20.6, 20.9, 21.5, 37.9, 51.1, 52.6, 53.4, 61.1, 62.4, 74.2, 76.0, 127.2, 127.4, 
128.6, 129.3, 129.7, 135.6, 136.9, 143.8, 151.1, 152.0, 165.7, 168.1, 171.4, 173.8; ES-MS (m/z) 659.3 [M+1], calcd 
659.2; Elem. Anal. for C30H34N4O11S , calcd: C 54.70, H 5.20, N 8.51, S 4.87; found: C 54.65, H 5.26, N 8.50, S 4.82. 
Ts-Ala-(5’-Me-Oxd2)-(5’-Ph-Oxd3)-PheOMe (2f). IR (CH2Cl2) ν: 3407, 3350, 1790, 1740, 1699, 1660 cm
−1
; 
1
H-NMR 
(CDCl3) δ: 1.41 (d, J=7.2 Hz, 3H, AlaMe), 1.55 (d, J=6.2 Hz, 6H, Oxd
2
Me), 2.43 (s, 3H, TsMe), 3.12 (d, J=5.6 Hz, 2H, 
PheHβ), 3.78 (s, 3H, OMe), 4.53 (d, J=4.4 Hz, 1H, Oxd3H4), 4.66 (dq, J=2.0, 6.2 Hz, 1H, Oxd
2
H5), 4.90 (q, J=7.6 Hz, 1H, 
PheHα), 5.24 (dq, J=7.6, 10.8 Hz, 1H, AlaHα), 5.35 (d, J=2.0 Hz, 1H, Oxd2H4), 5.41 (d, J=10.8 Hz, 1H, AlaNH), 5.57 (d, 
J=4.4 Hz, 1H, Oxd
3
H5), 6.31 (d, J=7.7 Hz, 1H, PheNH), 7.04-7.12 (m, 2H, PheArH), 7.20-7.30 (m, 5H, PheArH+5’-
PhArH), 7.31 (d, J=8.0 Hz, 2H, TsArH), 7.39-7.44 (m, 3H, 5’-PhArH), 7.77 (d, J=8.0 Hz, 2H, TsArH); 13C-NMR 
(CDCl3) δ: 19.5, 21.1, 21.5, 37.2, 50.6, 52.7, 53.7, 61.2, 65.8, 73.8, 79.0, 125.2, 127.3, 127.6, 129.1, 129.4, 129.5, 129.9, 
130.1, 135.9, 136.6, 143.8, 151.1, 152.3, 166.1, 167.4, 173.1, 173.4; ES-MS (m/z) 721.2 [M+1], calcd 721.2; Elem. Anal. 
for C35H36N4O11S, calcd: C 58.32, H 5.03, N 7.77, S, 4.45; found: C 58.29, H 5.09, N 7.80, S, 4.40. 
Ts-Ala-(5’-Me-Oxd2)-D-(5’-Ph-Oxd3)-PheOMe (2g). IR (CH2Cl2) ν: 3409, 3345, 1779, 1730, 1700, 1656 cm
−1
; 
1
H-NMR 
(CDCl3) δ: 1.30 (d, J=7.3 Hz, 3H, AlaMe), 1.52 (d, J=6.4 Hz, 3H, Oxd
2
Me), 2.43 (s, 3H, TsMe), 3.03 (dd, J=7.2, 14.4 Hz, 
2H, PheHβ), 3.23 (dd, J=6.0, 14.4 Hz, 2H, PheHβ), 3.76 (s, 3H, OMe), 4.53-4.61 (m, 2H, Oxd2H5+Oxd
3
H4), 4.88 (q, 
J=7.6 Hz, 1H, PheHα), 5.13 (dq, J=7.6, 10.8 Hz, 1H, AlaHα), 5.29 (d, J=2.4 Hz, 1H, Oxd2H4), 5.50-5.58 (m, 2H, 
AlaNH+Oxd
3
H5), 6.63 (d, J=7.7 Hz, 1H, PheNH), 7.04-7.11 (m, 2H, PheArH), 7.15-7.20 (m, 2H, 5’-PhArH), 7.20-7.25 
(m, 3H, PheArH), 7.31 (d, J=8.0 Hz, 2H, TsArH), 7.39-7.43 (m, 3H, 5’-PhArH), 7.76 (d, J=8.0 Hz, 2H, TsArH); 13C-
NMR (CDCl3) δ: 19.3, 20.6, 21.5, 37.6, 50.7, 53.3, 53.5, 60.8, 63.4, 71.8, 79.0, 125.3, 127.4, 128.7, 129.2, 129.5, 129.7, 
130.1, 134.7, 135.7, 136.7, 143.6, 151.3, 152.3, 165.4, 167.0, 171.2, 173.1; ES-MS (m/z) 721.3 [M+1], calcd 721.2; 
Elem. Anal. for C35H36N4O11S, calcd: C 58.32, H 5.03, N 7.77, S, 4.45; found: C 58.22, H 5.07, N 7.71, S, 4.49. 
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4.4.3. Conformational analysis  
IR analyses. Infrared spectra were obtained at 2 cm
−1
 resolution using a 1 mm NaCl solution cell and a FT-IR 
spectrometer (64 scans). All spectra were obtained in 3 mM solutions in dry CH2Cl2 at 297 K. The compounds were dried 
in vacuo, and all the sample preparations were performed in a inert atmosphere. 
 
 
Figure 6. Amide NH stretching regions of the IR absorption spectra for samples of tetrapeptides 2a, 2d and 3b (3 mM in 
DCM) at room temperature. 
Circular Dichroism. ECD spectra were recorded from 200 to 400 nm at 25 °C. 1 mM solutions were made up in spectral 
grade solvents and run in a 0.1 cm quartz cell. Data are reported in molar ellipticity [] (degcm2dmol-1). 
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Figure 7. ECD spectra of 2a, 3b, and 2d; 1 mM in DCM or MeOH, path length 0.1 cm. 
NMR analyses. 
1
H-NMR spectra were recorded at 400 MHz in 5 mm tubes, using 0.01 M peptide at room temperature. 
Solvent suppression was performed by the solvent presaturation procedure implemented in Varian (PRESAT). 
13
C-NMR 
spectra were recorded at 100 MHz. Chemical shifts are reported as δ values. The unambiguous assignment of 1H-NMR 
resonances was performed by 2D gCOSY, HMBC, and HSQC. gCOSY experiments were conducted with a proton 
spectral width of 3103 Hz. VT-
1
H-NMR experiments were performed over the range of 298-348 °K. 2D spectra were 
recorded in the phase sensitive mode and processed using a 90°-shifted, squared sine-bell apodization. 2D ROESY 
experiments were recorded in 8:2 DMSO-d6/H2O, with a 250 ms mixing time with a proton spectral width of 3088 Hz. 
Peaks were calibrated on DMSO. 
Table 5. Selected 
1
H-NMR chemical shifts () of the model compds 2a, 2c, 2d, and 3b, 3c; solvents: S1 = CDCl3; S2 = 
8:2 DMSO-d6/H2O; amino acid stereochemistry has been omitted. 
              2a               2c               2d               3b              3c  
 S1 S2 S1 S2 S1 S2 S1 S2 S1 S2 
Ala1NH 5.39 8.36 5.44 8.42 5.61 8.41 5.92 7.94 5.66 7.93 
Ala1H 5.22 5.02 5.11 5.0 5.16 5.02 3.85 3.90 3.87 3.99 
Oxd2H4 5.26 5.17 5.24 5.0 5.42 5.03 - - - - 
Oxd2H5 4.58 4.66 4.53 5.06 4.58 5.10 - - - - 
AbuNH - - - - - - 8.66 9.53 8.28 9.73 
AbuH - - - - - - 6.04 5.71 6.27 5.65 
Oxd3H4 4.26 4.57 4.29 4.36 4.3 4.5 4.38 4.42 4.4 4.25 
Oxd3H5 4.75 4.5 4.64 3.84 4.3 4.5 4.4 4.33 4.6 3.6 
Phe4NH 6.28 8.98 6.55 8.94 6.63 8.89 7.64 8.78 7.98 8.85 
Phe4H 4.85 4.5 4.82 4.51 4.88 4.5 4.84 4.54 4.79 4.58 
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Figure 8. Variation of NH proton chemical shift (p.p.m.) of 2a, 2c, 2d and 3b as a function of increasing percentages of 
DMSO-d6 to the CDCl3 solution (v/v). 
ROESY and molecular dynamics. Only ROESY-derived constraints were included in the restrained molecular dynamics. 
Cross-peak intensities were classified very strong, strong, medium, and weak, and were associated with distances of 2.2, 
2.6, 3.0, and 4.5 Å, respectively. Geminal couplings and other obvious correlations were discarded. For the absence of 
H(i, i+1) ROESY cross peaks, all of the  bonds were set at 180° (force constant: 16 kcal mol-1Å-2). The restrained MD 
simulations were conducted using the AMBER force field in a 30×30×30 Å box of standard TIP3P models of equilibrated 
water.
29
 All water molecules with atoms that come closer than 2.3 Å to a solute atom were eliminated. A 100 ps 
simulation at 1200 °K was used for generating 50 random structures that were subsequently subjected to a 50 ps 
restrained MD with a 50 % scaled force field at the same temperature, followed by 50 ps with full restraints (distance 
force constant of 7 kcal mol
-1
 Å
-2
), after which the system was cooled in 20 ps to 50 °K. H-bond interactions were not 
included, nor were torsion angle restraints. The resulting structures were minimized with 3000 cycles of steepest descent 
and 3000 cycles of conjugated gradient (convergence of 0.01 kcal Å
-1
 mol
-1
). The backbones of the structures were 
clustered by the RMSD analysis module of HyperChem.
30 
Unrestrained MD simulation was performed in a 30×30×30 Å 
box of standard TIP3P water for 10 ns at 298 °K, at constant temperature and pressure (Berendsen scheme,
31
 bath 
relaxation constant of 0.2). For 1-4 scale factors, van der Waals and electrostatic interactions are scaled in AMBER to 
half their nominal value. The integration time step was set to 0.1 fs. 
Table 6. Non-obvious ROESY cross-peaks observed for 2a.
a 
Cross-peak intensity Cross-peak intensity 
PheNH-Oxd3Me w PheNH-PheH(up) s 
PheNH-PheH(dw) m PheNH-PheH m 
PheNH-Oxd3H4 s PheNH-Oxd3H5 m 
PheNH-Oxd2H5 w PheNH-PheArH m 
AlaNH-AlaMe vs AlaNH-AlaH s 
AlaNH-TsArH2,6 s TsArH2,6-AlaMe w 
TsArH2,6-Oxd2Me w TsArH2,6-AlaH m 
TsArH3,5-Oxd2Me s TsArH3,5- Oxd2H4 w 
PheArH-PheH s Oxd2H4-Oxd3H4 w 
Oxd2H4-AlaH w AlaH-Oxd2H5 w 
Oxd2H5-Oxd3H5 w COOMe-PheH w 
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong, s = strong, m = medium, w = 
weak. 
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Table 7. Non-obvious ROESY cross-peaks observed for 2c.
a 
Cross-peak intensity Cross-peak intensity 
PheNH-PheArH w PheNH-PheH m 
PheNH-Oxd3H4 vs PheNH-Oxd3H5 w 
PheNH-PheH(dw) w PheNH-PheH(up) s 
PheNH-Oxd3Me w PheNH-COOMe w 
AlaNH-TsArH2,6 m AlaNH-AlaH m 
AlaNH-AlaMe s TsArH2,6-AlaMe w 
TsArH2,6-Oxd2Me w TsArH2,6-AlaH m 
TsArH3,5-Oxd2Me w TsArH3,5-AlaH w 
PheArH2,4,6- Oxd3Me w PheArH2,4,6- PheH(up) s 
PheArH2,4,6- PheH(dw) s PheArH2,4,6- AlaMe w 
PheArH2,4,6- PheH m PheArH2,4,6-COOMe w 
PheArH2,4,6-Oxd3H5 w Oxd2H4-Oxd3H5 w 
Oxd2H4-Oxd3H4 w Oxd2H5-Oxd3H4 w 
Oxd2H5-PheH w AlaH-PheH w 
PheH-PheH(dw) s PheH-PheH(up) m 
PheH-COOMe w PheH- Oxd3H5 w 
PheH-Oxd3H4 w Oxd3H5-PheH(dw) w 
COOMe-AlaMe m COOMe-TsMe w 
COOMe-PheH(dw) m COOMe-PheH(up) m 
TsMe- Oxd2Me w   
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong, s = strong, m = medium, w = 
weak. 
Table 8. Non-obvious ROESY cross-peaks observed for 2d.
a
 
Cross-peak intensity Cross-peak intensity 
PheNH-AlaMe w PheNH-Oxd3Me w 
PheNH-PheH vs PheNH-COOMe w 
PheNH-PheH m PheNH-Oxd3H4 m 
PheNH-Oxd3H5 w PheNH-PheArH s 
AlaNH-AlaMe s AlaNH-COOMe w 
AlaNH-AlaH s AlaNH-TsArH2,6 s 
AlaNH-TsArH3,5 w TsArH2,6-AlaMe m 
TsArH2,6-Oxd2Me w TsArH2,6-AlaH s 
TsArH2,6-OxdH4 w TsArH3,5-Oxd2Me s 
TsArH3,5-AlaH m PheArH3,5-AlaMe m 
PheArH3,5-COOMe w PheArH3,5-PheH m 
PheArH-Oxd3Me w PheArH-COOMe s 
Oxd2H4-TsMe m PheH-AlaMe w 
COOMe-AlaMe w COOMe-PheH s 
PheH-AlaMe m TsMe-AlaMe w 
Oxd2Me-AlaMe w   
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong, s = strong, m = medium, w = 
weak. 
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Table 9. Non-obvious ROESY cross-peaks observed for 3b.
a 
Cross-peak intensity Cross-peak intensity 
AbuNH-AlaMe m AbuNH-AbuMe s 
AbuNH-AlaH vs AbuNH-AlaNH s 
AbuNH-PheNH w AbuNH-TsArH2,6 w 
PheNH-Oxd3H5 w PheNH-PheH vs 
PheNH-Oxd3H4 vs PheNH-PheH s 
PheNH-PheArH m PheNH-AlaNH w 
AlaNH-AlaMe vs AlaNH-AlaH s 
AlaNH-TsArH2,6 w TsArH2,6-AlaMe w 
TsArH2,6-AlaH m PheArH-COOMe w 
PheArH-PheH vs PheArH-PheH s 
PheArH-Oxd3H5 w AbuHb-Oxd3H4 w 
COOMe-PheH m COOMe-PheH w 
PheH-Oxd3H4 w COOMe-Oxd3Me w 
AbuMe-TsMe w AbuMe-AlaMe s 
AbuMe-Oxd3Me w   
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong, s = strong, m = medium, w = 
weak. 
Table 10. Non-obvious ROESY cross-peaks observed for 3c.
a 
Cross-peak intensity Cross-peak intensity 
AbuNH-AlaMe m AbuNH-AbuMe s 
AbuNH-Oxd3Me w AbuNH-AlaNH vs 
AbuNH-AbuH w AbuNH-TsArH2,6 w 
AbuNH-PheNH w PheNH-PheArH m 
PheNH-PheH(up) s PheNH-PheH(dw) w 
PheNH-Oxd3H5 m PheNH-Oxd3H4 s 
PheNH-PheH s PheNH-PheArH m 
AlaNH-AlaMe m AlaNH-AlaH m 
TsArH2,6-AlaMe m TsArH2,6-AlaH s 
TsArH2,6-AlaNH m TsArH3,5-AlaNH w 
PheArH3,5-Oxd3Me w PheArH3,5-PheH(up) w 
PheArH3,5-PheH w PheArH2,6-Oxd3Me w 
PheArH2,6-PheH(up) vs PheArH2,6-PheH(dw) vs 
PheArH2,6-Oxd3H5 w PheArH2,6-PheH s 
PheH-PheH(dw) vs PheH-PheH(up) s 
Oxd3H5-PheH(up) w COOMe-PheNH w 
COOMe-PheH m COOMe-PheH(dw) w 
COOMe-PheH(up) w   
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong, s = strong, m = medium, w = 
weak. 
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Figure 9. Top (left) and side (right) view of the intermediate anion A of Scheme 1, calculated for the cyclization of the 
model peptide Ts-Ala-Ser-NH2 with DSC and DIPEA, employing ab initio molecular orbital (MO) theory. A systematic 
conformational analysis for the structures was done at the HF/6-31G* level. The conformers were re-optimized at the 
HF/6-31G** level. Backbones are rendered in balls-and-cylinders, hydrogen atoms in sticks. Optimization was performed 
by conjugate gradient algorithm, convergence at 0.001; energies are expressed in Kcal mol
-1
. DIPEAH
+ 
was included in 
the computations, but is not visualized for clarity. 
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Chapter 5 
First example of 2-Freidinger lactam analogs: synthesis and conformational analysis of Amo ring 
 
Constrained peptidomimetic scaffolds are of considerable interest for the design of therapeutically useful analogues of 
bioactive peptides. In this chapter is presented the single step cyclization of (S)- or (R)--hydroxy-2- or -substituted--
hydroxy-2,2-amino acids already incorporated within oligopeptides to 5-aminomethyl-oxazolidine-2,4-dione (Amo) rings. 
These scaffolds can be regarded as unprecedented 2- or 2,2-homo Freidinger lactam analogs, and can be equipped with a 
proteinogenic side chain at each residue. In a biomimetic environment Amo rings act as inducers of extended, semi-bent or 
folded geometries, depending on the relative stereochemistry and the presence of -substituents. 
5.1. Introduction 
Although native biologically active peptides have a great potential for medical and biotechnological applications,
1
 their utility 
is reduced by severe inherent limitations, in particular poor stability against proteolytic breakdown and scarce biodistribution 
and bioavailability properties.
2
 Besides, peptides tend to be quite flexible, and conformations are highly dependent on 
environment, leading to modest receptor selectivity. These issues have been addressed by the design of highly stable and 
conformationally constrained peptidomimetics,
1,2 
i.e.
 
compounds whose pharmacophoric and stereostructural elements mimic 
the bioactive structure of the parent peptides.
3
 
One approach to obtaining more rigid peptidomimetics
1-3 
is to incorporate local constraints using conformationally restricted 
amino acid units or modified peptide backbones. Global constraints are introduced for instance via cyclization or by replacing 
portions of the peptides with non-peptide structures. In this context, large effort has been dedicated to design scaffolds 
mimicking turn structures. -Turns are common motifs in peptide structures (Figure 1), and very often are critical to peptide 
conformational stability and many interactions correlated to a variety of biological processes.
3,4 
Native β-turns involve four 
residues with Cα(i) to Cα(i+3) distances of less than 7.0 Å, and form a hydrogen-bond C=O(i)· · ·H-N(i+4) (1->4-type).5 As a 
consequence, small scaffolds which reproduce these features have been extensively investigated to discover compounds that 
can mimic or disrupt turn-mediated recognition events.
6 
For instance, the prototypic Freidinger lactam dipeptides
2,4,7
 have been 
widely used to constrain peptide conformations, stabilizing turn structures and acting as strand inducers (Figure 1).
8 
 
Figure 1. Sketch of a -turn, a classic Freidinger lactam, and the α-amino-β-lactam approach. 
However, the scaffold-strategy resulted in limited success with bioactive peptide ligands where the non-peptide or 
pseudopeptide scaffold itself contains most of the pharmacophore elements.
3,6 
Frequently, the side chains at some fundamental 
positions are not maintained, or one of the amino acids is omitted on the basis of the hypothesis that some residues play a 
structural rather than a recognition role, e.g. Pro or Gly at position i+1 of a -turn.6,9 Therefore, the structures of the turn 
mimetics may lack some relevant pharmacophores for specific targets. An example is represented by the early Freidinger 
lactams, (Figure 1) obtained by sacrificing the i+1 side chain with the formation of 5- to 8-membered rings. To overcome this 
limit, many efforts have been dedicated to the preparation of -substituted lactams;10 for instance, Palomo et al. proposed the 
separation of constraint and recognition elements, and introduced a α-alkyl-α-amino-β-lactam rings placed at the position i+1 
residue as potent nucleators of -turns (Figure 1).11 
Besides, the preparation of the constrained mimetics may require multi-step procedures, resulting in low overall yields, and 
many synthetic methods lack flexibility and are therefore not suited to introduce diversity.
6
 As a consequence, the development 
of a expedient procedure to constrain a peptide while maintaining all of the pharmacophores is of considerable interest. 
During my thesis work, we have been interested in the rapid and simple ring closure of -hydroxy--amino acids into turn-
inducer scaffolds. In the previous chapter is illustrated that the reaction of N-arylsulfonyl-peptides containing L- or D-
configured Ser and/or other -hydroxy--amino acids (Thr, PhSer), with N,N′-disuccinimidyl carbonate (DSC) and a catalytic 
amount of DIPEA, gave rise in a single step to the formation of oxazolidinone (Oxd) ring(s) (Scheme 1).
12
 Under the same 
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conditions, the corresponding Fmoc- or Boc-peptides gave elimination to dehydroalanine, in agreement to the literature,
13
 
suggesting that the N-sulfonyl group effectively promoted the cyclization. 
 
Scheme 1. Reaction of peptides containing Ser (top) or isoSer (bottom) with DSC. 
Another part of this project is been the development of a single step procedure to lock the geometry of a oligopeptide by 
cyclization of -hydroxy-2-amino acids or -substituted--hydroxy-2,2-amino acids, already present in the sequence, to 5-
aminomethyloxazolidine-2,4-dione rings (Amo). These unusual heterocyclic scaffolds (Scheme 1 and Figure 2) can be 
regarded as 2- or2,2-homo variants of a classic Freidinger lactam and can be equipped with a side chains at each -position. 
5.2. Results and Discussion 
5.2.1. Synthesis 
On repeating the same protocol of Scheme 1 on a peptide containing the -hydroxy-2-amino acid isoSer, we observed, not 
totally unexpected, a different outcome: the reaction gave exclusively the cyclization to 5-aminomethyloxazolidine-2,4-dione 
(Amo) comprising isoSer and the following amino acid (Scheme 1). To our knowledge, this peptide represents the first 
example of conformationally constrained peptide containing a oxazolidine-2,4-dione scaffold; in general, this heterocycle has 
been described and utilized very few times in organic or medicinal chemistry.
14 
Under the structural point of view Amo can be regarded as a novel constrained 2-amino acid. Among the -amino acids, the 
2-amino acids are less synthetically feasible respect to their 3-counterparts (Figure 2).15 Besides, the cyclic structure of 
Amo, achieved via acylation of the backbone nitrogen atom, embraces two consecutive amino acids, therefore  introducing a 
global constraint of Ci)-N(i+1)-type3a in the sequence. This kind of short range cyclizations16 can significantly reduce the 
conformational space accessible to the peptide segment in which they are incorporated. In this perspective, the Amo ring can 
be regarded as a novel 2-homo-analogue of a Freidinger lactam (Figure 2).17 Structures combining the conformational 
properties of the Freidinger lactams with the stability of the -amino acids have been the subject of much interest by Gmeiner 
and co. and some other groups;
18
 however, in all cases the reported structures were 3-homo variants of Freidinger lactams 
(Figure 2). 
 
Figure 2. Structures of2-, 2,2-, and 3-amino acids (top), and comparison of a classic Freidinger lactam composed of all -
amino acids (middle), with the 2- and2,2-homo Amo variants, and with a Gmeiner’s 3-homo lactams18 (bottom). 
Finally, the Amo-Phe sequence of Scheme 1 might also represent a constrained dipeptide unit composed of  and  
residues, of potential interest for the design of /-hybrid foldamers19 showing unprecedented secondary structures (see 
also the section “Conformational properties”). Indeed, unexpected conformational effects have been often observed when 2-
amino acids were present in the backbone instead of the more common  residues.15a 
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This potential interest prompted us to exploit the cyclization to prepare oligopeptide sequences containing the unusual 
scaffold under different reaction conditions. Accordingly, we prepared a mini-library of di-, tri- or tetrapeptides containing 
(S)- or (R)-configured isoSer, equipped with different groups at the N-terminus, amide or ester at the C-terminus (Scheme 2), 
and we reacted these peptides with different carbonates or dicarbonates, in solution (Scheme 3, Table 1) or in the solid phase 
(Scheme 4, Table 1). 
 
Scheme 2. Synthesis of isoSer-containing peptides 1 and 2. 
The dipeptide Boc-isoSer-PheNH2 (1a) was prepared in solution by coupling Boc-isoSerOH and H-PheNH2 under MW 
irradiation,
20
 using HBTU/HOBt/DIPEA as activating agents (Scheme 2, i).  Boc-isoSerOH
21
 was prepared according to the 
literature. The isoSer building block was incorporated without a protection for the OH function. Under these reaction 
conditions,
12 
the acylation of the OH-function and thus the formation of a depsipeptide side product was not observed, as 
confirmed by the 
1
H NMR and RP-HPLC MS analyses of the crude reaction mixture. After purification by flash 
chromatography over silica gel, 1a was utilized for the following cyclization step (Scheme 3, Table 1). 
By using the same protocol, Boc-isoSerOH and (R)-H-PheNH2 gave 1b, while (R)-Boc-isoSerOH
21
 and H-PheNH2 gave 1c. 
The tripeptides 1d and 1e were prepared from Boc-isoSerOH and H-Phe-ValOMe (1d), or (R)-Boc-isoSerOH and H-Phe-
ValOMe (1e). The crude 1b-e were analysed by RP-HPLC MS and utilized as intermediates for the preparation of longer 
sequences without further purifications. The dipeptide H-Phe-ValOMe was prepared in turn from Boc-Phe-ValOMe,
22
 by 
treatment with 25% TFA in DCM. The same conditions were utilized for Boc deprotection of the di- or tripeptides 1a-e 
(Scheme 2).  
The peptide-TFA salts from 1a-e were subjected to coupling with Tosyl (Ts)-AlaOH under the above described conditions, 
giving the corresponding tri- or tetrapeptides 2a-e (Scheme 2). Ts-AlaOH was prepared as described in the literature.
23 
Finally, the tetrapeptide 2d was obtained from 1d and Boc-AlaOH. The tri- or tetrapeptides 2a-f were isolated by flash 
chromatography over silica gel, and their structures were assigned by 
1
H NMR and HPLC-MS. 
The reaction of the Ts-tripeptides 2a, b containing (S)- or (R)-isoSer, and of the diastereoisomeric 2c, with DSC and DIPEA 
for 1 h in DCM/DMF gave the corresponding Amo-peptides 3a-c with excellent yields (Scheme 3, Table 1, entries 1-3). 
Other carbonates or dicarbonates gave inferior results (Table 1: entry 4, triphosgene 55%; entry 5, Boc2O traces; entry 6, CDI 
70%). Good yields were obtained with DSC for the synthesis of tetrapeptides 3d-f having Val methyl ester at the C-terminus 
(entries 7 to 9), and for the minimalist dipeptide Boc-Amo-PheNH2 3g (entry 10).  
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Scheme 3. Regioselective cyclization of isoSer-containing peptides 2 to Amo-peptides 3. 
Different protecting groups at the N-terminus such as Boc (entries 9 and 10) and Ac (entry 11), gave results very close to Ts. 
Clearly, for the comparatively simpler cleavage, carbamate protecting groups represent the most obvious choice.
24 
Nevertheless, the literature reports several methods for the mild cleavage of arylsulfonyl groups.
24,25
 Recently, we 
successfully removed the Ts group from peptides containing the Oxd ring with iodotrimethylsilane,
12,26
 while the treatment 
with SmI2-pyrrolidine-water
27
 was less efficient. 
Table 1. Cyclization of peptides 1a and 2 containing isoSer to Amo-peptides 3. 
Entry    1/2         R isoSer         Phe         R’                 carbonate          3         (%)a 
1 2a Ts-Ala S S NH2 DSC a 93 
2 2b Ts-Ala R S NH2 DSC b 90 
3 2c Ts-Ala S R NH2 DSC c 93 
4 2a Ts-Ala S S NH2 triphosgene a 55 
5 2a Ts-Ala S S NH2 Boc2O a traces 
6 2a Ts-Ala S S NH2 CDI a 70 
7 2d Ts-Ala S S ValOMe DSC d 90 
8 2e Ts-Ala R S ValOMe DSC e 93 
9 2f Boc-Ala S S ValOMe DSC f 91 
10 1a Boc S S NH2 DSC g 91 
11 2hb Ac-Ala S/R S Phe-Wang DSC hc 80d 
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The Ac-peptide 2h was prepared as a mixture of diastereoisomers from racemic isoSer (not protected at the OH function) by 
solid-phase synthesis (Scheme 4). N-Fmoc-protected amino acids were coupled on a standard Wang resin with 
HBTU/HOBt/DIPEA under MW irradiation (45°C).
12
 Fmoc deprotection was performed with 20% piperidine in DMF under 
MW irradiation. The resulting resin-bound peptide Ac-Ala-(S/R)-isoSer-Phe-Wang was then utilized for the following 
cyclization prior to cleavage by treatment with a moderate excess of DSC (3 equiv.) and DIPEA (1 equiv.) in 4:1 DCM/DMF 
for 2 h. The cleavage from resin was performed with TFA in DCM in the presence of scavengers. 
Analysis of the crude reaction mixture by RP-HPLC and ESI-MS revealed the presence of the two diastereomeric Amo-
peptide acids Ac-Ala-(S/R)-Amo-PheOH (3h) in 1:1 ratio, recovered in very satisfactory yield (80%, based on an average 
resin loading of 0.6 mmol/g) after semipreparative RP-HPLC (General Methods). 
 
Scheme 4. Solid-phase synthesis of Ac-tripeptides 3h. 
In all cases, epimerization during the cyclization of 2a-h was excluded on the basis of the NMR and HPLC analyses, 
including the HPLC on a chiral stationary phase (see General Methods). 
The structure of the ring closing products 3 was readily determined by 
1
H NMR and gCOSY. The disappearance of the 
PheNH resonance in the 
1
H NMR-spectrum, a significant downfield shift of PheH, and the loss of the PheH-PheNH 
coupling constant, accounted for the acylation of the adjacent Phe nitrogen. On the contrary, the proton pattern of the isoSer 
residue was maintained (apart from OH group), while the resonances of the Ala residue were practically unaffected.  
In principle, the cyclization of the isoSer residue with DSC could give rise also to the formation of a oxazolidin-2-one (Oxd) 
ring (Scheme 3, path b); this was obtained as the only product in peptides containing Ser (Scheme 1) or other -hydroxy--
amino acids. The concomitant formation of traces of oxazolidinones by alternative cyclization was excluded on the basis of 
the HPLC, MS, and 
1
H NMR analyses of the crude reaction mixtures. Apparently, all reactions of 2a-h proceeded with 
complete regioselectivity giving exclusively the Amo ring. This observation prompted us to verify whether the ring closure 
to Oxd would occur when the former would be prevented by choosing sarcosine (Sar, N-methylglycine), as the C-terminal 
amino acid. Consequently, we synthesized the tripeptide Ts-Ala-isoSer-SarNH2 (2i), and we attempted the cyclization 
reaction under the same conditions as before (Scheme 5). In effect, after 1h the cyclization to the corresponding peptide Ts-
Ala-Oxd-SarNH2 (4) was observed, albeit in low yield (25%) compared to the Amo-peptides 3, the rest being the 
intermediate isoSer-O-carbonate. The yield was improved to 55% by using 1 equiv. of DBU (1,8-diazabicyclo[5.4.0]undec-
7-ene) instead of catalytic DIPEA, an excess of DSC (3 equiv.), higher temperatures (40ºC), and prolonged reaction times 
(6h). Apparently, the cyclization to Amo 3 seems to be favored respect to the alternative cyclization to Oxd 4. 
 
Scheme 5. Reaction of sarcosine-containing 2i to Oxd-peptide 4.  
Presumably, the cyclization to Amo proceeds via the five-membered anionic intermediate with endocyclic C=O (Scheme 3, 
path a, and Scheme 8). The loss of 2,5-dioxopyrrolidin-1-olate leaving group, rapidly protonated by DIPEAH
+
, leads to the 
Amo-peptide 3 and DIPEA, which can be utilized in catalytic amount. The detailed study of the reaction mechanism is 
beyond the scope of this work. Preliminary computations (Scheme 8) suggested that the intermediate with endocyclic C=O is 
significantly more stable than the alternative intermediate with hexocyclic C=O (Scheme 3, path b), precursor of the Oxd.  
The Amo ring proved to be remarkably stable when dissolved in common organic solvents and in water. On the other hand, it 
was reported in the literature that the carbamate increased the reactivity of the inner peptide bond towards reduction by 
NaBH4.
14
 Accordingly, 3b was regioselectively reduced at the position 4 of the 5-membered ring in very satisfactory yield, 
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giving exclusively the 4-hydroxy-5-aminomethyl oxazolidin-2-one 5 in trans relative stereochemistry (Scheme 6). The trans-
relationships between the two substituents was substantiated by the very small coupling constant JH4-H5 in the 
1
H NMR 
spectra. 4,5-Disubstituted trans-oxazolidin-2-ones are characterized by coupling constants much lower than that of the cis-
stereoisomers
28
 (equilibrium between anomers was not observed).  
 
Scheme 6. Regio and stereoselective reduction of the Amo ring. 
The ring closure to Amo ring was made possible by the sacrifice of the OH group of the -hydroxy-2-amino acid isoSer. 
Therefore, Amo represents a constrained 2-amino acid deprived of a side chain.15 For this reason, we exploited the 
opportunity to utilize -substituted--hydroxy-2,2-amino acids for preparing  Amo-derivatives carrying a explicit 
proteinogenic side chain. The isoSer derivatives are interesting members of the 2-amino acid family present in many 
bioactive compounds, e.g. Taxol, bestatin, protease inhibitors, etc., therefore several synthetic protocols have been developed 
for their synthesis in optically active form, including asymmetric catalysis, enzymatic resolution, and the use of chiral 
auxiliaries and building blocks.
15,29
 
As a prototype for a side chain substituted amino acid surrogate, we prepared the model non-racemic (S)- or (R)--methyl-
isoSer from a keto ester and nitromethane, using an adaptation of the catalytic enantioselective Henry reaction reported by 
Jørgensen, Scheme 5.
30
 Methyl pyruvate was reacted with nitromethane in the presence of Cu(II), TEA, and (R)- or (S)-t-Bu-
bisoxazoline (Box), giving in high yields (S)- or (R)-configured -nitro--hydroxy ester 6a or 6b, respectively.31 The 
reduction of the nitro group gave the (S)- or (R)-2,2-amino ester 7a32 or 7b, and the coupling with the other residues under 
MW irradiation and standard coupling agents gave the linear homochiral tetrapeptide 9a or the heterochiral 9b, respectively. 
The treatment with DSC and the base afforded the 2,2-homo Freidinger lactam analogues 10a and 10b bearing a substituent 
at each -position, Scheme 7. 
 
Scheme 7. Synthesis of peptides 10 containing the (S)- or (R)-configured 5-methylAmo scaffold. 
5.2.2. Conformational properties 
For the novelty represented by the Amo scaffolds which incorporate (S)- or (R)-2- or a 2,2-amino acid, we decided to 
investigate the conformations of the Amo-containing tetrapeptides. Indeed, it is well known that the introduction of a -
residue in a peptide sequence can lead to secondary structures quite different from that of sequences composed of all -
residues.
15,19,33
  
Hofmann et al. have investigated by systematic theoretical analyses the intrinsic conformational preferences of Ac--amino 
amide monomers carrying single or multiple substitutions at the C and C backbone atoms. The most stable conformations 
were found to be different types of six- and eight-membered ring hydrogen bonded structures (C6, C8) corresponding to 
gauche rotamers around the C-C bond, a feature which is expected to promote local folding when incorporated into 
peptides.
33d,i
 
In a similar way, initially we performed theoretical studies to analyze the conformational preferences of representative 
models of unsubstituted and -substituted Amo monomers, that we identified in the structures Ac-3-methylAmo (11a) and 
Ac-3,5-dimethylAmo (11b). According to the convention of Banerjee and Balaram,
33a 
the soft torsional degrees of freedom in 
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a -amino acid are defined as (N-C),  (C-C), and  (C-C=O), respectively (Figure 3). It is apparent that the central 
torsion angle represents the most relevant geometric variable of Amo monomers. 
 
Figure 3. Minimum-energy conformations and relative energies of the +g, trans, and -g rotamers around the central 
backbone dihedral angle  of model compounds 11a and 11b. A systematic conformational analysis around  and  was 
performed in gas-phase employing DFT; ΔE are given in kcal/mol; ,  , and , are given into brackets in degrees; Amo is 
rendered in balls and cylinders, the rest in sticks. 
The relative energies of the minimum-energy conformations of the +g, trans, and -g rotamers around angle  of 11a and 11b 
have been estimated in the gas-phase with the aid of theoretical studies,
34
 employing the density functional theory. The 
calculated relative energies in increasing order were: for 11a, +g < trans < -g; for 11b, +g < -g < trans (Figure 3). For both 
structures the global minimum was a +g conformer of , which is consistent with the calculated geometries reported in the 
literature for - and disubstituted 2,2-amino acids, albeit the rigid angle  prevents the formation of the commonly observed 
6-membered hydrogen bonded pseudocycles (C6).
33
 For 11a, the -g conformer was by far the less stable. On the other hand, 
the presence of the methyl substituent at the position 5 of the Amo ring in 11b strongly reduced the ΔE between the +g 
global minimum and the -g rotamer, while the ΔE of the trans geometry was slightly higher (Figure 3).  
It is plausible that the geometric preferences of the Amo monomers could impact the conformations of Amo-containing 
oligopeptides. The computations indicated that the introduction of a bulk at the position  of the scaffold should increase the 
population of folded structures compared to unsubstituted Amo (Figure 3), since in the former the more extended trans 
rotamer was the least stable. Likely, when a -substituted Amo scaffold as 11b is inserted into a peptide, the preponderance 
of +g and -g rotamers should consent to further stabilize folded geometries by intra-molecular hydrogen-bonding. In 
oligomers, the occurrence of inter-residue hydrogen bonds or other interactions between monomers may significantly 
influence the stability relationships between competing alternatives, albeit they are not the main driving force for the 
formation of the corresponding conformers themselves.
19,33
 Besides, polar solvents are expected to have a influence on the 
stability and conformation of molecules, and generally tend to reduce the ΔE between conformers.33 
In order to experimentally determine the conformations of oligomers containing the Amo scaffolds, we performed a 
conformational analysis by NMR spectroscopy of the model tetrapeptides 3d and 3e, which include the unsubstituted (S)- or 
(R)-configured Amo scaffold, respectively, and 10a and 10b containing (S)- or (R)-5-methylAmo. To gain more information, 
analyses were occasionally performed on other Amo-peptides. The 
1
H NMR of the model compounds were recorded either in 
CDCl3 or in 8:2 [D6]DMSO/H2O; [D6]DMSO or mixtures of [D6]DMSO and H2O have been recommended by several 
authors as excellent representatives of biological fluids.
35
 The spectra showed a single set of resonances, suggestive of 
conformational homogeneity or a rapid equilibrium between conformers.  
In 100% CDCl3 amide protons that are hydrogen bonded are found downfield respect to non bonded protons. For all Amo-
oligopeptides, the chemical shifts of the amide protons appeared in the order AmoNH > ValNH > AlaNH. In particular, the 
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all-(S)- sequences 3d and 10a showed AmoNH resonances > 7.0 p.p.m., suggesting that these amide proton were bonded to a 
significant extent. 
The occurrence of intramolecular hydrogen bonding was deduced by analyzing the variations of the NH chemical shifts upon 
addition of increasing percentages of [D6]DMSO to solutions of the compounds in CDCl3 (Figure 4).  
During the titration of 3e and 10b AlaNH and AmoNH exhibited a moderate downfield shift, while ValNH was much more 
sensitive. For 3d, AmoNH was significantly less sensitive than AlaNH and ValNH. On the other hand, for 10a the chemical 
shifts of AlaNH and ValNH showed a marked variation, while that of AmoNH remained practically constant and is therefore 
less accessible. This suggested that in 10a AmoNH could be involved in a H-bond.
36
 
To gain more information, also the tripeptide 3a and 3c were analyzed by titration experiments (Figure 5). They both 
behaved as the tetrapeptides 3d and 10a, namely showing AmoNH possibly involved in a hydrogen bond, this observation 
reasonably excluding ValOMe as H-bond acceptor in the tetrapeptides. The reversal of configuration of the residue 3, from 
(S) in 3a to (R) in 3c, seemed to be well tolerated. 
 
Figure 4. Titration experiments: variation of NH proton chemical shift (p.p.m.) of 2 mM 3d, 3e, 10a, and 10b in CDCl3 as a 
function of increasing [D6]DMSO (% v/v). 
   
 
 
 
 
Figure 5. Titration experiments: variation of NH proton chemical shift (p.p.m.) of 2 mM 3a, 3c, 3f, in CDCl3 as a function of 
increasing [D6]DMSO (from 0 to 8 % v/v). 
Variable temperature (VT) NMR experiments were used to detect if amide protons were involved in intramolecular hydrogen 
bonding or are solvent exposed. The analyses were performed in CDCl3 and 8:2 [D6]DMSO/H2O (Table 1). In CDCl3, 3e and 
10b showed comparatively lower t values for ValNH respect to AlaNH and AmoNH (for 3e, t = -0.5 p.p.b./K; for 
10b, t = -1.0 p.p.b./K),37 suggestive of a preference for conformations having hydrogen bonded ValNH t| < or 
close to 2.0 p.p.b.⁄K). For 3d and 10a, the t parameters in CDCl3 did not allow clear deductions. In [D6]DMSO/H2O, the 
t parameters of 3d, 3e, and 10b did not reveal any H-bonded amide proton. On the contrary, for 10a the chemical shift 
of AmoNH was significantly less sensitive to increasing temperature (t in [D6]DMSO/H2O = -2.1 p.p.b./K), indicating a 
plausible conformation having this amide proton involved in a hydrogen bond. 
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Table 2. /t values (p.p.b.⁄K) for the amide protons of 3d, 3e, 10a, 10b, in CDCl3 or 8:2 [D6]DMSO/H2O. 
compd                  solvent         AlaNH       AmoNH       ValNH 
3d 
CDCl3 -5.1 -4.9 -2.9 
8:2 [D6]DMSO/H2O -7.0 -6.3 -4.5 
3e 
CDCl3 -7.0 -4.0 -0.5 
8:2 [D6]DMSO/H2O -7.0 -6.6 -5.0 
10a 
CDCl3 -4.2 -4.1 -2.4 
8:2 [D6]DMSO/H2O -6.8 -2.1 -4.7 
10b 
CDCl3 -6.7 -3.9 -1.0 
8:2 [D6]DMSO/H2O -7.1 -5.8 -4.5 
  Table 3. t values (p.p.b./°K) for the amide protons of peptides 3a, 3b, 3c, 3f, 5, in CDCl3. 
Compd                            sequence AlaNH AmoNH ValNH    CONH2 
3a Ts-Ala-(S)-Amo-PheNH2 -15.1 -8.1 - -14.3/-9.7 
3b Ts-Ala-(R)-Amo-PheNH2 -8.6 -6.2 - -8.6/-8.0 
3c Ts-Ala-(S)-Amo-(R)-PheNH2 -8.4 -6.0 - -7.7/-9.5 
3f Boc-Ala-(S)-Amo-Phe-ValOMe -4.5 -5.0 -4.5 - 
5 Ts-Ala-(R)-5-hydroxyAmo-PheNH2 -14.7 -10.0 - -13.7/-11.0 
The model compounds were analyzed by 2D-ROESY. In CDCl3 the spectra displayed a modest number of non-obvious inter-
residue cross-peaks (not shown), which was indicative of conformational freedom. On the contrary, in the biomimetic 8:2 
[D6]DMSO/H2O the spectra were much more satisfactory, and revealed meaningful inter-residue cross-peaks.  
Very often, changes in solvent composition cause meaningful changes in the shape of the peptides. Generally, apolar solvents 
such as chloroform are expected to increase hydrogen bonding, due to the absence of competitive solvation of donors and 
acceptors by individual solvent molecules.
19,36-38
 Apparently, for the Amo-tetrapeptides, VT NMR and titration experiments 
in chloroform differently supported the possible existence or not of hydrogen bonds, accounting for a scarce conformational 
definition, as suggested also by ROESY analyses. This behavior was investigated and confirmed by means of FT-IR 
spectroscopy and Electronic Circular Dichroism (ECD) in a non competitive solvent (DCM). 
FT-IR spectroscopy in DCM was utilized to analyze the amide stretching regions. Normally, non bonded amide protons show 
a peak above 3400 cm
-1
, while bonded amide NH exhibit a peak below 3400 cm
-1
.
39
 The spectra of each tetrapeptide showed 
a peak > 3400 cm
-1
 and one or more peaks < 3400 cm
-1
 (Figure 6), indicative of equilibria between non bonded and multiple 
bonded structures.  
The compounds were dried in vacuo, and all the sample preparations were performed under nitrogen atmosphere. All infrared 
spectra were obtained for 1 mM solutions in dry DCM at 297 °K at 2 cm
−1
 resolution, using a 1 mm NaCl solution cell and a 
FT-IR spectrometer (64 scans). (Figure 6).  
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Figure 6. Amide NH stretching regions of the IR absorption spectra for samples of 2 mM 3d, 3e, 10a, and 10b in DCM at r.t. 
Electronic Circular Dichroism (ECD) is a widely used technique for studying protein and peptide conformations. This 
technique is intrinsically a low-resolution method; however, it can furnish qualitative information on the presence of ordered 
secondary structures, although not too many examples on short peptides are reported.
40
 ECD spectra of the model 
tetrapeptides in DCM (Figure 7) showed a smooth negative band centered at about 240 nm. This observation could be 
compatible with the occurrence of non-classic β-turns, since the n-π* band of the latter generally appear near 225 nm.40 
ECD spectra were recorded from 200 to 400 nm at 25 °C. 1 mM solutions were made up in spectral grade solvents and run in 
a 0.1 cm quartz cell (Figure 7). Data are reported in molar ellipticity [] (deg cm2 dmol-1). 
 
 
Figure 7. ECD spectra of 3d, 3e, 10a, and 10b recorded in DCM at r.t.; 3d and 10b are practically superimposed. 
Plausibly, the results of the various experiments in non competitive environments reflected the existence of equilibria 
between diverse hydrogen bonded and non-bonded structures, as well as distorted or weak intra-residue hydrogen bonds, 
which can be observed in peptides composed of - and -residues.19,33,41 On the other hand, in DMSO/water the analyses 
gave clues of higher conformational homogeneity. It has been demonstrated that cryoprotective mixtures of high viscosities, 
such as DMSO/water, showed a remarkable ability to favor compact structures representative of the bioactive conformers 
over disordered ones.
35,42 
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Figure 8. Sketches of the structures of 3d and 10a, and short-range (distances ≤ 3 Å) proton-proton ROESY correlations, 
indicated by arrows. Intra-residue and long-range (> 3 Å) correlations are not shown. Grey dashed arrows connect protons 
belonging to consecutive residues (i-i+1), while black solid arrows connect protons of non-consecutive residues (i-i+2 or i-
i+3). 
As anticipated, the 2D-ROESY of the model compounds in 8:2 [D6]DMSO/H2O gave analyzable cross-peaks. Compared to 
the tetrapeptides 3e and 10b (not shown), the homochiral 3d and 10a showed a comparatively larger number of short-range 
inter-residue proton-proton correlations (Figure 8). In particular, 10a displayed also several short-range cross-peaks between 
remote residues (for the complete list of cross-peaks, see Tables 4-7), suggestive of a folded structure. 
Cross-peak intensities were ranked to infer plausible inter-proton distances as restraints (Tables 4-7). Structures (50) 
consistent with ROESY were obtained by simulated annealing with restrained molecular dymamics (MD) in a box of explicit 
TIP3P equilibrated water molecules. With the exception of Amo-Phe, the  bonds were set at 180°; indeed, it is well 
established that peptides comprising only secondary amide bonds adopt all-trans conformations.
43 
In any case, the absence of 
Hi)-Hi+1) cross-peaks reasonably excluded the occurrence of cis peptide bonds.44 The structures were minimized with 
the AMBER force field
45
 and clustered by the rmsd analysis of backbone atoms. For each peptide, this procedure essentially 
gave one major cluster comprising the large majority of the structures. The representative structures of 3d, 3e, 10a, and 10b, 
with the lowest energy, were selected and analyzed (Figure 9). 
In the ROESY-derived structures of the homochiral tetrapeptides 3d and 10a, the Ts-Ala and Val-OMe moieties occupied the 
same side underneath the heterocycle. The Amo residue of 3d displayed a +g conformation about the central dihedral angle 
( = +42°), and a partially bent disposition of the backbone (Figure 9). On the other hand, in 10a the central dihedral angle of 
Amo presented a -g conformation ( = -53°), and the peptide adopted a folded geometry compatible with an atypical turn 
centered on the dipeptide mimetic Amo-Phe. This secondary structure was stabilized by a clear 2->1-type H-bond between 
AmoNH and PheC=O, in agreement to the VT NMR temperature coefficient (Table 2). The representative structure of 10a 
shown in Figure 9 is characterized by the following dihedral angles (in degrees): Amo (, ,   -106, -53, -119; Phe (,  
+83, +143 (see also Figure 10). The distance between the amide nitrogen of Amo and the carbonyl oxygen of Phe is 3.0 Å, 
while that between AlaCα and PheCα is about 4.3 Å. 
 
Figure 9. Top, representative lowest energy structures 3d, 3e, 10a, and 10b, calculated by restrained MD in a 30x30x30 Å 
box of standard TIP3P water molecules. Backbones and Amo rings are rendered in balls and cylinders, the rest in sticks. 
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As for the tetrapeptides 3e and 10b, which include (R)-Amo scaffolds, the ROESY derived structures revealed more 
extended backbone conformations, with Ts-Ala and Val-OMe positioned at the opposite sides of Amo ring. For both 
compounds, the central dihedral angle of Amo adopted a -g conformation (3e:  = -64°; 10b:  = -55°). The marked 
differences between homo and hetero-chiral peptides are not unexpected, since it is well-known that short sequences may 
experience dramatic changes of backbone conformation by reversal of the configuration of even a single residue.
2,6,11
 
To analyze the dynamic behavior of the peptides, starting from the structures of Figure 9 we performed unrestrained MD 
simulations for 10 ns at 300 K in a box of explicit TIP3P water molecules. For all compounds, during the simulations the 
complete rotation of the Phe-Val moiety around the Amo-Phe bond was not observed; possibly, the two carbonyls at 
positions 2 and 4 of the Amo ring prevented this movement. The analyses of the trajectories of 10a showed that the folded 
geometry of the backbone was maintained during the simulation, albeit AmoNH and PheC=O were prone to rotate about the 
dihedral angles Amo and Phe, respectively, leading to a occasional fluctuation of the distance PheC=O-AmoN (Figure 8). 
The analyses of the trajectories of 3d, 3e, and 10b, did not reveal the occurrence of clear secondary structures (not shown), 
and confirmed the higher backbone mobility of heterochiral 3e and 10b. 
The role exerted by the residue i+3 on peptide conformation was not investigated. It can be expected that substitution of Phe
3
 
with other amino acids could modify the stability and geometry of the folded conformation.
8a,11c 
It was shown that peptides 
incorporating a central -lactam-Gly- pair can exhibit high conformational heterogeneity around the lactam-Gly bond, 
depending on the presence and relative disposition of the substituents of  the lactam scaffold.
8a,11b
 
On resuming the evidences of experimental results and theoretical computations, it can be perceived that the conformational 
features of 3d, 3e, and 10b, seem to be governed mainly by the stereochemistry and geometric preferences of the Amo 
scaffold, which preferentially adopt a +g orientation of the central torsion angle (the-g conformation of (R)-Amo is 
equivalent to the +g of the (S)-enantiomer). For 10a, a significant population of bent conformers was expected on the basis of 
the higher stability of the -g conformer (Figure 3), correlated in turn to the presence of the -substituent onto the Amo 
scaffold. This effect and the stabilization exerted by the 9-membered hydrogen bond appear as the major contributors to the 
folding of peptide 10a. 
 
Figure 10. Sketch of the pseudo -turn of 10a stabilized by a 9-membered 2->1 H-bond induced by the (S)-Amo scaffold, 
and relevant dihedral angles (deg) (a); a ideal -turn showing the 10-membered 1->4 H-bond (b); the peptide in ref.46 is 
characterized by 9-membered 2->1 H-bonds (grey dashed arrows) as observed for 10a, and distinct 11-membered i->i+3 
hydrogen bonds with opposite orientation (c);
 
anthranilic acid-Pro
47
 scaffold showing the 9-membered 2->1 H-bond, and 
relevant dihedral angles (deg) (d). 
The conformation adopted by the model peptide 10a in a solvent mimetic of biological fluids can be regarded as a pseudo -
turn, being characterized by a Cα(i) to Cα(i+3) distance < 7.0 Å.47 This structure requires only the mixed /-dipeptide to 
display the closed hydrogen-bonded network (Figure 10a). The dipeptide Amo-Phe contains a 9-membered hydrogen bonded 
ring between AmoNH and PheC=O of type 2->1. This structure is in contrast to native β-turns (Figure 10b), which involve 
four residues to form the hydrogen-bonded structure in the opposite direction (residues 1->4). To our knowledge, 10a 
represents a very rare example of short sequence showing this kind of pseudo -turn,48 while it was observed in linear 
oligomers composed of repetitive /-units (e.g. Figure 10c, d).  
The secondary structure formed by a given type of hybrid /-oligomer depends on the number and substitution of the - or 
-residues within the units, on their stereochemistry pattern, and conformational restraints such as the incorporation of cyclic 
structures within the amino acid. A variety of secondary structures have been reported in the literature, stabilized by 10- to 
15-membered hydrogen bonded rings in both orientations of the backbone direction, while 9-membered H-bonded rings of 
type 2->1 have been described more seldom.
19,33
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Hofmann et al. have carried out a detailed theoretical study of /-peptides, demonstrating the stability of a mixed helix with 
a 9-membered hydrogen bond in the forward direction and an 11-membered hydrogen bond in the backward direction of the 
peptide chain in apolar solvents.
33f
 On the other hand, the peptide Boc-[(R)-Phe-(R)-3-homo-Val]2-(R)-PheOMe (Figure 
10c),
46
 ‘heterochiral’ because the 3-residues derived from L--residues, was shown to adopt a mixed structure characterized 
by one classic 11-membered i->i+3 hydrogen bond, and a distinct 9-membered 2->1 H-bond with opposite orientation.
49
 
More recently, the 2->1 9-membered hydrogen bond was described by Sanjayan and Rajamohanan
49
 in oligopeptide 
foldamers consisting of the repeating building blocks L-Pro and anthranilic acid, the latter as a rigid -amino acid (Figure 
10d). The structure was explained as the result of the combined intrinsic conformational preferences of two local constraints 
and the repetitive /-hybrid structure.19 Replacing Pro with other residues had an adverse effect on the stabilization of this 
architecture. Later studies confirmed the stability of the turn motifs featuring the 9-membered hydrogen-bond also in 
tripeptides containing a distinct Ant-Pro scaffold.
48
 
Remarkably, the characteristic Freidinger-lactam-like structure of the mixed 2/-dipeptide mimetic Amo-Phe consented 10a 
to adopt in a very competitive and biomimetic environment a significant population of folded geometries, without the 
concomitant assistance of further constraint-inducers, and without the cooperative effect of repetitive units. 
5.3. Conclusions 
The cyclization of isoSer incorporated into short peptides with DSC and DIPEA was performed either in solution or in solid 
phase with very good yields, and allowed preparing in a single step peptidomimetics containing the unusual 
aminomethyloxazolidin-2,4-dione (Amo) scaffold comprising isoSer and the following residue. This unusual scaffold 
represents a unprecedented 2-homo variant of the classic Freidinger lactam. Besides, the availability of optically pure -
substituted -hydroxy-2,2-amino acids allowed preparing peptidomimetics carrying a single proteinogenic side chain at each 
residue. Conformational analyses indicated that the constrained -substituted Amo tends to favour in homochiral oligomers a 
rare pseudo -turn stabilized by a 9-membered hydrogen bond of type 2->1 in the opposite direction of the sequence. 
For the simple synthetic protocol and the atypical geometric features, the Amo ring deserves to be exploited for the design of 
new conformationally biased peptidomimetics or foldamers. The scope of the Amo scaffold could be extended by introducing 
a substituent with defined stereochemistry in the -position of the Amo motif, thus providing a constrained 2,3-amino acids 
building block. Further studies could include the preparation and analysis of the conformational preference of oligopeptides 
composed of repetitive Amo units, alone or in combination with other residues. 
5.4. Experimental Section 
5.4.1. General Methods 
Standard chemicals (including Boc- or Fmoc-protected -amino acids, (S)- and (R)-H-isoSerOH, Fmoc-rac-H-isoSerOH, 
(S)- and (R)-H-PheNH2, H-ValOMe, H-SarNH2), were purchased from commercial sources and used without further 
purification. Flash chromatography was performed on silica gel (230-400 mesh), using mixtures of distilled solvents. 
Compounds purities were assessed by analytical RP-HPLC and elemental analysis. Analytical RP-HPLC was performed on 
an Agilent 1100 series apparatus, using a RP column Phenomenex mod. Gemini 3 C18 110A 100x3.0 mm (P/No 00D-
4439-Y0); column description: stationary phase octadecyl carbon chain-bonded silica (C18) with TMS endcapping, fully 
porous organo-silica solid support, particle size 3 m, pore size 110 Å, length 100 mm, internal diameter 3 mm;  DAD 210 
nm; mobile phase: from a 9:1 H2O-CH3CN to a 2:8 H2O-CH3CN in 20 min at a flow rate of 1.0 mL min
-1
, followed by 10 
min at the same composition. Semi-preparative RP-HPLC was performed on an Agilent 1100 series apparatus, using a RP 
column ZORBAX mod. Eclipse XDB-C18 PrepHT cartridge 21.2x150 mm 7 (P/No 977150-102); column description: 
stationary phase octadecyl carbon chain-bonded silica (C18), double endcapped, particle size 7 µm, pore size 80 Å, lenght 
150 mm, internal diameter 21.2 mm; DAD 210 nm; mobile phase from 8:2 H2O-CH3CN to 100% CH3CN in 10 min at a flow 
rate of 12 mL min
-1
. Chiral HPLC analysis was performed on an Agilent 1200 series apparatus, using a CHIRALPAK IC 
column (P/No 83325); column description: chiral stationary phase cellulose tris (3,5-dichlorophenylcarbamate) immobilized 
on silica, particle size 5 µm, lenght 250 mm, internal diameter 4.6 mm, DAD 210/254 nm; mobile phase: 3:1 n-hexane/2-
propanol, at 0.8 mL min
-1
.The RP-HPLC of compounds 3h, H-Phe-ValOMe, 7, Ts-Ala--Me-isoSerOH, was performed as 
reported above, with the addition of 0.1% TFA in the mobile phase, and setting DAD at 254 nm. ESI analysis was performed 
using a MS single quadrupole HP 1100MSD detector, with a drying gas flow of 12.5 l/min, nebulizer pressure 30 psgi, 
drying gas temp. 350°C, capillary voltage 4500 (+) and 4000 (-),  scan 50-2600 amu. Elemental analyses were performer 
using a Thermo Flash 2000 CHNS/O analyzer. High quality IR were obtained at 2 cm
-1
 resolution using a FT-IR 
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spectrometer and 1 mm NaCl solution cell. Electronic circular dichroism (ECD) spectra were recorded on a Jasco J-710 
spectropolarimeter. The synthetic procedures by MW irradiation were performed using a microwave oven (MicroSYNTH 
Microwave Labstation for Synthesis) equipped with a built-in ATC-FO advanced fiber optic automatic temperature control. 
1
H NMR spectra were recorded using a Varian Gemini apparatus at 400 MHz in 5 mm tubes, using 0.01 M peptide at room 
temperature. Solvent suppression was performed by the solvent presaturation procedure implemented in Varian (PRESAT). 
13
C NMR spectra were recorded at 100 MHz. Chemical shifts are reported as  values relative to residual CHCl3 H (7.26 
p.p.m.), DMSO H (2.50 p.p.m.) and CDCl3 C (77.16 p.p.m.) as internal standards. The unambiguous assignment of 
1
H 
NMR resonances was performed by 2D gCOSY. VT-
1
H NMR experiments were performed over the range of 298-348 K; 
temperature calibration was done with the ethylene glycol OH-CHn chemical-shift separation method. 4.6 μm particle. 
5.4.2. Synthetic procedures 
Boc-(S)-isoSer-(S)-PheNH2 (1a). A stirred solution of Boc-isoSer-OH (0.20 g, 1.0 mmol) in 4:1 DCM/DMF (5 mL) was 
treated with HOBt (0.16 g, 1.2 mmol.) and HBTU (0.46 g, 1.2 mmol.), at r.t. and under nitrogen atmosphere. After 5 min, H-
PheNH2 (0.18 g, 1.1 mmol.) and DIPEA (0.42 mL, 2.4 mmol) were added, and the mixture was stirred under nitrogen 
atmosphere and under MW irradiation. The microwave-assisted reaction was performed with a initial irradiation power of 
150W, and monitoring the internal reaction temperature at 80°C with a built-in ATC-FO advanced fiber optic automatic 
temperature control. After 10 min, the mixture was concentrated at reduced pressure, and the residue was diluted with EtOAc 
(25 mL). The solution was washed with 0.1 M HCl (5 mL), and a saturated solution of NaHCO3 (5 mL). The organic layer 
was dried over Na2SO4 and the solvent was evaporated at reduced pressure. Peptide 1a was isolated (0.29 g, 80%, 91% pure 
by analytical RP-HPLC, see General Methods, Rt = 4.33 min) by flash chromatography over silica gel (eluant EtOAc/MeOH 
95:5). 
1
H NMR (CDCl3)  = 1.34 (s, 9H, t-Bu), 3.00-3.17 (m, 2H, PheH), 3.20-3.36 (m, 2H, isoSerH), 4.10 (m, 1H, 
isoSerH), 4.59 (q, J = 6.8 Hz, 1H, PheH), 5.38 (br.t, 1H, isoSerNH), 6.29 (s, 1H, CONH2), 6.79 (s, 1H, CONH2), 7.08-
7.12 (m, 3H, PheArH), 7.12-7.20 (m, 2H, PheArH), 7.61 (br.d, 1H, PheNH). ESI-MS m/z 374.4 (M+ Na)
+
, calcd 374.4 
Boc-(S)-isoSer-(R)-PheNH2 (1b); Boc-(R)-isoSer-(S)-PheNH2 (1c). The reaction of Boc-isoSerOH and (R)-H-PheNH2, or 
(R)-Boc-isoSerOH and H-PheNH2, using the same reagent quantities and under same MW-assisted conditions described for 
the preparation of 1a,
 
afforded dipeptides 1b or 1c, respectively. After the same work up, the crude 1b,c were precipitated 
from MeOH/Et2O and collected by filtration. The crude peptides were identified by ESI-MS, and purity was assessed by 
analytical RP-HPLC (General Methods). 1b (86%, 76% pure, Rt =  4.01 min) ESI-MS m/z 352.2 (M+1)
+
, calcd 352.4. 1c 
(85%, 78% pure, Rt =  3.49 min) ESI-MS m/z 352.3 (M+1)
+
, calcd 352.4. 
Boc-(S)-isoSer-(S)-Phe-ValOMe (1d); Boc-(R)-isoSer-(S)-Phe-ValOMe (1e). Boc- Phe-ValOMe
22
 (1.13 g, 3.0 mmol) was 
N-deprotected according to the General Procedure for Boc Deprotection, giving H-Phe-ValOMe-TFA salt in quantitative 
yield (90% pure by analytical RP-HPLC, see General methods, Rt = 1.82 min), identified by ESI analysis. ESI-MS m/z 279.2 
(M+1)
+
, calcd 279.2. The crude dipeptide was coupled with Boc-isoSerOH or Boc-(R)-isoSerOH using the same quantities 
and under same conditions described for the preparation of 1a,
 
affording dipeptides 1d or 1e, respectively. After the same 
work up, the crude 1d,e were analyzed by RP-HPLC ESI-MS (General Methods). 1d (82%, 75% pure, Rt = 4.30 min) ESI-
MS m/z 466.1 (M+1)
+
, calcd 466.2. 1e (80%, 73% pure, Rt = 4.62 min) ESI-MS m/z 466.2 (M+1)
+
, calcd 466.2. 
General Procedure for Boc Deprotection. The intermediate N-Boc peptides 1 (1.0 mmol) were deprotected by treatment with 
25% TFA in DCM (5 mL) while stirring at r.t. After 15 min, the solution was evaporated under reduced pressure, and the 
treatment was repeated. The residue was suspended in ice-cold Et2O (20 mL). The intermediate peptide-TFA salts which 
precipitated in almost quantitative yields were collected by centrifuge, and used for the next couplings without further 
purifications (80-85% pure by analytical RP-HPLC, General Methods). 
General Procedure for the Synthesis of Peptides 2e-f. The N-deprotected peptides-TFA salts prepared from peptides 1 as 
described above were subjected to coupling with Tosyl (Ts)-AlaOH or Boc-AlaOH in the same number of mmol and using 
the same procedure utilized for 1a, giving the corresponding tri- or terapeptides 2a-e or 2f, respectively. After the usual 
work-up, the peptides were isolated (80-85%) by flash chromatography over silica gel (eluant EtOAc/MeOH 95:5).  
Ts-(S)-Ala-(S)-isoSer-(S)-PheNH2 (2a). 90% pure by RP-HPLC (General Methods), Rt = 4.86 min. 
1
H NMR (CDCl3)  = 
1.00 (d, J=6.8 Hz, 3H, AlaMe), 2.37 (s, 3H, TsMe), 2.71 (ddd, J=5.0, 8.2, 13.8 Hz, 1H, isoSerHβ), 2.88 (dd, J=7.8, 13.8 Hz, 
1H PheHβ), 3.02 (dd, J=5.0, 13.8 Hz, 1H, PheHβ), 3.20 (ddd, J=4.4, 6.2, 13.8 Hz, 1H, isoSerHβ), 3.73 (dq, J=5.2, 6.8 Hz, 
1H, AlaHα), 3.79 (dd, J=4.4, 8.2 Hz, 1H, isoSerHα), 4.49 (ddd, J=5.0, 5.6, 7.8, 1H, PheHα), 5.86 (d, J=5.2 Hz, 1H, AlaNH), 
7.16-7.27 (m, 5H, PheArH), 7.35 (m, 2H, TsArH3,5), 7.51 (s, 1H, CONH2), 7.63-7.69 (m, 3H, TsArH2,6+PheNH), 7.77 (dd, 
J=5.0, 6.2 Hz, 1H, isoSerNH), 7.86 (s, 1H, CONH2). ESI-MS m/z 477.4 (M+H)
+
, calcd 477.2. 
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Ts-(S)-Ala-(R)-isoSer-(S)-PheNH2 (2b). 88% pure by RP-HPLC (General Methods), Rt = 4.16 min. 
1
H NMR (CDCl3)  = 
0.99 (d, J=6.8 Hz, 3H, AlaMe), 2.36 (s, 3H, TsMe), 2.86-2.98 (m, 2H, isoSerHβ+PheHβ), 3.01 (dd, J=4.8, 13.9 Hz, 1H, 
PheHβ), 3.22 (ddd, J=4.6, 6.2, 13.8 Hz, 1H, isoSerHβ),  3.74 (dq, J=5.0, 6.8 Hz, 1H, AlaHα), 3.78 (dd, J=4.6, 8.0 Hz, 1H, 
isoSerHα), 4.46 (ddd, J=4.8, 5.7, 7.6 Hz, 1H, PheHα), 5.79 (d, J=5.0 Hz, 1H, AlaNH), 7.16-7.27 (m, 5H, PheArH), 7.35 (m, 
2H, TsArH3,5), 7.51 (s, 1H, CONH2), 7.64-7.67 (m, 3H, TsArH2,6+PheNH), 7.75 (dd, J=4.8, 6.2 Hz, 1H, isoSerNH), 7.85 
(s,1H, CONH2). ESI-MS m/z 477.4 (M+H)
+
, calcd 477.2. 
Ts-(S)-Ala-(S)-isoSer-(R)-PheNH2 (2c). 91% pure by RP-HPLC (General Methods), Rt = 4.45 min. 
1
H NMR (CDCl3)  = 
1.18 (d, J=7.0 Hz, 3H, AlaMe), 2.42 (s, 3H, TsMe), 3.04 (dd, J=8.2, 14.0 Hz, 1H, PheHβ), 3.23 (dd, J=6.0, 14.0 Hz, 1H, 
PheHβ), 3.63 (ddd, J=4.8, 8.2, 13.8 Hz, 1H, isoSerHβ), 3.68-3.78 (m, 2H, AlaHα+isoSerHβ), 4.16 (m, 1H, isoSerHα), 4.49 
(dd, J=6.0, 6.4, 8.2 Hz, 1H, PheHα), 5.32 (d, J=2.4 Hz, 1H, isoSerOH), 5.93 (d, J=7.6 Hz, 1H, AlaNH), 6.34 (s, 1H, CONH2), 
6.79 (s, 1H, CONH2), 7.18-7.31 (m, 7H, TsArH3,5+PheArH), 7.61 (d, J=6.4 Hz, 1H, PheNH), 7.68 (dd, J=4.8, 6.0 Hz, 1H, 
isoSerNH), 7.75 (m, 2H, TsArH2,6). ESI-MS m/z 477.4 (M+H)
+
, calcd 477.2. 
Ts-(S)-Ala-(S)-isoSer-(S)-Phe-(S)-ValOMe (2d). 89% pure by RP-HPLC (General Methods), Rt = 4.90 min. 
1
H NMR 
(CDCl3)  = 0.84 (d, J=6.6 Hz, 3H, ValMe), 0.87 (d, J=6.8 Hz, 3H, ValMe), 1.17 (d, J=6.8 Hz, 3H, AlaMe), 2.10 (m, 1H, 
ValHβ), 2.41 (s, 3H, TsMe), 3.13 (d, J=7.6 Hz, 2H, PheHβ), 3.41 (ddd, J=5.6, 6.4, 14.0 Hz, 1H, isoSerHβ), 3.49 (ddd, J=6.0, 
8.0, 14.0 Hz, 1H, isoSerHβ), 3.69 (s, 3H, OMe), 3.79 (dq, J=6.8, 7.6 Hz, 1H, AlaHα), 4.13 (ddd, J=4.6, 6.0, 6.4 Hz, 1H, 
isoSerHα), 4.44 (dd, J=5.2, 8.4 Hz, 1H, ValHα), 4.70 (dt, J=7.6, 8.0 Hz, 1H, PheHα), 5.04 (d, J=4.6 Hz, 1H, isoSerOH), 6.14 
(d, J=7.6 Hz, 1H, AlaNH), 6.92 (d, J=8.4 Hz, 1H, ValNH), 7.18-7.30 (m, 7H, PheArH+TsArH3,5), 7.51 (dd, J=5.6, 8.0 Hz, 
1H, isoSerNH), 7.52 (d, J=8.0 Hz, 1H, PheNH), 7.73 (m, 2H, TsArH2,6). ESI-MS m/z 591.3 (M+H)
+
, calcd 591.4. 
Ts-(S)-Ala-(R)-isoSer-(S)-Phe-(S)-ValOMe (2e). 92% pure by RP-HPLC (General Methods), Rt = 4.78 min. 
1
H NMR 
(CDCl3)  = 0.93 (d, J=6.8 Hz, 3H, ValMe), 0.95 (d, J=7.2 Hz, 3H, ValMe), 1.15 (d, J=7.2 Hz, 3H, AlaMe), 2.15 (m, 1H, 
ValHβ), 2.45 (s, 3H, TsMe), 3.00 (dd, J=7.4, 13.9 Hz, 1H, PheHβ), 3.08 (dd, J=6.9, 13.9 Hz, 1H, PheHβ), 3.43 (ddd, J=3.0, 
5.2, 14.2 Hz, 1H, isoSerHβ), 3.74 (s, 3H, OMe), 3.87-3.95 (m, 2H, AlaHα+isoSerHβ), 4.20 (dd, J=3.0, 6.2 Hz, 1H, 
isoSerHα), 4.51 (dd, J=5.8, 8.1 Hz, 1H, ValHα), 4.55 (ddd, J=6.9, 7.4, 8.0 Hz, 1H, PheHα), 6.39 (d, J=8.1 Hz, 1H, ValNH), 
7.19-7.34 (m, 10H, PheArH+TsArH3,5+AlaNH+PheNH+isoSerNH), 7.77 (m, 2H, TsArH2,6). ESI-MS m/z 590.3 (M+H)
+
, 
calcd 591.4 
Boc-(S)-Ala-(S)-isoSer-(S)-Phe-(S)-ValOMe (2f). 87% pure by RP-HPLC (General Methods), Rt = 4.86 min.  
1
H NMR 
(CDCl3) two conformers in 6:4 ratio  = 0.80 (d, J=7.2 Hz, 3H, ValMe), 0.83 (d, J=6.8 Hz, 3H, ValMe), 1.21major 
conf+1.26minor conf (d, J =6.8 Hz, 3H, AlaMe), 1.37 (s, 9H, t-Bu), 2.05 (m, 1H, ValHβ), 3.01-3.11 (m, 2H, PheHβ), 3.35 (m, 1H, 
isoSerHβ), 3.48 (m, 1H, isoSerHβ), 3.65 (s, 3H, OMe), 4.03-4.08 (m, 2H, AlaHα+isoSerHα), 4.38 (m, 1H, ValHα), 4.63 
(br.q, 1H, PheHα), 5.05minor conf+5.31major conf (br.d, 1H, AlaNH), 6.84 (br.d, 1H, ValNH), 7.19-7.23 (m, 6H, 
PhArH+isoSerNH), 7.55 (br.d, J=8.4 Hz, 1H, PheNH). ESI-MS m/z 536.6 (M+H)
+
, calcd 536.7 
Solid-phase synthesis of Ac-(S)-Ala-(S/R)-Amo-(S)-Phe-Wang (2h). Wang resin pre-loaded with Fmoc-PheOH (0.5 g, 0.4-
0.8 mmol/g, resin particle size: 100-200 mesh) was introduced into a reactor for SPPS. Fmoc was removed with 4:1 
DMF/piperidine (5 mL) under MW irradiation for 1 min under mechanical shaking (40W, monitoring the internal 
temperature at 45°C with a built-in ATC-FO advanced fiber optic automatic temperature control). The suspension was 
filtered, the resin was washed with DCM (5 mL) and treated with a second portion of DMF/piperidine as above described. 
Then the suspension was filtered, and the resin was washed three times in sequence with DCM (5 mL) and MeOH (5 mL). 
All coupling steps were performed according to the following General Procedure. The resin was swollen in DCM (5 mL), 
and a solution of the Fmoc-N-protected amino acid (0.6 mmol) and HOBt (0.6 mmol) in DMF (4 mL) was added at r.t. and 
under nitrogen atmosphere, followed by HBTU (0.6 mmol.) and DIPEA (1.2 mmol). The mixture was mechanically shaken 
under MW irradiation as above described, and after 10 min the resin was filtered and washed three times with the sequence 
DCM (5 mL) and MeOH (5 mL). Coupling efficacy was determined by means of the Kaiser test. All subsequent deprotection 
steps were performed as above reported. 
Ts-Ala-isoSer-SarNH2 (2i). Boc-isoSerOH and H-SarNH2 were coupled in the same quantities and by the same procedure 
utilized for the preparation of 1a
 
(MW assisted peptide synthesis). The crude Boc-isoSer-SarNH2 was recovered as descrived 
for 1b,c (85%, 78% pure by analytical RP-HPLC, General methods, Rt =3.17 min). The dipeptide was N-deprotected 
according to the General Procedure for Boc Deprotection, and the corresponding peptide-TFA salt was coupled with Ts-
AlaOH under above described conditions. 2i was isolated (70%, 92% pure by analytical RP-HPLC, see General Methods, Rt 
= 3.54 min) by flash chromatography over silica gel (eluant EtOAc/MeOH 95:5). 
1
H NMR (CDCl3) major conformer  = 
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1.11 (d, J=7.2 Hz, 3H, AlaMe), 2.37 (s, 3H, TsMe), 3.45 (s, 3H, SarMe), 3.64-3.76 (m, 2H, isoSerH+AlaH), 3.82 (J=4.4, 
6.2, 13.8 Hz, 1H, isoSerHβ), 4.14 (d, J=18.2 Hz, 1H, SarH), 4.20 (d, J=18.2 Hz, 1H, SarH), 4.90 (br.t, 1H, isoSerH), 
6.31 (d, J=6.8 Hz, 1H, AlaNH), 6.90 (s, 1H, CONH2), 7.20 (s, 1H, CONH2), 7.35 (m, 2H, TsArH3,5), 7.53 (dd, J=5.0, 6.2 Hz, 
1H, isoSerNH), 7.66 (m, 2H, TsArH2,6). ESI-MS m/z 401.2 (M+H)
+
, calcd 401.1. 
In-solution synthesis of Amo-peptides 3a-g, 10a and 10b. DSC (0.36 mmol) was added to a stirred solution of 1 (0.33 mmol) 
in 3:1 DCM/DMF (4 mL) followed by DIPEA (0.07 mmol) at r.t. and under nitrogen atmosphere. After 1 h, the solvent was 
removed under reduced pressure, the residue was diluted with 0.1 M HCl (5 mL), and the mixture was extracted three times 
with DCM (5 mL). The combined organic layers were dried over Na2SO4, solvent was evaporated at reduced pressure. The 
residue was purified by semi-preparative RP-HPLC (General Methods). 
Ts-(S)-Ala-(S)-Amo-(S)-PheNH2 (3a). 95% pure by RP-HPLC (General Methods), Rt = 6.41 min. 
1
H NMR (CDCl3)  = 
1.17 (d, J=6.8 Hz, 3H, AlaMe), 2.42 (s, 3H, TsMe), 3.48-3.58 (m, 3H, PheHβ+AmoHβ), 3.69 (ddd, J=4.0, 6.4, 13.8 Hz, 1H, 
AmoHβ), 3.78 (dq, J=6.4, 6.8 Hz, 1H, AlaHα), 4.73 (dd, J=4.0, 7.6 Hz, 1H, AmoHα), 4.93 (t, J=8.4 Hz, 1H, PheHα), 6.10 
(br.d, J=6.4 Hz, 1H, AlaNH), 6.24 (s, 1H, CONH2), 6.52 (s, 1H, CONH2), 7.09 (br.t, 1H, AmoNH), 7.19 (m, 2H, TsArH3,5), 
7.20-7.34 (m, 5H, PhArH), 7.72 (m, 2H, TsArH2,6);
 13
C NMR (CDCl3)  = 18.4, 21.5, 33.8, 38.9, 52.7, 56.8, 76.7, 127.2, 
127.5, 128.9, 129.5, 129.9, 135.8, 136.3, 144.0, 154.7, 170.1, 171.6, 172.9. Elem. Anal. for C23H26N4O7S; calcd: C 54.97, H 
5.21, N 11.15, S 6.38; found: C 54.14, H 5.28, N 11.28, S 6.51. ESI-MS m/z 503.3 (M+H)
+
, calcd 503.2. 
Ts-(S)-Ala-(R)-Amo-(S)-PheNH2 (3b). 96% pure by RP-HPLC (General Methods), Rt = 6.32 min. 
1
H NMR (CDCl3)  = 
1.15 (d, J=7.1 Hz, 3H, AlaMe), 2.43 (s, 3H, TsMe), 3.37 (ddd, J=4.4, 4.8, 14.6 Hz, 1H, AmoHβ), 3.52 (d, J=8.7 Hz, 2H, 
PheHβ), 3.80 (dq, J=7.1, 8.2 Hz, 1H, AlaHα), 4.12 (ddd, J=4.2, 7.6, 14.6 Hz, 1H, AmoHβ), 4.70 (dd, J=4.2, 4.4 Hz, 1H, 
AmoHα), 4.97 (t, J=8.7 Hz, 1H, PheHα), 6.28 (m, 2H, CONH2+AlaNH), 6.41 (s, 1H, CONH2), 6.99 (dd, J=4.8, 7.6 Hz, 1H, 
AmoNH), 7.23-7.31 (m, 5H, PheArH), 7.33 (m, 2H, TsArH3,5), 7.73 (m, 2H, TsArH2,6); 
13
C NMR (CDCl3)  = 18.7, 21.3, 
33.2, 38.5, 52.5, 55.8, 76.7, 126.8, 127.0, 128.5, 128.6, 129.5, 136.1, 137.0, 143.3, 153.9, 169.3, 170.8, 172.6. Elem. Anal. 
for C23H26N4O7S; calcd: C 54.97, H 5.21, N 11.15, S 6.38, found: C 56.07, H 5.11, N 10.93, S 6.27. ESI-MS m/z 503.3 
(M+H)
+
, calcd 503.2. 
Ts-(S)-Ala-(S)-Amo-(R)-PheNH2 (3c). 95% pure by RP-HPLC (General Methods), Rt = 6.88 min.  
1
H NMR (CDCl3)  = 
1.11 (d, J=7.2 Hz, 3H, AlaMe), 2.42 (s, 3H, TsMe), 3.45-3.52 (m, 3H, AmoHβ+PheHβ), 3.75-3.84 (m, 2H, AlaHα+AmoHβ), 
4.69 (dd, J=4.0, 4.4 Hz, 1H, AmoHα), 4.91 (dd, J=6.4, 9.9 Hz, 1H, PheHα), 6.25 (d, J=7.2 Hz, 1H, AlaNH), 6.47 (s, 1H, 
CONH2), 6.79 (s, 1H, CONH2), 7.18-7.31 (m, 8H, TsArH3,5+PheArH+AmoNH), 7.73 (m, 2H, TsArH2,6); 
13
C NMR (CDCl3) 
 = 18.3, 21.0, 33.0, 38.5, 52.2, 55.6, 76.6, 126.6, 126.7, 128.3, 128.4, 129.3, 136.0, 136.8, 143.0, 153.8, 169.1, 170.3, 172.4.  
Elem. Anal. for C23H26N4O7S; calcd: C 54.97, H 5.21, N 11.15, S 6.38; found: C 55.62, H 5.16, N 11.24, S 6.20. ESI-MS m/z 
503.3 (M+H)
+
, calcd 503.2. 
Ts-(S)-Ala-(S)-Amo-(S)-Phe-(S)-ValOMe (3d). 96% pure by RP-HPLC (General Methods), Rt = 6.55 min. 
1
H NMR 
(CDCl3)  = 0.81 (d, J=6.4 Hz, 3H, ValMe), 0.88 (d, J=6.8 Hz, 3H, ValMe), 1.13 (d, J=7.2 Hz, 3H, AlaMe), 2.14 (m, 1H, 
ValHβ), 2.39 (s, 3H, TsMe), 3.44 (ddd, J=3.5, 5.2, 14.4 Hz, 1H, AmoHβ), 3.53 (d, J=8.6 Hz, 2H, PheHβ), 3.63 (ddd, J=4.0, 
6.0, 14.4 Hz 1H, AmoHβ), 3.73 (s, 3H, OMe), 3.82 (dq, J=7.2, 8.6 Hz, 1H, AlaHα), 4.51 (dd, J=4.8, 8.6 Hz, 1H, ValHα), 
4.67 (dd, J=3.5, 4.0 Hz, 1H, AmoHα), 4.95 (t, J=8.6 Hz, 1H, PheHα), 5.79 (d, J=8.6 Hz, 1H, AlaNH), 6.81 (d, J=8.6 Hz, 1H, 
ValNH), 7.00 (dd, J=5.2, 6.0 Hz, 1H, AmoNH), 7.23-7.33 (m, 7H, PheArH2+TsArH3,5), 7.68 (m, 2H, TsArH2,6); 
13
C NMR 
(CDCl3)  = 17.8, 18.8, 18.9, 21.4, 30.9, 34.1, 38.9, 52.3, 52.4, 57.4, 57.9, 77.3, 127.0, 127.4, 128.8, 128.9, 129.6, 135.7, 
136.9, 143.5, 154.4, 167.5, 171.1, 172.2, 172.5. Elem. Anal. for C29H36N4O9S; calcd: C 56.48, H 5.88, N 9.09, S 5.20; found: 
C 55.35, H 5.76, N 9.27, S 5.32. ESI-MS m/z 617.5 (M+H)
+
, calcd 617.2. 
Ts-(S)-Ala-(R)-Amo-(S)-Phe-(S)-ValOMe (3e). 94% pure by RP-HPLC (General Methods), Rt = 6.98 min. 
1
H NMR 
(CDCl3)  = 0.81 (d, J=6.8 Hz, 3H, ValMe), 0.89 (d, J=6.4 Hz, 3H, ValMe), 1.14 (d, J=7.0 Hz, 3H, AlaMe), 2.14 (m, 1H, 
ValHβ), 2.44 (s, 3H, TsMe), 3.28 (ddd, J=3.0 3.4, 14.4 Hz, 1H, AmoHβ), 3.54 (dd, J=8.0, 14.6 Hz, 1H, PheHβ), 3.58 (dd, 
J=8.4, 14.6 Hz, 1H, PheHβ), 3.77 (s, 3H, OMe), 3.87 (dq, J=7.0, 8.8 Hz, 1H, AlaHα), 4.28 (ddd, J=4.1, 9.0, 14.4 Hz, 1H, 
AmoHβ), 4.49 (dd, J=5.0, 8.2 Hz, 1H, ValHα), 4.76 (dd, J=3.0, 4.1 Hz, 1H, AmoHα), 5.03 (dd, J=8.0, 8.4 Hz, 1H, PheHα), 
6.21 (d, J=8.8 Hz, 1H, AlaNH), 6.41 (d, J=8.2 Hz, 1H, ValNH), 6.78 (dd, J=3.4, 9.0 Hz, 1H, AmoNH), 7.30-7.34 (m, 5H, 
PheArH), 7.38 (m, 2H, TsArH3,5), 7.72 (m, 2H, TsArH2,6); 
13
C NMR (CDCl3)  = 17.8, 18.7, 18.9, 21.5, 30.9, 34.0, 38.3, 
52.4, 52.9, 55.5, 58.3, 77.8, 127.0, 127.1, 127.9, 128.8, 128.9, 129.2, 129.4, 129.8, 129.9, 135.3, 137.1, 143.7, 153.9, 167.4, 
171.2, 171.5, 172.5. Elem. Anal. for C29H36N4O9S; calcd: C 56.48, H 5.88, N 9.09, S 5.20; found: C 55.57, H 5.97, N 8.90, S 
5.04. ESI-MS m/z 617.5 (M+H)
+
, calcd 617.2. 
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Boc-(S)-Ala-(S)-Amo-(S)-Phe-(S)-ValOMe (3f). 95% pure by RP-HPLC (General Methods), Rt = 7.02 min. 
1
H NMR 
(CDCl3)  = 0.84 (d, J=6.4 Hz, 3H, ValMe), 0.92 (d, J=6.8 Hz, 3H, ValMe), 1.25 (d, J=6.0 Hz, 3H, AlaMe), 1.42 (s, 9H, t-
Bu), 2.18 (m, 1H, ValHβ), 3.42 (ddd, J=4.4, 5.6, 14.4 Hz, 1H, AmoHβ), 3.53 (d, J=8.5 Hz, 2H, PheHβ), 3.76 (s, 3H, OMe), 
3.84 (ddd, J=4.8, 7.2, 14.4 1H, AmoHβ), 4.16 (m, 1H, AlaHα), 4.56 (dd, J=4.8, 8.2 Hz, 1H, ValHα), 4.74 (dd, J=4.4, 4.8 Hz, 
1H, AmoHα), 4.95 (t, J=8.5 Hz, 1H, PheHα), 5.30 (br.d, 1H, AlaNH), 6.81 (d, J=8.2 Hz, 1H, ValNH), 6.87 (dd, J=5.6, 7.2 
Hz, 1.H, AmoNH), 7.23-7.34 (m, 5H, PheArH); 
13
C NMR (CDCl3)  = 17.6, 18.5, 18.9, 25.4, 25.5, 28.2, 30.9, 34.2, 38.8, 
50.0, 52.4, 57.3, 57.7, 76.6, 127.5, 128.6, 128.8, 129.0, 135.5, 152.1, 154.4, 168.7, 171.4, 172.3, 173.9. Elem. Anal. for 
C27H38N4O9; calcd: C 57.64, H 6.81, N 9.96; found: C 56.66, H 6.95, N 10.11. ESI-MS m/z 585.3 (M+Na)
+
, calcd 585.3. 
Boc-(S)-Amo-(S)-PheNH2 (3g). 96% pure by RP-HPLC (General Methods), Rt = 6.88 min. 
1
H NMR (CDCl3)  = 1.42 (s, 
9H, t-Bu), 3.23 (ddd J=4.4, 5.4, 14.6 Hz, 1H, AmoH), 3.43 (ddd, J=4.0, 7.8, 14.6 Hz, 1H, AmoH), 3.46-3.53 (m, 2H, 
PheH), 4.70 (dd, J=4.0, 4.8 Hz, 1H, AmoH), 4.85-4.94 (m, 2H, AmoNH+PheH), 5.84 (br.s, 1H, CONH2), 6.43 (br.s, 1H, 
CONH2), 7.20 (d, J=6.8 Hz, 2H, PheArH), 7.26-7.35 (m, 3H, PheArH); 
13
C NMR (CDCl3)  = 28.2, 33.5, 38.5, 56.0, 79.8, 
80.9, 127.1, 128.7, 128.4, 136.5, 154.3, 155.7, 169.4, 171.1. Elem. Anal. for C18H23N3O6; calcd: C 57.29, H 6.14, N 11.13; 
found: C 58.43, H 6.26, N 10.91. ESI-MS m/z 400.4 (M+Na)
+
, calcd 400.2. 
Solid-phase synthesis of Ac-(S)-Ala-(S/R)-Amo-(S)-PheOH (3h). The resin-bound peptide 2h was suspended in 3:1 
DCM/DMF (4 mL), and DSC (0.9 mmol) and DIPEA (0.3 mmol) were added at r.t. and under nitrogen atmosphere. The 
reaction was conducted under mechanical shaking for 2 h, then the suspension was filtered, and the resin was washed three 
times in sequence with DCM (5 mL) and MeOH (5 mL). 
The resin-bound peptide was suspended in a solution of TFA (4.8 mL), H2O (0.20 mL), and PhOH (0.050 g), in DCM (5 
mL), and mechanically shaken at r.t. After 2 h, the mixture was filtered, the resin was washed twice with 10% TFA in Et2O 
(5 mL) and twice Et2O (5 mL). Filtrate and washes were collected, and solvent and volatiles were removed under N2 flow at 
r.t. The resulting residue was suspended in ice-cold Et2O, and the crude solid which precipitated was triturated and collected 
by centrifuge. The Amo-peptide acid 3h was isolated as a 1:1 mixture of diastereoisomers by semipreparative RP-HPLC (see 
General Methods) (80% based on the average resin loading of 0.6 mmol/g; >95% pure by analytical RP-HPLC). 
1
H NMR 
([D6]DMSO)  = 1.14+1.16 (d, J=8.0 Hz, 6H, AlaMe), 1.81 (s, 6H, Ac), 2.83 (ddd, J=3.2, 4.0, 14.2 Hz, 1H, AmoHβ), 3.17-
3.29 (m, 3H, AmoHβ+PheHβ), 3.38-3.48 (m, 3H, AmoHβ+PheHβ), 3.49 (ddd, J=3.6, 8.6, 14.4 Hz 1H, AmoHβ), 4.17-4.26 
(m, 2H, AlaHα), 4.82-4.94 (m, 2H, PheHα), 4.97 (dd, J=3.6, 7.2 Hz, 1H, AmoHα), 5.10 (dd, 3.2, 7.6, 1H, AmoHα), 7.18-
7.30 (m, 10H, PhArH), 7.90 (br.d, 1H, AlaNH), 7.92-8.04 (m, 2H, AlaNH+AmoNH), 8.19 (br.t, 1H, AmoNH); 
13
C NMR 
([D6]DMSO)  = 18.1, 18.2, 33.0, 33.1, 48.0, 48.1, 54.2, 54.5, 77.8, 78.1, 126.9, 128.1, 128.5, 128.8, 128.9, 129.1, 136.6, 
136.7, 154.0, 168.9, 169.0, 170.3, 170.4, 172.1, 172.7. 173.0, 173.1. Elem. Anal. for C18H21N3O7; C 55.24, H 5.41, N 10.74; 
found: C 54.14, H 5.52, N 10.55. ESI-MS m/z 392.2 (M+H)
+
, calcd 392.2. 
Ts-Ala-Oxd-SarNH2 (4). A solution of peptide 2i (0.1 g, 0.25 mmol) in 3:1 DCM/DMF (4 mL) was treated with DSC (0.20 
g, 0.75 mmol) and DBU (38 L, 0.25 mmol) at 40°C and under nitrogen atmosphere. After 6 h the reaction was stopped and 
work-up was done as described for the synthesis of 3a-g. The Oxd-peptide 4 was isolated by semi-preparative RP-HPLC (58 
mg, 55 %, 94% pure by RP-HPLC, general Methods, Rf = 4.60 min). 
1
H NMR (CDCl3) major conformer  = 1.32 (d, J=7.3 
Hz, 3H, AlaMe), 2.40 (s, 3H, TsMe), 3.47 (s, 3H, SarMe), 3.90 (dd, J=4.2, 8.6 Hz, 1H, OxdH4), 4.09 (d, J=18.0 Hz, 1H, 
SarH), 4.12 (dd, J=8.6, 9.3 Hz, 1H, OxdH4), 4.24 (d, J=18.0 Hz, 1H, SarH), 5.11 (dq, J=7.3, 8.8 Hz, 1H, AlaH), 5.45 
(dd, J=4.2, 9.3 Hz, 1H, OxdH5), 6.07 (br.s, 1H, CONH2), 6.38 (br.s, 1H, CONH2), 6.44 (m, 2H, CONH2+AlaNH), 7.18 (m, 
2H, TsArH3,5), 7.75 (m, 2H, TsArH2,6); 
13
C NMR ([D6]DMSO)  = 18.5, 20.8, 39.1, 38.6, 50.7, 60.5, 85.4, 128.3, 129.3, 
137.6, 141.5, 153.1, 168.4, 169.1, 175.0. Elem. Anal. for C17H22N4O7S; C 47.88, H 5.20, N 13.14; found: C 47.11, H 5.12, N 
13.29. ESI-MS m/z 427.1 (M+H)
+
, calcd 427.1. 
Ts-(S)-Ala-(4R,5R)-4-hydroxy-5-aminomethylOxd-(S)-PheNH2 (5). NaBH4 (4 mmol) was added to a solution of the 3b (0.4 
mmol) in MeOH (4 mL) at 0°C under nitrogen atmosphere. The mixture was stirred for 7 h, then the reaction was stopped 
with acetone (4 mL). The reaction mixture was concentrated at reduced pressure, and the residue was diluted with water 
(5mL), and extracted three times with DCM (5mL). The collected organic layers were dried with Na2SO4, filtered, and 
concentrated at reduced pressure. The residue was purified by semi-preparative RP-HPLC (see General Methods) giving 5 
(85%, 95% pure by RP-HPLC, general Methods, Rf = 5.12 min). 
1
H NMR (CDCl3)  = 1.17 (d, J=6.8 Hz, 3H, AlaMe), 2.44 
(s, 3H, TsMe), 3.04 (ddd, J=3.4, 5.0, 14.6 Hz, CH2N), 3.14-3.25 (m, 2H, CH2N+PheHβ) 3.34 (dd, J= 7.6, 14.0 Hz, 1H, 
PheHβ), 3.73 (dq, J=6.8, 7.2 Hz, 1H, AlaHα), 4.35 (br.t, 1H, OxdH5), 4.84 (dd, J=7.6, 8.6 Hz, 1H, PheHα), 5.21 (br.s, 1H, 
OxdH4), 5.95 (br.s, 1H, CONH2), 6.03 (d, J=7.2 Hz, 1H, AlaNH), 6.63 (br.s, 1H, CONH2), 7.08 (dd, J=5.0, 6.8 Hz, 1H, 
CH2NH), 7.27-7.35 (m, 7H, PhArH+TsArH3,5), 7.73 (m, 2H, TsArH2,6); 
13
C NMR (CDCl3)  = 19.2, 20.8, 34.8, 40.1, 52.7, 
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60.2, 79.7, 81.6, 125.7, 127.0, 127.6, 128.8, 129.0, 129.3, 130.1, 135.5, 138.1, 144.2, 157.3, 171.2, 172.9. Elem. Anal. for 
C23H28N4O7S; calcd: C 54.75, H 5.59, N 11.10, S 6.36; found: C 53.98, H 5.64, N 11.32, S 6.55. ESI-MS m/z 527.0 
(M+Na)
+
, calcd 527.2. 
Ts-(S)-Ala-(S)--Me-isoSerOMe (8a). Nitromethane (1.5 mL), methyl pyruvate (50 L, 0.5 mmol, and TEA (14 L, 0.1 
mmol) were mixed in the presence of Cu(OTf)2 (36 mg, 0.10 mmol) and 2,2’-isopropylidenebis[(4R)-4-tert-butyl-2-
oxazoline] (31 mg, 0.10 mmol), as described in the literature (Ref.
30 
main text). The reaction mixture was filtered through a 
plug of silica, and solvent was removed at reduced pressure. The resulting crude -nitro-(S)-hydroxy ester 6a obtained in 
quantitative yield was identified by RP-HPLC-ESI analysis, and was utilized without further purifications (81 mg, 99%, 85% 
pure by RP-HPLC analysis, Rt = 2.04 min, 87% e.e. as determined by chiral HPLC analysis of the crude mixture, see 
General Methods). ESI-MS m/z 186.2 (M+Na)
+
, calcd 186.1. Compound 6a was dissolved in EtOH (6 mL) and treated with 
10% Pd/C (100 mg) and H2 at atmospheric pressure for 6 h at r.t. giving after filtration over celite and evaporation of solvent 
at reduced pressure the 3-amino-2-hydroxy-2-methyl-propionic ester 7a in quantitative yield (67 mg, 99%, 82% pure by RP-
HPLC analysis, see General Methods, Rt = 1.67 min) utilized for the next step without purification. ESI-MS m/z 134.1 
(M+H)
+
, calcd 134.1. The crude 7a was coupled with Ts-AlaOH (120 mg, 0.5 mmol) by using the same procedure described 
for the synthesis of 1a. After the usual work up the dipeptide 8a (140 mg, 80%, 88% pure by RP-HPLC analysis, see General 
Methods, Rt = 3.85 min) was isolated by flash chromatography over silica gel (eluant: EtOAc: cyclohexane 2/8). 
1
H NMR 
(CDCl3)  1.25 (d, J=6.7 Hz, 3H, AlaMe), 1.40 (s, 3H, Me-isoSer), 2.44 (s, 3H, TsMe), 3.32 (dd, J=6.0, 14.0 Hz, 
isoSerHβ), 3.66-3.83 (m, 5H, AlaHα+Me-isoSerHβ+COOMe), 4.95 (br.d, J=8.4 Hz, 1H, AlaNH), 6.47 (dd, J=5.0, 6.0 Hz, 
1H, isoSerNH),7.33 (m, 2H, TsArH3,5), 7.75 (m, 2H, TsArH2,6). ESI-MS m/z 359.3 (M+H)
+
, calcd 359.1. 
Ts-(S)-Ala-(R)--Me-isoSerOMe (8b). The reaction of nitromethane and methyl pyruvate in the same quantities as described 
for the preparation of 6a in the presence of 2,2’-isopropylidenebis[(4S)-4-tert-butyl-2-oxazoline] gave 6b in quantitative 
yield (87% pure by RP-HPLC analysis, Rt = 2.04 min, 89% e.e. as determined by chiral HPLC analysis of the crude mixture, 
see General Methods). ESI-MS m/z 186.1 (M+Na)
+
, calcd 186.1. The reduction to -amino ester 7b and coupling with Ts-
AlaOH gave 8b after purification by flash chromatography (150 mg, 84%, 93% pure by RP-HPLC analysis, see General 
Methods, Rt = 3.85 min) was done as described for 8a. 
1
H NMR (CDCl3)  1.23 (d, J=6.7 Hz, 3H, AlaMe), 1.37 (s, 3H, 
Me-isoSer),  2.44 (s, 3H, TsMe), 3.20 (dd, J=4.8, 13.6 Hz, isoSerHβ), 3.66-3.83 (m, 5H, AlaHα+isoSerHβ+COOMe), 5.06 
(br.d, J=8.0 Hz, 1H, AlaNH)), 6.65 (br.t, 1H, isoSerNH), 7.33 (m, 2H, TsArH3,5), 7.75 (m, 2H, TsArH2,6). ESI-MS m/z 359.3 
(M+H)
+
, calcd 359.1. 
Ts-(S)-Ala-(S)--Me-isoSer-(S)-Phe-(S)-ValOMe (9a). The dipeptide ester 8a (140 mg, 0.39 mmol) was dissolved in MeOH 
(2 mL) and treated with 1 M LiOH (1 mL) while stirring. After 6 h, pH was adjusted to 7 with 0.1 M HCl and the solvent 
was removed at reduced pressure, giving Ts-Ala--Me-isoSerOH (128 mg, 95%, 90% pure by RP-HPLC analysis, see 
general Methods, Rt = 2.35 min). ESI-MS m/z 345.2 (M+H)
+
, calcd 345.1. The residue was suspended in 4:1 DCM/DMF (5 
mL) and treated with HOBt, HBTU, DIPEA, and H-Phe-ValOMe under MW irradiation as described for the prepaparation of 
1a. After the usual work up, the tetrapeptide 9a (0.20 g, 85%, 90% pure by analytical RP-HPLC, see general Methods, Rf = 
4.99 min) was isolated by flash chromatography over silica gel (eluant: EtOAc).
 1
H NMR (CDCl3)  0.79 (d, J=5.8 Hz, 3H, 
ValMe), 0.82 (d, J=6.8 Hz, 3H, ValMe), 1.09 (d, J=6.8 Hz, 3H, AlaMe), 1.22 (s, 3H, -Me-isoSer), 2.07 (m, 1H, ValHβ), 
2.36 (s, 3H, TsMe), 3.05 (dd, J=8.0, 14.8 Hz, 1H, PheHβ), 3.10 (dd, J=6.8, 14.8 Hz, 1H, PheHβ), 3.29 (d, J=5.8 Hz, 2H, 
isoSerHβ), 3.63 (s, 3H, OMe), 3.67 (dq, J=6.8, 7.6 Hz, 1H, AlaHα), 4.38 (dd, J=4.8, 8.0 Hz, 1H, ValHα), 4.48 (ddd, J=6.8, 
7.6, 8.0 Hz, 1H, PheHα), 6.69 (d, J=7.6 Hz, 1H, AlaNH), 6.96 (d, J=8.0 Hz, 1H, ValNH), 7.17-7.27 (m, 7H, 
PheArH+TsArH3,5), 7.38 (t, J=5.8 Hz, 1H, isoSerNH), 7.50 (d, J=7.6 Hz, 1H, PheNH), 7.66 (m, 2H, TsArH2,6). ESI-MS m/z 
605.5 (M+H)
+
, calcd 605.3. 
Ts-(S)-Ala-(R)--Me-isoSer-(S)-Phe-(S)-ValOMe (9b). The dipeptide ester 8b (150 mg, 0.42 mmol) was treated with 1 M 
LiOH in MeOH as described for 7a, affording the dipeptide acid (134 mg, 95%, 85% pure by RP-HPLC analysis, see general 
Methods, Rt = 2.38 min). after the same reaction work up. ESI-MS m/z 345.3 (M+H)
+
, calcd 345.1. Ts-Ala-(R)--Me-
isoSerOH was coupled with H-Phe-ValOMe, as described for the preparation of 9a. The tetrapeptide 9b (0.21 g, 83%, 91% 
pure by analytical RP-HPLC, see general Methods, Rf = 5.11 min) was isolated after the same work up described for 9a.
 1
H 
NMR (CDCl3)  0.87 (d, J=5.6 Hz, 3H, ValMe), 0.86 (d, J=6.8 Hz, 3H, ValMe), 1.03 (d, J=7.2 Hz, 3H, AlaMe), 1.15 (s, 
3H, -Me-isoSer), 2.06 (m, 1H, ValHβ), 2.35 (s, 3H, TsMe), 2.89 (dd, J=8.0, 14.2 Hz, 1H, PheHβ), 3.05 (dd, J=6.4, 14.2 Hz, 
1H, PheHβ), 3.17 (dd, J=5.6, 13.6 Hz, 1H, isoSerHβ), 3.51 (dd, J=6.8, 13.6 Hz, 1H, isoSerHβ), 3.65 (s, 3H, OMe), 3.76 (dq, 
J= 7.2, 7.8 Hz, 1H, AlaHα), 4.40 (dd, J=5.8, 8.2 Hz, 1H, ValHα), 4.53 (ddd, J=6.4, 7.6, 8.0 Hz, 1H, PheHα), 6.80 (d, J=7.8 
Chapter 5  
 
69 
 
Hz, 1H, AlaNH), 7.09-7.15 (m, 3H, ValNH+PheArH3,5), 7.18-7.26 (m, 6H, PheArH2,4,6+TsArH3,5
+
isoSerNH), 7.35 (d, J=7.6 
Hz, 1H, PheNH), 7.66 (m, 2H, TsArH2,6). ESI-MS m/z 605.5 (M+H)
+
, calcd 605.3 
Ts-(S)-Ala-(S)-5-Me-Amo-(S)-Phe-(S)-ValOMe (10a). The cyclization of 9a in solution as reported for 3a-g followed by the 
same work-up of the reaction and isolation by semi-preparative RP-HPLC afforded 10a (95%, 96% pure by analytical RP-
HPLC, see General methods, Rt = 7.23 min). 
1
H NMR (CDCl3)  = 0.87 (d, J=7.2 Hz, 3H, ValMe), 0.94 (d, J=7.2 Hz, 3H, 
ValMe), 1.14 (d, J=6.8 Hz, 3H, AlaMe), 1.31 (s, 3H, AmoMe), 2.22 (m, 1H, ValHβ), 2.42 (s, 3H, TsMe), 3.33 (dd, J=4.8, 
14.4 Hz, 1H, AmoHβ), 3.49 (dd, J=7.4, 14.0 Hz, 1H, PheHβ), 3.55 (dd, J=10.4, 14.0 Hz, 1H, PheHβ), 3.67 (dd, J=7.6, 14.4 
Hz, 1H, AmoHβ), 3.80 (s, 3H, OMe), 3.88 (dq, J=6.8, 8.8 Hz, 1H, AlaHα), 4.57 (dd, J=4.6, 8.2 Hz, 1H, ValHα), 4.95 (dd, 
J=7.4, 10.4 Hz, 1H, PheHα), 5.64 (d, J=8.8 Hz, 1H, AlaNH), 6.76 (d, J=8.2 Hz, 1H, ValNH), 6.97 (dd, J=4.8, 7.6 Hz, 1H, 
AmoNH), 7.24-7.36 (m, 7H, PheArH+TsArH3,5), 7.70 (m, 2H, TsArH2,6); 
13
C NMR (CDCl3)  17.5, 19.0, 19.3, 19.7, 21.5, 
31.0, 34.4, 43.5, 52.2, 52.7, 57.8, 58.1, 84.3, 127.0, 127.1, 127.9, 128.8, 128.8, 128.9, 129.1, 129.3, 129.7, 129.9 , 135.0, 
137.2, 143.5, 153.6, 167.7, 172.2, 172.5, 174.6. Elem. Anal. for C30H38N4O9S; calcd: C 57.13, H 6.07, N 8.88, S 5.08; found: 
C 58.27, H 6.18, N 8.81, S 4.97. ESI-MS m/z 631.1 (M+H)
+
, calcd 631.2. 
Ts-(S)-Ala-(R)-5-Me-Amo-(S)-Phe-(S)-ValOMe (10b). The cyclization of 9b in solution as reported for 3a-g and 9a 
followed by the same work-up of the reaction and isolation by semi-preparative RP-HPLC afforded 10b (92% 97% pure by 
analytical RP-HPLC, see General methods, Rt = 7.45 min). 
1
H NMR (CDCl3)  = 0.87 (d, J=7.2 Hz, 3H, ValMe), 0.94 (d, 
J=7.2 Hz, 3H, ValMe), 1.13 (d, J=7.2 Hz, 3H, AlaMe), 1.23 (s, 3H, AmoMe), 2.19 (m, 1H, ValHβ), 2.44 (s, 3H, TsMe), 3.12 
(dd, J= 3.6, 14.4 Hz, 1H, AmoHβ), 3.48 (dd, J=9.6, 14.0 Hz, 1H, PheHβ), 3.54 (dd, J=7.8, 14.0 Hz, 1H, PheHβ), 3.79 (s, 3H, 
OMe), 3.86 (dq, J= 7.2. 8.8 Hz, 1H, AlaHα), 4.09 (dd, J= 9.2, 14.4 Hz, 1H, AmoHβ), 4.51 (dd, J=4.8, 8.2 Hz, 1H, ValHα), 
4.99 (dd, J=7.8, 9.6 Hz, 1H, PheHα), 6.34 (d, J=8.8 Hz, 1H, AlaNH), 6.52 (d, J=8.2 Hz, 1H, ValNH), 6.76 (dd, J= 3.6, 9.2 
Hz, 1H, AmoNH), 7.19-7.32 (m, 5H, PheArH), 7.38 (m, 2H, TsArH3,5), 7.72 (m, 2H, TsArH2,6); 
13
C NMR (CDCl3)  = 18.0, 
18.4, 18.6, 21.1, 22.1. 31.4, 33.2, 43.0, 51.8, 52.3, 55.4, 58.0, 84.2, 126.4, 126.7, 128.3, 128.6, 129.4, 136.0, 137.0, 142.9, 
156.1, 167.6, 171.8, 172.1, 173.5. Elem. Anal. for C30H38N4O9S; calcd: C 57.13, H 6.07, N 8.88, S 5.08; found: C 56.00, H 
5.99, N 8.91, S 5.13. ESI-MS m/z 631.1 (M+H)
+
, calcd 631.2.  
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5.4.3. Conformationa analysis  
ROESY and molecular dynamics. 2D ROESY experiments in 8:2 [D6]DMSO/H2O were performed in the phase sensitive 
mode at r.t., spin-locking field (b2) was 2000 Hz, and mixing time was set to 250 ms; spectra were processed in the 
hypercomplex approach; peaks were calibrated on DMSO. Only ROESY-derived constraints were included in the restrained 
molecular dynamics.
50
 Cross-peak intensities were classified very strong, strong, medium, and weak, and were associated 
with distances of 2.3, 2.7, 3.3, and 5.0 Å, respectively.
51
 The intensities of the cross peaks arising from protons separated by 
known distances (e.g. geminal) were found to match with these associations. Geminal and other obvious correlations were 
discarded as constraints. For the absence of Hα(i, i+1) ROESY cross peaks, all of the ω bonds were set at 180° (force 
constant: 16 kcal mol
-1
 Å
-2
). 
Table 4. Non-obvious ROESY cross-peaks observed for 3d in 8:2 [D6]DMSO/H2O.
a 
Cross-peak intensity Cross-peak Intensity 
ValNH-ValMe vs PheArH3,5-AmoHup m 
ValNH-AlaMe w  PheArH3,5-PheHup m 
ValNH-ValH s PheArH3,5-PheHdw w 
ValNH-TsMe w  PheArH3,5-ValH w  
ValNH-AmoHup w PheArH3,5-PheH m 
ValNH-PheHup w PheArH4-ValMe w 
ValNH-PheHdw s PheArH4-TsMe w 
ValNH-COOMe w  PheArH2,6-ValMe w  
ValNH-ValH m PheArH2,6-AlaMe w  
ValNH-PheH vs PheArH2,6-TsMe w 
ValNH-AlaNH w PheArH2,6-AmoHup m 
ValNH-AmoNH w  PheArH2,6-PheHup vs 
AmoNH-ValMe w PheArH2,6-PheHdw s 
AmoNH-AlaMe m PheArH2,6-PheH vs 
AmoNH-AmoHup s AmoH-AlaMe m 
AmoNH-AmoHdw m AmoH-AmoHup m 
AmoNH-AlaH vs AmoH-AmoHdw vs 
AmoNH-AmoH m PheH-ValMe w 
AmoNH-TsArH2,6 m PheH-ValH w  
AmoNH-AlaNH m PheH-TsMe w 
AlaNH-ValMe w PheH-PheHup m 
AlaNH-AlaMe vs PheH-PheHdw s 
AlaNH-PheHdw w PheH-COOMe w 
AlaNH-AlaH m PheH-ValH w 
AlaNH-PheH w  ValH-AlaMe w  
AlaNH-TsArH2,4 w ValH-ValH vs 
TsArH2,6-ValMe w ValH-TsMe w  
TsArH2,6-AlaMe s ValH-PheHup w 
TsArH2,6-AmoHup w  ValH-PheHdw w 
TsArH2,6-AmoHdw m COOMe-ValH m 
TsArH2,6-AlaH s PheHdw-AlaMe w  
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TsArH2,6-ValH w  PheHup-ValMe m 
TsArH2,6-AmoH w  PheHup-ValH w 
TsArH3,5-ValMe w  AmoHdw-AlaMe w 
TsArH3,5-AlaMe w TsMe-ValMe w 
TsArH3,5-AmoHdw w TsMe-AlaMe w  
TsArH3,5-Val H w  TsMe-ValH w 
TsArH3,5-Amo H w ValH-AlaMe w  
PheArH3,5-AlaMe w  ValMe-AlaMe w 
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong,  s = strong, m = medium, w = weak. 
Table 5. Non-obvious ROESY cross-peaks observed for 3e in 8:2 [D6]DMSO/H2O.
a
 
Cross-peak Intensity Cross-peak Intensity 
ValNH-ValMe vs PheArH3,5-PheHup w 
ValNH-ValH s PheArH3,5-PheHdw w 
ValNH-AmoH w PheArH3,5-Phe H w 
ValNH-PheHup m PheArH2,6-AlaMe w  
ValNH-PheHdw w PheArH2,6-AmoHdw m 
ValNH-COOMe w PheArH2,6-PheHup s 
ValNH-ValH m PheArH2,6-PheHdw vs 
ValNH-PheH vs PheArH2,6-PheH vs 
ValNH-AlaNH w AmoH-ValMe w 
ValNH-AmoNH w AmoH-AmoHup m 
AmoNH-ValMe w AmoH-AmoHdw m 
AmoNH-AlaMe m AmoH-PheHdw w 
AmoNH-AmoHup m AmoH-ValH w 
AmoNH-AmoHdw s PheH-ValMe w 
AmoNH-AlaH vs PheH-ValH w  
AmoNH-AmoH w PheH-PheHup s 
AmoNH-AlaNH w PheH-PheHdw m 
AlaNH-ValMe w PheH-ValH w 
AlaNH-AlaMe vs ValH-AlaMe m 
AlaNH-AmoH w ValH-ValH m 
AlaNH-AlaH s ValH-ValMe vs 
AlaNH-TsArH2,6 s ValH-AmoHdw w 
AlaNH-TsArH3,5 s ValH-PheHup w 
TsArH2,6-ValMe w ValH-PheHdw w 
TsArH2,6-AlaMe m COOMe-ValMe w 
TsArH2,6-AlaH m COOMe-ValH w 
TsArH2,6-ValH w  COOMe-PheHup s 
TsArH2,6-AmoH w  AlaH-sMe w 
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TsArH2,6-PheH w TsMe-AlaMe w 
TsArH3,5-ValMe w  TsMe-ValH m 
TsArH3,5-AlaMe w ValH-AlaMe w  
PheArH3,5-AmoHdw w ValMe-AlaMe w 
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong, s = strong, m = medium, w = weak. 
Table 6. Non-obvious ROESY cross-peaks observed for 10a in 8:2 [D6]DMSO/H2O.
a 
Cross-peak intensity Cross-peak Intensity 
ValNH-ValMe vs PheArH3,5-AlaMe w  
ValNH-AlaMe m  PheArH3,5-AmoHup m 
ValNH-ValH s PheArH3,5-PheHup m 
ValNH-TsMe w  PheArH3,5-PheHdw w 
ValNH-AmoHup w PheArH3,5-ValH w  
ValNH-PheHup w PheArH3,5-PheH m 
ValNH-PheHdw s PheArH4-ValMe w 
ValNH-COOMe w  PheArH4-TsMe w 
ValNH-ValH m PheArH2,6-ValMe w  
ValNH-PheH vs PheArH2,6-AlaMe w  
ValNH-AlaNH w PheArH2,6-TsMe w 
ValNH-AmoNH w  PheArH2,6-AmoHup m 
AmoNH-ValMe w PheArH2,6-PheHup vs 
AmoNH-AlaMe m PheArH2,6-PheHdw s 
AmoNH-AmoMe m PheArH2,6-PheH vs 
AmoNH-ValH m PheH-ValMe w 
AmoNH-AmoHup s PheH-ValH w  
AmoNH-AmoHdw m PheH-TsMe w 
AmoNH-AlaH vs PheH-PheHup m 
AmoNH-ValH m PheH-PheHdw s 
AmoNH-PheH m PheH-COOMe w 
AmoNH-TsArH2,6 m PheH-ValH w 
AmoNH-AlaNH m ValH-AlaMe m  
AlaNH-ValMe m ValH-ValH vs 
AlaNH-AlaMe vs ValH-TsMe w  
AlaNH-ValH w ValH-PheHup w 
AlaNH-PheHdw w ValH-AlaH m 
AlaNH-AlaH m ValH-COOMe m 
AlaNH-ValH m ValH-PheHdw w 
AlaNH-PheH w  COOMe-ValH m 
AlaNH-TsArH2,4 w PheHdw-AlaMe w  
TsArH2,6-ValMe w PheHup-ValMe m 
TsArH2,6-AlaMe s PheHup-ValH w 
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TsArH2,6-AmoMe w  AmoHdw-AlaMe w 
TsArH2,6-AmoHup w  TsMe-ValMe w 
TsArH2,6-AmoHdw m TsMe-AlaMe w  
TsArH2,6-AlaH s TsMe-ValH w 
TsArH2,6-ValH w  ValH-AlaMe m 
TsArH3,5-ValMe w  AmoMe-AlaMe w 
TsArH3,5-AlaMe w AmoMe-AmoHup m 
TsArH3,5-AmoMe w AmoMe-AmoHdw vs 
TsArH3,5-AmoHdw w AlaMe-ValMe m 
TsArH3,5-ValH w    
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong,  s = strong, m = medium, w = weak. 
Table 7. Non-obvious ROESY cross-peaks observed for 10b in 8:2 [D6]DMSO/H2O.
a
 
Cross-peak Intensity Cross-peak Intensity 
ValNH-ValMe vs PheArH3,5-PheHup w 
ValNH-AmoMe m PheArH3,5-PheHdw w 
ValNH-ValH s PheArH3,5-PheH w 
ValNH-PheHup m PheArH2,6-AlaMe w  
ValNH-PheHdw w PheArH2,6-AmoHdw m 
ValNH-COOMe w PheArH2,6-PheHup s 
ValNH-ValH m PheArH2,6-PheHdw vs 
ValNH-PheH vs PheArH2,6-PheH vs 
ValNH-AlaNH w PheH-ValMe w 
ValNH-AmoNH w PheH-ValH w  
AmoNH-ValMe w PheH-PheHup s 
AmoNH-AlaMe m PheH-PheHdw m 
AmoNH-AmoMe m PheH-ValH w 
AmoNH-AmoHup m ValH-AlaMe m 
AmoNH-AmoHdw s ValH-ValH m 
AmoNH-AlaH vs ValH-ValMe vs 
AmoNH-AlaNH w ValH-AmoHdw w 
AlaNH-ValMe w ValH-PheHup w 
AlaNH-AlaMe vs ValH-PheHdw w 
AlaNH-AmoMe w COOMe-ValMe w 
AlaNH-AlaH s COOMe-ValH w 
AlaNH-TsArH2,6 s COOMe-PheHup s 
AlaNH-TsArH3,5 s AlaH-sMe w 
TsArH2,6-ValMe w TsMe-AlaMe w 
TsArH2,6-AlaMe m TsMe-ValH m 
TsArH2,6-AmoMe w  ValH-AlaMe w  
Chapter 5  
 
85 
 
TsArH2,6-AlaH m AmoMe-ValMe m 
TsArH2,6-ValH w  AmoMe-AmoHup m 
TsArH2,6-PheH w AmoMe-AmoHdw m 
TsArH3,5-ValMe w  AmoMe-PheHdw w 
TsArH3,5-AlaMe w AmoMe-ValH m 
PheArH3,5-AmoHdw w AlaMe-ValMe m 
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield;
 c
 vs = very strong, s = strong, m = medium, w = weak. 
The restrained MD simulations were conducted at 300 K and 1 atm using the AMBER force field in a 30×30×30 Å box of 
standard TIP3P models of equilibrated water.
52
 Periodic boundary conditions were applied, a dielectric constant of 1 was 
used, and the cutoff distance for the nonbonded interactions was 12 Å. All water molecules with atoms that come closer than 
2.3 Å to a solute atom were eliminated. A 100 ps simulation at 1200 K was used for generating 50 random structures that 
were subsequently subjected to a 50 ps restrained MD with a 50% scaled force field at the same temperature, followed by 50 
ps with full restraints (distance force constant of 7 kcal mol
-1
 Å
-2
), after which the system was cooled in 20 ps to 50 K. H-
bond interactions were not included, nor were torsion angle restraints. The resulting structures were minimized with 3000 
cycles of steepest descent and 3000 cycles of conjugated gradient (convergence of 0.01 kcal Å
-1
 mol
-1
). The backbones of the 
structures were clustered by the rmsd analysis.
50 
Unrestrained MD simulations
50
 were performed starting with the conformation derived from ROESY in a 30×30×30 Å box 
of standard TIP3P water for 10 ns at 298 K using periodic boundary conditions, at constant temperature and pressure 
(Berendsen scheme,
53
 bath relaxation constant of 0.2). For 1-4 scale factors, van der Waals and electrostatic interactions are 
scaled in AMBER to half their nominal value. The integration time step was set to 0.1 fs. The system coordinates were 
collected every picosecond.  
 
Figure 11. Distances (Å) between the amide nitrogen of Amo
2
 and the carbonyl oxygen of Phe
3
 sampled from a 10 ns 
unrestrained Molecular Dynamics simulation of 10a calculated in a 30x30x30
 
Å box of equilibrated standard TIP3P water 
molecules, using the ROESY-derived geometry as starting structure. 
Computational Methods. Theoretical calculations and full molecular geometry optimizations in the ground state have been 
performed in vacuo by using the Density Functional Theory (DFT)
54
 Methods implemented the Gaussian 09 package of 
programs.
34
 In particular, calculations were carried out by combining  the three-parameter hybrid functional (B3) for the 
exchange part
55
 and the Lee–Yang–Parr (LYP)56 to the 6-311++G(d,p) basis set. 
5.5. Plausible reaction pathway for the synthesis of Amo-peptides. 
A plausible reaction pathway for the cyclization of the model peptide Ts-Ala-isoSer-PheNH2 to Ts-Ala-Amo-PheNH2 with 
DSC and catalytic DIPEA is depicted in Scheme 8. In the proposed mechanism, the cyclization to Amo proceeds via the 
isoSer-O-succinimidyl carbonate intermediate A. The intermediate A is deprotonated by DIPEA at PheNH, giving the 5-
membered anionic intermediate B with endocyclic C=O (path a). The loss of 2,5-dioxopyrrolidin-1-olate leaving group, 
rapidly protonated by DIPEAH
+
, leads to the Amo-peptide 3 and DIPEA, which can be utilized in catalytic amount. The 
intermediate A can be deprotonated at isoSerNH as well (path b); this could give access to the alternative 5-membered cyclic 
anionic intermediate C with hexocyclic C=O, precursor of a Oxd-peptide. 
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Preliminary computations were performed for the intermediates B and C employing Density Functional Theory; a systematic 
conformational analysis for the structures was done at the B3LYP/6-311++G(d,p) level. Optimization was performed by 
conjugate gradient algorithm, convergence at 0.001. The results indicate that the intermediate B is about 2.0 Kcal mol
-1
 more 
stable than the alternative intermediate C. 
 
 
Scheme 8. Cyclization of the model peptide Ts-Ala-isoSer-PheNH2 2 to Ts-Ala-Amo-PheNH2 3. 
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Chapter 6 
Synthesis and conformational analysis of peptides containing the heterocycle Imd 
N-heterocycles, including cyclic ureas, are useful and multi-purpose tools in medicinal chemistry, thanks to their abilities to 
induce conformational constraints and to confer appropriate pharmacokinetic features. Therefore, in this chapter, are 
proposed two different synthetic pathways for obtaining Imidazolidin-2-one rings, directly on peptide sequences. This 
scaffold demonstrated to be easly functionalizable and displayed the capability to induce a -turn, as determined by 
spectroscopic analyses. 
6.1. Introduction 
Proteins and peptides play a central role in nearly all physiological processes associated with life, this together with a 
diversity of chemical structure, makes them particularly attractive starting point for drug discovery programs.
1
 In fact, 
peptides themselves have emerged relatively slowly as drugs, for example insulin in the treatment of diabetes and 
cyclosporin as an immunosuppressent. Their potential utilities as therapeutics are limited because of their inherent instability 
toward proteolytic cleavage by peptidases, lack of oral bioavailability, inability to cross the blood–brain barrier since their 
high molecular weight, and rapid excretion through the liver and kidneys.
2 These limitations have generated an intensive 
effort for overcoming these deficiencies in an attempt to develop peptidomimetics. The substitution of peptides with 
peptidomimetics has included a wide variety of strategies,
2c,d
 that involve the chemical modification of a peptide to 
introduce/delete those biological and chemical properties associated with effective/ineffective drug action.
2a,b
 
One of the major negative features that makes peptides inappropriate drug candidates is their flexibility. Peptide structure 
and conformation are strongly influenced by the nature of constituent amino acids and also the biophysical environment in 
which they exist. Therefore, the high conformational flexibility presents a potential problem in generating therapeutics and 
biological probes, since a peptide must attain a certain conformation in order to bind to its biological target, be it a receptor 
or an enzyme.  
Folding is the process nature has selected to control the conformation of its molecular machinery and carry out unsurpassed 
chemical functions such as enzyme catalysis, information storage and duplication in nucleic acids, as well as energy capture 
and conversion. Systematic case studies have revealed that there is typically a small cluster of well ordered key residues in 
the peptide backbone that contributes the majority of the recognition or binding aﬃnity.3 Therefore, the pre-organization of 
peptide shape, via the introduction of a structural motif that imparts conformational restriction, can enhance binding and 
hence therapeutic potential, moreover, can be useful for identification of biologically active conformers. 
Over the years, chemists have worked to geometrically restricted analogs that favors receptor binding surmounting the 
required loss of entropy for correct folding,
4
 thereby, improving potency, selectivity, and stability.
5
 The active conformation 
recognized by the receptor typically involves a turn structure (ß- or γ-turn),6 so, small-molecules and peptides with turn 
constraints have been successful in targeting this class of receptors.
6,7
  
With this purpose, a good deal of effort has gone into mimicking these structures using heterocyclic-based peptidomimetics. 
Some heterocyclic systems, called privileged scaﬀolds, appear frequently in bioactive products and marketed drugs. A 
number of common aromatic heterocycles have been employed in this context, examples used include pyrrole, tetrazole, 
triazole and pyrazoles.
8
 Over the years, extensive improvements have been made in the development of ligands, metals, 
reaction conditions, and building block availability, making this method one of the most useful tools to append aromatic 
rings into a small molecule or peptidomimetic.
9 With this powerful tool, it is not surprising to observe an increase of 
aromatic ring count in the new bioactive molecules.
10
 However, limitations in solubility, pharmacokinetics, and 
bioavailability of high-aromatic-ring-count molecules are now well recognized, leading scientists to favor saturated building 
blocks, especially saturated N-heterocycles.
11
  
Saturated N-heterocycles are prevalent in biologically active molecules and are increasingly attractive scaﬀolds in the 
development of new pharmaceuticals. Among these usefull scaffolds we can find pseudo-Pro analogues
12
 and  R-amino-γ-
lactams,
13
 so-called Freidinger-Veber lactams, that have been commonly proven particularly eﬀective in the design of 
constrained peptidomimetics for therapeutic targets.
13,14
  
Amid different N-heterocycles, cyclic urea scaffolds are of great and actual interest since they induce peptide turn geometry, 
by combining the covalent constraints of R-amino-γ-lactams with the electronic restrictions and side-chain diversity of aza-
amino acids. In fact, aza analogs of amino acids restrict backbone ψ-dihedral angle, due to the planarity of the urea moiety, 
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and the ϕ-dihedral angle, because of hydrazine N-N lone-pair repulsion.15 Azapeptides utilize electronic forces to stabilize 
turn conformations in peptides.
16
 Therefore, designed to favor turn secondary structures, aza-ciclic surrogates reserve both 
electronic and structural constraints to hinder rotation about the backbone ϕ-, ψ- and ω-dihedral angles, giving rise to γ- and 
ß- turns.
17
 
Cyclic urea moieties are found in many biologically active compounds,
18
 and are expected to have greater membrane 
solubility and increased conformational rigidity relative to the corresponding linear urea.
19
   
Particularly, imidazolidin-2-ones (Imds) are utilized as structural elements in a number of inhibitors of human 
immunodeficiency virus (HIV) protease and HIV replication.
 20
 Still, Imds have utility as antitumor agents,
21
 antibacterial 
MurB inhibitors,
22
 dopamine D 4 and CGRP receptor antagonists,
23
 antioxidants,
24
 and unnatural base pairs.
25
  
In literature, cyclic ureas such as Imds are most commonly constructed via treatment of 1,2-diamine precursors with 
phosgene equivalents such as carbonyl diimidazole,
19,26
 via Hofmann rearrangement of Asn,
27
 via ring expansion of aziridine 
derivatives,
28
 via cyclization of aza-propargylglycinamides,
29
 via alkylation of the urea nitrogen of semicarbazone residues,
30
 
via Pd-catalyzed urea carboamination reactions,
31
 and so on. 
Although a number of synthetic methods are available, many require multistep sequences for their preparation. Thus, 
alternative strategies for the construction of Imd would provide more facile access to derivatives that are not readily 
available. In addition, methods that allow for preparation of a variety of products from a common starting material would 
consent straightforward generation of analogues that could be used to optimize biological activity or pharmaceutical 
properties.  
Continuing with our work toward the synthesis of constrained peptidomimetics from modiﬁed peptides (chapter 4 and 5),12,32 
in this chapter is reported the synthesis of Imd-containing peptidomimetics starting from different protected amino acid 
sequences. 
6.2. Results and discussion 
6.2.1. Synthesis  
We propose two different synthetic pathways for the in-peptide synthesis of Imd rings.  
The preparation of di/tri and tetra-peptides 1a-c, 7, 9a-b and 11a-b was conducted by coupling the amino acids under MW 
irradiation, using a microwave oven specifically designed for organic synthesis,
33
 with HBTU/HOBt as activating agents. 
Moreover, -amino-Ala was prepared as described in the literature.34 
In the first route developed, the N-protected-dipeptides were treated with DSC and DIPEA, as base, for obtaining 
elimination to dehydroalanine (Ala), as illustrated in the literature (Scheme 1, 2a-c).35 The subsequent non-
diastereoselective aza-Michael addition of different amines to Ala, furnished racemic compounds 3a-e, in quantitative 
yields. Analysis of the crude reaction mixture by RP-HPLC and ESI-MS revealed the presence of the two diastereomeric 
compounds (3a-e) in 1:1 ratio (General Methods).  
Notably, we were able to adding not only simple primary amines but also an O-ptotected amino acid (PheOBn, compound 
3c) in quantitative yield. 
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Scheme 1. Synthesis of dipeptides, elimination of Ser to Ala and aza-Michael reaction. 
In order to optimize the cyclization of these amino peptides, we investigated the role of the carbonate, solvent, base, and 
protecting group, by reacting the model peptides 3a under different conditions (Table 1). 
On the basis of our precedent works (Chapter 4 and 5),
12,32
 we treated compound 3a with 1,2 eq. of DSC and catalytic 
amounts of DIPEA in a mixture of DCM/DMF, but the outcome of the reaction did not give the expected results (table 1, 
entry 1), also using larger quantities of reactants. Still, the use of an inorganic base did not influence the result (table 1 
entry 2). Due to these negative results, we tried to replace the DSC carbonate with p-nitrobenzylchloroformate (p-NBC), 
that in the presence of variable amounts of DIPEA (from catalitic to excess) in DCM/DMF, gave the intermediate 4a in 
traces, only when a large excess of base (10 eq.) was employed (table 1, entry 3). 
On the basis of these evidences, we were been interested in Dowson et al. work,
36
 who efficiently transformed o-
aminoanilides into an aromatic N-acylurea moiety through the addition of p-nitrophenylchloroformate (p-NPC) and DIPEA 
as base.
36
 Inspired by this paper, we have found that the treatment of our substrate 3a with p-NPC and 10 eq. of DIPEA, in 
DCM/DMF, allows a significative, but yet insufficient, increment of the intermediate 4a formation (table 1, entry 4). This 
result prompted us to attempt a better outcome by increasing the DIPEA amount and by adding DMAP as additive base 
(table 1, entry 5). Long last these conditions permitted the isolation of the intermediate (yield 70%) that was purified and 
treated with large quantities of DIPEA (10 eq) to afford the product 5a in 80% yield (table 1, entry 6). Obviously, the 
found reaction conditions were not optimal, since predicted an overuse of reagents and the necessity to isolate and purify 
the intermediate 4a, which in turn needed to much base for cyclization.  
At this  point, we tried to consider p-NPC as a constant and we used DBU as base. Fortunately, this strategy has proved 
successful, since 3 eq. of p-NPC and 3 eq. of DBU, in a mixture of DCM/DCM, furnished the desired product 5a in very 
satisfactory yield (85%), in only 5 h of reaction and avoiding to isolate the intermediate (table 1, entry 7). Finally, using the 
same reagents in only DMF improves even more the final yield (table 1, entry 8).  
The optimized reaction was extended also to different protected dipeptides, when N-/O-protecting groups were changed the 
outcome of the reaction was the same. Moreover the nature of the substituents on the amine function (R3=alchil, allyl, aryl, 
aminoacid) is dimonstrated irrelevant for the cyclization reaction. This is an evident advantage since permitted to obtain 
Imd rings with different substituents on N1 position.  
In all cases, epimerization during the cyclization of 3a-e was excluded on the basis of the NMR and HPLC analyses (see 
General Methods). 
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Scheme 2. Synthesis of Imd-containing dipeptides. 
 
Table1. Cyclization of 3a: reagents, yields and reaction times. 
 
entry compd Carbonate Base Solvent Product  Yield % Time (h) 
1 3a DSC DIPEA DCM/DMF - - 24 
2 3a DSC K2CO3 DCM/DMF - - 24 
3 3a p-NBC DIPEA DCM/DMF 4a  traces 24 
4 3a p-NPC DIPEA DCM/DMF 4a 20 12 
5 3a p-NPC DIPEA+DMAP DCM/DMF          4a 70 12 
6 4a - DIPEA DCM/DMF  5a   90 12 
7 3a p-NPC DBU DCM/DMF 5a 85 5 
8 3a p-NPC DBU DMF 5a 90 5 
As mentioned earlier, all compounds were obtained in racemic form. The two different diastereoisomers, in some cases, 
were separated by flash chromtography (5c-d, 5f-i) or by semipreparative RP-HPLC (5a-b).  
To afford the correct assignment of the stereochemistry, compounds 5a-b were hydrolyzed in a heated solution of MeOH 
and TEA, following a procedure reported in literature,
37
 for obtaining 6a-b. Since the optical rotation power of the S 
enantiomer of 6 is well known in literature,
38
 we were able to identify the stereochemistry of 5a-b. Thanks to this data we 
could assign the stereochemestry of the other separated diastereoisomers (5c-d, 5f-i), because a distinctive trend of the 
1
H 
NMR signals of S,S and S,R compounds.  
Unfortunately, in some cases (5f-i) was not feasible the complete isolation of diastereoisomers and, specifically, for 
mixture 5e the separation was impossible both with flash chromatography and semipreparative RP-HPLC.  
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Scheme 3. Hydrolysis of compounds 5a and 5b. 
This situation prompted us to explore an alternative route for obtaining only one diastereoisomer from the in-peptide 
synthesis of Imd scaffold.  
The Hofmann rearrangement is a well-known reaction that easily allows the transformation of primary amides into 
amines,
39
 utilizing bromine in aqueous basic conditions. Several methods have been described, employing different 
reagents that are generally able to deliver a positive halogen.
40
 In the recent years, iodine(III) reagents
41
 have been used to 
perform the same conversions under acidic conditions. The iodine(III) reagents normally employed are PhI(OCOCF3)2,
42
 
PhIO–HCO2H
43
 and PhI(OTs)OH,
44
 which lead to high yields of the corresponding ammonium salts. Moreover by reacting 
primary amides with iodine(III) compounds in methanol under basic conditions, the corresponding methyl carbamates are 
obtained,
45
 as methanol behaves both as a solvent and a reagent to trap the intermediate isocyanate. Furthermore, it’s 
important to note, that the one-pot synthesis of Imd from residues of Asn is already described in literature,
27
 but these 
approaches do not permit to obtain a full functionalization of the ring.  
In our strategy, Imd can be easily obtained starting from the Hofmann rearrangment of N-protected (S)-Asn into -amino-
(S)-Ala, using PhI(OAc)2 (Scheme 4),
34
 the successive protection of the amino-function with Cbz, the incorporation of the 
residue into different di-/tri-/tetrapepide sequences (7, 9a-b, 11a-b, 13, scheme 4) and the final cyclization that affords 
compounds 8, 10 and 12a-b in very good yields.  
In the case of tetrapeptidomimetic 14, the intermediate 11b was first N-deprotected by catalytic hydrogenation, then the 
Boc-glycinale was inserted through a reductive amination. Finally, the corresponding product 13 was easily ciclized under 
the optimized condition to gave the three-point substituted Imd 14.  
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Scheme 4. Synthesis of Imd-peptides starting from Boc-(S)-Asn.  
It’s then important to underline that N1 unsubstituted Imd can be easily functionalized using acyl chloride derivatives.46 
The reactions depicted in Scheme 2 and 4represent the first synthesis of an already N-functionalized-Imd directly within a 
peptide sequence. 
6.2.2. Conformational properties 
We can speculate that the structure of compound 10 is comparable with the structures described by Tomasini et al.
 
and
 
analyzed by X-ray diffraction study.
27a
 The molecular structure of  their compounds shows that the Imd ring is almost 
planar and this data is in agreement with other analogous compounds reported in literature.
47
  
To investigate the conformational bias exerted by the Imd in position 2 of the di-/tri-/tetrapeptides, on the overall structure 
of the peptide, we analyzed all compounds by NMR spectroscopy. 
In particular, 
1
H NMR analysis of all the final molecules showed a significantly downfield position in the Hof the 
residue preceding the Imd (Ala or Val). For instance, the AlaH in Boc-(S)-Ala-(S)-Imd-OMe (5a) it is at ca. 5.5 ppm, 
while in its precursor, 3a, it is at ca. 4.2 ppm. This accounts for a strong deshielding effect exerted by Imd(CO),48 
compatible with a non-conventional CH⋯O=C intramolecular hydrogen bond,49 and conﬁrms the trans conformation of 
the amide bond between the Imd and the preceding, deshielded residue.  
The occurrence of intramolecular H-bonds in 12b was evaluated by analyzing the variable temperature (VT)-
1
H-NMR 
experiments in 8:2 DMSO-d6/H2O. For this compound, the comparatively lower VT-
1
H-NMR t parameters of PheNH 
(-0.9) with respect to AlaNH (-3.7), ImdNH (-1.9) and ValNH (-4.5) were suggestive of a significative preference for 
conformations having PheNH involved in a H-bond t| < or close to 2.5 p.p.b..⁄K).50,51  
The described results are in agreement with the presence of a -turn between the PheNH and, presumably, the AlaC=O.  
In to this purpose, Boger and co-workers,
52
 recognizing that in the -turn one of the folding amino acids (i+1 or i+2) often 
serves a structural rather than a recognition role (e.g., Pro or Gly),
53
 sought to replace the two central amino acid with an 
N-heterocycle. From different analyzes, they found that trans-pyrrolidine-3,4-dicarboxamide could serve as a synthetically 
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accessible template upon which to display the amino acid side-chain groups. Rigidiﬁed by an intramolecular H-bond, 
precisely a -turn, the lowest energy conformation of the trans-pyrrolidine-3,4-dicarboxamide forces the lateral chains to 
assume the same triangle geometries that can be find in a -turn. In fact, an overlay of the low energy conformation with 
the peptide backbone of a type-I -turn demonstrates a potential mode of mimicry and yielded this conformation. In line 
with the design, the noncovalent constraints that stabilize the lowest energy conformer also permit a degree of ﬂexibility to 
allow the compound to adopt variable H-bond donor/acceptor patterns  (e.g., which the carbonyl is exo or endo in the 
pseudo-7-member ring) and permit the attached side chains to approximate the correct vector display of amino acid side 
chains in a wide range of -turn structures.53  
Likewise, the Imd ring can be considered an isoster of pyrrolidine and since it demonstrated to have a trans conformation 
and to induce a -turn, just like Boger’s heterocycle, we can conclude that the insertion of Imd scaffold into a peptide 
sequence could lead to the same conformational advantages found for trans-pyrrolidine-3,4-dicarboxamide. 
Signiﬁcantly, the trans-Imd can be substituted in three different positions, that allow a very wide combination of natural 
and unnatural amino acid side chains, lending to the development of diversified libraries of derivatives.   
6.3 Conclusions 
The cyclization to Imd with p-NPC and DBU was performed with very good yields starting from short peptidic sequences 
containing a -amino--amino acid. The latter was obtained from the aza-Michael addition of different substituted primary 
amine on a Ala, previously synthesized by Ser-containing dipeptides, or from the Hofmann rearrangement of a N-protected 
Asn residue. Both strategies permitted to abtain a three point functionalized Imd that, as highlighted by conformational 
analysis, shows a trans conformation and induces the formation of a well defined -turn.  
For the simple synthetic protocol, the peculiar geometric features and the easy functionalization, the Imd ring deserves to be 
exploited for the design of new conformationally biased peptidomimetics or foldamers or even small molecules. These 
characteristics can permit not only the synthesis of potential drugs but also labeling molecules for diagnostic purposes or for 
instance for PNAs synthesis, that always requires functionalizable moiety.  
Finally, by a purely synthetic point of view, would be interesting to explore a diastereoselective aza-Michael addition, in 
order to avoid the separation of diastereoisomers.    
6.4. Experimental Section 
6.4.1. General Methods 
Standard chemicals (including Boc- or Cbz-protected -amino acids, Boc-(S)-AlaOH, Z-ValOH, Boc-(S)-SerOH, Boc-(S)-
PheOH, (S)-H-PheOMe, (S)-H-ValOMe, Boc-(S)Asn), were purchased from commercial sources and used without further 
purification. Flash chromatography was performed on silica gel (230-400 mesh), using mixtures of distilled solvents. 
Compounds purities were assessed by analytical RP-HPLC and elemental analysis. Analytical RP-HPLC was performed on 
an Agilent 1100 series apparatus, using a RP column Phenomenex mod. Gemini 3 C18 110A 100x3.0 mm (P/No 00D-
4439-Y0); column description: stationary phase octadecyl carbon chain-bonded silica (C18) with TMS endcapping, fully 
porous organo-silica solid support, particle size 3 m, pore size 110 Å, length 100 mm, internal diameter 3 mm;  DAD 210 
nm; mobile phase: from a 9:1 H2O-CH3CN to a 2:8 H2O-CH3CN in 20 min at a flow rate of 1.0 mL min
-1
, followed by 10 
min at the same composition. Semi-preparative RP-HPLC was performed on an Agilent 1100 series apparatus, using a RP 
column ZORBAX mod. Eclipse XDB-C18 PrepHT cartridge 21.2x150 mm 7 (P/No 977150-102); column description: 
stationary phase octadecyl carbon chain-bonded silica (C18), double endcapped, particle size 7 µm, pore size 80 Å, lenght 
150 mm, internal diameter 21.2 mm; DAD 210 nm; mobile phase from 8:2 H2O-CH3CN to 100% CH3CN in 10 min at a 
flow rate of 12 mL min
-1
. Chiral HPLC analysis was performed on an Agilent 1200 series apparatus, using a CHIRALPAK 
IC column (P/No 83325); column description: chiral stationary phase cellulose tris (3,5-dichlorophenylcarbamate) 
immobilized on silica, particle size 5 µm, lenght 250 mm, internal diameter 4.6 mm, DAD 210/254 nm; mobile phase: 3:1 
n-hexane/2-propanol, at 0.8 mL min
-1
. ESI analysis was performed using a MS single quadrupole HP 1100MSD detector, 
with a drying gas flow of 12.5 l/min, nebulizer pressure 30 psgi, drying gas temp. 350°C, capillary voltage 4500 (+) and 
4000 (-),  scan 50-2600 amu. Elemental analyses were performer using a Thermo Flash 2000 CHNS/O analyzer. High 
quality IR were obtained at 2 cm
-1
 resolution using a FT-IR spectrometer and 1 mm NaCl solution cell. Electronic circular 
dichroism (ECD) spectra were recorded on a Jasco J-710 spectropolarimeter. The synthetic procedures by MW irradiation 
were performed using a microwave oven (MicroSYNTH Microwave Labstation for Synthesis) equipped with a built-in 
ATC-FO advanced fiber optic automatic temperature control. 
1
H NMR spectra were recorded using a Varian Gemini 
apparatus at 400 MHz in 5 mm tubes, using 0.01 M peptide at room temperature. Solvent suppression was performed by 
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the solvent presaturation procedure implemented in Varian (PRESAT). 
13
C NMR spectra were recorded at 100 MHz. 
Chemical shifts are reported as  values relative to residual CHCl3 H (7.26 p.p.m.), DMSO H (2.50 p.p.m.) and CDCl3 
C (77.16 p.p.m.) as internal standards. The unambiguous assignment of 1H NMR resonances was performed by 2D 
gCOSY. VT-
1
H NMR experiments were performed over the range of 298-348 K; temperature calibration was done with 
the ethylene glycol OH-CHn chemical-shift separation method. 4.6 μm particle. 
6.4.2. Synthetic procedures 
General procedure for the synthesis of peptides 1a-b, 7, 9a-b, 11. A stirred solution of N-protected amino acid (1.0 mmol) 
in in 4:1 DCM/DMF (5 mL, 0.2 M) was treated with HOBt (1.2 mmol) and HBTU (1.2 mmol), at r.t. and under nitrogen 
atmosphere. After 5 min, O-protected amino acid (1.1 mmol.) and DIPEA (2.4 mmol) were added, and the mixture was 
stirred under nitrogen atmosphere and under MW irradiation. The microwave-assisted reaction was performed with a initial 
irradiation power of 150W, and monitoring the internal reaction temperature at 80°C with a built-in ATC-FO advanced 
fiber optic automatic temperature control. After 10 min, the mixture was concentrated at reduced pressure, and the residue 
was diluted with EtOAc (25 mL). The solution was washed with 0.1 M HCl (5 mL), and a saturated solution of NaHCO3 (5 
mL). The organic layer was dried over Na2SO4 and the solvent was evaporated at reduced pressure.The peptides were 
isolated by flash chromatography over silica gel (eluant EtOAc/cyclohexane from 70:30 to 100:0). Yields 75-95%, 94-96 
% pure by analytical RP-HPLC.. 
General procedure for the synthesis of 2a-d. To a stirred solution of  1 (1.0 mmol) in DCM/CH3CN (2/1), DSC (1.5 mmol) 
and DIPEA (1.5 mmol) were added under inert atmosphere. After 3 h solvents were evaporated under reduced pressure, 
and the residue was diluted in EtOAc (25 mL) and washed with HCl 1 M (25 mL). The aqueous layer was extracted two 
more times with EtOAc (25 mL). The organic layers were dried over Na2SO4 and evaporated under reduced pressure. The 
peptides were isolated by flash chromatography over silica gel (eluant EtOAc/cyclohexane 70:30). Yield 75-85%,  94-96 
% pure by analytical RP-HPLC. 
General procedure for Boc deprotection. The intermediate N-Boc peptides  (1.0 mmol) were deprotected by treatment with 
25% TFA in DCM (5 mL) while stirring at r.t. After 15 min, the solution was evaporated under reduced pressure, and the 
treatment was repeated. The residue was suspended in ice-cold Et2O (20 mL). The intermediate peptide-TFA salts which 
precipitated in almost quantitative yields were collected by centrifuge, and used for the next couplings without further 
purifications (80-85% pure by analytical RP-HPLC, General Methods). 
General Procedure for Cbz Deprotection. The intermediates N-Cbz (1mmol) were deprotected by catalytic hydrogenation, 
consisting in the dissolution of peptides derivative in MeOH (5 mL) and in the addition of 10% Pd-C in the presence of H2 
atmosphere. After 8 h, the suspension was filtered over Celite® under suction, and the solvent was evaporated at reduced 
pressure. The residue was used for the next step without further purifications (85-90% pure by analytical RP-HPLC, 
General Methods). 
General procedure for the Michael addition with substituted amines 3a-e. To a stirred solution of 2 (1 mmol) in CH2Cl2 
(0.2 M), the substituted amine (4 mmol) was added under inert atmosphere. After 5 h solvent was evaporated under reduced 
pressure and the compound was used without further purification (yield up to 90%,). 
General procedure for the synthesis of Imd-peptides 5a-i, 10, 12a-b, 14. To a stirring solution of -Ala-peptides (1 mmol) 
in dry DMF (0.2 M) and under inert atmosphere, p-NPC (3 mmol) was added. After 40 minutes DBU (3 mmol) in DMF 
was added. After 3 h solvent was evaporated under reduced pressure, the residue was resuspended in EtOAc (25 mL) and 
washed three times with HCl 1M (25 mL). The organic layer was dried over Na2SO4 and evaporated under reduced 
pressure. The diasteroisomers 5c-d, 5f-i were separated and compound 12b was purified by flash-chromatography over 
silica gel (eluant EtOAc/cyclohexane from 30:70 to 70:30). Yields 80-95%. The diastereosimers 5a-b were separated and 
compounds 8, 10, 12a and 14 were purified with semipreparative RP-HPLC (yields 70-80%). 
 (S)-(N-Me)-ImdOMe 6a and (R)-(N-Me)-ImdOMe 6b. To a solution of 5a or 5b (0.33g, 1 mmol) in dry MeOH (3mL) 
under inert atmosphere, TEA (6 mmol) was added and the reaction was refluxed. After 6h solvent was evaporated under 
reduced pressure. The residue was purified by flash chromatography over silica gel (eluant EtOAc/cyclohexane from 50:50 
to 90:10) and the product 6a and 6b were obtained in 70% Yield. 
Boc-(S)-Ala-(S)-(NCH2CH2NHBoc)-Ala-(S)-Phe-(S)-ValOMe 13. Compound 11b (0.20g, 0.28 mmol) was deprotected 
following the General Procedure for Cbz Deprotection. The residue obtained was used for the next step without further 
purifications (Yield 95%, 85% pure by analytical RP-HPLC, General Methods). To a solution of deprotected-11b (0.20g, 
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0.35 mmol) in THF (5mL) were added N-Boc-2-aminoacetaldehyde (0.07g, 1.2 mmol) and 2 drops of AcOH. After 10 min 
NaCNBH3 (0.09g, 4 mmol). After 2 h the reaction was quenched with H2O and THF was evaporated under reduced 
pressure. The acqueous solution was extracted three times with EtOAc (25mL), and the organic layers were dried over 
Na2SO4. The intermediate 13 were used for the next cyclization reaction without further purifications (Yield 60%,  50% 
pure by analytical RP-HPLC, General Methods). 
Boc-(S)-Ala-(S/R)-(N-Me)-AlaOMe 3a. 90% pure by RP-HPLC (General Methods), Rt = 1.44 min. 1H NMR (CDCl3)  = 
1.38 (d, J=6.8 Hz, 6H, AlaMe), 1.45 (s, 18H, t-Bu), 2.43 (s, 6H, NMe), 2.79-3.08 (m, 4H, AlaH), 3.76 (s, 6H, OMe), 
4.14-4.22 (m, 2H, AlaH), 4.62-4.70 (m, 2H, AlaH), 5.07 (d, J=6.8 Hz, 1H, AlaNH), 5.16 (d, J=6.8 Hz, 1H, AlaNH), 
7.05 (d, J=6.8 Hz, 1H, AlaNH), 7.17 (d, J=6.8 Hz, 1H, AlaNH). ESI-MS m/z 304.1 (M+H)+, calcd 304.2. 
Boc-(S)-Ala-(S/R)-(N-Ph)-AlaOBn 3b. 95% pure by RP-HPLC (General Methods), Rt = 9.92 min. 1H NMR (CDCl3)  = 
1.34 (d, J=6.8 Hz, 3H, AlaMe), 1.35 (d, J=6.8 Hz, 3H, AlaMe), 1.44 (s, 18H, t-Bu), 3.60 (ddd, J=2.4, 4.8, 13.2 Hz, 2H, 
AlaH), 3.65 (ddd, J=2.4, 4.8, 13.2 Hz, 2H, AlaH), 4.14-4.17 (m, 2H, AlaH), 4.79-4.82 (m, 2H, AlaH), 4.83 (d, 
J=6.8 Hz, 1H, AlaNH), 4.87 (d, J=6.8 Hz, 1H, AlaNH), 5.18 (s, 4H, BnCH2), 6.59-6.62 (m, 4H, ArH), 6.79-6.82 (m, 10H, 
ArH), 6.86 (d, J=6.4, 1H, AlaNH), 7.13-7.21 (m, 3H, AlaNH+ArH), 7.33-7.39 (m, 4H, ArH). ESI-MS m/z 442.1 
(M+H)+, calcd 442.2. 
Ts-(S)-Ala-(S/R)-(N-PheOBn)-AlaOMe 3c. 92% pure by RP-HPLC (General Methods), Rt = 10.53 min. 1H NMR 
(CDCl3)  = 1.21 (d, J=7.2 Hz, 3H, AlaMe), 1.25 (d, J=7.2 Hz, 3H, AlaMe), 2.37 (s, 3H, TsMe), 2.41 (s, 3H, TsMe), 2.44 
(m, 1H, AlaH), 2.91-3.04 (m, 4H, AlaHPheH), 3.10-3.19 (m, 3H, AlaHPheH), 3.55 (m, 1H, AlaH), 3.59 (s, 
3H, OMe), 3.67 (s, 3H, OMe), 3.76 (m, 1H, AlaH), 3.85 (t, J=6.4, 2H, PheH), 4.29 (ddd, J=3.6, 7.6, 11.6 Hz, 1H, 
AlaH), 4.34 (ddd, J=4, 7.6, 11.2 Hz, 1H, AlaH), 5.12 (s, 2H, BnCH2), 5.15 (s, 2H, BnCH2), 5.39 (br s, 2H, AlaNH), 
6.45 (d, J=7.6 Hz, 1H, AlaNH), 7.06 (d, J=7.6 Hz, 1H, AlaNH), 7.12-7.38 (m, 24H, ArH), 7.70-7.75 (m, 4H, TsArH). 
ESI-MS m/z 582.3 (M+H)+, calcd 582.2. 
Z-(S)-Val-(S/R)-(N-isopropyl)-AlaOMe 3d. 93% pure by RP-HPLC (General Methods), Rt = 1.52 min. 1H NMR (CDCl3) 
 = 0.94 (d, J=6.6 Hz, 6H, ValMe), 0.99 (d, J=6.6 Hz, 6H, ValMe), 1.05-1.08 (m, 12H, N-isopropylMe), 2.14-2.21 (m, 2H, 
ValH), 2.81-2.83 (m, 2H, N-isopropylCH), 2.95-2.98 (m, 2H, AlaH), 3.13-3.15 (m, 2H, AlaH), 3.73 (s, 6H, OMe), 
4.05-4.13 (m, 2H, ValH), 4.64 (m, 2H, AlaH), 5.10 (s, 4H, BnCH2), 5.43 (d, J=7.6 Hz, 1H, ValNH), 5.52 (d, J=7.6 Hz, 
1H, ValNH), 7.07 (br s, 1H, AlaNH), 7.27-7.36 (m, 11H, AlaNH+ArH). ESI-MS m/z 394.2 (M+H)+, calcd 394.2. 
Z-(S)-Val-(S/R)-(N-allyl)-AlaOMe 3e. 80% pure by RP-HPLC (General Methods), Rt = 1.40 min. 1H NMR (CDCl3)  = 
0.91-0.99 (m, 12H, ValMe), 2.07-2.22 (m, 2H, ValH), 2.90-2.94 (m, 2H, NCH2CH=CH2), 3.05-3.08 (m, 2H, 
NCH2CH=CH2), 3.20-3.29 (m, 4H, AlaH), 3.75 (s, 6H, OMe), 4.05-4.11 (m, 2H, ValH), 4.62 (m, 2H, AlaH), 5.11 
(s, 4H, BnCH2), 5.17-5.20 (m, 4H, NCH2CH=CH2), 5.36 (br s, 2H, ValNH), 5.77-5.85 (m, 2H, NCH2CH=CH2), 7.30-7.40 
(m, 10H, ArH), 7.89 (d, J=8.4 Hz, 1H, AlaNH), 7.97 (d, J=9.2 Hz, 1H, AlaNH). ESI-MS m/z 392.1 (M+H)+, calcd 
392.2. 
Boc-(S)-Ala-(S/R)-(Me-N-COOPh(-NO2))-AlaOMe 4a. 90% pure by RP-HPLC (General Methods), Rt = 7.89 min. 
1
H 
NMR (CDCl3)  = 1.35 (d, J=3.2 Hz, 3H, AlaMe), 1.37 (d, J=3.2 Hz, 3H, AlaMe),  1.43 (s, 18H, t-Bu), 3.05 (s, 3H, NMe), 
3.15 (s, 3H, NMe), 3.55-3.92 (m, 10H, AlaH), 3.68 (s, 3H, OMe), 3.74 (s, 3H, OMe), 4.12-4.20 (m, 2H, AlaH), 4.804 
(ddd, J=2.8, 7.6, 10.8 Hz, 1H, AlaH), 4.87 (ddd, J=2.8, 7.6, 10.8 Hz, 1H, AlaH), 4.93 (d, J=6.0 Hz, 2H, AlaNH), 6.93 
(d, J=7.6 Hz, 1H, AlaNH), 7.10 (d, J=7.6 Hz, 1H, AlaNH), 7.28-7.35 (m, 4H, ArH), 8.22-8.24 (m, 4H, ArH). ESI-MS 
m/z 491.1 (M+Na), calcd 491.2. 
Boc-(S)-Ala-(S)-(N-Me)-ImdOMe 5a. 98% pure by RP-HPLC (General Methods), Rt = 9.86 min. 
1
H NMR (CDCl3)  = 
1.42 (s, 12H, AlaMe+ t-Bu), 2.87 (s, 3H, NMe), 3.39 (dd, J=3.4, 9.8 Hz, 1H, ImdH5), 3.71 (t, J=9.8 Hz, 1H, ImdH5), 3.77 
(s, 3H, OMe), 4.82 (dd, J=3.4, 9.8 Hz, 1H, ImdH4), 5.08 (d, J=7.6 Hz, 1H, AlaNH), 5.51 (quint., J=7.6, 1H, AlaH); 
13
C 
NMR (CDCl3)  = 18.4, 28.3, 30.5, 46.6, 48.7, 51.9, 52.9, 79.6, 153.1, 155.3, 169.9, 174.1. ESI-MS m/z 352.3 (M+Na), 
calcd 352.2. []D
20 
-66.6 (c 0.9, CHCl3). 
Boc-(S)-Ala-(R)-(N-Me)-ImdOMe 5b. 95% pure by RP-HPLC (General Methods), Rt = 9.98 min. 
1
H NMR (CDCl3)  = 
1.37 (d, J=7.2, 1H, AlaMe), 1.42 (s, 9H, t-Bu), 2.88 (s, 3H, NMe), 3.38 (dd, J=3.4, 9.8 Hz, 1H, ImdH5), 3.71 (t, J=9.8 Hz, 
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1H, ImdH5), 3.76 (s, 3H, OMe), 4.70 (dd, J=3.4, 9.8 Hz, 1H, ImdH4), 5.35 (d, J=7.6 Hz, 1H, AlaNH), 5.51 (quint., J=7.6, 
1H, AlaH); 13C NMR (CDCl3)  = 19.3, 29.3, 30.6, 46.6, 48.9, 51.8, 52.9, 79.3, 153.1, 154.8, 169.7, 173.9. ESI-MS m/z 
352.1 (M+Na)
+
, calcd 352.2. []D
20 
+10.3 (c 1.9, CHCl3). 
Boc-(S)-Ala-(S)-(N-Ph)-ImdOBn 5c. 98% pure by RP-HPLC (General Methods), Rt = 10.42 min. 
1
H NMR (CDCl3)  = 
1.40 (d, J=6.8 Hz, 3H, AlaMe), 1.44 (s, 9H, t-Bu), 3.84 (dd, J=3.2, 9.8 Hz, 1H, ImdH5), 4.19 (t, J=9.8 Hz, 1H, ImdH5), 5.00 
(dd, J=3.2, 9.8 Hz, 1H, ImdH4), 5.10 (d, J=7.2, 1H, AlaNH), 5.22 (dd, J=12.0, 36.0, 2H, BnCH2), 5.53 (quint., J=7.2 Hz, 
1H, AlaH), 7.18 (m, 2H, ArH), 7.35-7.40 (m, 6H, ArH), 7.49 (m, 2H, ArH); 13C NMR (CDCl3)  = 18.2, 28.3, 45.3, 49.1, 
51.6, 67.9, 79.8, 119.3, 124.9, 128.5, 128.7, 128.8, 129.1, 134.6, 137.9, 150.9, 155.3, 168.9, 174.4. ESI-MS m/z 468.1 
(M+H)
+
, calcd 468.2. 
Boc-(S)-Ala-(R)-(N-Ph)-ImdOBn 5d. 90% pure by RP-HPLC (General Methods), Rt = 10.69 min. 
1
H NMR (CDCl3)  = 
1.44 (d, J=6.4 Hz, 3H, AlaMe), 1.47 (s, 9H, t-Bu), 3.77 (dd, J=2.4, 10.0 Hz, 1H, ImdH5), 4.23 (t, J=10.0 Hz, 1H, ImdH5), 
4.88 (dd, J=2.8, 10.0 Hz, 1H, ImdH4), 5.23 (s, 2H, BnCH2), 5.44 (br d, 1H, AlaNH), 5.65 (m, 1H, AlaH), 7.19 (m, 1H, 
ArH), 7.35-7.41 (m, 7H, ArH), 7.49 (m, 2H, ArH);
 13
C NMR (CDCl3)  = 19.5, 28.4, 45.3, 49.5, 52.1, 67.9, 79.6, 119.2, 
125.0, 126.1, 128.3, 128.7, 129.2, 134.8, 137.8, 150.8, 154.8, 168.7, 174.2. ESI-MS m/z 468.1 (M+H)
+
, calcd 468.2. 
Ts-(S)-Ala-(S/R)-(N-(S)-PheOBn)-ImdOMe 5e. 90% pure by RP-HPLC (General Methods), Rt = 10.92 min. 
1
H NMR 
(CDCl3)  = 1.27 (s, 18H, t-Bu), 1.32 (d, J=6.8 Hz, 3H, AlaMe), 1.36 (d, J=6.8 Hz, 3H, AlaMe), 2.39 (s, 3H, TsMe), 2.41 
(s, 3H, TsMe), 2.91-3.03 (m, 3H, PheH), 3.25 (dd, J=3.6, 8.4 Hz, 2H, ImdH5), 3.38 (dd, J=4.6, 11.4 Hz, 1H, PheH), 3.52 
(s, 3H, OMe), 3.60 (s, 3H, OMe), 3.75 (dd, J=3.6, 8.4 Hz, 2H, ImdH5), 4.26 (dd, J=3.6, 8.4 Hz, 1H, ImdH4), 4.38 (dd, 
J=3.6, 8.4 Hz, 1H, ImdH4), 4.88 (dd, J=4.6, 11.4 Hz, 1H, PheH), 4.97 (dd, 5.0, 11.0 Hz, 1H, PheH), 5.06 (m, 1H, 
AlaH), 5.20 (s, 2H, BnCH2), 5.21-5.25 (m, 3H, AlaH+BnCH2), 5.73 (d, J=8.8 Hz, 1H, AlaNH), 5.80 (d, J=9.6 Hz, 1H, 
AlaNH), 7.10-7.13 (m, 3H, ArH), 7.17-7.39 (m, 21H, ArH), 7.67-7.71 (m, 4H, ArH); ESI-MS m/z 608.3 (M+H)+, calcd 
608.2. 
Z-(S)-Val-(S)-(N-isopropyl)-ImdOMe 5f. 80% pure by RP-HPLC (General Methods), Rt = 9.00 min. 
1
H NMR (CDCl3)  = 
0.84 (d, J=7.2 Hz, 3H, ValMe), 0.86 (d, J=7.2 Hz, 3H, ValMe), 1.05 (d, J=6.4 Hz, 3H, CHCH3), 1.10 (d, J=6.4 Hz, 3H, 
CHCH3), 2.18 (m, 1H, ValH), 2.37(m, 1H, NCH), 3.32 (dd, J=3.6, 9.8 Hz, 1H, ImdH5), 3.66 (t, J=9.8 Hz, 1H, ImdH5), 
3.76 (s, 3H, OMe), 4.69 (dd, J=3.6, 9.8 Hz, 1H, ImdH4), 5.11 (s, 3H, BnCH2+ValNH), 5.61 (m, 1H, ValH), 7.33-7.37 (m, 
5H, ArH); ESI-MS m/z 420.2 (M+H)+, calcd 420.2. 
Z-(S)-Val-(R)-(N-isopropyl)-ImdOMe 5g. 75% pure by RP-HPLC (General Methods), Rt = 9.05 min. 
1
H NMR (CDCl3)  
= 0.84 (d, J=7.2 Hz, 3H, ValMe), 0.86 (d, J=7.2 Hz, 3H, ValMe), 1.05 (d, J=6.4 Hz, 3H, CHCH3), 1.10 (d, J=6.4 Hz, 3H, 
CHCH3), 2.18 (m, 1H, ValH), 2.37(m, 1H, NCH), 3.32 (dd, J=3.6, 9.8 Hz, 1H, ImdH5), 3.66 (t, J=9.8 Hz, 1H, ImdH5), 
3.76 (s, 3H, OMe), 4.82 (dd, J=3.6, 9.8 Hz, 1H, ImdH4), 5.11 (s, 2H, BnCH2), 5.39 (d, J=8.0 Hz, 1H, ValNH), 5.61 (m, 1H, 
ValH), 7.33-7.37 (m, 5H, ArH); ESI-MS m/z 420.2 (M+H)+, calcd 420.2. 
Z-(S)-Val-(S)-(N-allyl)-ImdOMe 5i. % pure by RP-HPLC (General Methods), Rt = 9.19 min. 
1
H NMR (CDCl3)  = 0.84 
(d, J=6.8 Hz, 3H, ValMe), 0.87 (d, J=6.8 Hz, 3H, ValMe), 2.06 (m, 1H, ValH), 3.12 (d, 2H, NCH2CH), 3.34 (dd, J=3.6, 
10.2 Hz, 1H, ImdH5), 3.67 (t, J=10.2 Hz, 1H, ImdH5), 3.76 (s, 3H, OMe), 4.54 (dd, J=6.0, 8.8 Hz, 1H, ValH), 4.70 (dd, 
J=3.6, 10.2 Hz, 1H, ImdH4), 5.10 (s, 2H, BnCH2), 5.22-5.31 (m, 2H, CH2CH=CH2), 5.59 (d, J=8.8 Hz, 1H, ValNH), 5.75 
(m, 1H, CH2CH=CH2), 7.31-7.37 (m, 5H, ArH); ESI-MS m/z 418.4 (M+H)+, calcd 418.2. 
Z-(S)-Val-(R)-(N-allyl)-ImdOMe 5h. % pure by RP-HPLC (General Methods), Rt = 9.30 min. 
1
H NMR (CDCl3)  = = 
0.84 (d, J=6.8 Hz, 3H, ValMe), 0.87 (d, J=6.8 Hz, 3H, ValMe), 2.35 (m, 1H, ValH), 3.12 (d, 2H, NCH2CH), 3.34 (dd, 
J=3.6, 10.2 Hz, 1H, ImdH5), 3.67 (t, J=10.2 Hz, 1H, ImdH5), 3.76 (s, 3H, OMe), 4.54 (dd, J=6.0, 8.8 Hz, 1H, ValH), 4.83 
(dd, J=3.6, 10.2 Hz, 1H, ImdH4), 5.10 (s, 2H, BnCH2), 5.22-5.31 (m, 2H, CH2CH=CH2), 5.59 (d, J=8.8 Hz, 1H, ValNH), 
5.75 (m, 1H, CH2CH=CH2), 7.31-7.37 (m, 5H, ArH). ESI-MS m/z 418.4 (M+H)+, calcd 418.2. 
 (S)-(N-Me)-ImdOMe 6a. 98% pure by RP-HPLC (General Methods), Rt = 1.74 min. 
1
H NMR (CDCl3)  = 2.79 (s, 3H, 
NMe), 3.63 (dd, J=4.4, 9.6 Hz, 1H, ImdH5), 3.66 (dd, J=2.8, 9.6 Hz, 1H, ImdH5), 3.79 (s, 1H, OMe), 4.20 (dd, J=4.4, 9.6 
Hz, 1H, ImdH4), 5.13 (br s, 1H, ImdNH), 5.65 (m, 1H, AlaH); ESI-MS m/z 159.1 (M+H)
+
, calcd 159.1. []D
20 
+16.9 (c 
1.9, CHCl3). 
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(D)-(N-Me)-ImdOMe 6a. 98% pure by RP-HPLC (General Methods), Rt = 1.74 min. 
1
H NMR (CDCl3)  = 2.79 (s, 3H, 
NMe), 3.63 (dd, J=4.4, 9.6 Hz, 1H, ImdH5), 3.66 (dd, J=2.8, 9.6 Hz, 1H, ImdH5), 3.79 (s, 1H, OMe), 4.20 (dd, J=4.4, 9.6 
Hz, 1H, ImdH4), 5.13 (br s, 1H, ImdNH), 5.65 (m, 1H, AlaH); ESI-MS m/z 159.1 (M+H)
+
, calcd 159.1. []D
20 
-17.9 (c 
0.9, CHCl3). 
Boc-(S)-Ala-(S)-(N-Cbz)-AlaOMe 7. 97% pure by RP-HPLC (General Methods), Rt = 7.56 min. 1H NMR (CDCl3)  = 
1.33 (d, J=6.8 Hz, 1H, AlaMe), 1.42 (s, 9H, t-Bu), 3.62-3.69 (m, 2H, AlaH), 3.74 (s, 3H, OMe), 4.12 (m, 1H, AlaH), 
4.61 (dd, J=4.6, 7.2 Hz, 1H, AlaH), 5.08 (s, 3H, CbzNH+CbzCH2), 5.54 (br s, 1H, AlaNH), 7.03 (d, J=4.6 Hz, 1H, 
AlaNH), 7.27-7.35 (m, 5H, ArH); ESI-MS m/z 424.2 (M+H)+, calcd 424.2.  
Boc-(S)-(N-Cbz)-Ala-PheOMe 9. 98% pure by RP-HPLC (General Methods), Rt = 9.79 min. 1H NMR (CDCl3)  = 1.47 
(s, 9H, t-Bu), 3.06 (dd, J=6.4, 13.8 Hz, 1H, PheH), 3.21 (dd, J=6.4, 13.8, 1H, PheH), 3.52-3.57 (m, 2H, AlaH), 3.75 
(s, 3H, OMe), 4.23 (m, 1H, AlaH), 4.86 (q, J=7.2 Hz, 1H, PheH), 5.15 (s, 2H, CbzCH2), 5.41 (br s, 1H, CbzNH), 5.67 
(br s, 1H, AlaNH), 7.13-7.40 (m, 11H, PheNH+ArH); ESI-MS m/z 522.0 (M+Na), calcd 522.2.  
Boc-(S)-Ala-(S)-(N-Cbz)-Ala-(S)-PheOMe 11a. 98% pure by RP-HPLC (General Methods), Rt = 9.37 min. 1H NMR 
(CDCl3)  = 1.44 (s, 12H, AlaMe+t-Bu), 3.02 (dd, J=7.4, 14.2 Hz, 1H, PheH), 3.18 (dd, J=7.4, 14.2, 1H, PheH), 3.47 
(dt, J=4.4, 14.0, 1H, AlaH), 3.57 (dt, J=4.4, 14.0, 1H, AlaH), 3.71 (s, 3H, OMe), 4.10 (m, 1H, AlaH), 4.45 (q, J=5.6, 
1H, AlaH), 4.78 (q, J=7.4 Hz, 1H, PheH), 4.97 (br s, 1H, CbzNH), 5.11 (dd, J=12.4, 36.4 Hz, 2H, CbzCH2), 5.44 (br s, 
1H, Ala NH), 7.11-7.13 (m, 3H, AlaNH+PheNH+ArH), 7.21-7.29 (m, 3H, ArH), 7.31-7.36 (m, 6H, ArH); ESI-MS m/z 
571.2 (M+Na), calcd 571.3.  
Boc-(S)-Ala-(S)-(N-Cbz)-Ala-(S)-Phe-(S)-ValOMe 11b. 90% pure by RP-HPLC (General Methods), Rt = 9.83 min. 1H 
NMR (CDCl3)  = 0.83 (d, J=7.0 Hz, 3H, ValMe), 0.87 (d, J=7.0 Hz, 3H, ValMe), 1.31 (d, J=6.4 Hz, 3H, AlaMe), 1.44 (s, 
9H, t-Bu), 2.16 (m, 1H, ValHβ), 2.94 (dd, J=9.6, 14.2 Hz, 1H, PheHβ), 3.42-3.54 (m, 3H, PheHβ+AlaH), 3.69 (s, 3H, 
OMe), 3.98 (m, 1H, AlaH), 4.35 (m, 1H, AlaH), 4.46 (dd, J=6.4, 8.4 Hz, 1H, ValH), 4.83 (m, 1H, PheH), 4.96 (d, 
J=10.4 Hz, 1H, AlaNH), 5.02 (d, J=17.2 Hz, 1H, CbzCH2), 5.17-5.20 (m, 2H, AlaNH+ CbzCH2), 6.97 (d, J=6.4 Hz, 
ValNH), 7.18-7.25 (m, 5H, ArH), 7.30-7.38 (m, 6H, PheNH+ArH), 7.79 (br s, 1H, AlaNH); ESI-MS m/z 670.2 (M+H)+, 
calcd 670.3. 
Boc-(S)-Ala-(S)-(NCH2CH2NHBoc)-Ala-(S)-Phe-(S)-ValOMe 13. 50% pure by RP-HPLC (General Methods), Rt = 4.59 
min. ESI-MS m/z 679.4 (M+H)+, calcd 670.3. 
Boc-(S)-Ala-(S)-ImdOMe 8. 70% pure by RP-HPLC (General Methods), Rt = 4.05 min. ESI-MS m/z 338.0 (M+Na), calcd 
338.2.  
Boc-(S)-Imd-(S)-PheOMe 10. 50% pure by RP-HPLC (General Methods), Rt = 7.16 min. ESI-MS m/z 392.2 (M+H)+, 
calcd 392.2.  
Boc-(S)-Ala-(S)-Imd-(S)-PheOMe 12a. 70% pure by RP-HPLC (General Methods), Rt = 6.66 min. ESI-MS m/z 464.4 
(M+H)+, calcd 464.2.  
Boc-(S)-Ala-(S)-Imd-(S)-Phe-(S)-ValOMe 12b. 95% pure by RP-HPLC (General Methods), Rt = 7.37 min. 
1
H NMR 
(CDCl3)  = 0.83 (d, J=7.0 Hz, 3H, ValMe), 0.87 (d, J=7.0 Hz, 3H, ValMe), 1.33 (d, J=6.0 Hz, 3H, AlaMe), 1.39 (s, 9H, t-
Bu), 2.14 (m, 1H, ValHβ), 3.06 (dd, J=5.6, 13.2 Hz, 1H, PheHβ), 3.13 (dd, J=5.6, 13.2 Hz, 1H, PheHβ), 3.58-3.66 (m, 2H, 
ImdH5), 3.71 (s, 3H, OMe), 4.43 (dd, J=5.2, 8.2 Hz, 1H, ValH), 4.67 (m, 1H, PheH), 4.84 (m, 1H, ImdH4), 5.15(d, 
J=7.2 Hz, 1H, AlaNH), 5.39 (m, 1H, AlaH), 6.21 (d, J=8.2 Hz, ValNH), 6.97 (d, J=6.4 Hz, 1H, PheNH), 7.21-7.29 (m, 
5H, PheArH);
 1
H NMR ([D6]DMSO)  = 0.86 (d, J=6.6 Hz, 3H, ValMe), 0.88 (d, J=6.6 Hz, 3H, ValMe), 1.16 (d, J=7.2 Hz, 
3H, AlaMe), 1.35 (s, 9H, t-Bu), 2.02 (m, 1H, ValHβ), 2.75 (dd, J=4.4, 14 Hz, 1H, PheHβ), 2.99 (dd, J=4.4, 14 Hz, 1H, 
PheHβ), 3.09 (dd, J=2.8, 10.8 Hz, 1H, ImdH5), 3.59 (dd, J=2.8, 10.8 Hz, 1H, ImdH5), 3.62 (s, 3H, OMe), 4.14 (t, J=7.2 Hz, 
1H, ValH), 4.57 (m, 1H, PheH), 4.72 (dd, J=2.8, 10.8 Hz, 1H, ImdH4), 5.16 (t, J=7.8 Hz, 1H, AlaH), 7.00 (d, J=7.4 
Hz, 1H, AlaNH), 7.16-7.27 (m, 5H, PheArH); 8.24 (d, J=8.0 Hz, PheNH), 8.29 (d, J=7.8 Hz, 1H, ValNH); 
13
C NMR 
(CDCl3)  = 17.8, 18.8, 28.3, 29.7, 31.1, 38.1, 40.2, 52.2, 54.9, 56.0, 57.5, 79.9, 127.1, 127.2, 128.8, 129.1, 129.3, 136.0, 
154.6, 155.2, 168.5, 170.2, 171.6, 175.0. ESI-MS m/z 562.2 (M+H)
+
, calcd 562.3. 
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Boc-(S)-Ala-(S)-(NCH2CH2NHBoc)-Imd-(S)-Phe-(S)-ValOMe 14. 80% pure by RP-HPLC (General Methods), Rt = 9.86 
min. ESI-MS m/z 727.2 (M+Na), calcd 727.3.  
6.4.3. Conformational analysis 
NMR analyses. 
1
H-NMR spectra were recorded at 400 MHz in 5 mm tubes, using 0.01 M peptide at room temperature. 
Solvent suppression was performed by the solvent presaturation procedure implemented in Varian (PRESAT). 
13
C-NMR 
spectra were recorded at 100 MHz. Chemical shifts are reported as δ values. The unambiguous assignment of 1H-NMR 
resonances was performed by 2D gCOSY, HMBC, and HSQC. gCOSY experiments were conducted with a proton spectral 
width of 3103 Hz. VT-
1
H-NMR experiments were performed over the range of 298-348 °K. 2D spectra were recorded in 
the phase sensitive mode and processed using a 90°-shifted, squared sine-bell apodization.  
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Chapter 7 
Alternative synthesis of the antibiotic Linezolid starting from the -amino acid Isoserine 
In this chapter is described a new synthesis of the 5-aminomethyl-3-oxazolidinone core of linezolid in enantiomerically pure 
form. The expedient cyclization of the -hydroxy amide derived from isoserine and 3-fluoro-4-morpholinoaniline to 
aminomethyl-oxazolidin-2,4-dione and the mild selective reduction at the position C(4) gave linezolid in almost quantitative 
overall yield.  
7.1. Introduction 
The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.
1 
In 
fact, the infections caused by multidrug-resistant pathogens are responsible for significant morbidity and mortality in both 
the hospital and community settings.
2
 One possible approach to face this problem is to design novel classes of antibacterial 
agents employing new mechanisms of action. Such agents would exhibit a lack of cross-resistance with existing 
antimicrobial drugs. However, from the early 1970s to 1999 the innovative antibiotic pipeline dried up. All newly launched 
antibiotics were analogues of existing drugs except for mupirocin, a Gram-positive antibiotic launched in 1985.
 
Since 2000, 
the situation has improved, with five more new classes of antibiotics approved and launched: linezolid (LZD, 1),
3
 
daptomycin, retapamulin, fidaxomicin, and bedaquiline.
2 
Discovered in the 90’s, and approved in the U.S. by FDA in 2000, LZD (Figure 1) is currently the only antibiotic 
commercially available in the oxazolidinone class. Compounds containing the oxazolidinone moiety are interesting because 
their spectrum of activity covers the important Gram-positive pathogens, particularly those which have been the cause of 
resistance development.
2,3
 
LZD selectively inhibits bacterial protein synthesis through binding the peptidyltransferase center on the bacterial ribosome, 
thus forbidding the bacterial translation process.
4 
This action mechanism is unique among protein synthesis inhibitors and 
explains why LZD retains antibacterial activity against Gram-positive organisms which are resistant to members of other 
classes. 
When LZD came to the market, it was claimed that there would be no cross-resistance to this antibiotic and that resistance 
would be rare and difficult for the bacteria to develop.
5
 Nevertheless, with the increased wide use of LZD and the abuse in 
some degree in clinic in recent years, some clinically resistant strains to LZD have been found worldwide such as S. aureus 
and Enterococcus spp.,
6 
and although the LNZ-resistant strains (LinR) appear relatively infrequently in the clinic, the 
infections caused by them were found to be life-threatening. 
Consequently, several researchers have recently focused on modifying the oxazolidinone structure to seek analogues with an 
extended spectrum of antibacterial activity covering Gram-negative organisms, activity against LinR strains, and improved 
safety profile. Presently, only four oxazolidinones have entered clinical development.
7
 As a consequence, the identification 
of novel synthetic protocols to obtain the 5-aminomethyl-3-oxazolidinone core in enantiomerically pure form can be 
regarded of great interest for the preparation of LZD and novel analogues. 
 
Figure 1. The syntheses of LZD (1) utilize chiral building blocks. 
The key step of LZD synthesis is the formation of the (S)-configured 5-substituted oxazolidinone A ring. Most protocols 
described in patents or publications made use of chiral oxiranes
3,7,8
 such as epichlorohydrin
9 
(Figure 1), or other building 
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blocks, e.g. glyceraldehyde
10
 (Figure 1), while very few papers reported approaches based on asymmetric protocols.
11
 The 
optimized large-scale synthesis of LZD involves a total of 9 steps, and the oxazolidinone ring is built by adding 
enantiomerically pure (S)-3-chloropropane-1,2-diol to a Cbz-protected proper aniline (Scheme 1).
3,8
 
The large majority of LZD analogs reported in the literature display modifications at the ring B or C, and/or at the C(5)-side 
chain.
2,3,7
 By contrast, the replacement of the oxazolidinone ring A with other heterocycles has been described very few 
times.
12
 
In this contest, herein is reported an expedient synthesis of the oxazolidinone core from the very convenient chiral reagent 
isoserine, taking advantage of a synthetic strategy that is suitable to furnish novel LZD analogues carrying diverse 
substituents at the A ring.
 
 
Scheme 1. Synthesis of LZD (1) on a process scale. 
7.2. Results and Discussion
 
In the above chapters 3 and 4, is been reported the rapid and simple formation of 1,3-oxazolidin-2-one scaffolds for the 
design of -turn-like peptidomimetics,13 or as chiral auxiliaries for the stereoselective synthesis of unusual amino acids.14 
Interestingly, we observed that the reaction of peptide sequences containing the -hydroxy--amino acid15 isoserine (Isoser) 
with carbonate gave rise to 5-aminomethyloxazolidine-2,4-dione rings (chapter 5).
16
 
These heterocycles have been described and utilized quite rarely in organic and medicinal chemistry.
17
 This result prompted 
us to design a plausible retro-synthetic pathway for the synthesis of optically pure LZD (1) via the intermediate 5-
aminomethyloxazolidine-2,4-dione, taking advantage of the very convenient commercially available chiral reagent (S)-
isoserine (Scheme 2). The rationale for the other steps of the proposed strategy is discussed in the following sections. 
 
Scheme 2. Retro-synthetic approach to LZD (1) via a oxazolidine-2,4-dione intermediate, readily obtained in turn from the 
chiral building block isoserine. 
The approach depicted in Scheme 2 could be exploited in the preparation of a number of unprecedented LZD derivatives 
carrying diverse substituents at the A-ring and/or at the methylacetamide tail (see Figure 1). Indeed, Isoser can be purchased 
also in the (R)-configuration, and several enantiomerically pure Isoser derivatives are commercially available.
18
 Furthermore, 
many non-racemic substituted isoserines can be obtained from chiral starting materials or by enzymatic resolution, by the use 
of chiral auxiliaries,
19
 or by asymmetric catalysis, for example via catalytic enantioselective Henry reactions.
20
 These 
synthetic alternatives will be developed in due course. 
According to the retrosynthetic plan, the first step corresponded to the coupling of 3-fluoro-4-morpholin-4-yl-phenylamine 
(2), prepared as reported in the literature,
3
 and Isoser. Initially, we optimized the conditions for the coupling of Isoser 
carrying diverse protecting groups at the N-terminus. The reaction of 2 with N-Boc-IsoserOH (Scheme 3) was attempted 
according to a protocol described in the literature for the coupling of anilines with chiral -hydroxy acids. This strategy 
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appeared as a suitable process for the synthesis of the enantiomerically pure -hydroxy amide 3.21 Arylamine 2 was treated 
with SOCl2/IMD (imidazole) to give the corresponding N-sulfinylarylamine, and the reaction of the latter with N-Boc-
IsoserOH was performed in presence of 1,2,4-triazole. Despite several modifications aimed at optimizing the procedure, in 
our hands the reaction afforded the expected amide 3a with moderate yields, up to 40% (Table 1, entry 1).  
Consequently, the reactions of 2 and N-Boc-IsoserOH were conducted under various conditions (Table 1), and in different 
solvents (only the best results are reported in Table 1). All runs were monitored by tlc and stopped following the 
disappearance of the reagents, or in any case after 12 h. The reaction of 2 and the mixed anhydride obtained from N-Boc-
IsoserOH and ethylchloroformate/TEA gave only traces of 3a after 12 h (Table 1, entry 2). The use of EDC and HOBt as 
coupling activating agents in the presence of DIPEA (or TEA, not shown) at rt afforded 3a in low yield (15%, entry 3). The 
use of DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) gave a 40% yield (entry 4), while NMM (N-methylmorpholine) gave a 
more satisfactory 60% yield (entry 5). 
On the other hand, the use of the activating agents HBTU/HOBt/NMM or HATU/HOBt/NMM at rt for 12 h led to very good 
yields, 96% and 94% (entries 6 and 7 in Table 1), respectively. These two reactions were accelerated by heating for 10 min 
at 80 °C by MW irradiation, giving 3a in quantitative yields after isolation by flash chromatography over silica gel (entry 8 
with HBTU, and entry 9 with HATU).  
Noteworthy, Isoser was incorporated without a protection for the OH function. Under the reaction conditions reported 
above,
12 
the acylation of the OH-function and thus the formation of isoserine-isoserine side products was not observed, as 
confirmed by the 
1
H NMR and RP-HPLC ESI MS analyses of the crude reaction mixture. 
The availability of N-Ac-IsoserOH offered the opportunity to synthesize a direct precursor of LZD (1) already equipped with 
the desired methylacetamide tail (Scheme 2). Therefore, we reacted 2 and N-Ac-IsoserOH under the best-yielding conditions 
determined for the preparation of 3a at r.t. (entry 6 in Table 1), or under MW activation (entry 9 in Table 1). In particular, 
the use of HBTU/HOBt/NMM at r.t. gave 3b in 97% yield after 12 h (entry 10), while HATU/HOBt/NMM at 80 °C under 
MW irradiation gave the same product quantitatively in 10 min (entry 11). As a reference control, we repeated the coupling 
with EDC/HOBt/NMM (see entry 5), and obtained a low yield (20%, entry 12). This observation confirms the efficacy of 
HATU/HOBt/NMM coupling reagents and MW activation. 
 
Scheme 3. Coupling of 2 and Isoser. 
Table 1. Coupling reactions of isoserine and 2 to afford amides 3a-d. 
    entry        P        coupling agents  Temp (°C)    solvent   3      Yield (%)
[a]
 
1 Boc 1. SOCl2/IMD 
2. triazole 
1. -30 
2. r.t. 
DCM/DMF a 40[b] 
2 Boc EtOCOCl/TEA -20-r.t. DCM/DMF - -[b,c] 
3 Boc EDC/HOBt/DIPEA 0-r.t. DCM/DMF  a 15[b] 
4 Boc EDC/HOBT/DBU 0-r.t. DCM/DMF a 40[b] 
5 Boc EDC/HOBt/NMM 0-r.t. DCM/DMF a 60[b] 
6 Boc HBTU/HOBt/NMM 0-r.t. DCM/DMF a 96[b] 
7 Boc HATU/HOBt/NMM 0-r.t. DCM/DMF a 94[b] 
8 Boc HBTU/HOBt/NMM 80 (MW) DMF a 98[d] 
9 Boc HATU/HOBt/NMM 80 (MW) DMF a 98[d] 
10 Ac HBTU/HOBt/NMM 0-r.t. DCM/DMF b 97 
11 Ac HATU/HOBt/NMM 80 (MW) DMF b 98[d] 
12 Ac EDC/HOBt/NMM 0-r.t. DCM/DMF b 20 
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13 Ts[e] HATU/HOBt/NMM 80 (MW) DMF c 97[d] 
14 Ns[e] HATU/HOBt/NMM 80 (MW) DMF d 96[d] 
[a] Determined after isolation by flash chromatography over silica gel. [b]   
Reaction time 12 h. [c] Traces. [d] Reaction time 10 min. [e] Not further examined. 
We observed that N-Ts (tosyl)- and N-Ns (nosyl)-IsoserOH behaved similarly to N-Boc- and N-Ac-IsoserOH in the coupling 
with 2 under the same reaction conditions used in entry 9 (Table 1), giving in almost quantitative yields the corresponding -
hydroxy arylamides 3c and 3d (entries 13 and 14). The arylsulfonyl protecting groups might be of some interest for future 
developments of LZD analogues. For the comparatively simpler cleavage, the Boc protecting group represents the most 
convenient option.
22 
Nevertheless, the literature reports several methods for the mild cleavage of arylsulfonyl groups.
23  
The following synthetic step of the strategy depicted in Scheme 2 consisted in the cyclization of the Isoser arylamides 3 to 
the five-membered heterocycles 4 (Scheme 4). As anticipated, we observed that oligopeptides containing Isoser underwent 
cyclization to 5-aminomethyloxazolidin-2,4-diones by treatment with 1.1 equiv. of DSC (N,N′-disuccinimidyl carbonate) and 
a catalytic amount of DIPEA in DMF at r.t. for 1h.
16
 Under these conditions, 3a and 3b gave the corresponding 4a and 4b in 
very good yields, 96% (entry 1 in Table 2) and 92% (entry 2 in Table 2), respectively, after purification by flash 
chromatography over silica gel.  
Other carbonates or dicarbonates converted 3a to the 1,3-oxazolidin-2,4-dione 4a in lower yields: Boc2O 15% (Table 2, 
entry 3),
24
 triphosgene 35% (entry 4),
24
 CDI (1,1’-carbonyldiimidazole)25 30% (entry 5), p-nitrophenylchloroformate26 45% 
(entry 6). All reactions were conducted at r.t. for 12 h; increasing the equivalents of the reagents, time, and temperature, in 
different solvents, had scarce effects on the reactions. 
 
Scheme 4. Cyclization of 3a and 3b to 3-aryl-5-aminomethyl-1,3-oxazolidin-2,4-diones 4a and 4b. 
Table 2. Cyclization of 3a and 3b to 4a and 4b: reagents and yields. 
   entry     3                 carbonate  4   Yield (%)
[a]
 
1 a    DSC  a 96
[b] 
2 b    DSC  b 92
[b] 
3 a    Boc2O a 15
[c] 
4 a    triphosgene a 35
[c] 
5 a    CDI a 30
[c] 
6 a    pNO2-
phenylchloroformate 
a 45
[c] 
[a] Determined after isolation by flash chromatography over silica gel. [b] Reaction time 1 h. [c] Reaction time 12 h. 
Having the Boc-aminomethyl 4a and acetamidomethyl 4b at hand, the last step towards LZD (1) consisted in the reduction 
of the carbonyl at C(4) (Scheme 5 and Table 3). This step raised some concerns for the risk of simultaneous reduction of the 
acetamide segment. The reduction of amides to amines under mild conditions is regarded as a highly valuable but 
challenging transformation; many of the reported procedures utilize costly or harmful heavy metal catalysts, high pressure 
and/or high temperatures.
27
 The convenience of the strategy depicted in Scheme 2 was substantiated by the observations 
reported in the literature that in a 1,3-oxazolidine-2,4-dione, the N-carbamate moiety increases the reactivity of the inner 
amide bond towards reduction by NaBH4.
14 
This precedent motivated us to attempt conversion of 4b to LZD (1) upon 
identification of a proper reducing agent (Table 3).  
In effect, the 5-methylacetamide 4b was regioselectively reduced with 1.5 equiv. of NaBH4 in H2O/THF at 0 °C, giving 
exclusively the 5-aminomethyl-4-hydroxy 5 (Scheme 5) with trans relative stereochemistry (Table 3, entry 1). This LZD 
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derivative might be utilized for the introduction of substituents at C(4) in the oxazolidinone ring. Yields improved to 95% in 
MeOH/THF (entry 2), while other solvents gave inferior results (not shown). The trans-relationship was confirmed by the 
very small coupling constant JH4-H5 in the 
1
H NMR spectra; trans-4,5-disubstituted 1,3-oxazolidin-2-ones are characterized 
by coupling constants much lower than that of the cis-stereoisomers.
24
 Interestingly, the RP-HPLC and NMR analyses 
excluded an equilibrium between anomers at C(4).  
 
Scheme 5. Reduction of the carbonyl bond at C(4) of the 1,3-oxazolidin-2,4-dione: synthesis of LZD (1).  
Table 3. Mild reductions of 4a and 4b at C(4) with several reducing agents. 
Entry         4           Reducing agent Temp (°C) Solvent Prod. Yield (%)[a] 
1 b NaBH4 0 H2O/THF 5 50
[b] 
2 b NaBH4 0 MeOH/THF 5 95
[b] 
3 b LiAlH4 0 THF - -
[b,c] 
4 b H2/Pd-C r.t. MeOH - -
[d] 
5 b HCOO
-NH4
+/Pd-C 60 i-PrOH - -[d] 
6 b NH2NH2 100 (HOCH2)2 - -
[d] 
7 b Zn(OAc)2/(EtO)3SiH r.t.-40 THF - -
[d] 
8 b BH3/OEt2 0-r.t. THF - -
[d] 
9 b BH3·DMS 0 THF 1 55
[e] 
10 b BH3·DMS/MS  0 THF 1 88
[b] 
11 a BH3·OEt2 0-r.t. THF - -
[d] 
12 a BH3·DMS 0 THF 7 64
[b,f] 
13 a BH3·DMS/MS  0 THF 7 97
[b] 
[a] Determined after isolation by flash chromatography over silica gel. [b] reaction time 2h. [c] Traces of 1, and 6 as the 
major by-product. [d] Reaction time 24 h; 4 was recovered almost quantitatively. [e] 5 and 6 were the major by-products. [f] 
8 was the major by-product. 
Not unexpectedly, reaction with LiAlH4 at 0 °C resulted in the reduction of  both the carbonyl at C(4) and the N-Ac function, 
giving  a small amount of 1, and the 5-ethylaminomethyl 6 (Scheme 5) as the major by-product (Table 3, entry 3). Catalytic 
hydrogenation (entries 4 and 5),
27
 Wolff-Kishner reaction (entry 6),
28
 Zn(OAc)2 catalyzed reduction with (EtO)3SiH (entry 
7),
27d
 2M borane in diethyl ether (entry 8),
27
  gave only traces of the desired product after 24 h. 
On the other hand, borane dimethyl sulfide complex in anhydrous THF at 0 °C gave 1, which was  easily isolated in 55% 
yield by flash chromatography (entry 9 in Scheme 5). The analysis of the crude reaction mixture by RP-HPLC ESI revealed 
the presence of significant amounts of by-products 5 and 6 (not isolated). When the reaction was repeated in the presence of 
activated (dried) 4 Å molecular sieves, which effectively prevented the formation of 4-hydroxy 5, product 1 was obtained in 
the very satisfactory yield of 88% (entry 10), while 6 was present in traces. Increased reaction temperature resulted in higher 
amounts of N-ethylamino 6. 
Finally, we examined the reduction of 4a under the conditions described for entries 8-10 in Scheme 5 and Table 3. Borane in 
diethyl ether was again nearly ineffective (entry 11), while borane dimethyl sulfide complex gave the 1,3-oxazolidin-4-one 
7
29
 (64%, entry 12) and traces of 4-hydroxy-1,3-oxazolidin-4-one 8 (Scheme 5, not isolated). By contrast, in the presence of 
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molecular sieves, borane dimethyl sulfide complex afforded 7 quantitatively (entry 13). The subsequent treatment with TFA 
followed by treatment with acetic anhydride/TEA afforded 1 in 97% yield (Scheme 5). 
The enantiomeric purity of the reported compounds and intermediates was confirmed by HPLC analysis using a chiral 
stationary phase. The analyses of  the compounds 1, 3a, 3b, 4a, 4b, 5, 7 performed on a CHIRALPAK IC column were 
compared to the analyses of the corresponding racemates obtained from rac-isoserine (Experimental section) As concerning 
the compounds 1(LZD) and 7, the spectroscopic characterizations and specific optical rotations nicely matched the data 
reported in the literature (1,3
,11a 
7
29
, see Experimental Section). 
7.3. Conclusions 
We have demonstrated the feasibility of a new approach to the synthesis of LZD, based on the use of the chiral starting 
material N-acetyl-isoserine, which was efficiently coupled to 3-fluoro-4-morpholinoaniline. Cyclization of the resulting -
hydroxy--acetamido arylamide provided a 5-acetamidomethyl-1,3-oxazolidin-2,4-dione intermediate, which was reduced 
regioselectively to give LZD in very good yield under mild reaction conditions. The use of a N-Boc protected isoserine 
further improved the efficiency of the reduction, only requiring an extra deprotection/acetylation step to afford LZD. Further 
work could be done for the synthesis of optically pure substituted -hydroxy--aminoacids of type -, -, -, -, 
suitable precursors of diversely A ring-substituted LZD analogues. 
7.4. Experimental Section 
7.4.1. General Methods 
Standard chemicals, including (S)- and rac-isoserine, were purchased from commercial sources and used without further 
purification. 2 was prepared as reported in the literature. Flash chromatography was performed on silica gel (230-400 
mesh), using mixtures of distilled solvents. Compounds purities were assessed by analytical RP-HPLC and elemental 
analysis. Analytical RP-HPLC was performed on an Agilent 1100 series apparatus, using a RP column Phenomenex mod. 
Gemini 3C18 110A 100x3.0 mm (P/No 00D-4439-Y0); column description: stationary phase octadecyl carbon chain-
bonded silica (C18) with TMS endcapping, fully porous organo-silica solid support, particle size 3 m, pore size 110 Å, 
length 100 mm, internal diameter 3 mm; DAD 210 nm; mobile phase: from a 9:1 H2O/CH3CN to a 2:8 H2O/CH3CN in 20 
min at a flow rate of 1.0 mL min-1, followed by 10 min at the same composition. Epimerization of intermediates and 
products was excluded on the basis of chiral HPLC analysis, performed on an Agilent 1200 series apparatus, using a 
CHIRALPAK IC column (P/No 83325); column description: chiral stationary phase cellulose tris(3,5-
dichlorophenylcarbamate) immobilized on silica, particle size 5 m, lenght 250 mm, internal diameter 4.6 mm, DAD 
210/254 nm; mobile phase: 1:1 n-hexane/2-propanol, at 0.8 mL min
-1
. The synthetic procedures by MW irradiation were 
performed using a microwave oven (MicroSYNTH Microwave Labstation for Synthesis) equipped with a built-in ATC-FO 
advanced fiber optic automatic temperature control. 
1
H NMR spectra were recorded using a Varian Gemini apparatus at 
400 MHz in 5 mm tubes, using 0.01 M peptide at room temperature. 
13
C NMR spectra were recorded at 100 MHz. 
Chemical shifts are reported as values relative to residual CHCl3 H (7.26 p.p.m.), DMSO H (2.50 p.p.m.) and CDCl3 
C (77.16 p.p.m.) as internal standards. The unambiguous assignment of 1H NMR resonances was performed by 2D 
gCOSY.  
7.4.2. Synthetic procedures 
4-morpholino-3-fluoroaniline (2).
30
A solution of morpholine (1.1 mol) in DMSO (5 mL) was slowly added to a stirred 
solution of 3,4-difluoronitrobenzene (1.0 mmol) in DMSO (5 mL) under inert atmosphere, and the mixture was heated at 
75 °C while stirring. After 2 h, the mixture was allowed to cool to r.t. and ice-cold water (200 mL) was added. The nitro-
intermediate which precipitated quantitatively from the solution was filtered and re-crystallized from ethanol. The crude 
nitro intermediate was dissolved in MeOH (50 mL), and treated with H2 (1 atm) and a catalytic amount of Pd/C. The 
reaction was stirred for 3 h at r.t., than it was filtered through an Hirsch funnel fitted with Celite®. Solvent was evaporated 
at reduced pressure giving 2 as a gray solid (90%), not needing further purifications. 
N-protected-isoserinearylamides 3. 3-fluoro-4-morpholinoaniline (2) (1.0 mmol) was added to a stirred solution of N-
protected isoserine (1.05 mmol) in 9:1 DCM/DMF (5 mL) at 0 °C. After 15 min, HOBt (1.1 mmol) and NMM (2.0 mmol) 
were added, followed after 30 min by HBTU, or HATU (1.1 mmol). The mixture was stirred at r.t. for 12 h. Alternatively, 
the reaction was performed under MW irradiation for 10 min, with an initial irradiation power of 150W, while monitoring 
the internal reaction temperature at 80 °C. Then the reaction mixture was concentrated at reduced pressure, and the residue 
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was diluted with AcOEt (30 mL), washed with 0.1 M HCl (5 mL), and a saturated solution of NaHCO3 (5 mL). The 
organic layer was dried over Na2SO4 and the solvent was evaporated at reduced pressure, to afford 3 as a crude residue, 
which was purified (yield: see Table 1) by flash chromatography over silica gel (eluant: 40:60 cyclohexane/EtOAc). 
3a. []D
20
 = -98.6 (c 0.5, CHCl3); 
1
H NMR (CDCl3)  1.44 (s, 9H, tBu), 3.12 (t, J=4.4 Hz, 4H, morphH3,5), 3.59 (ddd, 
J=2.2, 5.8, 14.8 Hz, 1H, CH2N), 3.69 (ddd, J=2.2, 5.8, 14.8 Hz, 1H, CH2N), 3.92 (t, J=4.4 Hz, 4H, morphH2,6), 4.30 (m, 
1H, CH2CH), 5.19 (br. t, 1H, BocNH), 5.72 (br.d, 1H, OH) 6.93 (t, J=8.8 Hz, 1H, ArH2), 7.16 (m, 1H, ArH5), 7.58 (dd, 
J=2.4, 14 Hz, 1H, ArH6), 8.85 (s, 1H, CONH); 
13
C NMR (CDCl3)  28.2, 44.8, 51.0, 66.9, 71.8, 81.1, 108.6, 108.8, 115.5 
118.7, 118.8, 132.3, 132.4, 136.6, 136.7, 154.2, 156.6, 170.1; ES-MS m/z [M+H]
+ 
calcd 384.2, found 384.2. Elem. anal. 
for C18H26FN3O5 calcd: C 56.39, H 6.84, F 4.96, N 10.96; found: C 56.67, H 6.89, F 5.02, N 10.90. 
3b. []D
20
 = -77.1 (c 0.7, CHCl3); 
1
H NMR (CDCl3)  2.04 (s, 3H, Ac), 3.07 (t, J=4.4 Hz, 4H, morphH3,5), 3.68 (ddd, 
J=2.2, 5.8, 14.8 Hz, 1H, CH2N), 3.82 (ddd, J=2.2, 5.8, 14.8 Hz, 1H, CH2N), 3.89 (t, J=4.4 Hz, 4H, morphH2,6), 4.32 (m, 
1H, CH2CH), 6.07 (br.s, 1H, OH), 6.45 (br.t, 1H, AcNH), 6.95 (t, J=8.6 Hz, 1H, ArH2), 7.15 (m, 1H, ArH5), 7.55 (m, 1H, 
ArH6), 8.89 (s, 1H, CONH); 
13
CNMR (CDCl3)  22.7, 44.8, 51.1, 66.9, 74.2, 108.6, 108.8, 115.5, 119.0, 127.0, 128.3, 
154.2, 170.1, 174.7; ES-MS m/z [M+H]
+ 
calcd 326.2, found 326.3. Elem. anal. for C15H20FN3O4 calcd: C 55.38, H 6.20, F 
5.84, N 12.92; found: C 55.71, H 6.25, F 5.87, N 13.00. 
Synthesis of 3a, protocol of Table 1, entry 1.
31
 For the synthesis of N-sulfinyl 4-morpholino-3-fluoroaniline, a solution of 
1,1’-sulfinyldiimidazole (1 mmol) in dry DCM (2.5 mL) was added dropwise to a stirred solution of 2 in anhydrous 4:1 
DCM/THF (2.5 mL), under inert atmosphere at -30 °C. After 1 h, the reaction mixture was filtered still under inert 
atmosphere at r.t., and the filtrate was used for the next step without further purifications. The filtrate (a solution of N-
sulfinyl 4-morpholino-3-fluoroaniline) was added dropwise to a solution of N-Boc-isoSerine (1 mmol) and 1,2,4-triazole 
(1.4 mmol) in anhydrous 4:1 DCM/DMF (5 mL) while stirring, under nitrogen atmosphere at 0 °C. The reaction mixture 
was stirred for 3 h at 0 °C and for 15 h at r.t. Then the solvent was removed at reduced pressure, the residues was diluted 
with AcOEt (25 mL), washed with 1 M HCl (5 mL) and with a saturated solution of NaHCO3 (5 mL). The organic layer 
was dried over Na2SO4, filtered, and concentrated at reduced pressure to afford the product 3a as crude residue, which was 
isolated (yield: see Table 1) by flash chromatography over silica gel (eluant: 35:65 cyclohexane/EtOAc). 
5-aminometyloxazolidin-2,4-dione 4. DSC (1.1 mmol) was added to a stirred solution of 3 (1.0 mmol) in 3:1 DCM/DMF 
(4 mL), followed by DIPEA (0.1 mmol) at r.t. and under inert atmosphere. After 1 h, the solvent was distilled at reduced 
pressure, the residues was diluted with 1 M HCl (5 mL), and the aqueous phase was extracted three times with AcOEt 
(3x15 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated at reduced pressure. The oily 
residue was purified by flash chromatography over silica gel (eluant: 60:40 cyclohexane/EtOAc) giving the product 4 
(yield: see Table 2). 
4a. []D
20
 = -32.4 (c 0.5, CHCl3); 
1
H NMR (CDCl3)  1.45 (s, 9H, tBu), 3.13 (t, J=4.4 Hz, 4H, morphH3,5), 3.75-3.85 (m, 
2H, CH2N), 3.88 (t, J=4.4 Hz, 4H, MorphH2,6), 4.90 (t, J=6.0, 1H, CH2CH), 5.00 (br.t, 1H, BocNH), 7.01 (t, J=8.4 Hz, 1H, 
ArH2), 7.16-7.19 (m, 2H, ArH); 
13
C NMR (CDCl3)  28.2, 40.4, 40.7, 50.5, 66.7, 82.2, 113.8, 118.6, 118.7, 121.7, 
124.3, 124.4, 140.4, 140.6, 153.6, 153.7, 156.1, 169.8, 172.9; ES-MS m/z [M+H]
+ 
calcd 410.2, found 410.1. Elem. anal. 
for C19H24FN3O6 calcd: C 55.74, H 5.91, F 4.64, N 10.26; found: C 56.01, H 6.05, F 4.68, N 10.32. 
4b. []D
20
 = -27.3 (c 0.6, CHCl3); 
1
H NMR (CDCl3)  2.06 (s, 3H, Ac), 3.13 (t, J=4.8 Hz, 4H, morphH3,5), 3.83-3.94 (m, 
6H, CH2N+morphH2,6), 5.05 (t, J=5.4 Hz, 1H, CH2CH), 5.93 (br.t, 1H, AcNH), 7.01 (t, J=8.8 Hz, 1H, ArH2), 7.15-7.19 (m, 
2H, ArH6,5); 
13
C NMR (DMSO)  23.0, 39.4, 51.0, 66.8, 79.1, 115.2, 115.5, 119.7, 124.0, 125.4, 125.5, 140.8, 153.5, 
154.9, 171.1, 171.2; ES-MS m/z [M+H]
+ 
calcd 352.1, found 352.1. Elem. anal. for C16H18FN3O5 calcd: C 54.70, H 5.16, F 
5.41, N 11.96; found: C 55.02, H 5.19, F 5.45, N 12.04. 
5-acetamidomethyl-4-hydroxy-oxazolidin-2-one 5. Fresh NaBH4 (0.057 g, 1.5 mmol) was added to a stirred solution of 4b 
(0.35 g, 1.0 mmol) in 1:1 MeOH/THF (5 mL) at 0 °C under inert atmosphere. The reaction was quenched after 24 h by 
adding acetone. The mixture was concentrated at reduced pressure, and the residue was diluted with water (5mL). The 
mixture was extracted twice with DCM and once with EtOAc. The organic layers were collected and dried over Na2SO4. 
The solution was filtered and solvent was evaporated at reduced pressure. The oily 5 was isolated (0.33 g, 95%) by flash 
chromatography over silica gel (eluant: 50:50 cyclohexane/EtOAc). []D
20
 = +1.8 (c 0.5, CHCl3); 
1
H NMR (CDCl3)  1.98 
(s, 3H, Ac), 3.07 (dd, J=3.0, 5.8 Hz, 4H, morphH3,5), 3.55 (ddd, J=5.0, 9.0, 14.4 Hz, 1H, CH2N), 3.73 (ddd, J=5.0, 9.0, 14.4 
Hz, 1H, CH2N), 3.87 (dd, J=3.0, 5.8 Hz, 4H, morphH2,6), 4.47 (br.t, 1H, CH2CH), 5.02 (br.s, 1H, OH), 5.60 (s, 1H, 
CHOH), 6.36 (t, J=6.0 Hz, 1H, AcNH), 6.93 (t, J=9.2 Hz, 1H, ArH1), 7.22 (dd, J=2.0, 10.4 Hz, 1H, ArH6), 7.31 (dd, J=2.2, 
13.8 Hz, 1H, ArH5); 
13
C NMR (CDCl3)  22.9, 40.7, 50.9, 66.8, 80.9, 83.1, 111.0, 111.3, 118.3, 119.0, 125.5, 154.0, 
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154.8, 156.5, 171.9; ES-MS m/z [M+H]
+ 
calcd 354.1, found 354.0. Elem. anal. for C16H20FN3O5 calcd: C 54.39, H 5.71, F 
5.38, N 11.89; found: C 54.67, H 5.75, F 5.36, N 11.99. 
5-aminometyloxazolidin-2-ones 1 and 7. Dry 4 Å molecular sieves (100% w/w) were added under inert atmosphere to a 
solution of 4 (1.0 mmol) in freshly distilled THF (10 mL). BH3·DMS (2.0 mmol) was added to the suspension under inert 
atmosphere at 0 °C. After stirring for 7 hours, the reaction was quenched with 0.1 M HCl (10 mL). The mixture was 
concentrated at reduced pressure to half of the initial volume, and extracted 3 times with EtOAc (3x15 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated at reduced pressure. The products 1 or 7 (yields: see 
Table 3) were purified by flash chromatography over silica gel (eluant: 75:25 cyclohexane/EtOAc). 
LZD (1).
3,11a
 []D
20
 = -9.0 (c 0.5, CHCl3), lit.
11a
 []D
23
 = -9.8 (c 2.5, CHCl3); 
1
H NMR (CDCl3)  2.04 (s, 3H, Ac), 3.11 (t, 
J=4.2 Hz, 4H, morphH3,5), 3.62 (ddd, J=3.2, 6.0, 14.8 Hz, 1H, CH2N), 3.71(ddd, J=3.2, 6.0, 14.8 Hz, 1H, CH2N), 3.76 (dd, 
J=7.2, 9.0 Hz, 1H, OxdH4), 3.91 (t, J=4.4 Hz, 4H, morphH2,6), 4.04 (dd, J=7.2, 9.0 Hz, 1H, OxdH4), 4.78 (m, 1H, OxdH5), 
5.99 (br.t, J=6.0 Hz, 1H, AcNH), 7.05-7.10 (m, 2H, ArH1,6), 7.49 (dd, J=2.8, 15.2 Hz, 1H, ArH5); 
13
C NMR (CDCl3)  
23.1, 42.1, 47.7, 51.3, 66.5, 71.9, 107.5, 107.8, 113.9, 119.8, 132.8, 133.0, 136.4, 136.5, 154.2, 154.4, 156.8, 171.1; ES-
MS m/z [M+H]
+ 
calcd 338.2, found 338.2. Elem. anal. for C16H20FN3O4 calcd: C 56.97, H 5.98, F 5.63, N 12.46; found: C 
57.23, H 6.05, F 5.61, N 12.68. 
7.
29
 []D
20
 = -34.4 (c 0.3, CH3CN), lit. []D
25
 = -36 (c 0.71, CH3CN); 
1
H NMR (CDCl3)  1.41 (s, 9H, tBu), 3.06 (t, J=4.8 
Hz, 4H, morphH3,5), 3.46-3.54 (m, 2H, CH2N), 3.81 (dd, J=6.6, 9.0 Hz, 1H, OxdH4), 3.87 (t, 4.8 Hz, 4H, morphH2,6), 4.00 
(dd, J=6.6, 9.0 Hz, 1H, OxdH4), 4.74 (m, 1H, OxdH5), 5.02 (br.t, 1H, BocNH), 6.94 (t, J=9.0 Hz, 1H, ArH1), 7.09 (ddd, 
J=1.2, 2.8, 8.8 Hz, 1H, ArH6), 7.44 (dd, J=2.8, 14.2 Hz, 1H, ArH5); 
13
C NMR (CDCl3)  28.2, 47.5, 51.0, 66.9, 72.0, 80.3, 
107.4, 107.6, 113.9, 118.9, 119.0, 133.2, 133.3, 136.4, 154.3, 156.2, 156.7; ES-MS m/z [M+H]
+ 
calcd 396.2, found 396.2. 
Elem. anal. for C19H26FN3O5 calcd: C 57.71, H 6.63, F 4.80, N 10.63; found: C 57.98, H 6.62, F 4.91, N 10.89. 
Synthesis of 1 via 7. Compound 7 (0.40 g, 1.0 mmol) was treated with 1:3 TFA/DCM (5 mL) while stirring at r.t. After 15 
min, the solution was evaporated at reduced pressure, and the residue underwent the same treatment. The crude residue was 
suspended in Et2O (20 mL), and the precipitate was collected by centrifuge. A stirred suspension of the crude TFA salt was 
suspended in 5 mL of EtOAc and treated with Ac2O (0.14 mL, 1.5 mmol) and TEA (0.28 mL, 2.0 mmol) at r.t. After 3 h, 
the mixture was diluted with EtOAc (40 mL), and washed with 0.1 M HCl (5 mL) and brine (5 mL). The organic layer was 
dried over Na2SO4, filtered, and concentrated at reduced pressure. The product 1 was isolated (0.33 g, 97%) by flash 
chromatography over silica gel (eluant: 75:25 cyclohexane/EtOAc). 
7.4.3. Determination of the enantiomeric purity of the reported compounds. 
Chiral HPLC analyses of rac-1/(S)-1, rac-3a/(S)-3a, rac-3b/(S)-3b, rac-4a/(S)-4a, rac-4b/(S)-4b, rac-5/(S)-5, rac-7/(S)-7, 
performed on an Agilent 1200 series apparatus, using a CHIRALPAK IC column (P/No 83325). 
Column description: chiral stationary phase cellulose tris(3,5-dichlorophenylcarbamate) immobilized on silica, particle size 
5 m, lenght 250 mm, internal diameter 4.6 mm. Mobile phase: 1:1 n-hexane/2-propanol, at 0.8 mL min-1. DAD 210/254 
nm. 
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Chapter 8 
Synthesis and biological assay of retroinverse-41 integrin antagonists 
 
In recent years, several research groups proposed new peptidomimetic antagonists of integrins v3, 51, IIb3, 
αvβ6, αvβ5, etc. based on retro-sequences of the classic integrin-binding motif RGD. The retro-strategy is still largely 
ignored for the non-RGD-binding41 integrin. Herein is presented the first examples of retro-sequences for targeting 
this integrin, composed of Asp or isoAsp equipped with an aromatic cap at the N-terminus, (S)-pyrrolidine-3-carboxylic 
acid (2-Pro) as a constrained core, and the amino variant (AMPUMP) of the well known 4-targeting diphenylurea 
MPUPA. Moreover, it is discussed 41 receptor affinity (SPA), cell adhesion assays, stability in mouse serum, and 
conformational analysis. For their significant ability to inhibit cell adhesion and remarkable stability, the retro-peptide 
mimetics BnCO-Asp--Pro-AMPUMP (3) and BnCO-isoAsp--Pro-AMPUMP (4) represent promising candidates for 
designing small molecules as potential anti-inflammatory agents. 
8.1. Introduction 
The integrin 41 (VLA-4, very late activation antigen-4, CD49d/CD29) is a cell surface receptor expressed on 
lymphocytes (and also on monocytes, eosinophils, basophils, macrophages), that mediates cellular adhesion events 
crucial to leukocyte trafficking and activation during inflammatory processes.
1,2 
If the condition becomes chronic, there 
can be a sustained extravasation of lymphocytes that can exacerbate the inflammatory condition, which in turn will 
continue to recruit more inflammatory cells resulting in tissue destruction. 
Their involvement in disease processes prompted several pharmaceutical companies to pursue 4 integrin antagonists 
as potential anti-inflammatory agents.
3
 Monoclonal 4 integrin antibodies have been shown to be modulators in animal 
models for auto-inflammatory diseases such as asthma, rheumatoid arthritis, and inflammatory bowel diseases.
4,5
 The 
humanized monoclonal antibody Natalizumab has been approved for multiple sclerosis.
5
 However, the inherent 
limitations of antibody therapy, high cost, potential immunogenicity, and the requirement for intravenous 
administration, strongly spurred efforts to develop small molecule antagonists. 
The primary ligands of 41 integrin are vascular cell adhesion molecule (VCAM), and the extracellular matrix (ECM) 
protein fibronectin (FN). Their integrin binding sites contain a critical aspartic acid located within a highly conserved 
tripeptide sequences, Ile-Asp-Ser (IDS) in VCAM and Leu-Asp-Val (LDV) in FN.
6,7 
Consequently, peptidomimetics 
and non-peptide mimetics of the recognition sequences can effectively inhibit the integrin.
6,7
 For instance, the 
combination of a LDVP sequence and N-terminal o-methylphenylureaphenylacetyl group (MPUPA) lead to the potent 
selective BIO1211 (MPUPA-LDVP-OH 1, Table 1).
8,9,10
 However, the residual peptidic nature of 1 and related 
compounds resulted in rapid enzymatic hydrolysis
11,12
 and clearance in vivo.
13 
Among the non-peptides, the N-(2,6-
diclorobenzoyl)-2,6-dimethoxy biphenylalanine TR-14035 was highlighted as a non-specific 4 integrin antagonist.14 In 
general, the large majority of the peptidomimetic compounds share common structural features: a 4-targeting aromatic 
cap at the N-terminus (eventually an aromatic urea such as MPUPA), a suitable spacer, and a -carboxylate mimetic of 
Asp.
6,7
 
In search for new lead structures, the similarities between the different types of integrins prompted several research 
groups to test the Arg-Gly-Asp (RGD) sequence for inhibition of 41. This epitope, discovered several years earlier, 
was found on numerous ECM proteins, collagen, fibrinogen, vitronectin (VT), and FN, and was known to interact with 
several integrins, including v3, 51, IIb3, etc.15 Mould et al. described the ability of peptide GRGDS and 
homologues to inhibit the interaction of 41 with the alternatively spliced type III connecting segment (IIICS) region 
of fibronectin,
16
 and Cardarelli et al. provided evidence that RGD-containing cyclopeptide 1-adamantaneacetyl-
CGRGDSPC(S-S)
17
 was a inhibitor of cell adhesion mediated by 41. Also, Nowlin, Cardarelli, et al. showed that the 
RCD-containing cyclic peptide RCD(ThioP)C(S-S) inhibited 41 and 51 integrin-mediated cell adhesion,18 and 
Jackson et al. observed that cyclic  eptides containing RCD blocked the interaction of 41with VCAM-1.19 Using 
atomic force microscopy measurement of monocyte-endothelial cell interaction, Elitok et al. demonstrated that a cRGD 
peptide inhibited their adhesion through 41-VCAM-1, resulting in the inhibition of monocyte/macrophage 
infiltration.
20
 
Albeit the 41 receptor was not definitively documented to interact RGD peptides with high affinity, these results 
suggest that the strategies successfully developed for designing a variety of RGD-derived analogues
21,22
 could 
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potentially be used to identify new 41 antagonists.6,7 In this respect, we sought to investigate the opportunity to 
design retro sequences of the common MPUPA-spacer-Asp peptidomimetic binding-motif (see above) of the integrin 
41 as potential antagonists. In the last few years, the use of retro-sequences of the classic RGD binding motif for 
v3 and 51-integrin has became popular. Initially, Kessler et al. investigated the biological activity of retro (DGR), 
inverso (rGd), retro-inverso (dGr) analogues (plus their stereoisomers) of the selective and superactive αvβ3 integrin 
inhibitor c[RGDfV].
23
 Some years later, we proposed cyclopeptides containing the partially modified retro Arg-Gly-
Asp sequence ψ(NHCO)Aspψ-(NHCO)Gly-Arg.24 Novellino, Kessler, et al., grafted the isoDGR motif onto c[phg-
isoDGRG], achieving activity enhancement toward α5β1 integrin;25,26 further, selectivity toward FN-binding integrins 
α5β1 and αvβ6 over VT-binding integrins αvβ3 and αvβ5 was improved changing the flanking amino acids.26  
Some researchers have proposed that deamidation of the Asn-Gly-Arg (NGR) motif in FN into isoDGR might result in 
a gain of protein function by creating a new adhesion binding site for integrins.
27,28 
However, this hypothesis was 
questioned in a report using recombinant FN with mutations in the NGR motif.
29
 Later investigations suggested that the 
isoDGR sequence can fit into the RGD-binding pocket of integrin, establishing the same electrostatic clamp as well as 
additional polar interactions.
30,31,32
 
These considerations prompted us to transfer the retro strategy into peptidomimetic sequences showing Asp or isoAsp, a 
central spacer, and the amino variant 1-(4-(aminomethyl)phenyl)-3-(o-methylphenyl)urea (AMPUMP) of the well-
known 4-targeting MPUPA, giving the retro sequences Asp-spacer-AMPUMP, and isoAsp-spacer-AMPUMP.6,7,8,9,10 
8.2. Results and discussion 
8.2.1. Design and synthesis 
The structures of the peptidomimetics 2-6 (Table 1) were designed on the basis of the models developed by 3D-QSAR 
analysis of large libraries of compounds containing diphenylureas such as MPUPA, or other substituted aromatic 
groups.
13,33,34
 3D geometries of plausible candidates were screened prior to synthesis by molecular modeling;
35
 Figure 
1 shows the bioactive geometries and structures of the prototypic model compounds 7
13,36
 and 8.
 2,33
 This selection led 
to the retro sequences Asp-2-Pro-AMPUMP 3 and 5, and isoAsp-2-Pro-AMPUMP 4 and 6 (2-Pro, (S)-pyrrolidine-
3-carboxylic acid). The straight sequence MPUPA-2-Pro-Asp 2 was considered for comparison, and BIO1211 
(MPUPA-Leu-Asp-Val-Pro-OH, 1) was chosen as 41 integrin antagonist reference compound.  
 
 
Figure 1. Structures of the model compounds 7 (and top, left) and 8 (and top, right) as reported in the literature. 
 
The sequences 2-6 were assembled by connecting 2-Pro to MPUPA or AMPUMP. The 2-Pro core was chosen to 
increase peptide stability,
37
 and for the conformational control exerted on the overall structure.
38,39,40,41
 Further, we 
took advantage of our previous experience in the use of 2-Pro or equivalent heterocycles42 for preparing highly stable 
peptidomimetics,
43
 including highly active integrin ligands.
44
 Asp and isoAsp were equipped with aromatic 
substituents; it is well known that the presence of an aromatic moiety adjacent to Asp can favor integrin binding.
6,7
 
The compounds 3 and 4 show a phenylacetyl N-cap (BnCO), while 5 and 6 include the N-2,6-dicholorobenzoyl group, 
which was shown to efficiently bind to the 1-subunit, 45 and is present in many ligands, including TR-14035.6,7,14 
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After synthesis and bioassay, the coherence of the most active compounds with the geometries of the 3D-QSAR 
models was confirmed by 2D ROESY and molecular dynamics (see Experimental section). 
As a representative example, the preparation of the BnCO-isoAsp-2-Pro-AMPUMP sequence 4 is described in 
Scheme 1; for the details on the intermediates, see Experimental section. Fmoc-Asp(Ot-Bu)-OH was treated with 
BnBr, giving 9, and Fmoc was replaced with the phanylacetyl group via 10. The resulting fully protected Asp 11 was 
treated with TFA giving 12. In parallel, Boc-4-(aminomethyl)aniline was treated with 2-methylbenzene isocyanate 
affording Boc-AMPUMP 13. This was treated with TFA, and resulting AMPUMP 14 was coupled with Boc--Pro-
OH in solution under MW irradiation and in the presence of HOBt/HBTU/DIPEA, giving 15. Boc deprotection was 
followed by coupling with 12 under the same conditions as before. The resulting 17 was deprotected by catalytic 
hydrogenation, giving 4 in very good yield. The strategies for the syntheses of the remaining compounds are given in 
Experimental section. The products were purified (96-98%) by semi-preparative reversed-phase (RP) HPLC. 
 
Scheme 1. Synthesis of BnCO-isoAsp-2-Pro-AMPUMP (4). 
8.2.2.  Scintillation proximity-binding assay 
The binding of the peptidomimetics 1-6 to 41 integrin was measured by (SPA), using Jurkat cells stably expressing 
human 4 integrin, and 125I-FN as the specific radioligand.46,47 Western blot analysis of the 41 integrin, extracted 
from cell lysate and purified by chromatography, confirmed that both 4 and 1 integrin subunits were present in the 
eluate employed for the test (Experimental section).  
Table 1. SPA binding to bead-associated 41 integrin and inhibition of Jurkat cell adhesion of BIO1211 (1) and 
compounds 2-6.
a
 
 structure Purity 
(%)b 
m/z [M+1] 
vs calcd 
SPA 
IC50 (nM) 
SPA 
Ki (nM) 
α4β1/VCAM-1  
IC50 (nM) 
v3/VT 
IC50 (nM) 
 
1 
 
 
- 
  
4.80±2.4 
 
1.50±0.37 
 
7.60±3.0 
 
- 
 
2 
   
 
96 
587.2/ 
587.2 
 
>105 
 
>105 
 
>105 
 
- 
 
3 
   
 
98 
586.2/ 
586.3 
 
100±40 
 
60±10 
 
80±10 
 
>105 
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4 
 
 
97 
 
586.1/ 
586.3 
 
290±20 
 
180±40 
 
93±10 
 
>105 
 
5 
     
 
96 
 
640.1/ 
640.2 
 
3.90±0.54 
103 
 
2.4±0.25 
103 
 
>105 
 
- 
 
6 
  
 
96 
 
640.1/ 
640.2 
 
>105 
 
>105 
 
>105 
 
- 
a
 Mean of four determinations ± SE. 
b
 Determined by analytical RP-HPLC; see Materials and instruments
 
Specific binding of 
125
I-FN to an antibody-captured 4 and 1 integrin was time-dependent; the signal reached a 
plateau in 10 h and remained constant for the rest of the 24 h incubation (Experimental section). The relatively slow 
kinetics of the SPA may require the establishment of equilibrium between the different components.
46,47
 
125
I-FN 
specific binding to the SPA bead-associated 41 integrin, measured after overnight incubation, was inhibited in a 
concentration-dependent manner by BIO1211, MPUMP-Leu-Asp-Val-Pro-OH (1), with IC50 and Ki values of 4.8 and 
1.5 nM, respectively (Table 1). Furthermore, 
125
I-FN selective binding was blocked by an anti-human 4 integrin 
antibody (5 mg/tube) to capture the integrin complex (data not shown). 
The straight  sequence MPUMP-2-Pro-Asp-OBn 2 was not able to inhibit 125I-FN binding. On the contrary, the retro 
compounds 3-5 caused concentration-dependent inhibition of 
125
I-FN binding (Table 1). The sequence BnCO-Asp-2-
Pro-AMPUMP 3 showed IC50 and Ki values (M) of 1.0×10
-7
 and 6.0×10
-8
, respectively. The analogue of 3 containing 
isoAsp 4 showed IC50 of 2.9×10
-7
 and Ki of 1.8×10
-7
 M. The analogue of 3 equipped with the 2,6-dicholorobenzoyl 
group 5 revealed a modest affinity, in the micromolar range, while 6, analogue of 4 with the 2,6-dicholorobenzoyl 
instead of the phanylacetyl (BnCO) group, did not displace 
125
I-FN in a significant way.  
8.2.3. Cell adhesion inhibition 
Subsequently, we assayed the ability of 1-6 to inhibit the adhesion of 41 integrin-expressing Jurkat cells to VCAM-
1. In a first series of experiments, we ascertained that adhesion of these cells to 96-well plates coated with human 
recombinant VCAM-1 was concentration-dependent and was not observed in BSA-coated wells.
46,47
 The adhesion of 
Jurkat cells (5×10
5
 cells per well) to VCAM-1 (2-25 mg/ml) ranged from 1.9 to 3.2×10
4
 cells. The adhesion to 
VCAM-1 (10 mg/ml) was inhibited (>92%) after pretreatment with 5 mg/ml of an anti-4 integrin antibody. As 
shown in Table 1, the reference compound BIO1211 (MPUPA-Leu-Asp-Val-Pro-OH, 1) behaved as a potent 41 
integrin ligand and inhibited Jurkat cell adhesion to VCAM-1 with a IC50 of 7.6 nM. Peptidomimetics 2 and 6 did not 
affect cell adhesion to a significant extent, confirming the results of the SPA assay. Interestingly, the retro compounds 
BnCO-Asp-2-Pro-AMPUMP (3) and BnCO-isoAsp-2-Pro-AMPUMP (4) inhibited cell adhesion with an IC50 of 80 
and 93 nM, respectively. On the contrary, 5 failed to behave as adhesion antagonist, despite of the micromolar affinity 
revealed by the SPA (Table 1). In addition, 3 and 4 did not show any significant activity (IC50 > 100 M) in cell 
adhesion assays (Table 1) aimed to evaluate any potential antagonist activity towards v3 integrin (SK-MEL-24 
cells coated with 10 mg/ml VT). Finally, neither compound (up to 2 mM) influenced cell viability, evaluated by 
Trypan blue exclusion (data not shown). 
8.2.4. In vitro metabolic stability 
BIO1211 (1) was found to be very unstable in heparinized blood, plasma and rat liver, lung and intestinal 
homogenates, being metabolized by hydrolytic cleavage of the terminal dipeptide moiety, giving a sequence
11,12
 much 
less active than the parent compound.8 For their peptidomimetic nature the sequences BnCO-Asp-2-Pro-urea 3 and 
BnCO-isoAsp-2-Pro-urea 4 were supposed to be significantly more stable, in particular for the presence of the central 
-Pro. The resistance of 3 and 4 to enzymatic degradation was estimated using 100% mouse serum (Sigma)48 and 
compared to that of 1 under the same conditions. After 120 min, 3 was degraded to a moderate extent (about 10%), 
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and 4 was only slightly degraded (< 5%) after incubation in the mouse serum, while 1 was almost completely 
hydrolyzed, being present only in traces, as detected by RP-HPLC and ESI-MS analyses. Apparently, the presence of 
isoAsp increased the stability of 4 compared to 3.  
8.2.5. Conformational analyses 
The significant biological activity of the structurally correlated BnCO-Asp-2-Pro-AMPUMP (3) and BnCO-isoAsp-
2-Pro-AMPUMP (4) prompted us to analyze the conformations by NMR spectroscopy and MD simulations 
(Experimental section) in particular to check the fulfillment of the geometric requisites of the 3D models utilized for 
structure design (Experimental section). 
As expected on the basis of the literature,
38,39,40,41
 the 
1
H-NMR of both 3 and 4 revealed two sets of resonances, in 
about 1:1 ratio, corresponding to the cis and trans conformers of the peptide bond linking the pyrrolidine ring. The cis 
conformations were assigned by detection of the NOE cross peaks between AspH (3) or isoAspH (4) and 
PyrrolidineH-2, while the trans conformations were deduced by detection of the NOE cross peaks between AspH (3) 
or isoAspH (4) and PyrrolidineH-5 (for this numbering, see the structures 3 and 4 in Table 1, and structures 
associated to Tables 2 to 5).
49
 
Molecular conformations were investigated by 2D ROESY in 8:2 DMSO-d6/H2O; DMSO-d6 alone or mixtures of 
DMSO-d6 and H2O have been recommended by several authors as biomimetic media.
50,51
 Cross-peak intensities were 
ranked to infer plausible inter-proton distances as restraints. Structures consistent with ROESY were obtained by 
simulated annealing with restrained MD
35
 in a box of explicit TIP3P water molecules. The structures were minimized 
with the AMBER force field and clustered by the rmsd analysis of backbone atoms (Experimental section). 
For 3, computations essentially gave one major cluster for the all-trans conformer and one cluster for the trans-cis-
trans conformer, each comprising almost 95% of the structures. For each cluster, the representative geometries all-
trans-3A and trans-cis-trans-3C with the lowest internal energy and no violations of the distance constraints were 
selected and analyzed (Figure 2). 
 
Figure 2. Representative low-energy structure all-trans-3A (3, BnCO-Asp-2-Pro-AMPUMP) consistent with ROESY 
analysis and calculated by restrained MD; alternative minor conformer 3B (low energy structure), determined by 
unrestrained MD; representative low-energy structure of trans-cis-trans-3C calculated by restrained MD; minor 
conformer 3D (low energy structure) determined by unrestrained MD. All structures obtained in a 45×45×45 Å box of 
standard TIP3P water molecules. 
To investigate the dynamic behavior, the structures 3A and 3C were analyzed by unrestrained MD for 10 ns in a 
45×45×45 Å box of explicit, equilibrated water molecules. Besides to the all-trans-3A, the analysis of the trajectories 
revealed the occurrence of the minor all-trans conformer 3B, differing almost exclusively in the orientation of BnCO-
Asp--Pro dipeptide respect to the AMPUMP group. The analysis of the trajectories of trans-cis-trans-3C revealed the 
presence of the minor conformer 3D, showing the alternative orientation of BnCO-Asp--Pro respect to AMPUMP 
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(Figure 2). On the other hand, the conversion of the all-trans conformers into the trans-cis-trans conformers was 
observed very seldom. 
In a similar way, computations for 4 gave one cluster for the all-trans conformer and one cluster for the trans-cis-trans 
conformer (> 90% of the structures). Figure 3 shows the representative low energy geometries of all-trans-4A and 
trans-cis-trans-4C. Unrestrained MD performed as described for 3 revealed the alternative minor conformers all-trans-
4B and trans-cis-trans-4D, differing from 4A and 4C in the display of the Asp--Pro dipeptide respect to the 
AMPUMP group. 
Despite of potentially high flexibility of the linear ligands, the -Pro scaffold conferred them markedly bent 
conformations. Indeed, the conformers A and C determined by restrained MD were clearly predominant during the 
unrestrained MD simulations in water. Apparently, both all-trans-A and trans-cis-trans-C conformations seemed 
compatible with one or the other 3D model 7 or 8 (Figure 1).
2,13,33,36,52,53
 For the moment, the determination of the 
different contribution of the cis and trans geometries to the bioactive conformations of the compounds is not possible. 
The most significant differences between the corresponding conformations of 3 and 4 were related to the position of 
the aromatic group adjacent to Asp or isoAsp, respectively. This might be correlated to the slightly different IC50 and 
Ki values determined by SPA, confirming the role of the flanking aromatic substituent for efficient binding of the 
receptor.
23,24,25,33
 
 
Figure 3. Representative low-energy structure all-trans-4A (4, BnCO-isoAsp-2-Pro-AMPUMP) consistent with 
ROESY analysis and calculated by restrained MD; alternative minor conformer 4B (low energy structure), determined 
by unrestrained MD; representative low-energy structure of trans-cis-trans-4C calculated by restrained MD; minor 
conformer 4D (low energy structure) determined by unrestrained MD. All structures obtained in a 45×45×45 Å box of 
standard TIP3P water molecules. 
8.3. Conclusions 
In summary, herein is reported the first implementation of the retro-sequence strategy for the design of new 41 
integrin inhibitors. Starting from the well known41 integrin binding motif “MPUPA-spacer-Asp”, exemplified by 
the potent and selective ligand BIO1211 (MPUPA-Leu-Asp-Val-Pro-OH), we assembled the retro peptidomimetic 
sequences by connecting Asp or isoAsp, and the amino variant (AMPUMP) of the widely utilized diphenylurea 
MPUPA, to a pyrrolidine-3-carboxylate (2-Pro) scaffold, the latter selected by inspection of the 3D models (3D-
QSAR) reported in the literature. After syntheses, the conformational analyses confirmed the good agreement with the 
models. 
Interestingly, while the straight sequence MPUPA--Pro-Asp-OBn (2), analogue of BIO1211, was completely inactive, 
the retro sequences BnCO-Asp--Pro-AMPUMP (3) and BnCO-isoAsp--Pro-AMPUMP (4), displayed a moderate 
binding affinity (SPA), and efficiently inhibited the adhesion of 41 integrin-expressing cells to VCAM-1. Besides, 
the peptidomimetic nature conferred these compounds good in vitro metabolic stability (mouse serum). Albeit 3 was a 
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slightly more potent inhibitor than 4, the latter was significantly more stable. These evidences support that the retro 
approach can furnish promising candidates for the development of a new class of peptidomimetic anti-inflammatory 
agents. 
 
8.4. Experimental section 
8.4.1. General methods 
Unless stated otherwise, chemicals were obtained from commercial sources and used without further purification. The 
MW-assisted synthesis was performed using a MicroSYNTH microwave labstation. Flash chromatography was 
performed on silica gel (230-400 mesh), using mixtures of distilled solvents. Purities were determined to be ≥ 96% by 
analytical RP-HPLC and combustion analysis. Analytical RP-HPLC was performed on an C18 column (4.6 μm 
particle size, 100 Å pore diameter, 250 μm, DAD 210 nm, from a 9:1 H2O/CH3CN to a 2:8 H2O/CH3CN, with the 
addition of 0.05% TFA, in 20 min) at a flow rate of 1.0 mL/min, followed by 10 min at the same composition. 
Elemental analyses were performer using a Thermo Flash 2000 CHNS/O analyzer. Semipreparative RP-HPLC was 
performed on a C18 column (7 μm particle size, 21.2 mm×150 mm, from 8:2 H2O/CH3CN to 100% CH3CN, with the 
addition of 0.05% TFA, in 10 min) at a flow rate of 12 mL/min. Mass analysis was done by ESI. 
1
H NMR and 
13
C 
NMR spectra were recorded at 400 and 100 MHz, respectively, in 5 mm tubes, at rt. Chemical shifts are reported as δ 
values relative to the solvent peak. 2D spectra were recorded in the phase sensitive mode and processed using a 90°-
shifted, squared sinebell apodization. 
8.4.2. Synthetic procedures 
Peptide coupling, general procedure. HOBt (1.1 mmol) and HBTU (1.1 mmol) were added to a stirred solution of the 
acid partner (1.0 mmol) in 4:1 DCM/DMF (5 mL) at rt under inert atmosphere. After 5 min, the amino partner-TFA 
salt (1.1 mmol) and DIPEA (2.2 mmol) were added at rt, and the mixture was stirred under MW irradiation, keeping 
irradiation power fixed at 150W and monitoring the internal reaction temperature at 80 °C with a built-in ATC-FO 
advanced fiber optic automatic temperature control. After 10 min the mixture was diluted with DCM, and the solution 
was washed with 0.5 M HCl (5 mL) and saturated NaHCO3 (5 mL). The organic layer was dried over Na2SO4, and 
solvent was removed at reduced pressure. The intermediates were isolated by crystallization from EtOH/Et2O or by 
flash chromatography over silica-gel. For the preparation of the different Asp or isoAsp derivatives and of 11, see 
S.M. Compounds 2-6 were purified by semipreparative RP-HPLC (see 7.4.1.), (70-85% yield, 96-98% pure by 
analytical RP-HPLC). 
Fmoc-Asp(OtBu)-OBn (9). A mixture of Fmoc-Asp(OtBu)-OH (1.50 g, 3.65 mmol), BnBr (1.7 mL, 14.6 mmol) 
NaHCO3 (0.92 g, 10.9 mmol) in DMF (6 mL), was stirred for 8 h. Then the mixture was diluted with water (10 mL) 
and extracted three times with EtOAc (20 mL). The combined organic layers were dried over Na2SO4, and solvent 
was distilled at reduced pressure. The oily residue was purified by flash chromatography over silica-gel (eluant 
EtOAc/cyclohexane 1:9) giving 7 (1.58 g, 85%). The analyses were in agreement with the literature.
54
  
BzCO-Asp(OtBu)-OBn (11). 9 (0.89 g, 1.71 mmol) was treated with 2M dimethylamine in THF (4 mL) under inert 
atmosphere while stirring. After 10 min, the solvent was distilled at reduced pressure, and the residue was treated as 
before for additional 40 min. After solvent evaporation, the residue was triturated with Et2O, and the precipitate 10 
(quantitative yield) was utilized without purification. ESI-MS m/z 293.1 (M+H)
+
, calcd 293.1. Crude 10 was dissolved 
in DCM (10 mL) and treated with BnCOCl (0.250 mL, 1.71 mmol) and pyridine (0.21 mL, 2.6 mmol) under inert 
atmosphere. After 4 h the reaction was diluted with EtOAc (30 mL) and washed with 0.5 M HCl (5 mL), sat. NaHCO3 
(5 mL), and brine (5 mL), and dried over Na2SO4. Solvent was distilled at reduced pressure, and the residue was 
purified by flash chromatography over silica-gel (eluant EtOAc/cyclohexane 2:8) giving 11 (0.64 g, 94%). 
1
H NMR 
(CDCl3, 200 MHz)  (ppm): 1.40 (s, 9H, t-Bu), 2.73 (dd, J = 4.2, 17.1 Hz, 1H, AspH), 2.95 (dd, J= 4.0, 17.1 Hz, 1H, 
AspH), 3.60 (s, 2H, CH2Ph), 4.86 (q, J = 8.2 Hz, 1H, AspH), 5.10 (d, J = 13.0 Hz, 1H, CH2Ph), 5.22 (d, J = 13.0 
Hz, 1H, CH2Ph), 6.51 (br.d, J = 7.2 Hz, 1H, AspNH), 7.40-7.80 (m, 10H, ArH); ESI-MS m/z 398.1 (M+H)
+
, calcd 
398.2. 
BzCO-Asp-OBn (12). 11 (0.64 g, 1.61 mmol) was stirred in 1:3 TFA/DCM (4 mL). After 30 min the mixture was 
concentrated at reduced pressure, and the procedure was repeated. The oily residue was triturated in Et2O, and the 
crude 12 which precipitated (0.54 g, 98%), was utilized without purification. ESI-MS m/z 342.1 (M+H)
+
, calcd 342.1  
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Synthesis of Boc-AMPUMP (13). 2-Methylphenyl isocyanate (0.56 mL, 4.50 mmol) was added to a stirred solution of 
t-Bu-4-aminobenzylcarbamate (1.0 g, 4.50 mmol) in DMF (8 mL) at r.t. under inert atmosphere. After 2 h the reaction 
was diluted with EtOAc (30 mL), giving the precipitate 13 (1.44 g, 90%) collected by filtration. 
1
H NMR (DMSO-d6, 
200 MHz)  (ppm): 1.38 (s, 9H, t-Bu), 2.22 (s, 3H, CH3Ph), 4.06 (d, J = 5.8 Hz, 2H, CH2Ph), 4.24 (d, J = 5.4 Hz, 1H, 
NH), 6.86 (dd, J = 6.2, 13.2 Hz, 2H, ArH), 6.91-7.22 (m, 4H, ArH), 7.35 (d, J = 8.6 Hz, 1H, ArH), 7.76 (s, 1H, NH), 
7.81 (d, J = 8.0 Hz, 1H, ArH), 8.82 (s, 1H, NH); ESI-MS m/z 356.1 (M+H)
+
, calcd .356.2. 
Synthesis of 15. Boc deprotection of 13 (1.44 g, 4.05 mmol) was performed as described for the preparation of 12. The 
residue was suspended in Et2O (20 mL). The TFA-AMPUMP salt 14 which precipitated in quantitative yield was used 
for the next coupling without further purifications. ESI-MS m/z 256.1 (M+H)
+
, calcd 256.1. The TFA salt 14 was 
coupled with Boc-(S)--isoPro-OH (1.13 g, 5.0 mmol) under MW irradiation as described in the main text (Peptide 
coupling, general procedure). The residue was purified by flash chromatography over silica-gel (eluant EtOAc) giving 
15 as a waxy solid (1.55 g, 85%). 
1
H NMR (CDCl3, 200 MHz)  (ppm): 1.44 (s, 9H, t-Bu),1.50-1.63 (m, 1H, 
PyrrolidineH-4), 1.90-2.01 (m, 2H, PyrrolidineH-4+H-3), 2.13 (s, 3H, CH3Ph), 2.76-2.90 (m, 1H, PyrrolidineH-5), 
3.10-3.22 (m, 1H, PyrrolidineH-5), 3.38-3.58 (m, 2H, PyrrolidineH-2), 4.06 (d, J = 5.8 Hz, 2H, CH2Ph), 4.24 (d, J = 
5.4 Hz, 1H, NH), 6.86 (dd, J = 6.2, 13.2 Hz, 2H, ArH), 6.91-7.22 (m, 4H, ArH), 7.35 (d, J = 8.6 Hz, 1H, ArH), 7.76 (s, 
1H, NH), 7.81 (d, J = 8.0 Hz, 1H, ArH), 8.82 (s, 1H, NH); ESI-MS m/z 475.1 (M+Na)
+
, calcd 475.2.  
Synthesis of 17. 15 (1.55 g, 3.4 mmol) was deprotected as described for 14; the TFA salt 16 (quantitative yield) was 
used without further purifications. ESI-MS m/z 353.1 (M+H)
+
, calcd 353.2. Crude 16 (0.26 g, 0.73 mmol) was 
coupled with 12 (0.25 g, 0.73 mmol) under MW irradiation as described in the main text (Peptide coupling, general 
procedure). The residue was purified by flash chromatography over silica-gel (eluant EtOAc/cyclohexane 2:8) giving 
17 (0.39 g, 80%). 
1
H NMR (CDCl3, 200 MHz)  (ppm): 1.84-2.19 (m, 2H, PyrrolidineH-4), 2.19 (s, 3H, CH3), 2.58 
(m, 1H, AspH), 2.70-2.81 (m, 1H, PyrrolidineH-3), 2.94 (m, 1H, AspH), 3.20-3.30 (m, 2H, PyrrolidineH-5), 3.41-
3.51 (m, 4H, CH2Ph+PyrrolidineH-2), 3.51-3.62 (m, 2H, PyrrolidineH-5), 4.23-4.40 (m, 4H, CH2Ph+PyrrolidineH-
2), 4.82 (m, 1H, AspH), 5.25 (m, 2H, CH2Ph), 6.30 (br.t, 1H, NH), 6.40 (s, 1H, NH), 6.60 (br.d, 1H, AspNH), 6.70 
(s, 1H, NH), 6.90 (t, J = 7.4 Hz, 1H, ArH), 6.94-7.20 (m, 9H, ArH), 7.20-7.25 (m, 5H, ArH), 7.25-7.36 (m, 2H, ArH), 
7.59 (d, J = 8.0 Hz, 1H, ArH); ESI-MS m/z 676.2 (M+H)
+
, calcd 676.3.  
Synthesis of 4. 17 (0.39 g, 0.58 mmol) was treated with H2 and catalytic Pd/C in EtOH (20 mL). After 6 h, the mixture 
was filtered over Celite, and the solvent was evaporated at reduce pressure. The residue was purified by semi-
preparative RP-HPLC (general methods) giving 4 (0.27 g, 80 %). 
1
H NMR (8:2 DMSO-d6/H2O, 400 MHz)  (ppm): 
1.85 (m, 1H, PyrrolidineH-4cis), 1.95-2.05 (m, 2H, PyrrolidineH-4transPyrrolidineH-4cis), 2.15 (m, 1H, PyrrolidineH-
4trans), 2.18 (s, 3H, CH3), 2.57 (m, 1H, AspH), 2.94 (m, 1H, AspH), 2.97 (m, 1H, PyrrolidineH-3trans), 3.22 (dd, J = 
6.0, 10.0 Hz, 1H, PyrrolidineH-5cis), 3.39-3.48 (m, 4H, PyrrolidineH-3cis+ NCH2Ar+PyrrolidineH-2trans), 3.49-3.55 (m, 
3H, PyrrolidineH-5trans+PyrrolidineH-5cisPyrrolidineH-2trans), 3.58 (m, 1H, PyrrolidineH-5trans), 4.21 (d, J = 6.0 Hz, 
2H, PhCH2CO), 4.34 (dd, J = 4.8, 8.8 Hz, 1H, PyrrolidineH-2cis), 4.43 (t, J = 9.2 Hz, 1H, PyrrolidineH-2cis), 4.59 (m, 
1H, AspHcis), 4.63 (m, 1H, AspHtrans), 6.90 (t, J = 7.2 Hz, 1H, ArH4), 7.10-7.19 (m, 4H, ArH3,5+ArH3’,5’), 7.13-
7.24 (m, 5H, ArH’’), 7.40 (d, J = 8.2 Hz, 2H, ArH2’,6’), 7.79 (d, J = 8.0 Hz, 1H, ArH6), 7.90 (s, 1H, NHa), 8.41 (br.t, 
1H, NHctrans), 8.45 (br.t, 1H, NHccis), 8.50 (br.d, 1H, AspNHtrans), 8.54 (br.d, 1H, AspNHcis), 8.91 (s, 1H, NHb); 
13
C 
NMR (DMSO-d6, 400 MHz)  (ppm): 18.3, 28.3, 29.5, 29.9, 39.4, 42.4, 42.7, 44.1, 45.0, 47.7, 48.2, 49.2, 55.0, 118.4, 
121.5, 126.4, 127.8, 128.4, 129.2, 129.3, 130.4, 132.7, 136.4, 137.7, 139.1, 153.1, 171.7, 172.0, 172.2, 172.3. Elem. 
Anal. for C32H35N5O6, calcd: C 65.63, H 6.02, N 11.96, found: C 66.94, H 6.19, N 11.72; ESI-MS m/z 586.1 
(M+H)+, calcd 586.3. 
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Scheme 2. Synthesis of 2. 
Synthesis of 18. Fmoc-(S)--isoPro-OH (0.13 g, 0.38 mmol) was coupled with 10 (0.10 g, 0.34 mmol) under MW 
irradiation as described in the main text (Peptide coupling, general procedure). The residue was purified by flash 
chromatography over silica-gel (eluant EtOAc/cyclohexane 1:1) giving 18 (0.20 g, 85%). ESI-MS m/z 621.2 
(M+Na)
+
, calcd 621.3.  
Synthesis of 20. Fmoc deprotection of 18 (0.20 g, 0.32 mmol) was performed as reported for the synthesis of 10; after 
solvent evaporation, the residue containing 19 (quantitative yield) was utilized without purification. ESI-MS m/z 
377.1 (M+H)
+
, calcd 377.2. Crude 19 was coupled with 4-[N-(2-methylphenyl)ureido]phenylacetyl [
55
] (0.14 g, 0.50 
mmol) as described in the main text (Peptide coupling, general procedure). The residue was purified by flash 
chromatography over silica-gel (eluant EtOAc/ cyclohexane 1:1) giving 20 (0.18 g, 84%). 
1
H NMR (CDCl3, 400 
MHz)  (ppm): (two sets of resonances: > = major conformer; < = minor conformer) 1.36 (s, 9H, t-Bu), 2.03 (q, J = 
7.4 Hz, 1H, PyrrolidineH-4), 2.16 (s, 4H, CH3+PyrrolidineH-4), 2.72 (dd, J = 4.6, 17.0 Hz, 1H, AspH), 2.82-2.98 (m, 
2H, PyrrolidineH-3+AspH), 3.38 (m, 1H, PyrrolidineH-5), 3.40-3.50 (m, 3H, CH2Ph+PyrrolidineH-
2>+PyrrolidineH-5), 3.51-3.60 (m, 6H, PyrrolidineH-2+PyrrolidineH-2+CH2Ph+PyrrolidineH-5), 4.80 (m, 1H, 
AspH), 5.10 (d, J = 12.4 Hz, 1H, CH2Ph<), 5.13 (d, J = 12.0 Hz, 1H, CH2Ph>), 5.15 (d, J = 12.4 Hz, 1H, CH2Ph<), 
5.18 (d, J = 12.0 Hz, 1H, CH2Ph>), 6.76 (d, J = 8.0 Hz, 1H, AspNH<), 6.87 (d, J = 8.4 Hz, 1H, AspNH>), 6.93-7.04 (m, 
4H, ArH), 7.04-7.14 (m, 5H, ArH), 7.21-7.33 (m, 4H, ArH+NH), 7.63 (d, J = 7.6 Hz, 1H, ArH), 7.68 (s, 1H, NH); 
ESI-MS m/z 665.2 (M+Na)
+
, calcd 665.3  
Synthesis of 2. The deprotection of 20 (0.18 g, 0.27mmol) was performed as described for 12 . The residue was 
purified by semi-preparative RP-HPLC (general methods) giving 2 (0.14 g, 89%). 
1
H NMR (CDCl3)  (ppm):
 
(two 
sets of resonances: > = major conformer; < = minor conformer) 1.95 (m, 1H, PyrrolidineH-4), 2.05-2-19 (m, 4H, 
CH3+PyrrolidineH-4), 2.74 (m, 1H, AspH), 2.90-2.99 (m, 2H, PyrrolidineH-3+AspH), 3.36 (m, 2H, PyrrolidineH-
5<+PyrrolidineH-2>), 3.41-3.50 (m, 2H, PyrrolidineH-2>+PyrrolidineH-5), 3.54 (d, J = 5.2 Hz, 2H, ArCH2CON), 
3.51-3.60 (m, 4H, PyrrolidineH-2+PyrrolidineH-5), 4.78 (m, 1H, AspH), 5.07 (br.s, 2H, CH2Ph), 6.96 (t, J = 7.6 
Hz, 1H, ArH), 7.00-7.08 (m, 3H, ArH), 7.09-7.18 (m, 5H, ArH), 7.24-7.32 (m, 4H, ArH+NH), 7.35 (d, J = 8.8 Hz, 
1H, AspNH), 7.56 (s, 1H, NH), 7.60 (d, J = 8.0 Hz, 1H, ArH); 
13
C NMR (CDCl3)  (ppm): 18.3, 28.3, 36.7, 36.4, 
40.6, 42.4, 44.1, 47.7, 48.8, 48.9, 49.2, 118.4, 123.0, 126.4, 127.0, 128.0, 128.4, 129.2, 129.3, 130.4, 132.7, 136.4, 
137.7, 139.1, 153.1, 169.0, 170.3, 172.0, 172.2. Elem. Anal. for C32H34N4O7, calcd C 65.52, H 5.84, N 9.55, found C 
63.88, H 6.00, N 9.64; ESI-MS m/z 587.2 (M+H)
+
, calcd 587.2. 
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Scheme 3. Synthesis of 3. 
Synthesis of 21. Fmoc-Asp(OtBu)OH (0.321 g, 0.78 mmol) was coupled with 16 (0.25 g, 0.71 mmol) as described in 
the main text (Peptide coupling, general procedure). The residue was purified by flash chromatography over silica-gel 
(eluant EtOAc/cyclohexane 8:2) giving 21 (0.45 g, 85%). 
1
H NMR (CDCl3, 400 MHz)  (ppm) 1:1 mixture of two 
conformers: 1.31+1.33 (s, 9H, t-Bu), 1.90 (q, J = 7.2 Hz, 1H, PyrrolidineH-4), 1.98 (m, 1H, PyrrolidineH-4), 
2.04+2.05 (s, 3H, CH3), 2.45 (m, 1H, AspH), 2.62-2.73 (m, 2H, PyrrolidineH-3+AspH), 3.22 (m, 1H, 
PyrrolidineH-5), 3.36-3.49 (m, 2H, PyrrolidineH-2+PyrrolidineH-5), 3.58 (dd, J = 7.0, 9.0 Hz, 1H, PyrrolidineH-2), 
3.65-3.76 (m, 2H, PyrrolidineH-2+PyrrolidineH-5), 4.09, (d, J = 6.4 Hz, 2H, CH2Ph), 4.14-4.30 (m, 3H, Fmoc), 4.78 
(br.q, 1H, AspH), 5.85+5.90 (d, J = 9.2 Hz, 1H, AspNH), 6.80 (d, 1H, J = 8.8 Hz, 1H, ArH), 6.85-6.90 (m, 2H, 
ArH), 6.94-7.09 (m, 5H, ArH), 7.12-7.22 (m, 2H, ArH), 7.22-7.35 (m, 3H, ArH+NH), 7.42-7.54 (m, 3H, ArH+NH), 
7.64 (d, J = 8.0 Hz, 2H, ArH), 7.92 (s, 1H, NH); ESI-MS m/z 746.3 (M+H)
+
, calcd 746.4. 
Synthesis of 23. Fmoc deprotection of 21 (0.32 g, 0.43 mmol) was performed as described for the preparation of 10 
giving crude 22 in quantitative yield. ESI-MS m/z 524.3 (M+H)
+
, calcd 524.4. The resulting residue was coupled with 
phenylacetic acid (0.065 g, 0.48 mmol) as described in the main text (Peptide coupling, general procedure). The 
residue was purified by flash chromatography over silica-gel (eluant EtOAc/cyclohexane 8:2) giving 23 (0.22 g, 
80%). 
1
H NMR (CDCl3, 200 MHz)  (ppm): (two sets of resonances: > = major conformer; < = minor conformer) 
1.39 (s, 9H, t-Bu), 1.95-2.05 (m, 2H, PyrrolidineH-4), 2.28 (s, 3H, CH3), 2.50 (m, 1H, AspH), 2.75-2.90 (m, 2H, 
AspH+PyrrolidineH-3), 3.22 (m, 1H, PyrrolidineH-5<), 3.37-3.52 (m, 6H, PyrrolidineH-2>+CH2Ph+PyrrolidineH-
5>+PyrrolidineH-5<), 3.61-3.80 (m, 3H, PyrrolidineH-2<+PyrrolidineH-5>), 4.15-4.25 (m, 2H, CH2Ph), 4.99 (m, 1H, 
AspH), 6.82-7.12-7.20  (m, 10H, ArH), 7.23-7.40 (m, 4H, ArH+AspNH+NH), 7.48-7.55 (m, 2H, NH), 7.65 (br.d, 
1H, ArH); ESI-MS m/z 642.2 (M+H)
+
, calcd 642.3.  
Synthesis of 3. 23 (0.22 g, 0.34 mmol) was deprotected as described for 12. The residue was purified by semi-
preparative RP-HPLC (general methods) giving 3 (0.18 g, 90%). 
1
H NMR (8:2 DMSO-d6/H2O, 400 MHz)  (ppm): 
1.89 (m, 1H, PyrrolidineH-4cis), 1.92 (m, 1H, PyrrolidineH-4trans), 2.00 (m, 1H, PyrrolidineH-4cis), 2.06 (m, 1H, 
PyrrolidineH-4trans), 2.22 (s, 3H, CH3), 2.39 (m, 1H, AspH), 2.72 (m, 1H, AspH), 2.91 (m, 1H, PyrrolidineH-3trans), 
2.96 (m, 1H, PyrrolidineH-3cis), 3.21 (m, 1H, PyrrolidineH-5cis), 3.28 (m, 1H, PyrrolidineH-2trans), 3.39-3.45 (m, 3H, 
PyrrolidineH-5trans+ NCH2Ar), 3.45 (m, 1H, PyrrolidineH-5cis), 3.54 (m, 1H, PyrrolidineH-2cis), 3.56 (m, 1H, 
PyrrolidineH-2trans), 3.63 (m, 1H, PyrrolidineH-5trans), 3.75 (t, J = 8.8 Hz, 1H, PyrrolidineH-2cis), 4.19 (s, 2H, 
PhCH2COcis), 4.21 (s, 2H, PhCH2COtrans), 4.75 (m, 1H, AspHcis), 4.81 (m, 1H, AspHtrans), 6.93 (t, J = 7.2 Hz, 1H, 
ArH4), 7.09-7.18 (m, 4H, ArH3,5+ArH3’,5’), 7.16-7.28 (m, 5H, PhCH2CON), 7.39 (d, J = 8.4 Hz, 2H, ArH2’,6’), 7.81 (d, 
J = 8.0 Hz, 1H, ArH6), 7.89 (s, 1H, NHa), 8.43 (br.t, 1H, NHctrans), 8.46 (br.t, 1H, NHccis), 8.54 (br.d, 1H, AspNHtrans), 
8.56 (br.d, 1H, AspNHcis), 8.98 (s, 1H, NHb); 
13
C NMR (DMSO-d6)  (ppm): 18.3, 28.3, 29.9, 39.4, 40.2, 42.4, 44.1, 
45.8, 46.0, 47.4, 48.8, 48.9, 49.2, 118.4, 121.5, 126.4, 126.6, 127.8, 128.4, 129.3, 130.4, 132.7, 133.0, 136.4, 137.7, 
139.1, 153.1, 168.8, 170.3, 171.7, 172.0. Elem. Anal. for C32H35N5O6, calcd C 65.63, H 6.02, N 11.96, found C 66.20, 
H 6.18, N 11.70; ESI-MS m/z 586.2 (M+H)
+
, calcd 586.3. 
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Scheme 4. Synthesis of 5. 
Synthesis of 24. 22 was prepared as described above and in the same amount, and it was coupled with 2,6-
dichlorobenzoic acid (0.090 g, 0.48 mmol) under MW irradiation as described in the main text (Peptide coupling, 
general procedure). The residue was purified by flash chromatography over silica-gel (eluant EtOAc/cyclohexane 8:2) 
giving 24 (0.24 g, 80 %). 
1
H NMR (CDCl3, 200 MHz)  (ppm): (two sets of resonances:  > = major conformer; < = 
minor conformer) 1.35 (s, 9H, t-Bu), 2.05-2.20 (m, 2H, PyrrolidineH-4), 2.39 (s, 3H, CH3Ph), 2.52 (m, 1H, AspH), 
2.89-2.99 (m, 2H, PyrrolidineH-3>+AspH), 3.10 (m, 1H, PyrrolidineH-3<), 3.25 (m, 1H, PyrrolidineH-5<), 3.45-3.63 
(m, 2H, PyrrolidineH-2>+PyrrolidineH-5+PyrrolidineH-5>), 3.69-3.78 (m, 2H, PyrrolidineH-2>+PyrrolidineH-2<), 
4.09-4.10 (m, 2H, PyrrolidineH-5>+PyrrolidineH-2<), 4.26 (d, J = 5.7 Hz, 2H, CH2Ph), 4.99 (m, 1H, AspH), 6.84 
(br.t, 1H, ArH), 7.05-7.15 (m, 5H, ArH+NH), 7.15-7.26 (m, 5H, ArH+AspNH+NH), 7.25-7.33 (m, 3H, ArH+NH), 
7.75-7.87 (m, 2H, ArH+NH). ESI-MS m/z 696.1 (M+H)
+
, calcd 696.2 
Synthesis of 5. 24 (0.24 g, 0.34 mmol) was deprotected as described for 12. The residue was purified by semi-
preparative RP-HPLC (general methods) giving 5 (0.20 g, 92%). 
1
H NMR (DMSO-d6, 400 MHz)  (ppm): (two sets 
of resonances: > = major conformer; < = minor conformer) 2.00-2.18 (m, 2H, PyrrolidineH-4<), 2.20-2.38 (m, 2H, 
PyrrolidineH-4>), 2.39 (s, 3H, CH3Ph), 2.58 (m, 1H, AspH), 2.90 (m, 1H, PyrrolidineH-3>), 2.98 (m, 1H, AspH), 
3.08 (m, 1H, PyrrolidineH-3<), 3.35 (m, 1H, Pro<), 3.46 (dd, J = 8.0, 12.0 Hz, 1H, Pro>), 3.59 (m, 2H, 
PyrrolidineH-5+ PyrrolidineH-5), 3.70 (dd, J = 8.0, 12.0 Hz, 1H, Pro>), 3.79 (dd, J = 7.6, 9.2 Hz, 1H, Pro<), 4.00 
(m, 1H, Pro>), 4.09 (m, 1H, Pro<), 4.24 (d, J = 5.6 Hz, 2H, CH2Ph), 5.12 (m, 1H, AspH), 6.81 (t, J = 7.6 Hz, 1H, 
ArH), 7.02-7.14 (m, 4H, ArH), 7.15-7.26 (m, 3H, ArH), 7.35 (t, J = 8.4 Hz, 2H, ArH), 7.58 (s, 1H, NH), 7.79 (d, J = 
8.4 Hz, 1H, ArH), 7.81 (br.t, 1H, NH>), 7.85 (br.t, 1H, NH<), 8.40 (d, J = 7.6 Hz, 1H, AspNH<), 8.55 (d, J = 7.6 Hz, 
1H, AspNH>), 8.62 (s, 1H, NH>), 8.64 (s, 1H, NH<). Elem. Anal. for C31H31Cl2N5O6, calcd C 58.13, H 4.88, N 10.93 
found C 57.00, H 4.81, N 10.15; ESI-MS m/z 640.1 (M+H)
+
, calcd 640.2 
 
Scheme 5. Synthesis of 6. 
Synthesis of 26. Fmoc-Asp(Ot-Bu)-OBn (9) (0.20 g, 0.39 mmol) was deprotected as described for 12, giving 25 in 
quantitative yield. ESI-MS m/z 640.1 (M+H)
+
, calcd 640.2. Crude 25 was coupled with 16 (0.13 g, 0.38 mmol) as 
described in the main text (Peptide coupling, general procedure). The residue was purified by flash chromatography 
over silica-gel (eluant EtOAc/cyclohexane 8:2) giving 26 (0.23 g, 79 %). 
1
H NMR (95:5 CDCl3/DMSO-d6, 400 MHz) 
 (ppm): (two sets of resonances: > = major conformer; < = minor conformer) 1.99 (m, 2H, PyrrolidineH-4<), 2.10 (m, 
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2H, PyrrolidineH-4>), 2.20 (s, 3H, CH3Ph), 2.66 (m, 1H, AspH), 2.90 (m, 1H, PyrrolidineH-32.99 (m, 1H, 
AspH), 3.30 (m, 1H, PyrrolidineH-5<), 3.42-3.60 (m, 4H, PyrrolidineH-2>+PyrrolidineH-5 +PyrrolidineH-5), 3.64 
(m, 1H, PyrrolidineH-2<), 4.00-4.13 (m, 2H, PyrrolidineH-5>+PyrrolidineH-2<), 4.20-4.40 (m, 5H, CH2Ph+Fmoc), 
4.61 (m, 1H, AspH), 5.10 (br.s, 2H, CH2Ph), 6.47 (br.d, 1H, AspNH>), 6.52 (br.d, 1H, AspNH<), 6.89 (br.t, 1H, 
ArH), 7.00-7.20 (m, 4H, ArH), 7.20-7.30 (m, 7H, ArH+NH), 7.30-7.40 (m, 4H, ArH), 7.45-7.55 (m, 3H, ArH), 7.70 
(br.d, 2H, ArH), 7.75-7.82 (m, 2H, ArH+NH), 8.59 (s, 1H, NH); ESI-MS m/z 780.2 (M+H)
+
, calcd 780.3 
Synthesis of 28. Fmoc deprotection of 26 (0.23 g, 0.30 mmol) was performed for the preparation of 10, giving 27 in 
quantitative yield. ESI-MS m/z 558.2 (M+H)
+
, calcd 558.3. The resulting crude 27 was coupled with 2,6-
dichlorobenzoic acid (0.057 g, 0.30 mmol) as described in the main text (Peptide coupling, general procedure). The 
residue was purified by flash chromatography over silica-gel (eluant EtOAc) giving 28 (0.18 g, 82 %). 
1
H NMR 
(CDCl3, 200 MHz)  (ppm): (two sets of resonances: > = major conformer; < = minor conformer) 1.90 (m, 2H, 
PyrrolidineH-4<), 2.10 (m, 2H, PyrrolidineH-4>), 2.15 (s, 3H, CH3Ph), 2.55 (m, 1H, AspH), 2.90-3.00 (m, 2H, 
PyrrolidineH-3+AspH), 3.20 (m, 1H, PyrrolidineH-5<), 3.37-3.58 (m, 3H, PyrrolidineH-2>+PyrrolidineH-
5+PyrrolidineH-5 ), 3.59-3.89 (m, 3H, PyrrolidineH-2>+PyrrolidineH-2<+PyrrolidineH-5>), 4.10-4.27 (m, 3H, 
PyrrolidineH-2<+CH2Ph), 4.98-5.18 (m, 3H, CH2Ph+AspH), 6.90 (br.t, 1H, ArH), 7.01-7.14 (m, 8H, ArH+NH), 
7.15-7.26 (m, 6H, ArH+AspNH), 7.26-7.34 (m, 3H, ArH+NH), 7.70 (m, 2H, ArH+NH); ESI-MS m/z 730.1. (M+H)
+
, 
calcd 730.2 
Synthesis of 6. 28 (0.18 g, 0.24 mmol) was deprotected as described for 4. The residue was purified by semi-
preparative RP-HPLC (general methods) giving 6 (0.14 g, 88 %). 
1
H NMR (DMSO-d6, 400 MHz)  (ppm): (two sets 
of resonances: > = major conformer; < = minor conformer) 1.95 (m, 2H, PyrrolidineH-4<), 2.05 (m, 2H, PyrrolidineH-
4>), 2.29 (s, 3H, CH3Ph), 2.56 (m, 1H, AspH), 2.92-2.98 (m, 2H, PyrrolidineH-3+AspH), 3.25 (m, 1H, Pro<), 3.47 
(m, 1H, PyrrolidineH-2>), 3.60 (m, 2H, PyrrolidineH-5+PyrrolidineH-5), 3.69-3.79 (m, 2H, Pro>+Pro<), 3.99 (m, 
1H, Pro>), 4.11 (m, 1H, Pro<), 4.27 (br.s, 2H, CH2Ph), 5.09 (m, 1H, AspH), 6.81 (br.t, 1H, ArH), 7.01-7.14 (m, 
4H, ArH), 7.15-7.26 (m, 3H, ArH), 7.27-7.35 (m, 2H, ArH), 7.52 (s, 1H, NH), 7.70 (d, J = 8.4 Hz, 1H, ArH), 7.75 
(br.t, 1H, NH>), 7.81 (br.t, 1H, NH<), 8.20 (br.d, 1H, AspNH<), 8.25 (br.d, 1H, AspNH>), 8.51 (s, 1H, NH); 
13
C NMR 
(CDCl3)  (ppm): 18.2, 28.4, 29.5, 39.4, 42.7, 48.7, 49.0, 51.2, 118.6, 121.8, 124.1, 127.0, 128.6, 129.5, 131.0, 131.4, 
132.8, 133.8, 136.6, 136.8, 138.0, 153.4, 167.4, 171.2, 172.0, 173.1. Elem. Anal. for C31H31Cl2N5O6, calcd C 58.13, H 
4.88, N 10.93 found C 57.60, H 4.79, N 11.13; ESI-MS m/z 640.1 (M+H)
+
, calcd 640.2 
8.4.3. Scintillation proximity-binding assay (SPA) 
We developed a SPA assay to detect competitive binding of drugs to soluble 
125
I-human FN (Mw approximately 440 
kDa) bound to an antibody-captured integrin complex.
46,47
 The assay uses microspheres coated with an anti-rabbit IgG 
antibody capable of binding the complex 4 integrin anti-4 antibody. The radioligand binds to the 41 integrin and 
the close proximity of the isotope to the scintillant incorporated in the beads allows the radiation energy to transfer to 
the scintillant where it can be detected as counts per min (cpm). 
Materials employed for Scintillation proximity-binding assay (SPA) and cell adhesion assays. Cell culture media, 
phosphate-buffered saline (PBS) and fetal bovine serum (FBS)  were from Lonza (Euroclone S.p.A, Milan, Italy); 
HBSS and chloromethylfluorescein diacetate (CMFDA) were from Invitrogen (Carlsbad, CA, USA). Lectin from 
Triticus vulgaris, soluble fibronectin (FN) from human plasma were purchased from Sigma-Aldrich (Steinheim, 
Germany). Jurkat clone E6.1 was obtained from the European Cell Culture Collection (ECACC, Wiltshire, UK); SK-
MEL-24 cell line was from American Type Culture Collection (ATCC, Manassas, VA, USA). 
Black 96-well clear-bottom plates were purchased from Corning Costar (Celbio, Milan, Italy). Soluble human 
VCAM-1 was purchased from R&D Systems (Minneapolis, MN, USA). BIO-1211 (N-[[4-[[[(2-
methylphenyl)amino]carbonyl]amino]-phenyl]acetyl]-L-leucyl-L-aspartyl-L-valyl-L-proline) was purchased from 
Bachem (Weil am Rhein, Germany). Tissue Protein Extraction Reagent (TPER1) and BCA1 protein assay were 
purchased from Pierce (Rockford, IL, USA).  
Rabbit anti-human monoclonal antibodies against the 4 subunit of 41 integrin was purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA). Mouse anti-human monoclonal antibody against β1 subunit (MAB 2000) 
was obtained from Chemicon (Millipore, Billerica, MA, USA). Secondary antibody (goat anti-mouse or goat anti-
rabbit) were purchased from Santa Cruz Biotechnology Inc. Polyacrylamide gel, N,N,N0,N0-tetramethy-
lethylenediamine (TEMED), ammonium persulfate (PSA) and SDS were purchased from Sigma-Aldrich. Hybond-
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ECL Nitrocellulose Membrane was from Amersham Biosciences (GE Healthcare Europe, Milan, Italy). Na
125
I was 
obtained from PerkinElmer Inc., Waltham, Massachussets, USA). Polyvinyltoluene (PVT) anti-rabbit binding beads 
were supplied by Amersham Biosciences as a powder and reconstituted in distilled water. Plastic disposables were 
from Sarstedt (Verona, Italy). All other reagents were of analytical grade or the highest purity available, purchased 
from Sigma. 
Scintillation proximity-binding assay (SPA). The radioligand binds to the 41 integrin and the close proximity of the 
isotope to the scintillant incorporated in the beads allows the radiation energy to transfer to the scintillant where it can 
be detected as counts per min (cpm). FN was labeled with Na[
125
I] using the IodogenKit, as specified by the 
manufacturer (Pierce). 
125
I-FN was purified from unincorporated iodine by gel filtration chromatography on PD-10 
columns; trichloroacetic acid-precipitable radioactivity was 6.30x10
10
 Ci/mol. The experiments were carried out in 
scintillation vials; in each vial 1mg/50 l anti-rabbit-coated beads, 400 ng of rabbit anti-4 integrin antibody and a 
portion of cell eluate (containing approximately 100 g of 41 integrin) were added. The 41integrin was 
extracted from Jurkat cells (cultured in RPMI 1640 medium, supplemented with L-glutamine, 10% FBS, antibiotic-
antimicotycotic solution and kept in a humidified incubator at 37°C in a 5% CO2 atmosphere). The cells were 
collected and then cytoplasmic proteins were extracted with the T-PER extraction buffer and 41 integrin was 
purified by affinity chromatography, as described.
56
 For Western blot experiments on extracts we used antibodies 
against 4 and 1 integrin subunits to confirm that both integrins partitioned to the cell lysate collected from the 
affinity column. The binding buffer contained Tris-HCl 25 mM pH 7,5; CaCl2 1 mM; MgCl2 1 mM; MnCl2 1mM; 
BSA 2% (w/v); phenylmethanesulfonyl fluoride (PMSF) 1 mM; aprotinin 1 mg/ml; leupeptin 50 mM. 
First, we allowed for the slow interaction between the 4 integrin protein and the compound under examination by 
incubating together for 1,5 hr at room temperature. Then we added the rabbit anti-human 4 integrin antibody, 
followed by an incubation time of 2 hours at 4°C. From this point on, all incubations were conducted at room 
temperature Then the anti-rabbit antibody binding beads were added, and the solution containing the four components 
was incubated for 2 h at room in the dark. 
125
I-FN was added to the vials, which were then incubated overnight on a 
shaker in the dark.  
The samples were read using a LS 6500 multipurpose scintillation counter (Beckham Coulter, Fullerton, CA, USA). 
The SPA procedure was optimized in preliminary experiments, as described.
57
 As shown in Figure 4, western blot 
analysis of cell lysates, purified by a chromatographic technique already reported,
56
 confirmed that both 4 and 1 
integrin subunits were present in the eluate employed for the SPA. Specific binding of 
125
I-FN to an antibody-captured 
41 integrin was time-dependent; the signal increasing during the first 10 h, then reaching a plateau and remaining 
constant for the remainder of the 24 h incubation (data not shown). The relatively slow kinetics of the SPA may 
require the establishment of equilibrium between the different components.
58,59 
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Figure 4. A. Representative autoradiogram of Western blot experiments to evaluate the α4 and β1 integrin subunits in 
cell lysates of Jurkat E6.1 cells endogenously expressing α4β1 integrin. The lysates were purified by affinity 
chromatography and fractions of approximately 0.5 ml were collected; the presence of the α4 or β1 integrin subunit 
was evaluated by Western blotting. 1: total lysate; 2-5: four eluted fractions. Fractions 2-5 were used for SPA. B. 
Saturation SPA binding of 
125
I-FN to the purified α4β1 integrin extracted from Jurkat E6.1 cells and incubated with 
increasing concentrations of the radioligand (cpm) as described in Materials and Methods section. Nonspecific 
binding was determined in the presence of 100 mM unlabeled fibronectin. (■) Non-specific binding; (▲) specific 
binding obtained by subtraction of the non-specific binding from total binding counts. Mean ± S.E.M. of three 
experiments done in triplicate. 
8.4.4. Adhesion assays 
Jurkat cell adhesion assays were done was as described.
56,60
 Briefly, 96-well plates were coated at 4°C overnight with 
2 g/ml of VCAM-1 and a saturation curve for the ligand was plotted to establish the best signal-to-noise ratio. Non-
specific hydrophobic binding sites were blocked by incubation with a BSA 1%/HBSS (w/v) solution for 30 min at 
37°C. The day of the assay, the cells were counted and stained with 12.5 M CMFDA (30 min at 37°C).  After three 
rinses with BSA/HBSS to wash away the excess dye, aliquots of 500,000 (Jurkat) cells were divided among a number 
of tubes corresponding to the number of treatments.  For inhibition experiments, cells were mixed with the drug and 
pre-incubated at 37°C for 30 min to reach equilibrium before being plated.  After 30 min incubation at 37°C in the 
coated wells, the non-specifically bound cells were washed away with BSA/HBSS solution. Adherent cells were lysed 
by the addition of 0.5% Triton-X-100 in PBS (30 min at 4°C).  Released CMFDA was quantified by fluorescence 
imaging at Ex485 nm/Em535 nm (Wallac ARVO 1420 multilabel counter) and adherent cells was counted by 
interpolation on a standard curve. The fluorescence intensity with and without VCAM-I was taken as respectively 
100% and 0%. Alternatively, the number of adherent cells was calculated by comparison with a standard curve 
prepared in the same plate using known concentrations of labeled cells.  
SK-MEL-24 cell adhesion assays were carried out as described.
61
 96-well plates were coated by passive adsorption 
with FN (10 μg/ml) or nonspecific substrate poly-l-lysine (0.002 %) overnight at 4°C. Cells (routinely grown in 
minimum essential medium supplemented with 10% FBS, nonessential amino acids, and sodium pyruvate) were 
counted with a hemocytometer and pre-incubated with various concentrations of each compound for 30 min at room 
temperature to reach a ligand–receptor equilibrium. At the end of the incubation time, the cells were plated (50000 
cells per well) and incubated at room temperature for 1 h. All the wells were then washed with PBS to remove 
nonadherent cells, and 50 μL hexosaminidase [4-nitrophenyl-N-acetyl-β-d-glucosaminide dissolved at a concentration 
of 7.5 mM in 0.09 M citrate buffer (pH 5) and mixed with an equal volume of 0.5% Triton X-100 in H2O] was added. 
This product is a chromogenic substrate for β-N-acetylglucosaminidase, whereby it is transformed into 4-nitrophenol; 
absorbance was measured at 405 nm. The reaction was blocked by the addition of 100 μL of a stopping solution [50 
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mM glycine and 5 mM EDTA (pH 10.4)], and the plates were read in a Victor2 Multilabel Counter (PerkinElmer, 
Waltham, MA, USA).  
The efficacy of putative antagonists (at least eight different concentrations were used) was determined by the 
reduction in adherent cells compared to the untreated control. Each experiment was conducted in quadruplicate and 
the data are presented as the mean ± S.E.M. of at least three independent assays.  
8.4.5. Data analysis.  
All data are expressed as mean ± S.E.M., for the number of experiments indicated. SPA binding data and ligand 
concentration-response curves were analyzed using GraphPad software (GraphPad Software Inc., San Diego, CA, 
USA). IC50 values indicate the molar ligand concentration required to inhibit the response by 50% and were 
converted, in SPA experiments, to Ki values using the method of Cheng and Prusoff.
62
  
8.4.6. In vitro metabolic stability 
Enzymatic degradation studies of 1, 3, and 4 were carried out in triplicate and repeated three times using mouse serum 
purchased from Sigma-Aldrich. Peptides were dissolved in Tris buffer pH 7.4 and 10 L aliquots of a 10 mM peptide 
stock solution were added to 190 L of serum. Incubations were carried out at 37°C for 120 min. Aliquots of 20 L 
were withdrawn from the incubation mixtures and enzyme activity was terminated by precipitating proteins with 90 
L of glacial acetonitrile. Samples were then diluted with 90 L of 0.5% acetic acid to prevent further enzymatic 
breakdown and centrifuged at 13,000×g for 15 min. The supernatants were collected and the stability of peptides was 
determined by RP-HPLC ESI-MS analysis.  
8.4.7. Conformational analysis 
The unambiguous assignment of 
1
H-NMR resonances was performed by 2D gCOSY. 2D ROESY experiments were 
recorded in 8:2 DMSO-d6/H2O, with a 250 ms mixing time with a proton spectral width of 3088 Hz. Peaks were 
calibrated on DMSO. Only ROESY-derived constraints (force constant: 7 kcal mol
-1
Å
-2
) were included in the 
restrained molecular dynamics. Cross-peak intensities were classified very strong, strong, medium, and weak, and 
were associated with distances of 2.2, 2.6, 3.0, and 4.5 Å, respectively. Geminal couplings and other obvious 
correlations were discarded. The  bonds were set at 180° (16 kcal mol-1Å-2). The restrained MD simulations were 
conducted using the AMBER force field in a 45×45×45 Å box of standard TIP3P models of equilibrated water.  
NMR analysis. 
1
H-NMR spectra were recorded at 400 MHz or 200 MHz in 5 mm tubes using 0.01 M peptide at r.t. 
1
H 
NMR spectra of the peptides in CDCl3 at 298 K were poorly resolved with very broad resonances, so the experiments 
were recorded in mixtures of CDCl3 and DMSO-d6; in particular, the NMR experiments on 3 and 4 were performed in 
the biomimetic 8:2 DMSO-d6/H2O. The unambiguous assignment of 
1
H-NMR resonances was done by 2D gCOSY, 
conducted with a proton spectral width of 3103 Hz. 2D spectra were recorded in the phase sensitive mode and 
processed using a 90°-shifted, squared sine-bell apodization. 2D ROESY experiments of 3 and 4 were recorded in 8:2 
DMSO-d6/H2O, with a 250 ms mixing time with a proton spectral width of 3088 Hz. Peaks were calibrated on DMSO. 
The 
1
H-NMR of both 3 and 4 revealed two sets of resonances, in about 1:1 ratio, suggestive of a slow equilibrium 
between the cis and trans conformers of the peptide bond between Asp or isoAsp and -Pro. The cis conformations 
were assigned by detection of the NOE cross peaks between AspH (3) or isoAspH (4) and -PyrrolidineH-2 while 
the trans conformations were deduced by detection of the NOE cross peaks between AspH (3) or isoAspH (4) and 
-isoPyrrolidineH-5 
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Table 2. Non-obvious ROESY cross-peaks observed for cis-3.
a,b,c             
 
Cross peakb Intensityc Cross peakb Intensityc 
NHb-NHa  vs  NHb-ArH2’,6’  vs 
NHb-ArH3’,5’  w NHb-Me  w 
AspNH-AspH m AspNH-CH2Ph’’ s 
AspNH-AspHdw  m AspNH-AspHup  m 
NHc-ArH3’,5’  m NHc-CH2Ph’ s 
NHc-PyrrolidineH-2up,un w   NHc-PyrrolidineH-3 s 
NHc-PyrrolidineH-4dw,on w   NHc-PyrrolidineH-4up,un  w 
NHa-Me  s Ph’’-AspH w 
ArH3’,5’-PyrrolidineH-2up,un  w ArH3’,5’-PyrrolidineH-4dw,on   w 
AspH-PyrrolidineH-2dw,on  vs AspH-PyrrolidineH-2up,un  s 
AspH-AspHdw s AspH-AspHup vs 
CH2Ph’-PyrrolidineH-4dw,on w AspH-CH2Ph’’ m 
CH2Ph’-AspHdw w CH2Ph’-PyrrolidineH-4up,un w 
-PyrrolidineH-2dw,on-AspHup  w -PyrrolidineH-2dw,on-AspHdw  w 
a
 up = upfield; dw = downfield; 
b
 on = same side of H; un = opposite side of H; c vs = very strong, s = strong, m = 
medium, w =weak. 
Table 3. Non-obvious ROESY cross-peaks observed for all-trans-3.
a,b        
Cross peaka,b Intensityc Cross peakb Intensityc 
NHb-NHa vs NHb-ArH6’ vs 
NHb-ArH5’ w NHb-Me w 
AspNH-AspH m AspNH-CH2Ph’’ s 
AspNH-PyrrolidineH-2up,un w AspNH-AspHdw m 
AspNH-AspHup m NHc-ArH3’,5’ m 
NHc-CH2Ph’ s NHc-PyrrolidineH-2up,un w 
NHc-PyrrolidineH-3 s NHc-PyrrolidineH-4dw,on w 
NHc-PyrrolidineH-4up,un w NHa-Me s 
Ph’’-AspH w ArH3’,5’-PyrrolidineH-3 w 
ArH3’,5’-PyrrolidineH-4up,un w AspH-PyrrolidineH-5dw,un s 
AspH-PyrrolidineH-5up,on s AspH-PyrrolidineH-2up,un w 
AspH-AspHdw s AspH-AspHup s 
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CH2Ph’-PyrrolidineH-4dw,on w AspH-CH2Ph’’ m 
CH2Ph’-AspHdw w CH2Ph’-PyrrolidineH-4up,un w 
-PyrrolidineH-5dw,un-AspHup w CH2Ph’-PyrrolidineH-3 w 
a
 up = upfield; dw = downfield; 
b
 on = same side of H; un = opposite side of H; c vs = very strong, s = strong, m = 
medium, w =weak. 
Table 4. Non-obvious ROESY cross-peaks observed for cis-4.
a,b            
Cross peaka,b Intensityc Cross peakb Intensityc 
NHb-NHa vs NHb-ArH6’ vs 
NHb-ArH5’ w NHb-Me w 
AspNH-AspH m AspNH-CH2Ph’’ s 
AspNH-AspHdw m AspNH-AspHup m 
NHc-ArH3’,5’ m NHc-CH2Ph’ s 
NHc-PyrrolidineH-2up,un m NHc-PyrrolidineH-3 vs 
NHc-PyrrolidineH-4dw,on w NHa-Me vs 
Ph’’-AspH w ArH3’,5’-PyrrolidineH-3 w 
ArH3’,5’-PyrrolidineH-4up,un w AspH-AspHdw s 
AspH-AspHup s AspH-CH2Ph’’ m 
CH2Ph’-PyrrolidineH-4dw,on w CH2Ph’-PyrrolidineH-4up,un w 
CH2Ph’-AspHdw w CH2Ph’-PyrrolidineH-3 w 
-PyrrolidineH-5dw,un-AspHup w AspHdw-PyrrolidineH-2dw,on  s 
AspHdw-PyrrolidineH-2up,un  s AspHup-PyrrolidineH-2dw,on  s 
AspHup-PyrrolidineH-2up,un  s   
a
 up = upfield; dw = downfield; 
b
 on = same side of H; un = opposite side of H; c vs = very strong, s = strong, m = 
medium, w =weak. 
Table 5. Non-obvious ROESY cross-peaks observed for trans-4.
a,b             
Cross peaka,b Intensityc Cross peakb Intensityc 
NHb-NHa vs NHb-ArH6’ vs 
NHb-ArH5’ w NHb-Me w 
AspNH-AspH m AspNH-CH2Ph’’ s 
AspNH-AspHdw s AspNH-AspHup s 
NHc-ArH3’,5’ m NHc-CH2Ph’ s 
NHc-PyrrolidineH-2up,un m NHc-PyrrolidineH-3 vs 
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NHc-PyrrolidineH-4dw,on w NHa-Me vs 
Ph’’-AspH w ArH3’,5’-PyrrolidineH-3 w 
ArH3’,5’-PyrrolidineH-4up,un w AspH-AspHdw s 
AspH-AspHup s AspH-CH2Ph’’ s 
CH2Ph’-PyrrolidineH-4dw,on w CH2Ph’-PyrrolidineH-4up,un w 
CH2Ph’-AspHdw w CH2Ph’-PyrrolidineH-3 w 
AspHdw-PyrrolidineH-5dw,un  s AspHdw-PyrrolidineH-2up,on  s 
AspHup-PyrrolidineH-5dw,un  s AspHup-PyrrolidineH-5up,on  s 
a
 up = upfield; dw = downfield; 
b
 on = same side of H; un = opposite side of H; c vs = very strong, s = strong, m = 
medium, w =weak. 
Restrained molecular dynamics. Molecular conformations were investigated by 2D ROESY and restrained molecular 
dynamics. The intensities of the cross-peak were ranked to infer plausible inter-proton distances as restraints (Tables 
2-5). Only ROESY-derived constraints were included in the restrained molecular dynamics. Cross-peak intensities 
were classified very strong, strong, medium, and weak, and were associated with distances of 2.2, 2.6, 3.0, and 4.5 Å, 
respectively. Geminal couplings and other obvious correlations were discarded. The bonds were set at 180° (force 
constant: 16 kcal mol
-1
Å
-2
). 
The restrained MD simulations
63
 were conducted using the AMBER 
64
 force field in a 45×45×45 Å box of standard 
TIP3P models of equilibrated water.
65
 All water molecules with atoms that come closer than 2.3 Å to a solute atom 
were deleted. A 100 ps simulation at 1200 °K was used for generating 50 random structures that were subsequently 
subjected to a 50 ps restrained MD with a 50% scaled force field at the same temperature, followed by 50 ps with full 
restraints (distance force constant of 7 kcal mol
-1
 Å
-2
), after which the system was cooled in 20 ps to 50°K. H-bond 
interactions were not included, nor were torsion angle restraints. The resulting structures were minimized with 3000 
cycles of steepest descent and 3000 cycles of conjugated gradient (convergence of 0.01 kcal Å
-1
 mol
-1
). The 
backbones of the structures were clustered by the rmsd analysis module.
63 
To investigate the dynamic behavior, the ROESY-restrained structures were analyzed by unrestrained MD for 10 ns in 
a 45×45×45 Å box of explicit, equilibrated water molecules, at 298 °K, constant temperature and pressure (Berendsen 
scheme,
66
 bath relaxation constant of 0.2). For 1-4 scale factors, van der Waals and electrostatic interactions are scaled 
in AMBER to half their nominal value. The integration time step was set to 0.1 fs.  
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Chapter 9 
Synthesis of active 41 integrin antagonists containing Amo hybrid /-dipeptide scaffolds as 
inductor of constrained conformations 
Peptidomimetics represent an attractive starting point for drug discovery programs; in particular, peptidomimetics that result 
from the incorporation of a heterocycle may take advantage of increased enzymatic stability and higher ability to reproduce 
the bioactive conformations of the parent peptides, resulting in enhanced therapeutic potential. Herein are presented 
mimetics of the 41 integrin antagonist BIO1211 (MPUPA-Leu-Asp-Val-Pro-OH), containing a aminomethyloxazolidine-
2,4-dione scaffold (Amo). Interestingly, the retro-sequences PhCOAsp(OH)-Amo-APUMP including either (S)- or (R)-
configured Amo displayed significant ability to inhibit the adhesion of 41 integrin expressing cells, and remarkable 
stability in mouse serum. Conformational analysis confirmed that the conformational bias exerted by the Amo scaffolds 
determined ligand’s affinity for the receptors. These peptidomimetics could be of interest for the development of small 
molecule agents effective against inflammatory processes and correlated autoimmune diseases. 
9.1. Introduction 
Many fundamental processes associated with life are mediated by interactions of peptide ligands with protein receptors.
1
 
Very often, events mediated by protein-protein interactions depend on the recognition of limited portions of their exposed 
surfaces, bringing again the matter to interactions between short peptide sequences (continuous or discontinuous epitopes).
2
 
Several reports have discussed the role of oligopeptide motifs in stabilizing proteins, in protein evolution, and in generating 
secondary structures. Evidence from the literature
3,4,5
 suggested that motifs as small as three contiguous amino acids can still 
play important roles in biology, medicine, and biotechnology.
6
  
Very few peptides can be utilized as drugs in their native state; for example, insulin in the treatment of diabetes, and 
cyclosporine as an immunosuppressant.
6
 Generally, the utility of native peptides is limited by an instability in vivo towards 
hydrolysis by many proteases, and a lack of bioavailability, due to inability to cross the biological barriers.
1,6,7
 One way to 
improve stability is represented by the peptidomimetic approach, consisting in the modification of peptide structure while 
maintaining or improving the biological activity.
1,6,8
 For instance, peptidomimetic protease inhibitors have been obtained by 
substitution of the cleavable peptide bond with a moiety that resembles the transition state of its hydrolysis.
9
 In azapeptides, 
the -CH group of the backbone is substituted by a isoelectronic nitrogen atom, the side chains remaining unaltered.10 The 
peptoids, introduced by Zuckermann and co,
11
 are peptidomimetics in which the side chain of an amino acid is “shifted” to 
the -amino group. The retro-inverso peptides are obtained when the normal sequence from N- to C-terminus is reversed, 
and the natural L-amino acids are changed by D-amino acids.
12,13
 Finally, the peptidomimetics containing a isoster of one or 
more peptide bonds (e.g. a reduced amide CH2-NH or a C=C) are often referred to as pseudopeptides.
1,2,6,7
 
The linear native peptides also show high flexibility, that may result in scarce target affinity and/or poor selectivity. In this 
respect, the pre-organization of peptide shape via introduction of structural motifs that impart conformational restriction can 
minimize the unfavorable loss of entropy in peptide-receptor recognition, giving enhanced binding affinity and hence 
therapeutic potential.
1,6,7,14 
To this purpose, constrained peptidomimetics
1,14
 can be obtained by the incorporation of non-
natural amino acids, including D-configured residues,
15
 residues with modified side chains, N-alkylated amino acids, -
substituted or -substituted -amino acids, proline analogues,16 etc. These specialized residues generally exert a “local” 
constraint, namely a significant conformational bias in the close proximity of where are situated. For instance, ,-
dialkylated residues (e.g. -aminoisobutyric acid, Aib) tend to stabilize a 310-helix,17,18,19 while N-alkyl substitution reduces 
the predominance of trans versus cis peptide bond configuration, and -substitution restraints the side chain angle (). The 
introduction of a single -amino acid is expected to increase peptide backbone flexibility, due to the presence of a extra 
rotating bond. Nevertheless, Seebach et al.,
20,21
 Gellman et al.,
22,23,24
 and others,
25
 observed that short oligomers composed of 
-amino acids (-peptides), or - and -amino acids (hybrid /-peptides), folded into well-defined three dimensional 
structures (foldamers), similar to those of natural peptides.  
“Global” constraints can be introduced by “head-to-tail” cyclization or “side-chain-to-head/tail” cyclization of the peptides. 
Apart from the use of (di)sulfide, amide, and other obvious bridges, strategic macrocyclizations have been achieved by ring-
closing metathesis (RCM),
26
 or by copper-catalyzed azide-alkyne cycloaddition reaction (click-chemistry).
27,28
 For instance, 
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the RCM of alkene-containing dialkylated amino acids at the beginning and at the end of full turns allowed to stabilize a 
helix (“stapled” peptides).29,30,31 
Constrained peptidomimetics may result from the incorporation of a heterocyclic scaffold into a peptide.
1,7,14,32
 The most 
well-known approach for constraining a dipeptide is the Freidinger lactam,
33
 consisting in the cyclization of the i-side chain 
functional group onto the i+1 nitrogen (Figure 1). Such lactams or spirolactams have been utilized as -turn inducers, and 
for preparing different classes of bioactive peptidomimetics, including peptide hormones (LHRH, GH), enkephalin, 
dopamine, inhibitors of ACE, or NEP, antagonists of renin, neurokinin, thrombin, etc.
34
 Other constrained dipeptide 
analogues are differently fused Aza, thiaza, diazabicycloalkane amino acids (Figure 1),
35
 widely utilized for the design of -
turn mimetics, -lactam antibacterial peptides, NK antagonists, metalloprotease inhibitors, etc. 
 
Figure 1. (a) Structures of a model dipeptide showing the dihedral angles (N-C),  (C-C=O),  (C(O)-N), and  (C-
C); (b) sketch of a Friedinger lactam; (c) a prototypic bicyclic turn-mimetic.  
Unfortunately, the preparations of the heterocyclic scaffolds generally require multistep procedures, resulting in low overall 
yields. Besides, many synthetic methods lack flexibility and are therefore not suited to the introduction of diversity. Finally, 
the structures of the turn mimetics may lack some relevant pharmacophores for specific targets. For these reasons, many 
efforts have been dedicated to the expedient introduction of constrained scaffolds within a peptide sequence.
1,7,14,32,34
 
In the chapter 4 is proposed the expedient cyclization of -hydroxy--amino acids already embedded in a oligopeptide 
sequence, by treatment with disuccinimidyldicarbonate (DSC) and a base, to give oxazolidinone-peptides (Oxd).
36,37
 
Depending from the stereochemistry, linear peptides including two consecutive -hydroxy--amino acids gave rise to 
sequences Oxd-Oxd or Abu-Oxd; these scaffolds adopted well defined extended or folded conformations, in particular 
normal or inverse -turns of type I or II. (Scheme 1).38 
 
Scheme 1. The cyclization of linear peptides including two consecutive -hydroxy--amino acids giave rise to Oxd-Oxd or 
Abu-Oxd sequences, characterized by extended or folded conformations. 
On the other hand, the cyclization of isoserine (iSer) or other -hydroxy--amino acids within oligomeric sequences 
afforded a 5-aminomethyloxazolidine-2,4-dione (Amo) scaffold, comprising iSer and the amine function of the following 
residue (Chapter 5, Scheme 2).
39
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Scheme 2. The cyclization of linear peptides containing iSer or other -hydroxy--amino acids gives rise to a 5-
aminomethyloxazolidin-2,4-dione (Amo) dipeptide scaffold.  
To date, the oxazolidine-2,4-dione heterocycle has found very little use in organic and medicinal chemistry.
40,41,42
 In the 
chapter 7, we discussed a new procedure fort the synthesis of the 5-aminomethyl-3-oxazolidinone core of the antibiotic 
linezolid (LNZ) in enantiomerically pure form (Scheme 3). The cyclization of the -hydroxy amide derived from iSer and 3-
fluoro-4-morpholinoaniline to Amo, and the mild selective reduction at the position C(4), gave linezolid in excellent overall 
yield.
43
 
 
Scheme 3. Retro-synthetic approach to LZD via Amo intermediate, readily obtained in turn from the chiral building block 
iSer. 
From the structural point of view, the Amo dipeptide scaffold can be regarded as a unprecedented 2-homo analogue of a 
Freidinger lactam (Figure 2). In the field,
44
 Gmeiner and co. and others, previously combined the Freidinger lactams with -
amino acids (Figure 2).
45,46,47
 The cyclic structure of Amo, achieved via acylation of the backbone nitrogen atom, embraces 
two consecutive amino acids, therefore introducing a global constraint of C(i)-N(i+1) type.
1,14
 This cyclization is expected to 
significantly reduce the conformational space accessible to the peptide segment in which it is incorporated.
48
 Finally, the 
Amo dipeptide might also rise potential interest for the design of hybrid oligomers composed of - and 2-residues,21,22,25 
being these latter less synthetically accessible respect to their 3-counterparts (Figure 2).49,50 
 
Figure 2. (a) Structures of 2- and (b) 3-amino acids with the soft torsional angles  (N-C),  (C-C), and (see the 
section Conformational Analysis); (c) classic Freidinger lactam composed of all -amino acids; (d) 2-homo Amo variant; 
(e) Gmeiner’s 3-homo lactam. 
Chapter 9 
145 
 
Herein is described the use of the Amo /-dipeptide scaffold for the design of highly stable peptidomimetic antagonists of 
the integrin 41, or Very Late Activation antigen-4 (VLA-4), a heterodimeric cell-surface receptor expressed on 
lymphocytes, monocytes, eosinophils, basophils, macrophages. For the involvement of the integrin 41 in inflammatory 
processes associated to a sustained recruitment of these cells,
51
 monoclonal 4 integrin antibodies52,53 or small-molecule 
antagonists
54,55,56,57,58
 can find applications as anti-inflammatory agents. 
9.2. Results and discussion 
Pepetidomimetic design. The natural ligands of 41 integrin are fibronectin (FN), a protein of the extracellular matrix 
(ECM), and the vascular cell adhesion molecule-1 (VCAM-1). FN and VCAM-1 bind to and activate the integrin by 
recognition of the tripeptide motifs Leu-Asp-Val (LDV), and Ile-Asp-Ser (IDS), respectively. As a consequence, several 
researchers designed small-molecule antagonists starting from these recognition sequences.
54,55
 The peptide BIO1211, 
MPUPA-LDVP-OH (1, Figure 2) represents a prototypic example of LDV derivative.
59
 It is equipped with the o-
methylphenylureaphenylacetyl (MPUPA) moiety, which demonstrated a strong efficacy to target the 4 subunit. However, 
this peptide 1 was found to undergo rapid clearance in vivo,
60
 and very unstable in heparinized blood, plasma and rat liver, 
lung and intestinal homogenates, being metabolized by hydrolytic cleavage of the terminal dipeptide moiety.
61,62
 In search 
for new lead structures, several research groups proposed peptidomimetic integrin antagonists; selected examples are shown 
in Figure 3. 
 
Figure 3. Structures of the peptide BIO1211 (1) and of the peptidomimetics 2 and 3. 
Moving from our previous experience in the field of highly stable and biologically active peptides containing -amino 
acids,
63,64,65,66,67
 including integrin ligands,
68,69,70,71,72,73
 we envisaged the opportunity to design new peptidomimetic 41 
integrin antagonists containing the Amo /-dipeptide scaffold. In this sense, we observed that the large majority of the 
peptidomimetic 41 ligands share common structural features: a 4-targeting diphenylurea moiety at the N-terminus, a 
suitable spacer, and a C-terminal Asp or a mimetic containing a carboxylic acid. In general, optimal distance between the C-
terminal carboxylic acid and the urea carbonyl seems to be 14-15 bonds. Very often, the presence of an aromatic group at or 
adjacent to Asp favors integrin binding.
54,55
  
Starting from these premises, we selected and synthesized the diastereoisomeric Amo-containing sequences MPUPA-(S)-
Amo-(S)-Asp(NHPh)-OH (4), and MPUPA-(R)-Amo-(S)-Asp(NHPh)-OH (5), and the diastereoisomeric PhCO-(S)-
Asp(OH)-(S)-Amo-APUMP (6), and PhCO-(S)-Asp(OH)-(R)-Amo-APUMP (7) (Scheme 4); APUMP (9, 1-(4-
(aminomethyl)phenyl)-3-(o-methylphenyl)urea),
74
 represents an amino variant of MPUPA. The building blocks were chosen 
to maintain a 14-bond carboxylate-urea distance. Having the diphenylurea moiety at the C-terminus, and the Asp at the N-
terminus, 6 and 7 can be regarded to as retro sequences
12,13
 of the straight sequences 4 and 5, respectively. Besides, while 4 
and 5 appear characterized by a flexible diphenylurea-Amo junction, and a more rigid Amo-Asp portion, the compounds 6 
and 7 show a more flexible Asp-Amo, and a highly rigid Amo-diphenylurea scaffold (Scheme 4). 
After synthesis and bioassay as potential inhibitors of the integrin 41, we confirmed the coherence of the most effective 
compound(s) with the models developed by 3D-QSAR analysis of large libraries of compounds containing diphenylureas or 
other substituted aromatic groups,
56,60,75,76,77
 with the aid of 2D ROESY and molecular dynamics simulations
78
 (see the 
section Conformational Analysis).  
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Scheme 4. Design of the straight Amo peptidomimetics MPUPA-Amo-Asp(NHPh)-OH, (S,S)-4, and (R,S)-5, and of the 
retro variants PhCOAsp(OH)-Amo-APUMP (S,S)-6 and (S,R)-7. 
Peptidomimetic synthesis. The straight Amo compounds 4 and 5 were prepared by cyclization of the corresponding 
precursors containing the building blocks (S)- or (R)-iSer, respectively, Asp, MPUPA (8),
59
 and aniline (Scheme 4). In a 
similar way, the cyclization of the linear precursors composed of a benzoyl moiety, Asp, (S)- or (R)-iSer, APUMP,
74
 gave 6 
or 7 (Scheme 4). As a representative example, the preparation of MPUPA-(S)-Amo-(S)-Asp(NHPh)-OH (4) is briefly 
described in Scheme 5. The diastereoisomer 5 containing (R)-Amo was obtained using the same protocol. The tBuprotecting 
group of Fmoc-Asp(OtBu)-OBn 10
79
 was removed by treatment with TFA, and the -carboxylate functionality was reacted 
with aniline using HBTU, HOBt and DIPEA as coupling agents, giving the fully protected 11. Then, this was treated with 
DMA to remove the Fmoc protecting group, and the intermediate was coupled with Boc-iSer-OH in 10 min under MW 
irradiation, in the presence of HOBt/HBTU/DIPEA. The resulting 12 was treated with TFA and subsequently coupled with 
MPUPA (8) under the previous conditions, giving 13. The cyclization to Amo 14 was done with DSC and a catalytic amount 
of DIPEA. Epimerization of isoserine during the cyclization was excluded on the basis of the NMR and HPLC analyses (see 
General Methods). After each coupling, the intermediates were isolated by flash chromatography over silica gel. The purity 
and identity of the intermediates was determined by RP-HPLC and ESI MS analysis and eventually by NMR. Final 
deprotection of the benzyl ester 14 by catalytic hydrogenation gave 4, which was isolated > 95% pure by semi-preparative 
RP-HPLC (Scheme 5).  
 
Scheme 5. Synthesis of MPUPA-Amo-Asp(NHPh)-OH (4). 
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The synthesis of PhCOAsp(OH)-Amo-APUMP (6) is briefly sketched in Scheme 6, while 7 was obtained from (R)-iSer 
using the same protocol. APUMP (9) was preparing using a modified version of a procedure described in the literature,
74
 
from Boc-4-(aminomethyl)aniline and 2-methylbenzene isocyanate; the resulting Boc-APUMP was deprotected with TFA. 
The TFA salt of 9 was coupled with Boc-iSer-OH in solution under MW irradiation and in the presence of 
HOBt/HBTU/DIPEA, giving 15. The Boc deprotection of 15 was followed by coupling with PhCOAsp(OtBu)-OH (16) 
under the same conditions as before. The resulting 17 was treated with DSC and DIPEA to give PhCOAsp(OtBu)-Amo-
APUMP (18). The latter was treated with TFA, giving 6 which was purified by semi-preparative RP-HPLC. The 
characterization of the final compound was done by MS, NMR, and elemental analysis.  
 
Scheme 6. Synthesis of PhCOAsp(OH)-Amo-APUMP (6). 
In vitro enzymatic stability. The enzymatic stability of peptidomimetics 4-7 was estimated by incubation in mouse serum for 
3 h.
80
 During this period, samples of the incubation mixtures were withdrew at intervals chosen so that a kinetic curve of the 
hydrolysis could be constructed (Figure 6). At 180 min, compounds 4, 5, and 7, were only slightly degraded (< 10 %), while 
6 was degraded to a moderate extent (about 10-15 %) in the mouse serum (Table 1). On the contrary, BIO1211 (1) was 
almost completely hydrolyzed, being present only in traces, as detected by RP-HPLC and ESI-MS analyses. These data 
support that the presence of the Amo scaffold strongly increased the enzymatic stability of the peptidomimetics respect to 1. 
Cell adhesion inhibition. The efficacy of the compounds 4-7 as antagonists of the integrin 41 was determined by 
measuring their ability to inhibit the adhesion of 41 integrin-expressing Jurkat cells to the natural ligand VCAM-1 (Table 
1). BIO1211 (MPUPA-Leu-Asp-Val-Pro-OH, 1) was chosen as 41 integrin antagonist reference compound. The adhesion 
of these cells to 96-well plates coated with human recombinant VCAM-1 was concentration-dependent and was not observed 
in BSA-coated wells.
81
 The adhesion of Jurkat cells (5×10
5
 cells per well) to VCAM-1 (2-25 g/ml) ranged from 1.9 to 
3.2×10
4
 cells. The adhesion to VCAM-1 (10 g/ml) was inhibited (> 92%) after pretreatment with 5 g/ml of an anti-4 
integrin antibody. 
As expected,
59
 the reference compound BIO1211 (MPUPA-Leu-Asp-Val-Pro-OH, 1) behaved as a potent 41 integrin 
ligand and inhibited cell adhesion to VCAM-1 with a IC50 of 7.6 nM. On the contrary, peptidomimetics 4 and 5 did not affect 
cell adhesion to a significant extent. Possibly, the rigid Amo-Asp scaffolds prevented these compounds from adopting a 3D 
display of the pharmacophores (urea, carboxylate, and aromatic substituent) compatible with the bioactive conformation(s) 
of 41 integrin ligands (see Conformational Analysis). On the other hand, the retro compounds PhCO-(S)-Asp(OH)-(S)-
Amo-APUMP 6, and PhCO-(S)-Asp(OH)-(R)-Amo-APUMP 7, inhibited cell adhesion with an IC50 of 19 and 148 nM, 
respectively. Therefore, both the compounds behaved as integrin antagonists, albeit with different affinity. Apparently, the 
rigid (S)-configured Amo-urea scaffold of 6 imposed a better overall geometry compared to the  (R) one. The different in-
solution conformations of 6 and 7 were analyzed by 2D ROESY and restrained molecular dynamics, and were compared to 
the 3D models determined by 3D QSAR and molecular docking (Conformational Analysis). 
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Table 1. HPLC and MS analysis,
a
 inhibition of Jurkat cell adhesion,
b
 and peptide stability (PS)
c
 in mouse serum after 3 h, of 
BIO1211 (1) and compounds 4-7. 
n structure Purity 
(%) 
m/z [M+1] vs 
calcd 
α4β1/VCAM-1 
IC50 (nM) 
PS 3h (%) 
1 MPUPA-Leu-Asp-Val-Pro-OH - - 7.60±3.0 traces 
4 MPUPA-(S)-Amo-(S)-Asp(NHPh)-OH 96 588.2/588.2 >10
4
 91±5 
5 MPUPA-(R)-Amo-(S)-Asp(NHPh)-OH 98 588.3/588.2 >10
4
 94±6 
6 PhCO-(S)-Asp(OH) -(S)-Amo-APUMP 97 574.3/574.2 19±20 85±4 
7 PhCO-(S)-Asp(OH) -(R)-Amo-APUMP 96 574.2/574.2 148±24 88±6 
a
 Determined by analytical RP-HPLC. 
b
 Mean ± SE. 
c
 Mean amounts (%) of intact peptides ± SE after a 3 h incubation in 
mouse serum, determined by RP-HPLC; peak areas were normalized to 100 at t=0.
 
Conformational analysis. The significant biological activity of the structurally correlated PhCO-(S)-Asp(OH)-(S)-Amo-
APUMP (6) and PhCO-(S)-Asp(OH)-(R)-Amo-APUMP (7) prompted us to analyze the in-solution conformations by NMR 
spectroscopy and MD simulations, to check the coherence with the 3D geometric requisites of the models reported in the 
literature for 41 antagonists.56,60,75,76,77,82,83,84 Molecular conformations were investigated by 2D ROESY in 8:2 
[D6]DMSO/H2O; [D6]DMSO alone or mixtures of [D6]DMSO and H2O have been recommended by several authors as 
excellent biomimetic media. It has been demonstrated that cryoprotective mixtures of high viscosities, such as DMSO/water, 
showed a remarkable ability to favor compact structures representative of the bioactive conformers over disordered 
structures.
85,86,87
  
The 
1
H NMR spectra showed a single set of resonances, suggestive of conformational homogeneity or a rapid equilibrium 
between conformers. 2D-ROESY of the model compounds in [D6]DMSO/H2O (8:2) mixture gave well analyzable cross-
peaks (Tables S1 and S2). Cross-peak intensities were ranked to infer plausible inter-proton distances as restraints. The 
amide bonds were set at 180°; indeed, it is well established that peptides comprising only secondary amide bonds adopt all-
trans conformations. In any case, the absence of H(i)-H(i+1) cross-peaks reasonably excluded the occurrence of cis 
amide bonds.
88
 Structures consistent with ROESY were obtained by simulated annealing with restrained molecular dynamics 
in a box of explicit TIP3P water molecules.89 Random structures generated by unrestrained high temperature molecular 
dynamics were subjected to restrained dynamics with a scaled force field at high temperature, followed by dynamics with 
full restraints, after which the system was cooled and minimized with the AMBER force field
90
 and clustered by the rmsd 
analysis of backbone atoms.
78
  
For both 6 and 7, the computations gave one major cluster comprising the large majority of the structures. The representative 
geometries with the lowest internal energy and no violations of the distance constraints were selected and analyzed (Figure 
4). Both 6 and 7 displayed a partially bent disposition of the backbone; however, the presence of (S)-Amo or (R)-Amo 
scaffolds conferred the compounds distinct 3D shapes (Figure 4 and 5). 
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Figure 4. Top: representative low-energy structures of PhCO-(S)-Asp(OH)-(S)-Amo-APUMP (6), and PhCO-(S)-Asp(OH)-
(R)-Amo-APUMP (7), consistent with ROESY analysis and calculated by restrained MD in a 45×45×45 Å box of standard 
TIP3P water molecules. Bottom: bioactive geometry of the prototypic model compound 1
77
 (for clarity, only urea-Leu-Asp is 
shown), and peptidomimetic 2 (Figure 3), as reported in the literature.
56,60,75
  
Clearly, the central torsion angle between the C-C carbons represents the most relevant geometric variable of the Amo 
compounds. According to the convention of Banerjee and Balaram,
91 
the soft torsional degrees of freedom in a -amino acid 
are defined as  (N-C),  (C-C), and  (C-C=O), respectively (Figure 2). The ROESY-derived structure of the 
homochiral 6 display a partially bent backbone disposition (Figure 4 and 5), and the PhCO-Asp moiety is placed below the 
plane of the heterocycle. The Amo residue adopts a +g conformation about the central dihedral angle , which is consistent 
with the calculated geometries previously reported for -amino acids.49,91,92,93 In the diastereoisomer 7, the central dihedral 
angle  of Amo adopts a -g conformation (due to the reversal of stereochemistry, the –g conformation of (R)-Amo 
corresponds to the +g of (S)-Amo), and the PhCO-Asp group is positioned on the opposite side of the Amo ring respect to 6 
(Figure 5). 
 
Figure 5. Sketches of the geometries about the (S)- or (R)-configured Amo rings in 6 and 7, respectively. 
Figure 4 shows also a comparison of the representative structures of 6 and 7 calculated by ROESY and restrained molecular 
dynamics, with the bioactive geometries of the compounds 1 and 2 as reported in the literature,
56,60,75
 representative of the 
3D models developed by 3D QSAR or molecular docking.
76,77,82,83,84
 Both 6 and 7 tend to adopt similar semi-bent 
conformations; however, the relative display of the diphenylurea, the carboxylate group, and the aromatic group, imposed by 
the (S)-Amo-urea rigid scaffold of the antagonist 6, reproduce the geometries of the pharmacophores of reference 
compounds more closely, accounting for the comparatively higher efficacy to inhibit Jurkat cells adhesion to VCAM-1 
(Table 1). 
9.3. Conclusions 
In summary, herein is reported the design and synthesis of 41 integrin inhibitors, mimetics of the well-known BIO1211 
(1), readily assembled by connecting a diphenylurea pharmacophore and an aryl-substituted Asp, to a (S)- or (R)-configured 
Amo scaffolds, obtained in turn by the expedient cyclization of the corresponding (S)- or (R)-isoserine-containing sequences. 
Different assemblies lead to “normal” or retro-sequences, and the resulting compounds showed remarkable chemical and 
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enzymatic stability, as determined by incubation in mouse serum, while under the same conditions 1 was rapidly degraded. 
The retro sequences PhCO-(S)-Asp(OH)-(S)-Amo-APUMP (6), and PhCO-(S)-Asp(OH)-(R)-Amo-APUMP (7), were shown 
to inhibit the adhesion of the 41 integrin-expressing Jurkat cells to the ligand VCAM in a dose-dependent manner, in 
particular the homochiral 6 showed IC50 in the low 10
-8
 M range. The comparatively higher activity of 6 compared to 7 was 
rationalized on the basis of the different 3D molecular geometries imposed by the (S)- or (R)-Amo scaffolds. 2D ROESY 
analysis in a biomimetic environment and restrained molecular dynamics gave for 6 a preferential conformation which was 
more compatible with the 3D requisites reported in the literature for BIO1211 and similar compounds. These results support 
that the Amo approach can furnish bioactive peptidomimetics, potentially useful as anti inflammatory agents.  
9.4. Experimental Section 
9.4.1. General Methods 
Standard chemicals and biological reagents were purchased from commercial sources and used without further purification. 
In particular: mouse serum, lectin from Triticus vulgaris, were obtained from Sigma-Aldrich; cell culture media, 
phosphate-buffered saline (PBS) and fetal bovine serum (FBS), from Lonza; HBSS and chloromethylfluorescein diacetate 
(CMFDA) from Invitrogen; Jurkat clone E6.1 was obtained from the European Cell Culture Collection; black 96-well 
clear-bottom plates were purchased from Corning Costar. Soluble human VCAM-1 was purchased from R&D Systems. 
BIO-1211 (1) was purchased from Bachem. Flash chromatography was performed on silica gel (230-400 mesh), using 
mixtures of distilled solvents. The purities of the intermediates were determined by analytical RP-HPLC; the purities of the 
Amo peptides 6 and 7 were assessed also by elemental analysis. RP-HPLC was performed on an Agilent 1100 series 
apparatus, using a RP column Phenomenex mod. Gemini 3 C18 110A 100x3.0 mm (P/No 00D-4439-Y0); column 
description: stationary phase octadecyl carbon chain-bonded silica (C18) with TMS endcapping, fully porous organo-silica 
solid support, particle size 3 m, pore size 110 Å, length 100 mm, internal diameter 3 mm;  DAD 210 nm; mobile phase 
from a 9:1 H2O-CH3CN to a 2:8 H2O-CH3CN in 20 min at a flow rate of 1.0 mL min
-1
, followed by 10 min at the same 
composition (mobile phase A). The analytic RP-HPLC of compounds 4-7 and other intermediates with a free amino or 
carboxylate group was performed as reported above, with the addition of 0.1% HCOOH in the mobile phase (mobile phase 
B), and setting DAD at 254 nm. Semi-preparative RP-HPLC of compounds 4-7 was performed on an Agilent 1100 series 
apparatus, using a RP column ZORBAX mod. Eclipse XDB-C18 PrepHT cartridge 21.2x150 mm 7 (P/No 977150-102); 
column description: stationary phase octadecyl carbon chain-bonded silica (C18), double endcapped, particle size 7 µm, 
pore size 80 Å, lenght 150 mm, internal diameter 21.2 mm; DAD 210 nm; mobile phase from 8:2 H2O-CH3CN to 100% 
CH3CN, both H2O and CH3CN with the addition of 0.1% HCOOH, in 10 min, at a flow rate of 12 mL min
-1
. ESI analysis 
was performed using a MS single quadrupole HP 1100MSD detector, with a drying gas flow of 12.5 l/min, nebulizer 
pressure 30 psgi, drying gas temp. 350°C, capillary voltage 4500 (+) and 4000 (-),  scan 50-2600 amu. Elemental analyses 
were performer using a Thermo Flash 2000 CHNS/O analyzer. The synthetic procedures by MW irradiation were 
performed using a microwave oven (MicroSYNTH Microwave Labstation for Synthesis) equipped with a built-in ATC-FO 
advanced fiber optic automatic temperature control. 
1
H NMR spectra were recorded using a Varian Gemini apparatus at 
400 MHz in 5 mm tubes, using 0.01 M peptide at room temperature. For spectra in water/[D6]DMSO, solvent suppression 
was performed by the solvent presaturation procedure implemented in Varian (PRESAT). 
13
C NMR spectra were recorded 
at 100 MHz. Chemical shifts are reported as  values relative to residual CHCl3 H (7.26 p.p.m.), DMSO H (2.50 p.p.m.) 
and CDCl3 C (77.36 p.p.m.) as internal standards. The unambiguous assignment of 
1
H NMR resonances was performed 
by 2D gCOSY.  
9.4.2. Synthetic procedures 
MPUPA (8) was prepared as reported in the literature.
59
 Briefly, o-tolyl isocyanate (0.82 mL, 6.6 mmol) was added to a 
stirred solution of 2-(4-aminophenyl)acetic acid (1.0 g, 6.6 mmol) in DMF (5 mL) at r.t. After 3 h, the mixture was diluted 
with EtOAc (40 mL) and the solid 8 which precipitated in almost quantitative yield was collected by filtration under 
suction, and was used without further purifications (1.75 g, 93%, 90% pure by analytical RP-HPLC, see General Methods, 
mobile phase B, Rt = 6.08 min). ES-MS (m/z) 285.0 [M+1], calcd 285.1. The analyses were in agreement with the 
literature.
59
 
APUMP (9) was prepared using a modified version of a procedure reported in the literature.
74
 o-Tolyl isocyanate (0.6 mL, 
4.8 mmol) was added at r.t. to a stirred solution of N-Boc-p-phenylenediamine (1.0 g, 4.8 mmol) in DMF (5 mL). After 3h, 
the mixture was diluted with EtOAc (40 mL), the solid Boc-APUMP which precipitated in almost quantitative yield was 
collected by filtration under suction, and used without further purifications (1.44 g, 90%, 90% pure by analytical RP-
HPLC, see General Methods, mobile phase A, Rt = 8.87 min). ES-MS (m/z) 342.0 [M+1], calcd 342.1. Boc-APUMP (1.0 
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g, 2.9 mmol), was treated with 25% TFA in DCM (5 mL) while stirring at r.t. After 15 min, the volatiles was removed 
under reduced pressure, and the treatment was repeated. The residue was triturated in Et2O, the solid 9 (APUMP) was 
collected as a TFA salt by filtration in almost quantitative yield, and used for the next couplings without further 
purifications (0.94 g, 91%, 90% pure by analytical RP-HPLC, see General Methods, mobile phase B, Rt = 1.47 min). ES-
MS (m/z) 241.2 [M+1], calcd 241.1. 
Fmoc-Asp(OtBu)-OBn (10) was prepared as reported in the literature.
79
 Briefly, a mixture of Fmoc-Asp(OtBu)-OH (1.50 
g, 3.65 mmol), BnBr (1.7 mL, 14.6 mmol) NaHCO3 (0.92 g, 10.9 mmol) in DMF (6 mL), was stirred for 8 h at r.t. The 
mixture was diluted with water (20 mL) and extracted three times with EtOAc (20 mL). The combined organic layers were 
dried over Na2SO4, and the solvent was distilled at reduced pressure. The oily residue was purified by flash 
chromatography over silica-gel (eluant EtOAc/cyclohexane 1:9) giving 8 (1.58 g, 85%, 94% pure by analytical RP-HPLC, 
see General Methods, mobile phase A, Rf = 13.7 min). ES-MS (m/z) 502.0 [M+1], calcd 502.2. The analyses were in 
agreement with the literature.
79
 
Fmoc-Asp(NHPh)-OBn (11). The compound 10 (0.50 g, 1.0 mmol) was treated with 25% TFA in DCM (5 mL) as reported 
for the preparation of 9. After the same work-up, the resulting 11 was used for the following reactions without further 
purifications (0.44 g, 98%, 85% pure by analytical RP-HPLC, see General Methods, mobile phase B, Rf = 1.78 min). ES-
MS (m/z) 446.2 [M+1], calcd 446.2. The residue (0.44 g, 0.98 mmol) was dissolved in 3:1 DCM/DMF (5 mL), and HOBT 
(0.135 g, 1.0 mmol), HBTU (0.76 g, 2.0 mmol), DIPEA (0.52 mL, 3.0 mmol), and aniline (0.14 g, 1.5 mmol), were added 
while stirring. The mixture was heated under MW irradiation, keeping irradiation power fixed at 150W and monitoring the 
internal reaction temperature at 80 °C with a built-in ATC-FO advanced fiber optic automatic temperature control. After 10 
min, the mixture was allowed to reach r.t. and diluted with DCM (20 mL), and the solution was washed with 0.5 M HCl (5 
mL) and saturated NaHCO3 (5 mL). The organic layer was dried over Na2SO4, and solvent was removed at reduced 
pressure. The compound 11 (0.44 g, 85%, 94% pure by analytical RP-HPLC, see General Methods, mobile phase A, Rt = 
11.84 min) was isolated by flash chromatography over silica-gel (eluant EtOAc/cyclohexane 1:1). ES-MS (m/z) 521.3 
[M+1], calcd 521.2.  
Boc-iSer-Asp(NHPh)-OBn (12). Fmoc deprotection of compound 11 (0.26 g, 0.5 mmol) was done with 2M DMA in THF 
(4 mL) while stirring at r.t for 20 min. After that, the volatiles were removed under reduced pressure and the residue treated 
again under the same conditions. The deprotected intermediate was triturated twice with ice-cold Et2O and was utilized for 
the next coupling without further purifications (0.12 g, 80%, 75% pure by analytical RP-HPLC, see General Methods, 
mobile phase B, Rt = 1.17 min). ES-MS (m/z) 299.0 [M+1], calcd 299.1. The residue (0.12 g, 0.4 mmol) was coupled with 
Boc-iSer-OH (0.1 g, 0.48 mmol) under the same conditions and work-up procedures utilized for the synthesis of 11. The 
dipeptide 12 (0.18 g, 92%, 95% pure by analytical RP-HPLC, see General Methods, mobile phase A, Rt = 8.50 min) was 
isolated by flash chromatography over silica-gel (eluant EtOAc/cyclohexane 7:3). ES-MS (m/z) 486.2 [M+1], calcd 486.2. 
MPUPA-iSer-Asp(NHPh)-OBn (13). The Boc-protected 12 (0.18 g, 0.37 mmol) was treated with TFA in DCM under the 
same conditions and work up procedure described for the deprotection of 9. The resulting intermediate dipeptide-TFA salt 
(0.18 g, 98%, 90% pure by analytical RP-HPLC, see General Methods, mobile phase B, Rt = 1.31 min), was utilized 
without further purifications. ES-MS (m/z) 386.3 [M+1], calcd 386.2. The TFA salt  (0.18 g, 0.36 mmol) was reacted with 
MPUPA (0.12 g, 0.43 mmol) using the same coupling conditions and work up procedure described for the preparation of 
11. The residue was purified by flash chromatography over silica-gel (eluant: EtOAc) giving 13 (0.22 g, 94%, 95% pure by 
analytical RP-HPLC, see General Methods, mobile phase A, Rt = 8.69 min). ES-MS (m/z) 652.2 [M+1], calcd 652.3. 
1
H 
NMR (400 MHz, [D6]DMSO) : 2.21 (s, 3H, Me), 2.80 (dd, J = 10.4, 15.0 Hz, 1H, AspH), 2.90 (dd, J = 5.6, 15.0 Hz, 
1H, AspH), 3.23 (m, 1H, iSerH), 3.46 (m, 1H, iSerH), 3.56-3.60 (m, 2H, CH2CON), 4.03 (m, 1H, iSerH), 4.79 (ddd, J 
= 5.6, 8.4, 10.4 Hz, 1H, AspH), 5.07 (d, J = 12.6 Hz, 1H, CH2Ph), 5.13 (d, J = 12.6 Hz, 1H, CH2Ph), 6.90 (br.t, 1H, ArH), 
7.00 (m, 1H, ArH), 7.08-7.22 (m, 10H, ArH+NH), 7.23-7.31 (m, 2H, ArH), 7.32-7.39 (m, 2H, ArH), 7.57 (d, J = 7.8 Hz, 
2H, ArH), 7.64 (br.t, 1H, iSerNH), 7.80 (s, 1H, ureaNH), 7.83 (d, J = 7.8 Hz, 1H, ArH), 8.08 (d, J = 8.4 Hz, 1H, AspNH), 
8.82 (s, 1H, ureaNH). 
MPUPA-Amo-Asp(NHPh)-OBn (14). DSC (0.092 g, 0.36 mmol) and DIPEA (12 L, 0.07 mmol) were added to a stirred 
solution of 13 (0.21 g 0.33 mmol) in 3:1 DCM/DMF (4 mL) at r.t. and under inert atmosphere. After 1 h, the solvent was 
removed at reduced pressure, the residue was diluted with 0.1 M HCl (5 mL), and the mixture was extracted three times 
with DCM (10 mL). The combined organic layers were dried over Na2SO4, and solvent was evaporated at reduced 
pressure. The Amo compound 12 was isolated (0.20 g, 89%, 96% pure by analytical RP-HPLC, see General Methods, 
mobile phase A, Rt = 9.48 min) by flash chromatography over silica-gel (eluant EtOAc/cyclohexane 6:4). ES-MS (m/z) 
678.0 [M+1], calcd 678.3. 
1
H NMR (400 MHz, [D6]DMSO) : 2.15 (s, 3H, Me), 2.83 (m, 1H, AspH), 3.10 (m, 1H, 
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AspH), 3.22-3.37 (m, 2H, CH2CON), 3.50-3.60 (m, 2H, AmoH), 5.06 (d, J = 12.8 Hz, 1H, CH2Ph), 5.09-5.15 (m, 2H, 
CH2Ph+AspH), 5.16 (m, 1H, AmoH), 6.91 (br.t, 1H, ArH), 7.02 (m, 1H, ArH), 7.06-7.21 (m, 10H, ArH+NH), 7.21-
7.32 (m, 2H, ArH), 7.32-7.38 (m, 2H, ArH), 7.56 (d, J = 7.8 Hz, 2H, ArH), 7.80 (s, 1H, ureaNH), 7.83 (d, J = 7.8 Hz, 1H, 
ArH), 8.36 (br.t, 1H, AmoNH), 8.99 (s, 1H, ureaNH). 
MPUPA-(S)-Amo-Asp(NHPh)-OH (4). The benzyl ester 14 (0.20 g, 0.29 mmol) was dissolved in MeOH (10 mL), 10% 
Pd-C (0.05 g) was added, and the reaction vessel was filled with H2. After 8 h, the suspension was filtered over Celite® 
under suction, and the solvent was evaporated at reduced pressure. The residue was isolated (0.16 g, 93%, 97% pure by 
analytical RP-HPLC, see General Methods, mobile phase B, Rt = 7.92 min) by semi-preparative RP-HPLC (see General 
Methods, mobile phase B). ES-MS (m/z) 588.2 [M+1], calcd 588.2.
 1
H NMR (400 MHz, [D6]DMSO) : 2.23 (s, 3H, Me), 
2.90 (m, 1H, AspH), 3.30 (m, 1H, AspH), 3.33-3.40 (m, 2H, CH2CON), 3.53 (m, 1H, AmoH), 3.62 (m, 1H, AmoH), 
5.11 (br.t, 1H, AspH), 5.21 (m, 1H, AmoH), 6.92 (br.t, 1H, ArH), 7.01 (m, 1H, ArH), 7.09-7.19 (m, 5H, ArH+NH), 
7.23-7.31 (m, 2H, ArH), 7.32-7.38 (m, 2H, ArH), 7.57 (d, J = 7.8 Hz, 2H, ArH), 7.82 (d, J = 7.8 Hz, 1H, ArH), 7.94 (s, 1H, 
ureaNH), 8.36 (br.t, 1H, AmoNH), 9.02 (s, 1H, ureaNH), 10.12 (br.s, 1H, COOH). 
MPUPA-(R)-Amo-Asp(NHPh)-OH (5). The use of (R)-isoserine instead of (S)-isoserine, under the same reactions 
conditions, the same reagents, in the same quantities, and the same work-up and isolation procedures, utilized for the 
preparation of 4, gave the diastereoisomer 5 (96% pure by analytical RP-HPLC, see General Methods, mobile phase B, Rt 
= 7.92 min). ES-MS (m/z) 588.3 [M+1], calcd 588.2.
 1
H NMR (400 MHz, [D6]DMSO) : 2.23 (s, 3H, Me), 2.94 (m, 1H, 
AspH), 3.26 (m, 1H, AspH), 3.35-3.45 (m, 2H, CH2CON), 3.53 (m, 1H, AmoH), 3.61 (m, 1H, AmoH), 5.11 (br.t, 1H, 
AspH), 5.25 (m, 1H, AmoH), 6.90 (br.t, 1H, ArH), 7.02 (m, 1H, ArH), 7.09-7.20 (m, 5H, ArH+NH), 7.23-7.30 (m, 2H, 
ArH), 7.31-7.37 (m, 2H, ArH), 7.56 (d, J = 7.8 Hz, 2H, ArH), 7.80 (d, J = 7.8 Hz, 1H, ArH), 7.93 (s, 1H, ureaNH), 8.38 
(br.t, 1H, AmoNH), 9.01 (s, 1H, ureaNH), 10.10 (br.s, 1H, COOH). 
Boc-iSer-APUMP (15). APUMP TFA salt (9, 0.86 g, 2.42 mmol) was coupled with Boc-(S)-isoSerOH (0.45 g, 2.19 mmol) 
using the same quantities of coupling agents and under same conditions described for the synthesis of 11. After the usual 
work up, 15 (0.85 g, 91%, 93% pure by analytical RP-HPLC, see General Methods, mobile phase A, Rt = 7.11 min), was 
isolated by flash chromatography over silica gel (eluant cyclohexane/EtOAc from 75:25). ES-MS (m/z) 451.0 [M+Na], 
calcd 451.2. 
PhCO-Asp(OtBu)-OH (16). Fmoc-Asp(OtBu)-OH (1.0 g, 2.42 mmol) was treated with 2M DMA in THF, as reported for 
the Fmoc deprotection of 12, and after the same work-up, the crude H-Asp(OtBu)-OH (0.39 g, 85%, 73% pure by 
analytical RP-HPLC, see General Methods, mobile phase B, Rt = 1.61 min) was used for the following step without further 
purifications. ES-MS (m/z) 190.1 [M+1], calcd 190.1. The crude H-Asp(OtBu)-OH (0.39 g, 2.0 mmol) was diluted with 
DCM (4 mL), and benzoyl chloride (0.35 mL, 3.0 mmol), and pyridine (0.33 mL, 3 mmol) were added while stirring at r.t. 
After 3 h, 1M HCl (5 mL) was added, the mixture was shaken with a separating funnel, and the organic layer was 
separated. The aqueous layer was extracted twice with DCM (5 mL), and the collected organic layers were dried over 
Na2SO4. The solvent was evaporated at reduced pressure, the residue was triturated twice in Et2O, and was utilized without 
further purifications (0.54 g, 92%, 80% pure by analytical RP-HPLC, see General Methods, mobile phase B, Rt = 6.00 
min). ES-MS (m/z) 293.1 [M+1], calcd 293.1. 
PhCO-Asp(OtBu)-isoSer-APUMP (17). Compound 15 (0.4 g, 0.93 mmol) was N-deprotected according to the procedure 
described for the preparation of 9, giving H-isoSer-APUMP as a TFA salt in quantitative yield, utilized without 
purification (0.44 g, 99%, 90% pure by analytical RP-HPLC, see General Methods, mobile phase B, Rt = 1.23 min), ES-
MS (m/z) 329.2 [M+1], calcd 329.2. The crude salt (0.16 g, 0.36 mmol) was coupled with 16 (0.11 g, 0.37 mmol) using the 
same quantities and under same conditions described for the preparation of 11, affording compound 17. After the usual 
work up, 17 was isolated (0.19 g, 88%, 94% pure by analytical RP-HPLC, see General Methods, mobile phase A, Rt = 
7.95 min) by flash chromatography over silica gel (eluant cyclohexane/EtOAc 20:80). ES-MS (m/z) 604.2 [M+1], calcd 
604.3. 
1
H NMR (400 MHz, [D6]DMSO) : 1.34 (s, 9H, tBu), 2.21 (s, 3H, Me), 2.65 (dd, J = 7.4, 15.8 Hz, 1H, AspH), 
2.80 (dd, J = 6.4, 15.8 Hz, 1H, AspH), 3.40 (m, 1H, iSerH), 3.58 (m, 1H, iSerH), 4.16 (m, 1H, iSerH), 4.89 (ddd, J = 
6.4, 7.4, 8.0 Hz, 1H, AspH), 6.85 (br.t, 1H, ArH), 7.00-7.08 (m, 3H, ArH), 7.09-7.20 (m, 5H, ArH), 7.24-7.32 (m, 4H, 
ArH+NH), 7.60 (d, J = 8.0 Hz, 1H, ArH), 7.64 (br.t, 1H, iSerNH), 8.00 (s, 1H, ureaNH), 8.22 (d, J = 8.0 Hz, 1H, AspNH), 
9.02 (s, 1H, ureaNH). 
PhCO-Asp(OtBu)-Amo-APUMP (18). The cyclization of 17 (0.19 g, 0.31 mmol) was performed with DSC and DIPEA 
according to the same conditions and work-up procedures utilized for the synthesis of 14, giving 18 (0.18 g  95%, 92% 
pure by analytical RP-HPLC, see General Methods, mobile phase A, Rt = 8.87 min) after flash chromatography over silica 
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gel (eluant cyclohexane/EtOAc from 20:80). ES-MS (m/z) 630. [M+1], calcd 630.3. 
1
H NMR (400 MHz, [D6]DMSO) : 
1.21 (s, 9H, tBu), 2.18 (s, 3H, Me), 2.55-2.62 (m, 2H, AspH), 3.53 (m, 1H, AmoH), 3.65 (m, 1H, AmoHβ), 4.75 (m, 1H, 
AspHα), 5.12 (br.t, 1H, AmoHα), 6.96 (t, J = 7.4 Hz, 1H, ArH), 7.12-7.20 (m, 2H, ArH), 7.29 (d, J = 8.0 Hz, 2H, ArH), 
7.46 (br.t, 2H, ArH), 7.53-7.60 (m, 3H, ArH), 7.75 (d, J = 8.0 Hz, 1H, ArH), 7.90 (d, J = 7.6 Hz, 2H, ArH), 7.98 (s, 1H, 
ureaNH), 8.30 (br.t, 1H, AmoNH), 8.44 (br.d, 1H, AspNH), 9.03 (s, 1H, ureaNH). 
PhCO-Asp(OH)-(S)-Amo-APUMP (6). The intermediate 18 (0.185 g  0.29 mmol) was deprotected with TFA according to 
the same procedure described for 9, giving 6 (0.14 g  86%, 96% pure by analytical RP-HPLC, see General Methods, 
mobile phase B, Rt = 7.02 min) after isolation by semi-preparative RP-HPLC (see General Methods, mobile phase B). ES-
MS (m/z) 574.3 [M+1], calcd 574.2. 
1
H NMR (400 MHz, 8:2 [D6]DMSO/H2O) : 2.25 (s, 3H, Me), 2.66-2.75 (m, 2H, 
AspH), 3.62 (ddd, J = 4.2, 8.0, 14.8 Hz, 1H, AmoH), 3.80 (ddd, J = 4.2, 8.0, 14.8 Hz, 1H, AmoHβ), 4.81 (m, 1H, 
AspHα), 5.20 (br.t, 1H, AmoHα), 6.96 (t, J = 7.4 Hz, 1H, ureaArH4’), 7.12-7.20 (m, 2H, ureaArH3’+5’), 7.30 (d, J = 8.0 Hz, 
2H, ureaArH2), 7.46 (dd, J = 7.2, 7.6 Hz, 2H, BzArH3+5), 7.53 (t, J = 7.2 Hz, 1H, BzArH4), 7.56 (d, J = 8.0 Hz, 2H, 
ureaArH3), 7.82 (d, J = 8.0 Hz, 1H, ureaArH6’), 7.87 (d, J = 7.6 Hz, 2H, BzArH2+6), 8.02 (s, 1H, ureaNH’), 8.45 (br.t, 1H, 
AmoNH), 8.66 (d, J = 8.6 Hz, 1H, AspNH), 9.23 (s, 1H, ureaNH); 
13
C NMR (100 MHz, [D6]DMSO) : 17.9, 36.1, (40), 
50.2, 78.2, 118.1, 121.3, 123.0, 124.6, 126.2, 127.3, 127.6, 127.8, 128.2, 130.3, 131.4, 134.0, 137.2, 140.23, 152.6, 154.4, 
166.3, 170.6, 171.7, 171.8. Elem. Anal. for C29H27N5O8; calcd: C 60.73, H 4.74, N 12.21; found: C, 60.95; H, 4.69; N, 
12.11. 
PhCO-(S)-Asp(OH)-(R)-Amo-APUMP (7). The use of (R)-isoserine instead of (S)-isoserine, under the same reactions 
conditions, the same reagents, in the same quantities, and the same work-up and isolation procedures, described for the 
preparation of 6, gave the diastreoisomer 7 (95 % pure by analytical RP-HPLC, see General Methods, mobile phase B, Rt 
= 7.02 min). 
1
H NMR (400 MHz, 8:2 [D6]DMSO/H2O) : 2.24 (s, 3H, Me), 2.67 (dd, J = 8.0, 14.6 Hz, 1H, AspH), 2.75 
(dd, J = 4.4, 14.6 Hz, 1H, AspH), 3.69 (m, 1H, AmoHβ), 3.72 (m, 1H, AmoHβ), 4.82 (ddd, J = 4.4, 8.0, 8.6 Hz, 1H, 
AspHα), 5.20 (br.t, 1H, AmoH), 6.98 (t, J = 7.4 Hz, 1H, ureaArH4’), 7.11-7.19 (m, 2H, ureaArH3’+5’), 7.29 (d, J = 8.0 Hz, 
2H, ureaArH2), 7.46 (dd, J = 7.2, 7.6 Hz, 2H, BzArH3+5), 7.54 (t, J = 7.2 Hz, 1H, BzArH4), 7.56 (d, J = 8.0 Hz, 2H, 
ureaArH3), 7.82 (d, J = 8.0 Hz, 1H, ureaArH6’), 7.87 (d, J = 7.6 Hz, 2H, BzArH2+6), 8.00 (s, 1H, ureaNH’), 8.43 (br.t, 1H, 
AmoNH), 8.65 (d, J = 8.6 Hz, 1H, AspNH), 9.25 (s, 1H, ureaNH); 
13
C NMR (100 MHz, [D6]DMSO) : 17.9, 36.1, (40), 
50.2, 78.4, 118.0, 121.3, 123.0, 124.6, 126.2, 127.3, 127.6, 127.8, 128.2, 130.3, 131.4, 133.9, 137.2, 140.23, 152.6, 154.4, 
166.3, 170.6, 171.6, 171.8 . Elem. Anal. for C29H27N5O8; calcd: C 60.73, H 4.74, N 12.21; found: C 60.62, H 4.78, N 
12.29. 
Cell adhesion assay. Jurkat cell adhesion assay was done as described.
94,95
 Briefly, 96-well plates were coated at 4 °C 
overnight with 2 g/ml of VCAM-1 and a saturation curve for the ligand was plotted to establish the best signal-to-noise 
ratio. Non-specific hydrophobic binding sites were blocked by incubation with a BSA 1 % /HBSS (w/v) solution for 30 
min at 37°C. The day of the assay, the cells were counted and stained with 12.5 M CMFDA (30 min at 37 °C).  After 
three rinses with BSA/HBSS to wash away the excess dye, aliquots of 500,000 (Jurkat) cells were divided among a number 
of tubes corresponding to the number of treatments.  For inhibition experiments, cells were mixed with the drug and pre-
incubated at 37 °C for 30 min to reach equilibrium before being plated.  After 30 min incubation at 37 °C in the coated 
wells, the non-specifically bound cells were washed away with BSA/HBSS solution. Adherent cells were lysed by the 
addition of 0.5 % Triton-X-100 in PBS (30 min at 4°C).  Released CMFDA was quantified by fluorescence imaging at 
Ex485 nm/Em535 nm (Wallac ARVO 1420 multilabel counter) and adherent cells was counted by interpolation on a 
standard curve. The fluorescence intensity with and without VCAM-I was taken as respectively 100% and 0%. 
Alternatively, the number of adherent cells was calculated by comparison with a standard curve prepared in the same plate 
using known concentrations of labeled cells. The efficacy of putative antagonists (at least eight different concentrations 
were used) was determined by the reduction in adherent cells compared to the untreated control.  
Data analysis. Three independent experiments were run in quadruplicate; all data are expressed as mean ± S.E.M. IC50 
values indicate the molar ligand concentration required to inhibit the response by 50%. Data were analyzed using 
GraphPad software 5.0 (GraphPad Software Inc., San Diego, CA, USA). 
In vitro enzymatic  stability. Enzymatic degradation studies of 1, 4-7 were carried out in triplicate and repeated three times 
using mouse serum purchased from Sigma-Aldrich. Peptides were dissolved in Tris buffer pH 7.4 and 10 L aliquots of a 
10 mM peptide stock solution were added to 190 L of serum. Incubations were carried out at 37°C for 120 min. Aliquots 
of 20 L were withdrawn from the incubation mixtures and enzyme activity was terminated by precipitating proteins with 
90 L of glacial acetonitrile. Samples were then diluted with 90 L of 0.5% acetic acid to prevent further enzymatic 
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breakdown and centrifuged at 13,000×g for 15 min. The supernatants were collected and the stability of peptides was 
determined by RP-HPLC ESI-MS analysis. 
 
Figure 6. Stability curves of BIO1211 (1) and compounds 4-7 in mouse serum. Sampling intervals were chosen so that a 
kinetic curve could be constructed. Peak areas were normalized to 100 at t=0. Each hydrolysis experiment was repeated 3 
times, and the reported data are mean values. Error ranges were estimated on the basis of the standard deviation. 
9.4.3. Conformational analysis 
ROESY and molecular dynamics. 2D ROESY experiments in 8:2 [D6]DMSO/H2O were performed in the phase sensitive 
mode at r.t., spin-locking field (b2) was 2000 Hz, and mixing time was set to 250 ms; spectra were processed in the 
hypercomplex approach; peaks were calibrated on DMSO. Only ROESY-derived constraints were included in the 
restrained molecular dynamics.
78
 Cross-peak intensities were classified very strong, strong, medium, and weak, and were 
associated with distances of 2.3, 2.7, 3.3, and 5.0 Å, respectively.
96
 The intensities of the cross peaks arising from protons 
separated by known distances (e.g. geminal) were found to match with these associations. Geminal and other obvious 
correlations were discarded as constraints. For the absence of H(i, i+1) ROESY cross peaks, all of the ω bonds were set 
at 180° (force constant: 16 kcal mol
-1
 Å
-2
). 
The restrained MD simulations were conducted at 1 atm using the AMBER force field in a 45×45×45 Å box of standard 
TIP3P models of equilibrated water.
89
 Periodic boundary conditions were applied, a dielectric constant of 1 was used, and 
the cutoff distance for the nonbonded interactions was 12 Å. All water molecules with atoms that come closer than 2.3 Å to 
a solute atom were eliminated. A 100 ps simulation at 1200 K was used for generating 50 random structures that were 
subsequently subjected to a 50 ps restrained MD with a 50% scaled force field at the same temperature, followed by 50 ps 
with full restraints (distance force constant of 7 kcal mol
-1
 Å
-2
), after which the system was cooled in 20 ps to 50 K. H-
bond interactions were not included, nor were torsion angle restraints. The resulting structures were minimized with 3000 
cycles of steepest descent and 3000 cycles of conjugated gradient (convergence of 0.01 kcal Å
-1
 mol
-1
). The backbones of 
the structures were clustered by the rmsd analysis.
78  
Table 2. Non-obvious ROESY cross-peaks observed for 6
a
 in 8:2 [D6]DMSO/H2O. 
Cross-peak
b
 Intensity
c
 Cross-peak
b
 Intensity
c
 
Me-ureaNH w AmoHdw-AmoH s 
Me-ureaNH’ vs AmoHdw-AmoNH m 
AspH-AmoHup w AmoHdw-AspNH w 
AspH-AmoHdw w AspH-AmoH w 
AspH-AspH s AspH-BzArH2+6 w 
AspH-BzArH2+6 w AspH-AmoNH vs 
AspH-AmoNH m AspH-AspNH m 
AspH-AspNH s AmoH-ureaArH2 w 
AmoHup-AspH w AmoH-AmoNH m 
AmoHup-AmoH m ureaArH2-AmoNH w 
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AmoHup-ureaArH2 w ureaArH3-ureaArH6’ w 
AmoHup-AmoNH vs BzArH2+6-AspNH vs 
AmoHup-AspNH w ureaNH’-ureaNH vs 
AmoHdw-AspH w AmoNH-AspNH w 
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield, Bz = benzoyl;
 c
 vs = very strong, s = strong, m = 
medium, w = weak. 
Table 3. Non-obvious ROESY cross-peaks observed for 7
a
 in 8:2 [D6]DMSO/H2O. 
Cross-peak
b
 Intensity
c
 Cross-peak
b
 Intensity
c
 
Me-ureaNH w AmoHdw-AspH w 
Me-ureaNH’ vs AmoHdw-AmoH m 
AspHup-AmoHup w AmoHdw-AmoNH s 
AspHup-AspH m AspH-AmoH w 
AspHup-BzArH2+6 w AspH-BzArH2+6 w 
AspHup-AmoNH w AspH-AmoNH vs 
AspHup-AspNH s AspH-AspNH m 
AspHdw-AspH s AmoH-ureaArH2 w 
AspHdw-BzArH2+6 w AmoH-AmoNH m 
AspHdw-AmoNH w ureaArH2-AmoNH w 
AspHdw-AspNH m ureaArH3-ureaArH6’ w 
AmoHup-AspH w BzArH2+6-AspNH vs 
AmoHup-AmoH s ureaNH’-ureaNH vs 
AmoHup-AmoNH m AmoNH-AspNH w 
AmoHup-AspNH w   
a
 Stereochemistry has been omitted; 
b 
up = upfield, dw = downfield, Bz = benzoyl;
 c
 vs = very strong, s = strong, m = 
medium, w = weak. 
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Chapter 10 
Self-Assembled monolayers of zeolite L nanocrystals functionalized with the integrin 
ligand c[RGDfK] as model devices for the specific detection of cancer cells 
In this chapter is reported the preparation of nanostructured substrate, readily obtained by immobilizing the 
cyclic c[RGDfK] targeting ligand onto patterned zeolite L monolayers. The functionalized surface allows fast 
and specific entrapment of cancer cells via integrin-mediated cell adhesion. With its high specificity towards 
cancer cells and fast adhesion ability, this biocompatible monolayer candidates itself as promising platform for 
implementation in diagnostics and personalized therapy formulation devices.   
10.1. Introduction  
Integrins are heterodimeric glycoproteinic adhesion receptors that mediate cellular attachment to the 
extracellular matrix (ECM) and to other cells.
1
 Upon interaction with specific substrates (i.e. fibrinogen, 
fibronectin, plasminogen, etc.) they also regulate various cellular functions, such as cell adhesion, migration, 
invasion, proliferation and survival/anoikis.
1,2
 Recent studies have demonstrated the crucial role of integrins (e.g. 
αvβ3, αvβ5, αvβ1, α6β4, α4β1, etc.) in the development of invasive tumors that preferentially metastasize to 
bone, such as breast and prostate carcinomas.
2,3
 For example, studies examining the expression of αvβ3 integrin 
in various breast cancer tissues have evidenced a correlation between the overexpression of integrin αvβ3 and the 
formation of bone metastases in breast cancer patients.
4
 In pancreatic tumor, the increased expression of αvβ3 
integrin is associated with an increased activation of MMP-2 and lymph node metastases,
5
 and in prostate 
carcinoma again to bone metastases formation.
3,4 
 
Since the discovery of the Arg-Gly-Asp (RGD) tripeptide as the prominent minimal recognition motif for many 
integrins (including αvβ3, αvβ5, and αvβ1),1,2,6 this sequence has been employed for the development of small-
molecule antagonists, focused on the use of RGD-mimetics,
3,4,7
 which efficiently led to important results in 
blocking tumor progression.
8 
Nowadays, interest has also focused on the construction of RGD-functionalized 
bio-active substrates for the preparation of integrin-mediated cell adhesion surfaces to be employed for 
biomedical applications, especially for the bio-integration of implant materials.
9
 The successful design of these 
scaffolds relies on understanding the interactions of the cells with the coating components. Cell adhesion, 
migration, proliferation, and differentiation onto bio-active substrates are quite sensitive to the bioactivity, tether 
length, interspacing, and density of the biological ligands attached to the surface.
9,10
 An attractive way to 
improve the organization and consequently the efficacy of cell-binding substrates, regards the intercalation 
between the bioactive recognition moiety and the support surface of self-assembled monolayers (SAM) of 
nanoparticles (NPs). The large surface area of SAMs superficially functionalized with bioactive molecules, 
provides a large number of contact points in a confined surface (high density of ligands on the NP’s surface), 
which can be exploited for a more effective binding to biological systems.
10
 Furthermore, the organization of the 
biomolecules on the SAMs can be controlled thanks to a series of micro-fabrication techniques recently 
developed that allow the creation of pre-definite morphologies, dimensions, and molecular orientations (i.e. soft 
lithography and microcontact printing).
11  
In this respect, it has been demonstrated that zeolite L SAMs can be 
successfully employed as nano-motif for the functional patterning of glass for biotechnological applications.
11
 
The formation of the monolayer is achieved by a chemical functionalization
12
 of the channel entrances of this 
porous material, allowing the control of the crystals orientation.  
Based on these premises, in this chapter is reported the preparation and the preliminary biological assays of an 
integrin-targeted patterned SAM of disk-shaped zeolite L on glass substrates for cancer cell adhesion. By coating 
with a cyclic RGD peptide (c[RGDfK]) the surface of the zeolite SAM a faster, more spatially controlled, and 
more selective adhesion of cancer cells is achieved. This interaction could hence be exploited for diagnostic 
purposes for the entrapment and study of an important biomarker, namely circulating tumor cells (CTCs).
13
  
CTCs are cells that have shed into the vasculature from a primary tumor, constituting seeds for subsequent 
growth of metastasis.
14
 Their importance in cancer diagnostic has grown
15
 as their concentration in the blood 
may represent an indicator of a tumor's invasiveness, as well as its sensitivity/resistance to a specific therapy. 
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Moreover, CTCs could serve as “liquid biopsy” by providing representative tumor tissue, essential for biomarker 
identification and subsequent formulation of a personalized therapeutic treatment.
16
 
10.2. Results and discussion 
To construct our bio-compatible substrate we have employed ultra-flat disk-shaped zeolite L crystals 
approximately 1000 nm width and 250 nm height (Figure 1a; see also synthetic procedures section).
17 
The 
crystals were first loaded with a fluorescent dye, N,N’-bis(2,6-dimethylphenyl)perylene-3,4,9,10-tetracarboxylic 
acid diimide (DXP; exc = 490 nm; em = 564 nm), for visualization purposes (DXP-Zeo) and subsequently their 
surface functionalized with 3-(isocyano)propyltriethoxysilane (ICPTES; DXP-Zeo-IC) for both the synthesis of 
the monolayer, and successive grafting of the RGD-peptide. Qualitative and quantitative characterization of the 
functionalized zeolites was performed by means of X-ray photoelectron spectroscopy (XPS) and 
thermogravimetric analysis (TGA). The first technique allowed detection of the modifications of the elemental 
composition of the material along with the synthetic modifications. Indeed, upon DXP insertion first, and surface 
functionalization with ICPTES later (see synthesis section), the relative atomic percentages (At%) of the 
elements composing the materials change. The signals of C(1s) and N(1s), very low for the pristine zeolites 
(C(1s): 6.1 At%; N(1s) 0.7 At%), increased significantly and consequentially in DXP-Zeo and DXP-Zeo-IC 
(C(1s): 20.7 and 33.0 At%; N(1s) 2.0 and 5.5 At%; Figure 8, Table 1). TGA further confirmed the occurrence of 
each step of the functionalization by displaying an increasing weight loss passing from zeolites (negligible 
weight loss in the analyzed temperature range) to DXP-Zeo and DXP-Zeo-IC (1.7 and 5.7 % respectively; 
contribution of water excluded), confirming an always more important ratio of organic material in the hybrids 
(Figure 9, Supporting Information). Ultimately, scanning electron microscopy (SEM) analysis demonstrated that 
the morphology of the zeolites (important for fostering efficient cellular adhesion) was preserved throughout the 
functionalization steps (Figure 10). 
The SAMs were then prepared according to a protocol developed in our laboratories (Figure 1).
11 
Specifically, 
activated silica plates where functionalized with aminopropyltriethoxysilane (APTES; see synthesis section for 
details) to obtain amino functional groups on the surface for reaction with DXP-Zeo-IC. This coupling step, key 
to the formation of the monolayer, was then performed by sonicating the amino-functionalized glass substrates in 
a suspension of DXP-Zeo-IC (1 mg/mL) in toluene for 30 minutes. To pattern the zeolite SAMs a stripe-
patterned (50 m) elastomeric poly(dimethyl siloxane) (PDMS) stamp was pressed on the monolayer for about 
30 s and peeled off quickly.
11,12
 Stripes of about 50 m of SAMs remained on the surface of the glass. This 
topography was chosen to better prove the attachment of the cells only on the zeolites functionalized with the 
peptide, thus highlighting the specificity of its action.  
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Figure 1. a-d) SEM images of: a) zeolite L crystals employed in the preparation of the SAM; b) close-up image 
of the prepared SAM, displaying the DXP-Zeo-IC covalently attached on the surface; the SAM before (c) and 
after (d) PDMS patterning; in the inset of (d) the confocal image of the printed SAM (exc = 490 nm); e) 
graphical representation of the cRGD-SAM bound onto a glass substrate; f-h) confocal images of c[RGDfK]-
SAM after reaction with RITC dye. i-k) As control for the lack of reaction of the RITC in absence of c[RGDfK], 
also naked SAM was tested. f,i) DXP channel (green): exc= 490 nm; g,j) RITC channel (orange): exc= 540 nm; 
h,k) overlay. Scale bar = 200 m; l) high resolution N(1s) XPS analysis of c[RGDfK]-SAM. In the inset the 
high-resolution N(1s) XPS analysis of the naked SAM. 
Once prepared, to enable the SAM to promote efficient cell adhesion, the printed substrate was coupled with the 
αvβ3 integrin ligand c[RGDfK], developed by Kessler and co-workers.18 This sequence was specifically chosen 
since RGD-containing cyclopeptides (cRGD) were shown to be more resistant to chemical degradation, more 
effective, and more selective than the linear equivalents.
7,19 
Moreover, c[RGDfK] allows conjugation to the 
isocyanate-functionalized monolayer thanks to the presence of the amino group in the lysine.
20
 The ligand 
c[RGDfK] was readily prepared by cyclization of the linear precursor H-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Mtr)-
Gly-OH, obtained in turn by solid phase peptide synthesis using the acid-labile 2-chlorotrityl resin and 
TBTU/HOBt/DIPEA as coupling agents under controlled microwave heating, according to a recently optimized 
procedure (Synthesis section).
21
 After peptide cleavage with AcOH/CF3CH2OH (TFE) in DCM, the cyclization 
step was performed by slowly adding (12 h) the linear peptide to a solution of HATU/DIPEA via a temporized 
syringe. The final deprotection with TFA in the presence of scavengers afforded the crude cyclopeptide, purified 
(>95 %) by semi-preparative RP-HPLC. Bio-conjugation of the peptide to the printed monolayer was thus 
ultimately performed upon immersion of the patterned SAMs into a solution of c[RGDfK] (1 mg/mL) in TEA 
and DMF (1:100) heated at 35 °C for 3 h. 
 
Effective functionalization of the monolayers with the peptide was assessed by XPS analysis and by selective 
functionalization with rhodamine B isothiocyanate (Figure 1 and Synthetic procedures section). In the latter 
experiment, both a c[RGDfK]-functionalized SAM and a naked one, used as control, were reacted with 
rhodamine B isothiocyanate (RITC). Due to its isothiocyanate group, this dye can react with the amino group 
present on the peptide (i.e. arginine residue), resulting to its covalent binding to the c[RGDfK]-SAM. Such 
reaction cannot occur on the naked SAM, presenting on its surface only isocyanate groups. Indeed, as shown in 
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Figure 1f-h, confocal imaging of the two substrates showed that only c[RGDfK]-SAM presents the 
characteristic emission of RITC, perfectly superimposable with the signal of the DXP entrapped in the zeolites 
channels. As expected, the signal of the rhodamine dye is not present on the naked SAM (Figure 1i-k), clearly 
indicating that the presence of the RITC signal in the c[RGDfK]-SAM cannot be due to non specific adsorption 
on the zeolites. Moreover, the images in Figure 1f-h show the homogeneous distribution of the dye exclusively 
along the stripes of the monolayer surface, highlighting at the same time both the successful patterning as well as 
the homogenous coverage obtained for the bio-coating. XPS analysis of the two substrates further indicated the 
presence of the peptide on the zeolites surface. In fact, the relative amount of C(1s) and N(1s) increased in the 
peptide-derivatized SAM, in comparison to the naked monolayer (C(1s): 30.6 and 5.1; N(1s) 42.6 and 8.7 % for 
SAM and c[RGDfK]-SAM respectively). Moreover, the high resolution XPS analysis of the N(1s) peak for 
c[RGDfK]-SAM displays a modification of its shape as compared to SAM (Figure 1l and inset). Indeed it 
results composed of two components, one at 399 eV (present also in SAMs) corresponding to the isocyanate 
form of N(1s) and one at 402 eV assigned to the peptidic and urea form of N(1s).
  
Once confirmed the morphology and the effective surface functionalization of the SAMs, adhesion experiments 
were performed with the integrin expressing cancer cells lines HeLa and Glioma C6. Specifically, 1 × 10
5
 cells 
of each cell line were stained (DiO staining, exc= 484 nm; em = 501 nm) and seeded on both naked and c-RGD-
functionalized SAMs in order to evaluate the effect of the peptide on the binding activity of the monolayers. 
After 30 min incubation at 37 °C, cells were washed, and fixed with paraformaldehyde (PFA). Confocal 
microscope images showed that the adhesion behavior on the SAMs of the cancerous cell lines is dramatically 
different depending on the presence of the bio-active cRGD on the monolayer surface. As shown in Figure 2, the 
population of both HeLa and Glioma C6 cells on c[RGDfK]-SAMs resulted much higher than the population on 
the naked monolayers. Accurate counting of the number of cells on the cRGD-functionalized versus the naked 
SAMs showed a 3.5 and 18.4 fold increase of population, for HeLa and Glioma C6 respectively. These results 
demonstrate that cancer cells undergo an efficient integrin-mediated adhesion onto the zeolite monolayers, 
already in the short time interval (30 min) employed for the incubation. Interestingly, the primary endothelial 
cells T-293 (DiD staining, exc= 644 nm; em = 665 nm) were also tested on both the c[RGDfK]-functionalized 
and the naked monolayer, and did do not bind to either types of SAMs . 
  
Figure 2. a-f) Confocal images of the c[RGDfK]-SAM (DXP, green channel, exc= 490 nm) and naked SAM 
(DXP, red channel, exc = 490 nm) after cancer cell adhesion experiments (1 × 10
5
, incubation 30 min at 37 °C); 
cells are visualized in blue (DiO staining, exc = 484 nm); scale bar = 100 m. The emission of the DXP is 
represented either as green (a-c) or red (d-f), depending if the monolayer is coated or not by the c[RGDfK] 
peptide respectively. Cancer cells are visualized in blue (DiO, exc = 484 nm), primary endothelial cells in yellow 
(DiD, exc = 644 nm); g) quantitative data of adhered cells on c[RGDfK]-functionalized and naked SAMs 
(analyzed area: 0.0025 cm
2
; cell count values normalized to an area of 1 cm
2
). 
 
To show that the selectivity of the here reported c[RGDfK]-SAMs could be used for specific cancer cell 
detection, we further tested the capacity of c[RGDfK]-SAM to sense cancer cells in presence of a heterogeneous 
mixed cell population. Cancer cells and primary cells (HeLa/T-293 and Glioma C6/T-293 1:1 ratio, 1 × 10
5
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each) were labeled with different fluorescent stains (for cancer cells DiO staining, exc= 484 nm; em = 501 nm; 
for primary cells DiD staining exc= 644 nm; em = 665 nm) and seeded on both naked and c[RGDfK]-SAMs.  
Analysis of the cell adhesion by confocal microscopy (Figure 3a-d) confirmed a very low healthy cell binding on 
both substrates. Most importantly, the number of cancer cells on the peptide coated SAMs is much higher 
compared to the non bio-compatible surfaces confirming the role of the cyclic peptide on the recognition of the 
overexpressed integrin receptors present in cancer cells. Indeed, as graphically represented in Figure 3e, the ratio 
cancer/primary cells resulted increased from 4.5 and 3 to 8.5 and 20.7 for HeLa and Glioma C6, respectively, 
when passing from the naked to the c[RGDfK]-SAMs. These results further confirm the ability of the substrate 
to capture a large number of cancer cells when the cyclic peptide is bound to the surface, and more interestingly 
to have a very effective adhesion, of mainly cancer cells, in the presence of the same amount of healthy cells.  
 
Figure 3. a-d) Confocal images of the c[RGDfK]-functionalized (DXP, green channel,exc= 490 nm) and naked 
SAMs (DXP, red channel, exc = 490 nm) after mixed population cell adhesion experiments (1 × 10
5
 of each cell 
line, incubation 30 min at 37 °C); cancer cells are visualized in blue (DiO, exc = 484 nm), primary endothelial 
cells in yellow (DiD, exc = 644 nm); scale bar = 100 m; g) quantitative data of adhered cells on c[RGDfK]-
functionalized and naked SAMs (analyzed area: 0.0025 cm
2
; cell count values normalized to an area of 1 cm
2
).  
10.3. Conclusion 
In conclusion, we have demonstrated the efficiency of our new bio-selective substrate based on zeolite L SAMs 
conjugated to the integrin ligand c[RGDfK], for the adhesion of  cancer cells. This adhesion resulted very 
efficient for both the cancer cell lines tested, HeLa and Glioma C6, even upon rapid incubation (only 30 min.). 
Finally, we challenged our new biocompatible surface with a mixed population of cancer and primary 
endothelial cells and, in these incubation conditions, almost exclusive adhesion of cancer cells was observed, 
thus demonstrating the high affinity of the c[RGDfK] peptide for the integrin proteins abundantly present on the 
surface of cancer cells.  
Perspectives. Further studies on the sensitivity and the tailoring of the surface coating of these monolayers are 
currently on going. Indeed, this substrate might represent a potential candidate for the development of new 
diagnostic kits or even implantable diagnostic devices capable to specifically recognize and trap CTCs present 
into biological fluids, thus enabling a significant advance in the early detection and study of cancer and other 
integrin-related diseases. In this context, we are now developing surfaces loaded with 41 integrin ligands in 
order to study inflammatory processes such as asthma and autoimmune diseases.  
Finally, since porous nanoparticles like zeolite L are very popular for drug delivery applications, we have 
already synthesized zeolite L crystals approximately 200 nm width and 50 nm height, loaded with DXP dye and 
functionalized with different integrin antagonists and cytotoxic peptides. These constructs are now under 
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investigation for their theranostic abilities, which means high capacity to ferry cargo and loads onto them both 
imaging and therapeutic functions. 
10.4. Experimental Section 
10.4.1. General Methods  
Standard chemicals, including protected amino acids, were purchased from commercial sources and used 
without further purification. Flash chromatography was performed on silica gel (230-400 mesh), using 
mixtures of distilled solvents. The purity of c[RGDfK] and its synthetic precursors was assessed by analytical 
RP-HPLC performed with an Agilent 1100 series apparatus, using a RP column [Phenomenex mod. Gemini 3 
C18 110A 100x3.0 mm (P/No 00D-4439-Y0)]; column description: stationary phase octadecyl carbon chain 
bonded silica (C18) with TMS end capping, fully porous organosilica solid support, particle size 3 mm, pore 
size 110 Å, length 100 mm, internal diameter 3 mm; DAD 210 nm; mobile phase: from 9:1 H2O/CH3CN to 2:8 
H2O/CH3CN with the addition of 0.1 % TFA, in 20 min at a flow rate of 1.0 mL/min, followed by 10 min at 
the same composition. Semi-preparative RP-HPLC was performed with an Agilent 1100 series apparatus, 
using a RP column [ZORBAX mod. Eclipse XDBC18 PrepHT cartridge 21.2 x 150 mm 7 (P/No 977150-
102)]; column description: stationary phase octadecyl carbon chain bonded silica (C18), double end capped, 
particle size 7 m, pore size 80 Å, length 150 mm, internal diameter 21.2 mm; DAD 210 nm; mobile phase 
from 8:2 H2O/CH3CN to 100 % CH3CN with the addition of 0.1 % TFA, in 10 min at a flow rate of 12 
mL/min. MS (ESI) analysis was performed using a MS single quadrupole HP 1100 MSD detector, with a 
drying gas flow of 12.5 L/min, nebulizer pressure 30 psgi, drying gas temp. 350 °C, capillary voltage 4500 (+) 
and 4000 (-), scan 50-2600 amu. The synthetic procedures by MW irradiation were performed with a 
microwave oven (Micro-SYNTH Microwave Labstation for Synthesis) equipped with a built-in ATC-FO 
advanced fiber optic automatic temperature control. 
1
H NMR spectrum of c[RGDfK] was recorded with a 
Varian Gemini apparatus at 400 MHz in a 5 mm tube, using 0.01 M peptide at RT.  
Zeolites were prepared according to a standard procedure previously reported in the literature.
22
 3-
isocyanatepropyltriethoxysilane, 3-aminopropyltriethoxysilane, TEA, DMF, Toluene, PFA, DiO, DiD, DiL, 
DXP were purchased from Sigma Aldrich. PDMS was obtained from Dow Corning corporation (184 silicon 
elastomer base, SYLGARD). Glass plates (1.2 cm) used for zeolite monolayers were purchased from 
Servoprax GmbH. Dulbecco’s modified culture medium (DMEM), FBS, penicillin, glutamine, trypsin and PBS 
solution (pH 7.2) were purchased from Gibco (Life Technologies). HeLa cells and Glioma C6 were obtained 
from ATCC/LGC Standards GmbH (Wesel, Germany) and cultivated according to the provider’s protocol. T-
293 cells were kindly provided by Dr. Eric Robinet at the IHU, Hopital Civil Strasbourg. XPS analyses were 
performed using a K-Alpha™+ X-ray Photoelectron Spectrometer (XPS) System (Thermo Scientific). 
Monochromatic Al K alpha X-rays were used (15 keV, 72 W, 200 m spot diameter). Spectra were measured 
using a pass energy of 200 eV for survey spectra and 50 eV for core level spectra. The analyzed zeolite 
samples were prepared by drop-casting an ethanolic dispersion (0.1 mg/mL) of the particles onto a glass 
coverslip pre-coated with Au (Emitech K575X peltier cooled) for 3 min at 60 mA. The monolayers were 
analyzed as they were, without further treatment. TGA analyses were conducted on a TGA 1 STAR System 
Mettler Toledo machine under nitrogen atmosphere. The samples (0.1 – 2 mg) were kept at 50 °C for 30 
minutes for stabilization, then heated from 50 to 750 °C at a speed of 10 °C/min, and held at this temperature 
for further 30 minutes before cooling. The analyses were performed under a gas flow of N2 at 50 mL/min. 
SEM images were recorded with a FEI Quanta FEG 250 instrument (FEI corporate, Hillsboro, Oregon, USA) 
at an operating distance of 10 mm and with an acceleration voltage of 5 kV. The zeolite samples were prepared 
by drop-casting a dispersion of particles in EtOH onto a glass cover slip, subsequently sputter coated with Au 
(Emitech K575X peltier cooled) for 60 s at 60 mA prior to fixation on an Al support. SAMs monolayers were 
analyzed without further manipulation. Powder X-ray diffraction (PXRD) measurements were performed on a 
Bruker D2 PHASER diffractometer using a Cu K-radiation (1.54184 Å) and a Ni K-filter at 300 W (30 kV, 
10 mA) power with a LYNXEYE scintillation detector. Samples were mounted on a zero background silicon 
sample holder. The measurement was performed from a 2θ value from 5 to 45 ° with exposure time of 1.5 
second per step. All measurements were performed at room pressure and RT. Confocal images were obtained 
with a Zeiss LSM 710 microscope system, 63X magnification, numerical aperture 1.3 of Zeiss LCI Plan-
NEOFLUAR water immersion objective lens (Zeiss GmbH). All image processing was performed with the 
ZEN 2011 software.  
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10.4.2. Synthetic procedures 
Synthesis of H-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Mtr)-Gly-OH. The linear pentapeptide precursor of c[RGDfK] 
was assembled on the commercially-available Gly-preloaded 2-chlorotrityl resin (Gly loading 1.1 mmol/g 
resins). The resin (0.5 g) was swollen in 1:2 DMF/dimehylpirrolidone (5 mL) for 30 min before use. Fmoc-
amino acid (3 equiv), the coupling reagents TBTU (3 equiv), HOBt (3 equiv), DIPEA (6 equiv), were added to 
the resin and the mixture was reacted for 10 min under MW irradiation (50 W, 50 
o
C). The resin was washed 3 
times with DMF (5 mL) and MeOH (5 mL). Deprotection of Fmoc group was carried out by treatment of 20 % 
piperidine/DMF for 3 min under MW irradiation (50 W, 50 
o
C). After that, the resin was washed 3 times with 
DMF (5 mL) and MeOH (5 mL). The resulted peptidyl resin was treated with AcOH and TFE in CH2Cl2 (1:1:4 
v/v/v, 15 mL) for 90 min at RT. The solution of the cleaved cyclic peptide was concentrated at reduced 
pressure. The residue was lyophilized to afford 0.32 g of crude peptide. The purity of the product was 
determined 85 % by reversed-phase (RP) HPLC (see General Methods); Rt = 6.55 min. MS (ESI) m/z: [M + 
H]
+
 calcd for C46H71N9O13S, 990.5; found, 990.8. 
Synthesis of c[Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Mtr)-Gly]. The linear peptide (0.32 g, circa 0.32 mmol) in 
DMF (10 mL) was added dropwise at RT using a temporized syringe in 12 h, to a stirred solution of HATU (3 
equiv) and DIPEA (6 equiv) in DMF (40 mL). The reaction mixture was stirred for other 12 h. The solvent was 
evaporated at reduced pressure, the residue diluted with water (5 mL) was extracted 3 times with EtOAc (15 
mL). The residue was purified by flash chromatography over silica gel (eluent: 100 % EtOAc) giving the 
cyclopeptide (205 mg, 66 %), 90% pure by RP-HPLC (General Methods). Rt = 9.69 min. MS (ESI) m/z: [M + 
H]
+
 calcd for C46H69N9O12S, 972.5; found, 972.8. 
Procedure for the final deprotection to c[RGDfK]. The fully-protected cyclopeptide (0.2 g mg, 0.20 mmol) 
was dissolved in TFA-TIS-H2O (95:2.5:2.5 v/v/v, 20 mL) and the solution was stirred at RT for 2 h. The 
solution was concentrated at reduced pressure and the residue was lyophilized to afford the crude peptide. The 
product c[RGDfK] was isolated by semi-preparative RP-HPLC (General Methods) as a TFA salt (121 mg, 85 
%), >95% pure as determined by analytical RP-HPLC, see General Methods; Rt = 1.00 min. MS (ESI) m/z: [M 
+ H]
+
 calcd for C27H41N9O7, 604.3; found, 604.5. 
1
H NMR was found to match with the literature
[2]
 (400 MHz, 
D2O, δ): 0.67-0.73 (m, 2H, LysHγ), 1.27-1.56 (m, 7H, LysHβ, LysHδ, ArgHγ, ArgHβ), 1.73 (m, 1H, ArgHβ), 
2.40 (dd, J = 7.2, 15.6 Hz,  1H, AspHβ), 2.51 (dd, J = 6.9, 15.6 Hz, 1H, AspHβ), 2.69-2.73 (m, 2H, LysHε), 
2.80 (m, 1H, PheHβ), 2.95 (dd, J = 5.2, 13.2 Hz, 1H, PheHβ), 3.050-3.09 (m, 2H, ArgHδ), 3.30 (d, J = 14.2 Hz, 
1H, GlyHα), 3.73 (m, 1H, LysHα), 4.05 (d, J = 14.2 Hz, 1H, GlyHα), 4.26 (m, 1H, ArgHα), 4.40 (dd, J = 5.2, 
10.4 Hz, 1H, PheHα), 4.55 (m, 1H, AspHα), 7.10-7.24 (m, 5H, PheArH).  
Zeolite synthesis. Zeolite L nanocrystals were synthesized according to a procedure largely described in 
literature.
17 
  
 
Figure 4. SEM image of disk-shaped zeolite L crystals; scale bar = 500 nm. 
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Figure 5. Size distribution diagram of disk-shaped zeolite L (derived from SEM images).  
 
 
Figure 6. Powder XRD diffraction pattern of zeolite L.
 
Zeolite loading with DXP 170 dye (Zeo-DXP). Zeolites
[S1]
 (300 mg) and DXP (6.23 mg) were kept overnight 
under high vacuum. The solid mixture was then introduced in a sealed flask and heated in a rotary furnace at 
300 °C for 48 h. The flask was then opened and the powder washed and centrifuged (30 min, 40 krcf) in butan-
1-ol until the supernatant ceased UV emission. The material was characterized by means of XPS, TGA, and 
SEM.  
Functionalization of Zeo-DXP with 3-Isocyanopropyltriethoxysilane (IC-Zeo-DXP). Zeo-DXP (50 mg) were 
suspended in a 50 mL flask containing a mixture of toluene (5 mL) and TEA (0.2 mL), and sonicated for 15 
min until the precipitate was dissolved. Then 3-(triethoxysilyl)propyl isocyanate (0.8 mL) was added, and the 
mixture further sonicated for 3 h. The suspension was then cooled to RT and centrifuged for 20 min at 40 krcf. 
The precipitate was then redispersed by sonication in toluene and centrifuged three times to remove unreacted 
silane. The material was characterized by means of XPS, TGA, and SEM. 
Preparation of IC-Zeo-DXP SAMs. Glass plates were introduced into a 100 mL flask and activated with 3:1 
H2SO4/H2O2 (10 mL) at 100 °C for 1 h. The solution was removed and the plates were washed with bi-distilled 
water (3 × 30 mL) followed by ethanol (3 × 20 mL) and finally dried under nitrogen flow. The plates were then 
fixed onto a Teflon support to avoid any surface overlap and the system was placed into a 100 mL round 
bottom flask containing toluene (30 mL). APTES (0.8 mL) and TEA (0.2 mL) were added and the flask was 
heated at 115 °C overnight. Subsequently, the plates were removed from the solution and washed with toluene 
(5 mL) and ethanol (5 mL) and dried with nitrogen flow. The plates were then placed into a suspension of 
isocyanate-functionalized zeolites in toluene (1 mg/mL, 2 mL), and sonicated for 30 minutes, before 
recovering the plates, rinsing them with toluene (5 mL) and air-drying them before use. The SAM was 
characterized by means of SEM. 
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Preparation of the PDMS elastomeric stamp and patterning of IC-Zeo-DXP SAMs. The monomeric silicon 
elastomer and the activator agent were introduced in a plastic test tube (10:1 w/w). The components were 
mixed and the mixture was spilled into a Petri dish containing three patterned Si wafers (50 m × 50 m, width 
× depth). The viscous liquid on Petri dish was degassed at reduced pressure, then heated at 50 °C for 3 h. 
Finally, the polymer was cut around the negative stamp, the latter was removed, and the resulting elastomeric 
stamp employed for the soft lithography of the SAMs. The elastomeric stamp was pressed onto the monolayer 
for 30 sec. Effective patterning was analyzed by SEM. 
Functionalization of IC-Zeo-DXP SAMs with c[RGDfK]. c[RGDfK] (1 mg) and TEA (10 L) were dissolved 
in DMF (1 mL). The solution was sonicated for 5 min to favor the complete dissolution of the peptide. A plate 
of patterned monolayer composed of DXP-loaded zeolite NPs was immersed in the solution and heated at 35 
°C for 3 h. Finally, the plate was removed from the solution and washed with DMF (5 mL) and EtOH (5 mL), 
then air dried. The SAM was characterized by means of XPS, and SEM. 
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Figure 7. Preparation of DXP-loaded c[RGDfK]-functionalized patterned SAMs of zeolite L crystals: i) 
synthesis of IC-Zeo-DXP used for the monolayer preparation; ii) c[RGDfK]-SAM preparation.  
Zeo       Zeo-DXP 
 
 
IC-Zeo-DXP      SAM 
 
 
c[RGDfK]-SAM     N(1s) comparison 
 
 
Figure 8. XPS survey spectra for the pristine, the derivatized, and the monolayers of zeolite L materials, and 
comparison of the high resolution XPS analysis of N(1s) of the SAM (dashed line) and c[RGDfK]-SAM (full 
line) samples. 
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Table 1. XPS analysis results for the pristine, the derivatized and the monolayers of zeolite L materials.*  
 Si(2p)** Al(2p)** O(1s)** K(2p)** C(1s)** N(1s)** 
Zeo 21.4 ± 0.1 6.9 ± 0.8 58.4 ± 0.7 6.5 ± 1.0 6.1 ± 1.0 0.7 ± 0.2 
Zeo-DXP 18.9 ± 2.5 8.7 ± 3.3 44.0 ± 5.8 5.6 ± 0.7 20.7 ± 3.7 2.0 ± 0.1 
IC-Zeo-DXP 16.0 ± 2.3 12.7 ± 1.6 29.3 ± 3.6 3.5 ± 1.2 33.0 ± 6.7 5.5 ± 0.8 
SAM 17.5 ± 3.1 7.5 ± 0.9 37.2 ± 0.1 2.1 ± 1.2 30.6 ± 2.9 5.1 ± 2.8 
c[RGDfK]-SAM 14.2 ± 2.1 1.5 ± 0.7  32.8 ± 3.1 0.2 ± 0.2 42.6 ± 4.7 8.7 ± 1.2 
* Data not to be considered quantitative. 
**Atomic %. 
  a)              b) 
      
Figure 9. a) TGA analysis of the pristine and the derivatized zeolite L materials; b) normalization of the TGA 
curves after removing the contribution of the water present in the zeolite materials (pristine zeolites used as 
reference). 
Zeo-DXP 
 
 
IC-Zeo-DXP 
 
Figure 10. SEM images of the functionalized particles: Zeo-DXP and IC-Zeo-DXP. Scale bar = 500 nm.  
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Functionalization of c[RGDfK]-SAMs with rhodamine B isothyocyanate isomer I. A c[RGDfK]-functionalized 
SAMs was immersed in a solution of rhodamine B isothiocyanate in EtOH (10 mg/mL) at RT for 30 min. 
Finally the plate was removed from the solution and washed in EtOH (5 mL) and air dried. The SAM was 
characterized by means of XPS, and confocal microscope. 
10.4.3. Biological methods 
Cell culture. Complete culture media was prepared as following: 88 % Dulbecco's Modified Eagle Medium 
(DMEM), 10 % Fetal Bovine Serum, 1 % Penicillin-Streptomycin and 1 % L-Glutamine 200 nM. The cell 
culture flask was washed twice with PBS, trypsinated and incubated for 5 min before neutralization of the 
trypsin with an equal volume of CCM. The cells suspension was then centrifuged 3 min at 1000 rpm and hence 
re-suspended in fresh CCM until a homogenous dispersion was obtained. 1 mL of the cell suspension was 
added to a new flask and diluted with 10 mL of CCM, before returning in the incubator.  
Cell staining. Cells (1 × 10
6
/mL) were suspended in a serum-free culture medium, and the dye (5 L/mL) was 
added. Glioma C6 and HeLa cells were stained with DiO while T-293 cells were stained with DiD. The 
suspension was then gently mixed and incubated for 10-20 minutes at 37 °C, before being centrifuged at 1500 
rpm for 5 min. The supernatant was finally removed, and the cells gently resuspended in fresh medium at 37 
°C. The washes were repeated twice.  
Cell adhesion and counting. The monolayers were washed with PBS solution to remove all the impurities. The 
printed DXP SAMs, either naked or functionalized with the peptide, were placed in a 24 well plate and seeded 
with cells (1 × 10
5
 HeLa, Glioma C6, or T-293 cells). Each plate was covered with the culture medium (2 mL) 
and incubated for 30 min. Then the culture medium was removed, the plates washed twice with PBS (5 mL) 
and fixed with PFA (3 mL). After 10 minutes, PFA was removed, and the plates were washed twice with bi-
distilled water (5 mL) and mounted on microscopy glass for confocal microscope analysis. The cells counting 
is an average of three values each referred to a surface of 0.0025 cm
2
. This averaged value is then normalized 
to the total area of the monolayer, 1 cm
2
. 
a) 
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b) 
 
 
c) 
 
 
Figure 11. Representative confocal microscopy images for the adhesion experiments of HeLa (a), Glioma C6 
(b) and T-293 cells (c) on isocyanate-functionalized SAMs (in red; DXP exc= 490 nm) and c[RGDfK]-
functionalized SAMs (in green; DXP exc= 490 nm): HeLa and Glioma C6 cells are visualized in blue (DiO 
staining, exc= 484 nm); T-293 in yellow (DiD staining, exc= 644 nm). Scale bar = 100 M.  
Table 2. Cell counting analysis for the single population adhesion experiments.* 
Surface HeLa** Glioma C6** T-293** 
SAM 3.2 ± 1.1 0.8 ± 0.4 0.1 ± 0.05 
c[RGDfK]-SAM 11.4 ± 0.8 15.3 ± 0.5 0.2 ± 0.05 
ratio cells on c[RGDfK]-SAM/SAM 3.5 19.1 2 
* Total area monitored = 0.0025 cm
2
; cell count values normalized to an area of 1 cm
2
 
**x 10
3
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Figure 12. Representative confocal microscopy images for the adhesion experiment of HeLa and T-293 cells 
(DiO and DiD staining, respectively; DiO exc = 484 nm; DiD exc= 644 nm) on naked (top) or on c[RGDfK]-
functionalized SAMs (bottom): HeLa cells are visualized in blue; T-293 in yellow. Scale bar = 50 M. 
 
 
Figure 13. Confocal microscopy image for the adhesion experiment of Glioma C6 and T-293 cells (DiO and 
DiD staining, respectively; DiO exc = 484 nm; DiD exc= 644 nm) onto isocyanate-functionalized SAMs (top) 
or c[RGDfK]-functionalized SAMs (bottom): Glioma C6 cells are visualized in blue; T-293 in yellow. Scale 
bar = 50 M. 
Table 3. Cell counting analysis for the mixed population adhesion experiments. 
Surface HeLa/ T-293 Glioma C6/T293 
 HeLa** T-293** Glioma C6** T-293** 
SAM 3.6 ± 0.4 0.8 ± 0.1 2.5 ± 0.3 0.8 ± 0.1 
c[RGDfK]-SAM 19.7 ± 2.2 2.3 ± 0.5 20.7 ± 6.6 1.0 ± 0.2 
cancer/primary cells on c[RGDfK]-SAM 8.5 20.7 
* Total area monitored = 0.0025 cm
2
; cell count values normalized to an area of 1 cm
2
 
**x 10
3 
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Conclusions 
This thesis work deals, principally, with the development of different chemical protocols ranging from environmental 
sustainability peptide synthesis to asymmetric synthesis of modified tryptophans to a series of straightforward procedures for 
constraining peptide backbones without the need for a pre-formed scaffold. 
Much efforts have been dedicated to the structural analysis in a biomimetic environment, fundamental for predicting the in 
vivo conformation of compounds, as well as for giving a rationale to the experimentally determined bioactivity. The 
conformational analyses in solution has been done mostly by NMR (2D gCosy, Roesy, VT, titration experiments, molecular 
dynamics, etc.), FT-IR and ECD spectroscopy. 
As a practical application, 3D rigid scaffolds have been employed for the synthesis of biological active compounds based on 
peptidomimetic and retro-mimetic structures. These mimics have been investigated for their potential as antiflammatory 
agents and actually the results obtained are very promising. 
Moreover, the synthesis of Amo ring permitted the development of an alternative high effective synthetic pathway for 
obtaining Linezolid antibiotic.  
The final section is, instead, dedicated to the construction of a new biosensor based on zeolite L SAMs functionalized with 
the integrin ligand c[RGDfK], that has showed high efficiency for the selective detection of tumour cells. Such kind of 
sensor could, in fact, enable the convenient, non-invasive detection and diagnosis of cancer in early stages, from a few drops 
of a patient's blood or other biological fluids.  
In conclusion, the researches described herein demonstrate that the peptidomimetic approach to 3D definite structures, 
allows unambiguous investigation of the structure-activity relationships, giving an access to a wide range bioactive 
compounds of pharmaceutical interest to use not only as potential drugs but also for diagnostic and theranostic applications.  
 
 
 
